{"6f7ff3f53cd3c2a5aefebc3910077d22191d0c17": [["IntroductionRoselle (Hibiscus sabdariffa L.) is one of the most popular species belonging to the Malvaceae family.", [["Hibiscus sabdariffa L.", "ORGANISM", 21, 43], ["Malvaceae", "GENE_OR_GENE_PRODUCT", 97, 106], ["Hibiscus sabdariffa L.", "SPECIES", 21, 43], ["Hibiscus sabdariffa L.", "SPECIES", 21, 43]]], ["Roselle is essential for the prevention and treatment of hypertension, hepatitis, cardiovascular diseases, atherosclerosis, and diabetes [1] [2] [3] [4] .", [["cardiovascular", "ANATOMY", 82, 96], ["Roselle", "CHEMICAL", 0, 7], ["hypertension", "DISEASE", 57, 69], ["hepatitis", "DISEASE", 71, 80], ["cardiovascular diseases", "DISEASE", 82, 105], ["atherosclerosis", "DISEASE", 107, 122], ["diabetes", "DISEASE", 128, 136], ["[1] [2] [3] [4]", "SIMPLE_CHEMICAL", 137, 152], ["treatment", "TREATMENT", 44, 53], ["hypertension", "PROBLEM", 57, 69], ["hepatitis", "PROBLEM", 71, 80], ["cardiovascular diseases", "PROBLEM", 82, 105], ["atherosclerosis", "PROBLEM", 107, 122], ["diabetes", "PROBLEM", 128, 136], ["hypertension", "OBSERVATION", 57, 69], ["hepatitis", "OBSERVATION", 71, 80], ["cardiovascular", "ANATOMY", 82, 96], ["atherosclerosis", "OBSERVATION", 107, 122]]], ["The extracts had powerful effects on reducing high cholesterol, preventing cancer and hepatitis, and inhibiting pathogen microorganisms' growth [2, 5] .", [["extracts", "ANATOMY", 4, 12], ["cancer", "ANATOMY", 75, 81], ["cholesterol", "CHEMICAL", 51, 62], ["cancer", "DISEASE", 75, 81], ["hepatitis", "DISEASE", 86, 95], ["cholesterol", "CHEMICAL", 51, 62], ["extracts", "ORGANISM_SUBSTANCE", 4, 12], ["cholesterol", "SIMPLE_CHEMICAL", 51, 62], ["cancer", "CANCER", 75, 81], ["reducing high cholesterol", "PROBLEM", 37, 62], ["cancer", "PROBLEM", 75, 81], ["hepatitis", "PROBLEM", 86, 95], ["inhibiting pathogen microorganisms' growth", "PROBLEM", 101, 143], ["cancer", "OBSERVATION", 75, 81], ["hepatitis", "OBSERVATION", 86, 95]]], ["Roselle's red calyces are processed to juice and tea, or incorporated in confectionary (e.g., chocolate) and dairy products as natural flavoring, and coloring agents.", [["red calyces", "ANATOMY", 10, 21], ["juice", "ANATOMY", 39, 44], ["tea", "ANATOMY", 49, 52], ["red calyces", "MULTI-TISSUE_STRUCTURE", 10, 21], ["juice", "ORGANISM_SUBSTANCE", 39, 44], ["tea", "ORGANISM_SUBDIVISION", 49, 52], ["chocolate", "ORGANISM_SUBDIVISION", 94, 103], ["dairy products", "TREATMENT", 109, 123], ["natural flavoring", "TREATMENT", 127, 144]]], ["The calyces remain as the primary by-product and provide natural antioxidants and odorants [6] [7] [8] .IntroductionFood and plant bioactives are nowadays very important in supporting the immune system within the COVID-19 pandemic era [9] .", [["calyces", "ANATOMY", 4, 11], ["calyces", "ORGAN", 4, 11], ["[6] [7] [8]", "SIMPLE_CHEMICAL", 91, 102], ["natural antioxidants", "TREATMENT", 57, 77]]], ["Roselle calyces contain bioactive compounds that are useful Different letters (a, b, c) in the same column indicate statistical differences (p < 0.05).FTIRThe FTIR spectra of all the DESs studied were shown in Figure 1 .", [["calyces", "ANATOMY", 8, 15], ["Roselle calyces", "MULTI-TISSUE_STRUCTURE", 0, 15], ["bioactive compounds", "OBSERVATION", 24, 43]]], ["The peaks at 2800 and 2650 cm \u22121 (Figure 1a) were assigned to C-H stretching frequencies associated with formic acid and sodium acetate, respectively.", [["C-H", "CHEMICAL", 62, 65], ["formic acid", "CHEMICAL", 105, 116], ["sodium acetate", "CHEMICAL", 121, 135], ["C-H", "CHEMICAL", 62, 65], ["formic acid", "CHEMICAL", 105, 116], ["sodium acetate", "CHEMICAL", 121, 135], ["C-H", "SIMPLE_CHEMICAL", 62, 65], ["formic acid", "SIMPLE_CHEMICAL", 105, 116], ["sodium acetate", "SIMPLE_CHEMICAL", 121, 135], ["The peaks", "TEST", 0, 9], ["C-H stretching frequencies", "PROBLEM", 62, 88], ["formic acid and sodium acetate", "TREATMENT", 105, 135], ["peaks", "OBSERVATION_MODIFIER", 4, 9]]], ["The frequencies at 1650 and 1550 cm \u22121 were related to C=O of formic acid and sodium acetate, respectively.", [["formic acid", "CHEMICAL", 62, 73], ["sodium acetate", "CHEMICAL", 78, 92], ["C=O", "CHEMICAL", 55, 58], ["formic acid", "CHEMICAL", 62, 73], ["sodium acetate", "CHEMICAL", 78, 92], ["C=O", "SIMPLE_CHEMICAL", 55, 58], ["formic acid", "SIMPLE_CHEMICAL", 62, 73], ["sodium acetate", "SIMPLE_CHEMICAL", 78, 92], ["formic acid", "TREATMENT", 62, 73], ["sodium acetate", "TREATMENT", 78, 92]]], ["The stretching of C-O at 1350 cm \u22121 , CH bending at 1250 and 1000 cm \u22121 and stretching of C-C at 900 cm \u22121 were used to recognize sodium acetate.", [["C-O", "CHEMICAL", 18, 21], ["sodium acetate", "CHEMICAL", 130, 144], ["C-O", "CHEMICAL", 18, 21], ["CH", "CHEMICAL", 38, 40], ["C-C", "CHEMICAL", 90, 93], ["sodium acetate", "CHEMICAL", 130, 144], ["C-O", "SIMPLE_CHEMICAL", 18, 21], ["C-C", "SIMPLE_CHEMICAL", 90, 93], ["sodium acetate", "SIMPLE_CHEMICAL", 130, 144], ["sodium acetate", "TREATMENT", 130, 144]]], ["From spectroscopy data, it can be assumed that the strong COOH...COOH bonds in sodium acetate and formic acid were broken down during the formation of sodium acetate and formic acid mixture to produce new strong intramolecular COOH bonds.", [["sodium acetate", "CHEMICAL", 79, 93], ["formic acid", "CHEMICAL", 98, 109], ["sodium acetate", "CHEMICAL", 151, 165], ["formic acid", "CHEMICAL", 170, 181], ["COOH", "CHEMICAL", 58, 62], ["COOH", "CHEMICAL", 65, 69], ["sodium acetate", "CHEMICAL", 79, 93], ["formic acid", "CHEMICAL", 98, 109], ["sodium acetate", "CHEMICAL", 151, 165], ["formic acid", "CHEMICAL", 170, 181], ["COOH", "CHEMICAL", 227, 231], ["sodium acetate", "SIMPLE_CHEMICAL", 79, 93], ["formic acid", "SIMPLE_CHEMICAL", 98, 109], ["sodium acetate", "SIMPLE_CHEMICAL", 151, 165], ["formic acid", "SIMPLE_CHEMICAL", 170, 181], ["intramolecular COOH bonds", "SIMPLE_CHEMICAL", 212, 237], ["COOH", "PROTEIN", 58, 62], ["spectroscopy data", "TEST", 5, 22], ["sodium acetate", "TREATMENT", 79, 93], ["formic acid", "TEST", 98, 109], ["sodium acetate", "TREATMENT", 151, 165], ["formic acid mixture", "TREATMENT", 170, 189], ["new strong intramolecular COOH bonds", "PROBLEM", 201, 237], ["bonds", "OBSERVATION_MODIFIER", 70, 75], ["new", "OBSERVATION_MODIFIER", 201, 204], ["strong", "OBSERVATION_MODIFIER", 205, 211], ["intramolecular", "OBSERVATION", 212, 226], ["COOH bonds", "OBSERVATION", 227, 237]]], ["This explains the low melting point and high viscosity of the pure SAFA 0 [35] .FTIRMolecules 2020, 25ViscosityThe DESs prepared in molar and molarity ratios were encoded as SAFA0 and SAFAm, respectively.", [["SAFA", "CHEMICAL", 67, 71], ["SAFA0", "PROTEIN", 174, 179], ["SAFAm", "PROTEIN", 184, 189], ["the low melting point", "PROBLEM", 14, 35], ["FTIRMolecules", "TEST", 80, 93], ["The DESs", "TREATMENT", 111, 119], ["molarity ratios", "TEST", 142, 157], ["low melting", "OBSERVATION_MODIFIER", 18, 29], ["high viscosity", "OBSERVATION_MODIFIER", 40, 54]]], ["Each DES was characterized by high viscosity ranged between 6.15 and 3651.6 mPa.s ( Table 1 ).", [["DES", "CHEMICAL", 5, 8], ["DES", "CHEMICAL", 5, 8], ["high viscosity", "OBSERVATION_MODIFIER", 30, 44]]], ["The presence of carboxyl groups and alkyl chains causes extremely high viscosity [35, 50] .", [["alkyl", "CHEMICAL", 36, 41], ["carboxyl", "CHEMICAL", 16, 24], ["alkyl chains", "SIMPLE_CHEMICAL", 36, 48], ["carboxyl groups and alkyl chains", "TREATMENT", 16, 48], ["extremely high viscosity", "PROBLEM", 56, 80], ["carboxyl groups", "OBSERVATION", 16, 31], ["alkyl chains", "OBSERVATION", 36, 48], ["high viscosity", "OBSERVATION_MODIFIER", 66, 80]]], ["The pure SAFA0 (0% water content) was semi-solid at room temperature and displayed an extremely high viscosity of 3651.6 mPa.s.", [["SAFA0", "CHEMICAL", 9, 14], ["SAFA0", "CHEMICAL", 9, 14], ["SAFA0", "SIMPLE_CHEMICAL", 9, 14], ["The pure SAFA0", "TEST", 0, 14], ["high viscosity", "OBSERVATION_MODIFIER", 96, 110]]], ["This high viscosity is associated with the H bonding network generated by the combination of sodium acetate and formic acid in eutectic terms.", [["sodium acetate", "CHEMICAL", 93, 107], ["formic acid", "CHEMICAL", 112, 123], ["H", "CHEMICAL", 43, 44], ["sodium acetate", "CHEMICAL", 93, 107], ["formic acid", "CHEMICAL", 112, 123], ["sodium acetate", "SIMPLE_CHEMICAL", 93, 107], ["formic acid", "SIMPLE_CHEMICAL", 112, 123], ["This high viscosity", "PROBLEM", 0, 19], ["sodium acetate", "TREATMENT", 93, 107], ["formic acid in eutectic terms", "TREATMENT", 112, 141], ["high viscosity", "OBSERVATION_MODIFIER", 5, 19]]], ["The addition of water decreased DES viscosity.", [["DES", "CHEMICAL", 32, 35], ["DES", "CHEMICAL", 32, 35], ["water", "SIMPLE_CHEMICAL", 16, 21], ["DES", "SIMPLE_CHEMICAL", 32, 35], ["water decreased DES viscosity", "TREATMENT", 16, 45], ["water decreased", "OBSERVATION", 16, 31]]], ["The application of water in DESs has been reported to weaken and disintegrate the DESs nanostructure [35, 40] .", [["DESs", "CHEMICAL", 28, 32], ["water", "SIMPLE_CHEMICAL", 19, 24], ["The application of water in DESs", "TREATMENT", 0, 32]]], ["In the present study, the application of water decreased the viscosity to 61.6 mPa.s at 20% (v/v), 17.36 mPa.s at 40% (v/v), 10.81 mPa.s at 60% (v/v) and 7.66 mPa.s at 80% (v/v).", [["water", "SIMPLE_CHEMICAL", 41, 46], ["mPa.s", "TEST", 79, 84], ["v/v", "TEST", 93, 96], ["mPa.s", "TEST", 105, 110], ["v/v", "TEST", 119, 122], ["mPa.s", "TEST", 131, 136], ["v/v", "TEST", 145, 148], ["mPa.s", "TEST", 159, 164]]], ["The lowest viscosity was recorded in the DES prepared in molarity ratio (SAFAm), suggesting that it contained more water.", [["DES", "CHEMICAL", 41, 44], ["DES", "CHEMICAL", 41, 44], ["molarity", "SIMPLE_CHEMICAL", 57, 65], ["SAFAm", "SIMPLE_CHEMICAL", 73, 78], ["the DES", "TREATMENT", 37, 44], ["lowest", "OBSERVATION_MODIFIER", 4, 10], ["viscosity", "OBSERVATION_MODIFIER", 11, 20]]], ["Therefore, the interaction between sodium acetate and formic acid might be the lowest since high water concentration in DESs reduces the intermolecular and intramolecular reactions between the components constituting DESs [39, 40, 51] .", [["sodium acetate", "CHEMICAL", 35, 49], ["formic acid", "CHEMICAL", 54, 65], ["DESs", "CHEMICAL", 120, 124], ["sodium acetate", "CHEMICAL", 35, 49], ["formic acid", "CHEMICAL", 54, 65], ["sodium acetate", "SIMPLE_CHEMICAL", 35, 49], ["formic acid", "SIMPLE_CHEMICAL", 54, 65], ["water", "SIMPLE_CHEMICAL", 97, 102], ["DESs", "SIMPLE_CHEMICAL", 120, 124], ["sodium acetate", "TREATMENT", 35, 49], ["formic acid", "TREATMENT", 54, 65], ["high water concentration in DESs", "TREATMENT", 92, 124], ["the intermolecular and intramolecular reactions", "PROBLEM", 133, 180], ["intramolecular reactions", "OBSERVATION", 156, 180]]], ["The peaks at 2800 and 2650 cm \u22121 (Figure 1a) were assigned to C-H stretching frequencies associated with formic acid and sodium acetate, respectively.", [["C-H", "CHEMICAL", 62, 65], ["formic acid", "CHEMICAL", 105, 116], ["sodium acetate", "CHEMICAL", 121, 135], ["C-H", "CHEMICAL", 62, 65], ["formic acid", "CHEMICAL", 105, 116], ["sodium acetate", "CHEMICAL", 121, 135], ["C-H", "SIMPLE_CHEMICAL", 62, 65], ["formic acid", "SIMPLE_CHEMICAL", 105, 116], ["sodium acetate", "SIMPLE_CHEMICAL", 121, 135], ["The peaks", "TEST", 0, 9], ["C-H stretching frequencies", "PROBLEM", 62, 88], ["formic acid and sodium acetate", "TREATMENT", 105, 135], ["peaks", "OBSERVATION_MODIFIER", 4, 9]]], ["The frequencies at 1650 and 1550 cm \u22121 were related to C=O of formic acid and sodium acetate, respectively.", [["formic acid", "CHEMICAL", 62, 73], ["sodium acetate", "CHEMICAL", 78, 92], ["C=O", "CHEMICAL", 55, 58], ["formic acid", "CHEMICAL", 62, 73], ["sodium acetate", "CHEMICAL", 78, 92], ["C=O", "SIMPLE_CHEMICAL", 55, 58], ["formic acid", "SIMPLE_CHEMICAL", 62, 73], ["sodium acetate", "SIMPLE_CHEMICAL", 78, 92], ["formic acid", "TREATMENT", 62, 73], ["sodium acetate", "TREATMENT", 78, 92]]], ["The stretching of C-O at 1350 cm \u22121 , CH bending at 1250 and 1000 cm \u22121 and stretching of C-C at 900 cm \u22121 were used to recognize sodium acetate.", [["C-O", "CHEMICAL", 18, 21], ["sodium acetate", "CHEMICAL", 130, 144], ["C-O", "CHEMICAL", 18, 21], ["CH", "CHEMICAL", 38, 40], ["C-C", "CHEMICAL", 90, 93], ["sodium acetate", "CHEMICAL", 130, 144], ["C-O", "SIMPLE_CHEMICAL", 18, 21], ["C-C", "SIMPLE_CHEMICAL", 90, 93], ["sodium acetate", "SIMPLE_CHEMICAL", 130, 144], ["sodium acetate", "TREATMENT", 130, 144]]], ["From spectroscopy data, it can be assumed that the strong COOH...COOH bonds in sodium acetate and formic acid were broken down during the formation of sodium acetate and formic acid mixture to produce new strong intramolecular COOH bonds.", [["sodium acetate", "CHEMICAL", 79, 93], ["formic acid", "CHEMICAL", 98, 109], ["sodium acetate", "CHEMICAL", 151, 165], ["formic acid", "CHEMICAL", 170, 181], ["COOH", "CHEMICAL", 58, 62], ["COOH", "CHEMICAL", 65, 69], ["sodium acetate", "CHEMICAL", 79, 93], ["formic acid", "CHEMICAL", 98, 109], ["sodium acetate", "CHEMICAL", 151, 165], ["formic acid", "CHEMICAL", 170, 181], ["COOH", "CHEMICAL", 227, 231], ["sodium acetate", "SIMPLE_CHEMICAL", 79, 93], ["formic acid", "SIMPLE_CHEMICAL", 98, 109], ["sodium acetate", "SIMPLE_CHEMICAL", 151, 165], ["formic acid", "SIMPLE_CHEMICAL", 170, 181], ["intramolecular COOH bonds", "SIMPLE_CHEMICAL", 212, 237], ["COOH", "PROTEIN", 58, 62], ["spectroscopy data", "TEST", 5, 22], ["sodium acetate", "TREATMENT", 79, 93], ["formic acid", "TEST", 98, 109], ["sodium acetate", "TREATMENT", 151, 165], ["formic acid mixture", "TREATMENT", 170, 189], ["new strong intramolecular COOH bonds", "PROBLEM", 201, 237], ["bonds", "OBSERVATION_MODIFIER", 70, 75], ["new", "OBSERVATION_MODIFIER", 201, 204], ["strong", "OBSERVATION_MODIFIER", 205, 211], ["intramolecular", "OBSERVATION", 212, 226], ["COOH bonds", "OBSERVATION", 227, 237]]], ["This explains the low melting point and high viscosity of the pure SAFA0 [35] .", [["SAFA0 [35]", "CHEMICAL", 67, 77], ["the low melting point", "PROBLEM", 14, 35], ["low melting", "OBSERVATION_MODIFIER", 18, 29], ["high viscosity", "OBSERVATION_MODIFIER", 40, 54]]], ["After the addition of water, the stronger bonding between HBD and HBA was affected and weakened with the appearance of O-H ( Figure 1 ).", [["HBA", "CHEMICAL", 66, 69], ["O-H", "CHEMICAL", 119, 122], ["HBA", "CHEMICAL", 66, 69], ["O-H", "CHEMICAL", 119, 122], ["water", "SIMPLE_CHEMICAL", 22, 27], ["HBD", "GENE_OR_GENE_PRODUCT", 58, 61], ["HBA", "SIMPLE_CHEMICAL", 66, 69], ["O-H", "SIMPLE_CHEMICAL", 119, 122], ["HBD", "PROTEIN", 58, 61], ["water", "TREATMENT", 22, 27], ["HBA", "TEST", 66, 69]]], ["The absence of O-H in SAFA0 suggested that the mixture was too anhydrous.", [["O-H", "CHEMICAL", 15, 18], ["SAFA0", "CHEMICAL", 22, 27], ["O-H", "CHEMICAL", 15, 18], ["O-H", "SIMPLE_CHEMICAL", 15, 18], ["SAFA0", "SIMPLE_CHEMICAL", 22, 27], ["too anhydrous", "PROBLEM", 59, 72]]], ["The stretching of O-H at 3400 cm \u22121 appeared progressively in DESs, got higher as water content increased and became stronger in SAFAm (Figure 1b-e).", [["O-H", "CHEMICAL", 18, 21], ["O-H", "CHEMICAL", 18, 21], ["O-H", "SIMPLE_CHEMICAL", 18, 21], ["water", "SIMPLE_CHEMICAL", 82, 87], ["stretching", "OBSERVATION_MODIFIER", 4, 14], ["stronger", "OBSERVATION_MODIFIER", 117, 125]]], ["Similar phenomena have been reported in choline chloride and oxalic acid, as well as in choline chloride and glycol-based DESs, and might be due to alternative possibilities for H bonding in DES upon the introduction of water [35, 40] .", [["choline chloride", "CHEMICAL", 40, 56], ["oxalic acid", "CHEMICAL", 61, 72], ["choline chloride", "CHEMICAL", 88, 104], ["H", "CHEMICAL", 178, 179], ["DES", "CHEMICAL", 191, 194], ["choline chloride", "CHEMICAL", 40, 56], ["oxalic acid", "CHEMICAL", 61, 72], ["choline chloride", "CHEMICAL", 88, 104], ["glycol", "CHEMICAL", 109, 115], ["H", "CHEMICAL", 178, 179], ["DES", "CHEMICAL", 191, 194], ["choline chloride", "SIMPLE_CHEMICAL", 40, 56], ["oxalic acid", "SIMPLE_CHEMICAL", 61, 72], ["choline chloride", "SIMPLE_CHEMICAL", 88, 104], ["glycol-based DESs", "SIMPLE_CHEMICAL", 109, 126], ["H", "SIMPLE_CHEMICAL", 178, 179], ["DES", "SIMPLE_CHEMICAL", 191, 194], ["Similar phenomena", "PROBLEM", 0, 17], ["choline chloride", "TREATMENT", 40, 56], ["oxalic acid", "TREATMENT", 61, 72], ["choline chloride", "TREATMENT", 88, 104], ["glycol-based DESs", "TREATMENT", 109, 126], ["phenomena", "OBSERVATION", 8, 17]]], ["Hammond et al. (2017) have revealed that the introduction of a small quantity of water affected immensely the nanostructure of DES.", [["DES", "CHEMICAL", 127, 130], ["DES", "CHEMICAL", 127, 130], ["small", "OBSERVATION_MODIFIER", 63, 68], ["quantity", "OBSERVATION_MODIFIER", 69, 77], ["nanostructure", "OBSERVATION_MODIFIER", 110, 123], ["DES", "OBSERVATION", 127, 130]]], ["However, FTIR analysis showed that the shape of spectra was kept after addition of 80% water.", [["FTIR analysis", "TEST", 9, 22], ["80% water", "TREATMENT", 83, 92], ["shape", "OBSERVATION_MODIFIER", 39, 44]]], ["This indicates the tolerance of DES structure [35, 52] .", [["DES", "CHEMICAL", 32, 35], ["DES", "CHEMICAL", 32, 35]]], ["Nonetheless, C-H stretching weakened upon addition of water and disappeared completely in SAFAm.Evaluation of DESs EfficiencyIn the present study, sodium acetate:formic acid (1:2 molar ratio) was employed as a natural DES and coded as SAFA0 to extract polyphenolic compounds, especially anthocyanins and to evaluate the antioxidant activity of Roselle calyces.", [["calyces", "ANATOMY", 352, 359], ["C-H", "CHEMICAL", 13, 16], ["SAFAm", "CHEMICAL", 90, 95], ["sodium acetate", "CHEMICAL", 147, 161], ["formic acid", "CHEMICAL", 162, 173], ["DES", "CHEMICAL", 218, 221], ["anthocyanins", "CHEMICAL", 287, 299], ["C-H", "CHEMICAL", 13, 16], ["sodium acetate", "CHEMICAL", 147, 161], ["formic acid", "CHEMICAL", 162, 173], ["DES", "CHEMICAL", 218, 221], ["polyphenolic", "CHEMICAL", 252, 264], ["anthocyanins", "CHEMICAL", 287, 299], ["C-H", "SIMPLE_CHEMICAL", 13, 16], ["water", "SIMPLE_CHEMICAL", 54, 59], ["sodium acetate", "SIMPLE_CHEMICAL", 147, 161], ["formic acid", "SIMPLE_CHEMICAL", 162, 173], ["SAFA0", "SIMPLE_CHEMICAL", 235, 240], ["anthocyanins", "SIMPLE_CHEMICAL", 287, 299], ["Roselle calyces", "MULTI-TISSUE_STRUCTURE", 344, 359], ["Evaluation", "TEST", 96, 106], ["DESs EfficiencyIn", "TREATMENT", 110, 127], ["the present study", "TEST", 128, 145], ["sodium acetate", "TREATMENT", 147, 161], ["formic acid (1:2 molar ratio", "TREATMENT", 162, 190], ["a natural DES", "TREATMENT", 208, 221], ["polyphenolic compounds", "PROBLEM", 252, 274], ["anthocyanins", "TREATMENT", 287, 299], ["polyphenolic compounds", "OBSERVATION", 252, 274]]], ["The major roadblock of DESs which limits their applications and efficiency for phytochemicals is the high viscosity.", [["DESs", "TREATMENT", 23, 27], ["the high viscosity", "PROBLEM", 97, 115], ["major", "OBSERVATION_MODIFIER", 4, 9], ["roadblock", "OBSERVATION_MODIFIER", 10, 19], ["DESs", "OBSERVATION", 23, 27], ["high viscosity", "OBSERVATION_MODIFIER", 101, 115]]], ["This fact reduces consequently the mass transfer and solubility of phenolic compounds [42, 53, 54] .", [["phenolic compounds", "SIMPLE_CHEMICAL", 67, 85], ["the mass", "PROBLEM", 31, 39], ["mass", "OBSERVATION", 35, 39], ["phenolic compounds", "OBSERVATION", 67, 85]]], ["To alleviate this constraint, DES sodium acetate:formic acid was diluted with 20, 40, 60 and 80% of water and encoded SAFA20, SAFA40, SAFA60, and SAFA80, respectively.", [["DES", "CHEMICAL", 30, 33], ["sodium acetate", "CHEMICAL", 34, 48], ["formic acid", "CHEMICAL", 49, 60], ["DES sodium acetate", "CHEMICAL", 30, 48], ["formic acid", "CHEMICAL", 49, 60], ["DES sodium acetate", "SIMPLE_CHEMICAL", 30, 48], ["formic acid", "SIMPLE_CHEMICAL", 49, 60], ["SAFA20", "GENE_OR_GENE_PRODUCT", 118, 124], ["SAFA40", "GENE_OR_GENE_PRODUCT", 126, 132], ["SAFA60", "GENE_OR_GENE_PRODUCT", 134, 140], ["SAFA20", "PROTEIN", 118, 124], ["SAFA40", "PROTEIN", 126, 132], ["SAFA60", "PROTEIN", 134, 140], ["SAFA80", "PROTEIN", 146, 152], ["DES sodium acetate", "TREATMENT", 30, 48], ["formic acid", "TREATMENT", 49, 60], ["SAFA40", "TEST", 126, 132], ["SAFA60", "TEST", 134, 140]]], ["Furthermore, another sodium acetate:formic acid-based DES was designed in molarity ratio 1:2 (SAFAm), following the studies by the authors in [55] , who have suggested the DESs betaine:tartaric acid and betaine:citric acid prepared in molarity ratio.", [["sodium acetate", "CHEMICAL", 21, 35], ["formic acid", "CHEMICAL", 36, 47], ["DES", "CHEMICAL", 54, 57], ["betaine", "CHEMICAL", 177, 184], ["tartaric acid", "CHEMICAL", 185, 198], ["betaine", "CHEMICAL", 203, 210], ["citric acid", "CHEMICAL", 211, 222], ["sodium acetate", "CHEMICAL", 21, 35], ["formic acid", "CHEMICAL", 36, 47], ["DES", "CHEMICAL", 54, 57], ["tartaric acid", "CHEMICAL", 185, 198], ["betaine", "CHEMICAL", 203, 210], ["citric acid", "CHEMICAL", 211, 222], ["sodium acetate", "SIMPLE_CHEMICAL", 21, 35], ["formic acid", "SIMPLE_CHEMICAL", 36, 47], ["DES", "SIMPLE_CHEMICAL", 54, 57], ["SAFAm", "SIMPLE_CHEMICAL", 94, 99], ["betaine", "SIMPLE_CHEMICAL", 177, 184], ["tartaric acid", "SIMPLE_CHEMICAL", 185, 198], ["betaine", "SIMPLE_CHEMICAL", 203, 210], ["citric acid", "SIMPLE_CHEMICAL", 211, 222], ["molarity", "SIMPLE_CHEMICAL", 235, 243], ["another sodium acetate", "TREATMENT", 13, 35], ["formic acid", "TEST", 36, 47], ["the studies", "TEST", 112, 123], ["the DESs betaine", "TREATMENT", 168, 184], ["tartaric acid", "TREATMENT", 185, 198], ["citric acid", "TREATMENT", 211, 222]]], ["In addition, for the purposes of comparison, distilled water, 70% ethanol and 80% methanol were used After the addition of water, the stronger bonding between HBD and HBA was affected and weakened with the appearance of O-H ( Figure 1 ).", [["ethanol", "CHEMICAL", 66, 73], ["methanol", "CHEMICAL", 82, 90], ["HBA", "CHEMICAL", 167, 170], ["O-H", "CHEMICAL", 220, 223], ["ethanol", "CHEMICAL", 66, 73], ["methanol", "CHEMICAL", 82, 90], ["HBA", "CHEMICAL", 167, 170], ["O-H", "CHEMICAL", 220, 223], ["ethanol", "SIMPLE_CHEMICAL", 66, 73], ["methanol", "SIMPLE_CHEMICAL", 82, 90], ["water", "SIMPLE_CHEMICAL", 123, 128], ["HBD", "GENE_OR_GENE_PRODUCT", 159, 162], ["HBA", "SIMPLE_CHEMICAL", 167, 170], ["O-H", "SIMPLE_CHEMICAL", 220, 223], ["HBD", "PROTEIN", 159, 162], ["80% methanol", "TREATMENT", 78, 90], ["water", "TREATMENT", 123, 128], ["HBA", "TEST", 167, 170]]], ["The absence of O-H in SAFA 0 suggested that the mixture was too anhydrous.", [["O-H", "CHEMICAL", 15, 18], ["SAFA", "CHEMICAL", 22, 26], ["O-H", "CHEMICAL", 15, 18], ["SAFA 0", "CHEMICAL", 22, 28], ["O-H", "SIMPLE_CHEMICAL", 15, 18], ["SAFA 0", "SIMPLE_CHEMICAL", 22, 28], ["too anhydrous", "PROBLEM", 60, 73]]], ["The stretching of O-H at 3400 cm \u22121 appeared progressively in DESs, got higher as water content increased and became stronger in SAFA m (Figure 1b-e).", [["O-H", "CHEMICAL", 18, 21], ["O-H", "CHEMICAL", 18, 21], ["O-H", "SIMPLE_CHEMICAL", 18, 21], ["water", "SIMPLE_CHEMICAL", 82, 87], ["stretching", "OBSERVATION_MODIFIER", 4, 14]]], ["Similar phenomena have been reported in choline chloride and oxalic acid, as well as in choline chloride and glycol-based DESs, and might be due to alternative possibilities for H bonding in DES upon the introduction of water [35, 40] .", [["choline chloride", "CHEMICAL", 40, 56], ["oxalic acid", "CHEMICAL", 61, 72], ["choline chloride", "CHEMICAL", 88, 104], ["H", "CHEMICAL", 178, 179], ["DES", "CHEMICAL", 191, 194], ["choline chloride", "CHEMICAL", 40, 56], ["oxalic acid", "CHEMICAL", 61, 72], ["choline chloride", "CHEMICAL", 88, 104], ["glycol", "CHEMICAL", 109, 115], ["H", "CHEMICAL", 178, 179], ["DES", "CHEMICAL", 191, 194], ["choline chloride", "SIMPLE_CHEMICAL", 40, 56], ["oxalic acid", "SIMPLE_CHEMICAL", 61, 72], ["choline chloride", "SIMPLE_CHEMICAL", 88, 104], ["glycol-based DESs", "SIMPLE_CHEMICAL", 109, 126], ["H", "SIMPLE_CHEMICAL", 178, 179], ["DES", "SIMPLE_CHEMICAL", 191, 194], ["Similar phenomena", "PROBLEM", 0, 17], ["choline chloride", "TREATMENT", 40, 56], ["oxalic acid", "TREATMENT", 61, 72], ["choline chloride", "TREATMENT", 88, 104], ["glycol-based DESs", "TREATMENT", 109, 126], ["phenomena", "OBSERVATION", 8, 17]]], ["Hammond et al. (2017) have revealed that the introduction of a small quantity of water affected immensely the nanostructure of DES.", [["DES", "CHEMICAL", 127, 130], ["DES", "CHEMICAL", 127, 130], ["small", "OBSERVATION_MODIFIER", 63, 68], ["quantity", "OBSERVATION_MODIFIER", 69, 77], ["nanostructure", "OBSERVATION_MODIFIER", 110, 123], ["DES", "OBSERVATION", 127, 130]]], ["However, FTIR analysis showed that the shape of spectra was kept after addition of 80% water.", [["FTIR analysis", "TEST", 9, 22], ["80% water", "TREATMENT", 83, 92], ["shape", "OBSERVATION_MODIFIER", 39, 44]]], ["This indicates the tolerance of DES structure [35, 52] .", [["DES", "CHEMICAL", 32, 35], ["DES", "CHEMICAL", 32, 35]]], ["Nonetheless, C-H stretching weakened upon addition of water and disappeared completely in SAFA m .Evaluation of DESs EfficiencyIn the present study, sodium acetate:formic acid (1:2 molar ratio) was employed as a natural DES and coded as SAFA 0 to extract polyphenolic compounds, especially anthocyanins and to evaluate the antioxidant activity of Roselle calyces.", [["calyces", "ANATOMY", 355, 362], ["C-H", "CHEMICAL", 13, 16], ["sodium acetate", "CHEMICAL", 149, 163], ["formic acid", "CHEMICAL", 164, 175], ["DES", "CHEMICAL", 220, 223], ["anthocyanins", "CHEMICAL", 290, 302], ["C-H", "CHEMICAL", 13, 16], ["sodium acetate", "CHEMICAL", 149, 163], ["formic acid", "CHEMICAL", 164, 175], ["DES", "CHEMICAL", 220, 223], ["polyphenolic", "CHEMICAL", 255, 267], ["anthocyanins", "CHEMICAL", 290, 302], ["C-H", "SIMPLE_CHEMICAL", 13, 16], ["water", "SIMPLE_CHEMICAL", 54, 59], ["SAFA m", "GENE_OR_GENE_PRODUCT", 90, 96], ["sodium acetate", "SIMPLE_CHEMICAL", 149, 163], ["formic acid", "SIMPLE_CHEMICAL", 164, 175], ["anthocyanins", "SIMPLE_CHEMICAL", 290, 302], ["Roselle calyces", "MULTI-TISSUE_STRUCTURE", 347, 362], ["Evaluation", "TEST", 98, 108], ["DESs EfficiencyIn", "TREATMENT", 112, 129], ["the present study", "TEST", 130, 147], ["sodium acetate", "TREATMENT", 149, 163], ["formic acid (1:2 molar ratio", "TREATMENT", 164, 192], ["a natural DES", "TREATMENT", 210, 223], ["anthocyanins", "TREATMENT", 290, 302], ["polyphenolic compounds", "OBSERVATION", 255, 277]]], ["The major roadblock of DESs which limits their applications and efficiency for phytochemicals is the high viscosity.", [["DESs", "TREATMENT", 23, 27], ["the high viscosity", "PROBLEM", 97, 115], ["major", "OBSERVATION_MODIFIER", 4, 9], ["roadblock", "OBSERVATION_MODIFIER", 10, 19], ["DESs", "OBSERVATION", 23, 27], ["high viscosity", "OBSERVATION_MODIFIER", 101, 115]]], ["This fact reduces consequently the mass transfer and solubility of phenolic compounds [42, 53, 54] .", [["phenolic compounds", "SIMPLE_CHEMICAL", 67, 85], ["the mass", "PROBLEM", 31, 39], ["mass", "OBSERVATION", 35, 39], ["phenolic compounds", "OBSERVATION", 67, 85]]], ["To alleviate this constraint, DES sodium acetate:formic acid was diluted with 20, 40, 60 and 80% of water and encoded SAFA 20 , SAFA 40 , SAFA 60 , and SAFA 80 , respectively.", [["DES", "CHEMICAL", 30, 33], ["sodium acetate", "CHEMICAL", 34, 48], ["formic acid", "CHEMICAL", 49, 60], ["DES sodium acetate", "CHEMICAL", 30, 48], ["formic acid", "CHEMICAL", 49, 60], ["DES sodium acetate", "SIMPLE_CHEMICAL", 30, 48], ["formic acid", "SIMPLE_CHEMICAL", 49, 60], ["DES sodium acetate", "TREATMENT", 30, 48], ["formic acid", "TREATMENT", 49, 60], ["SAFA", "TEST", 118, 122], ["SAFA", "TEST", 128, 132], ["SAFA", "TEST", 138, 142], ["SAFA", "TEST", 152, 156]]], ["Furthermore, another sodium acetate:formic acid-based DES was designed in molarity ratio 1:2 (SAFA m ), following the studies by the authors in [55] , who have suggested the DESs betaine:tartaric acid and betaine:citric acid prepared in molarity ratio.", [["sodium acetate", "CHEMICAL", 21, 35], ["formic acid", "CHEMICAL", 36, 47], ["DES", "CHEMICAL", 54, 57], ["betaine", "CHEMICAL", 179, 186], ["tartaric acid", "CHEMICAL", 187, 200], ["betaine", "CHEMICAL", 205, 212], ["citric acid", "CHEMICAL", 213, 224], ["sodium acetate", "CHEMICAL", 21, 35], ["formic acid", "CHEMICAL", 36, 47], ["DES", "CHEMICAL", 54, 57], ["tartaric acid", "CHEMICAL", 187, 200], ["betaine", "CHEMICAL", 205, 212], ["citric acid", "CHEMICAL", 213, 224], ["sodium acetate", "SIMPLE_CHEMICAL", 21, 35], ["formic acid", "SIMPLE_CHEMICAL", 36, 47], ["DES", "SIMPLE_CHEMICAL", 54, 57], ["betaine", "SIMPLE_CHEMICAL", 179, 186], ["tartaric acid", "SIMPLE_CHEMICAL", 187, 200], ["betaine", "SIMPLE_CHEMICAL", 205, 212], ["citric acid", "SIMPLE_CHEMICAL", 213, 224], ["molarity", "SIMPLE_CHEMICAL", 237, 245], ["another sodium acetate", "TREATMENT", 13, 35], ["formic acid", "TEST", 36, 47], ["the studies", "TEST", 114, 125], ["the DESs betaine", "TREATMENT", 170, 186], ["tartaric acid", "TREATMENT", 187, 200], ["citric acid", "TREATMENT", 213, 224]]], ["In addition, for the purposes of comparison, distilled water, 70% ethanol and 80% methanol were used as conventional solvents.", [["ethanol", "CHEMICAL", 66, 73], ["methanol", "CHEMICAL", 82, 90], ["ethanol", "CHEMICAL", 66, 73], ["methanol", "CHEMICAL", 82, 90], ["ethanol", "SIMPLE_CHEMICAL", 66, 73], ["methanol", "SIMPLE_CHEMICAL", 82, 90], ["80% methanol", "TREATMENT", 78, 90], ["conventional solvents", "TREATMENT", 104, 125]]], ["Roselle calyces were extracted with these solvents using ultrasound.", [["calyces", "ANATOMY", 8, 15], ["Roselle calyces", "MULTI-TISSUE_STRUCTURE", 0, 15], ["these solvents", "TREATMENT", 36, 50], ["ultrasound", "TEST", 57, 67]]], ["Globally, when compared the efficiency of the solvents used in this study, the DESs were more efficient than the conventional solvents for the extraction of Roselle polyphenolics, except SAFA 0 and SAFA 20 ( Table 2 ).", [["SAFA", "CHEMICAL", 187, 191], ["DESs", "SIMPLE_CHEMICAL", 79, 83], ["Roselle", "SIMPLE_CHEMICAL", 157, 164], ["polyphenolics", "SIMPLE_CHEMICAL", 165, 178], ["the solvents", "TREATMENT", 42, 54], ["this study", "TEST", 63, 73], ["the DESs", "TREATMENT", 75, 83], ["the conventional solvents", "TREATMENT", 109, 134], ["the extraction of Roselle polyphenolics", "TREATMENT", 139, 178], ["SAFA", "TEST", 187, 191], ["SAFA", "TEST", 198, 202]]], ["The lowest results provided by SAFA 0 and SAFA 20 were due to their extremely viscosity ( Table 1 ).", [["SAFA", "TEST", 31, 35], ["SAFA", "TEST", 42, 46]]], ["The viscosity of DESs hinders the mass transfer in the extraction matrix, decreasing the extractability performance of DESs [34, 41, 44, 56] .", [["DESs", "CHEMICAL", 17, 21], ["DESs", "SIMPLE_CHEMICAL", 17, 21], ["The viscosity of DESs", "TREATMENT", 0, 21], ["the mass", "PROBLEM", 30, 38], ["the extraction matrix", "TREATMENT", 51, 72], ["viscosity", "OBSERVATION_MODIFIER", 4, 13], ["mass", "OBSERVATION", 34, 38]]], ["The highest TPC was detected with SAFA m , following SAFA 80 , SAFA 60 , SAFA 40 and SAFA 20 , respectively.", [["SAFA", "CHEMICAL", 53, 57], ["TPC", "SIMPLE_CHEMICAL", 12, 15], ["The highest TPC", "TEST", 0, 15], ["SAFA", "TEST", 53, 57], ["SAFA", "TEST", 63, 67], ["SAFA", "TEST", 73, 77], ["SAFA", "TEST", 85, 89], ["highest", "OBSERVATION_MODIFIER", 4, 11], ["TPC", "OBSERVATION", 12, 15]]], ["The TPC obtained with SAFA m was 43.11, 43.68 and 43.68% higher than the values obtained with distilled water, 70% ethanol and 80% methanol, respectively.", [["ethanol", "CHEMICAL", 115, 122], ["methanol", "CHEMICAL", 131, 139], ["ethanol", "CHEMICAL", 115, 122], ["methanol", "CHEMICAL", 131, 139], ["TPC", "CANCER", 4, 7], ["ethanol", "SIMPLE_CHEMICAL", 115, 122], ["methanol", "SIMPLE_CHEMICAL", 131, 139], ["The TPC", "TEST", 0, 7], ["SAFA m", "TEST", 22, 28]]], ["Similar results have been figured out in rosemary, where TPC obtained with acid-based DESs was 15-18% higher than ethanol [42] .", [["TPC", "CHEMICAL", 57, 60], ["ethanol", "CHEMICAL", 114, 121], ["ethanol", "CHEMICAL", 114, 121], ["TPC", "SIMPLE_CHEMICAL", 57, 60], ["ethanol", "SIMPLE_CHEMICAL", 114, 121], ["TPC", "TEST", 57, 60], ["acid-based DESs", "TEST", 75, 90]]], ["Likewise, the highest TFC, TACN, DPPH radical scavenging and FRAP were determined with SAFA m and SAFA 80 .", [["TACN", "CHEMICAL", 27, 31], ["DPPH", "CHEMICAL", 33, 37], ["TACN", "CHEMICAL", 27, 31], ["DPPH", "CHEMICAL", 33, 37], ["TACN", "SIMPLE_CHEMICAL", 27, 31], ["DPPH", "SIMPLE_CHEMICAL", 33, 37], ["radical", "SIMPLE_CHEMICAL", 38, 45], ["FRAP", "SIMPLE_CHEMICAL", 61, 65], ["TACN", "TREATMENT", 27, 31], ["DPPH radical scavenging", "TREATMENT", 33, 56], ["FRAP", "TEST", 61, 65], ["SAFA", "TEST", 98, 102]]], ["SAFA m yielded 1.22, 3.53 and 4.99-fold higher TFC than 70% ethanol, 80% methanol and distilled water, respectively.", [["SAFA", "CHEMICAL", 0, 4], ["ethanol", "CHEMICAL", 60, 67], ["methanol", "CHEMICAL", 73, 81], ["ethanol", "CHEMICAL", 60, 67], ["methanol", "CHEMICAL", 73, 81], ["ethanol", "SIMPLE_CHEMICAL", 60, 67], ["methanol", "SIMPLE_CHEMICAL", 73, 81], ["ethanol", "TREATMENT", 60, 67]]], ["Similarly, the TFC has been well-extracted from saffron with lactic acid-based DES [57] .", [["TFC", "CHEMICAL", 15, 18], ["lactic acid", "CHEMICAL", 61, 72], ["DES", "CHEMICAL", 79, 82], ["lactic acid", "CHEMICAL", 61, 72], ["DES", "CHEMICAL", 79, 82], ["saffron", "SIMPLE_CHEMICAL", 48, 55], ["lactic acid", "SIMPLE_CHEMICAL", 61, 72], ["lactic acid", "TEST", 61, 72]]], ["However, sodium acetate:formic acid provided higher yields of TPC of Roselle when compared to the yields of citric acid:glycerol (24.79 mg GAE/g) and citric acid:ethylene glycol (36.31 mg GAE/g) [49] , except SAFA 0 .", [["sodium acetate", "CHEMICAL", 9, 23], ["formic acid", "CHEMICAL", 24, 35], ["TPC", "CHEMICAL", 62, 65], ["Roselle", "CHEMICAL", 69, 76], ["citric acid", "CHEMICAL", 108, 119], ["glycerol", "CHEMICAL", 120, 128], ["citric acid", "CHEMICAL", 150, 161], ["ethylene glycol", "CHEMICAL", 162, 177], ["sodium acetate", "CHEMICAL", 9, 23], ["formic acid", "CHEMICAL", 24, 35], ["citric acid", "CHEMICAL", 108, 119], ["glycerol", "CHEMICAL", 120, 128], ["citric acid", "CHEMICAL", 150, 161], ["ethylene glycol", "CHEMICAL", 162, 177], ["SAFA", "CHEMICAL", 209, 213], ["sodium acetate", "SIMPLE_CHEMICAL", 9, 23], ["formic acid", "SIMPLE_CHEMICAL", 24, 35], ["TPC", "SIMPLE_CHEMICAL", 62, 65], ["Roselle", "SIMPLE_CHEMICAL", 69, 76], ["citric acid", "SIMPLE_CHEMICAL", 108, 119], ["glycerol", "SIMPLE_CHEMICAL", 120, 128], ["citric acid", "SIMPLE_CHEMICAL", 150, 161], ["ethylene glycol", "SIMPLE_CHEMICAL", 162, 177], ["sodium acetate", "TREATMENT", 9, 23], ["formic acid", "TEST", 24, 35], ["TPC of Roselle", "TREATMENT", 62, 76], ["citric acid", "TREATMENT", 108, 119], ["glycerol", "TREATMENT", 120, 128], ["citric acid:ethylene glycol", "TREATMENT", 150, 177]]], ["In addition, TACN obtained with SAFA m was 1.03, 1.09 and 1.23-fold higher than 70% ethanol, distilled water, and 80% methanol, respectively.", [["SAFA", "CHEMICAL", 32, 36], ["ethanol", "CHEMICAL", 84, 91], ["methanol", "CHEMICAL", 118, 126], ["ethanol", "CHEMICAL", 84, 91], ["methanol", "CHEMICAL", 118, 126], ["TACN", "SIMPLE_CHEMICAL", 13, 17], ["SAFA m", "GENE_OR_GENE_PRODUCT", 32, 38], ["ethanol", "SIMPLE_CHEMICAL", 84, 91], ["methanol", "SIMPLE_CHEMICAL", 118, 126], ["TACN", "PROTEIN", 13, 17]]], ["Meanwhile, the values of TACN determined in this study were in accordance with the findings previously detected in Roselle with citric acid:glycerol (5.44 mg C3G/g) and citric acid:ethylene glycol (9.36 mg C3G/g) [49] .", [["citric acid", "CHEMICAL", 128, 139], ["glycerol", "CHEMICAL", 140, 148], ["citric acid", "CHEMICAL", 169, 180], ["ethylene glycol", "CHEMICAL", 181, 196], ["citric acid", "CHEMICAL", 128, 139], ["glycerol", "CHEMICAL", 140, 148], ["C3G", "CHEMICAL", 158, 161], ["citric acid", "CHEMICAL", 169, 180], ["ethylene glycol", "CHEMICAL", 181, 196], ["C3G", "CHEMICAL", 206, 209], ["TACN", "SIMPLE_CHEMICAL", 25, 29], ["citric acid", "SIMPLE_CHEMICAL", 128, 139], ["glycerol", "SIMPLE_CHEMICAL", 140, 148], ["citric acid", "SIMPLE_CHEMICAL", 169, 180], ["ethylene glycol", "SIMPLE_CHEMICAL", 181, 196], ["TACN", "PROTEIN", 25, 29], ["this study", "TEST", 44, 54], ["citric acid", "TREATMENT", 128, 139], ["glycerol", "TREATMENT", 140, 148], ["citric acid:ethylene glycol", "TREATMENT", 169, 196]]], ["The high extraction yield of SAFA m is associated with the multiple hydrogen-bonding and low viscosity.", [["SAFA", "CHEMICAL", 29, 33], ["hydrogen", "CHEMICAL", 68, 76], ["SAFA", "SIMPLE_CHEMICAL", 29, 33], ["SAFA m", "PROBLEM", 29, 35], ["the multiple hydrogen-bonding and low viscosity", "PROBLEM", 55, 102], ["high", "OBSERVATION_MODIFIER", 4, 8], ["multiple", "OBSERVATION_MODIFIER", 59, 67], ["hydrogen", "OBSERVATION", 68, 76], ["low viscosity", "OBSERVATION_MODIFIER", 89, 102]]], ["The carboxyl group (-COOH) of formic acid presented more interactions between hydrogen-bonding [37] .", [["formic acid", "CHEMICAL", 30, 41], ["carboxyl", "CHEMICAL", 4, 12], ["COOH", "CHEMICAL", 21, 25], ["formic acid", "CHEMICAL", 30, 41], ["hydrogen", "CHEMICAL", 78, 86], ["formic acid", "SIMPLE_CHEMICAL", 30, 41], ["The carboxyl group (-COOH) of formic acid", "TREATMENT", 0, 41]]], ["The high efficiency of acid-based DESs for the extraction of polyphenolics have been proved and told to due to the H-bonding interactions among DES components and the low viscosity [57] [58] [59] [60] [61] .", [["DES", "CHEMICAL", 144, 147], ["polyphenolics", "CHEMICAL", 61, 74], ["H", "CHEMICAL", 115, 116], ["DES", "CHEMICAL", 144, 147], ["[57] [58] [59] [60]", "CHEMICAL", 181, 200], ["DESs", "SIMPLE_CHEMICAL", 34, 38], ["polyphenolics", "SIMPLE_CHEMICAL", 61, 74], ["DES", "SIMPLE_CHEMICAL", 144, 147], ["58] [59] [60] [61]", "SIMPLE_CHEMICAL", 187, 205], ["acid-based DESs", "TREATMENT", 23, 38], ["the extraction of polyphenolics", "TREATMENT", 43, 74], ["high", "OBSERVATION_MODIFIER", 4, 8], ["efficiency", "OBSERVATION_MODIFIER", 9, 19]]], ["SAFA m was found to be an ideal medium for the extraction of Roselle polyphenolics, allowing a high mass transfer and solubility of anthocyanins.Model AnalysisThe responses (total anthocyanin, total phenolic compound, DPPH radical scavenging, FRAP and total flavonoid values) and the coded independent factors of experimental points were shown in Table 3 .", [["SAFA", "CHEMICAL", 0, 4], ["anthocyanins", "CHEMICAL", 132, 144], ["anthocyanin", "CHEMICAL", 180, 191], ["phenolic compound", "CHEMICAL", 199, 216], ["DPPH", "CHEMICAL", 218, 222], ["flavonoid", "CHEMICAL", 258, 267], ["anthocyanins", "CHEMICAL", 132, 144], ["anthocyanin", "CHEMICAL", 180, 191], ["DPPH", "CHEMICAL", 218, 222], ["flavonoid", "CHEMICAL", 258, 267], ["SAFA", "SIMPLE_CHEMICAL", 0, 4], ["Roselle polyphenolics", "SIMPLE_CHEMICAL", 61, 82], ["anthocyanins", "SIMPLE_CHEMICAL", 132, 144], ["anthocyanin", "SIMPLE_CHEMICAL", 180, 191], ["DPPH", "SIMPLE_CHEMICAL", 218, 222], ["FRAP", "SIMPLE_CHEMICAL", 243, 247], ["flavonoid", "SIMPLE_CHEMICAL", 258, 267], ["the extraction", "TREATMENT", 43, 57], ["Roselle polyphenolics", "PROBLEM", 61, 82], ["a high mass transfer", "TREATMENT", 93, 113], ["anthocyanins", "TREATMENT", 132, 144], ["total anthocyanin", "TREATMENT", 174, 191], ["total phenolic compound", "TREATMENT", 193, 216], ["DPPH radical scavenging", "TREATMENT", 218, 241], ["FRAP", "TEST", 243, 247], ["total flavonoid values", "TEST", 252, 274], ["high", "OBSERVATION_MODIFIER", 95, 99], ["mass", "OBSERVATION", 100, 104]]], ["TPC was ranged from 105.81 to 233.20 mg GAE/g.", [["TPC", "CHEMICAL", 0, 3], ["TPC", "SIMPLE_CHEMICAL", 0, 3], ["TPC", "TEST", 0, 3]]], ["The TFC values were found between 3.78 and 10.13 mg ECE/g, while TACN values were ranged from 6.50 and 10.90 mg D3S/g.", [["TACN", "SIMPLE_CHEMICAL", 65, 69], ["The TFC values", "TEST", 0, 14], ["TACN values", "TEST", 65, 76]]], ["The values of FRAP were found between 305.86 and 493.88 mmol ISE/g, while DPPH radical scavenging values were ranged from 222.05 and 372 mmol TE/g.", [["DPPH", "CHEMICAL", 74, 78], ["DPPH", "CHEMICAL", 74, 78], ["FRAP", "SIMPLE_CHEMICAL", 14, 18], ["DPPH", "SIMPLE_CHEMICAL", 74, 78], ["The values of FRAP", "TEST", 0, 18], ["ISE/g", "TEST", 61, 66], ["DPPH radical scavenging values", "TEST", 74, 104]]], ["The highest TPC, TFC, TACN, FRAP and DPPH radical scavenging were detected at run 7 (SAFA m 1:4, 0% additional water and 25 mL solvent).", [["TPC", "CHEMICAL", 12, 15], ["TACN", "CHEMICAL", 22, 26], ["FRAP", "CHEMICAL", 28, 32], ["DPPH", "CHEMICAL", 37, 41], ["TACN", "CHEMICAL", 22, 26], ["DPPH", "CHEMICAL", 37, 41], ["TPC", "SIMPLE_CHEMICAL", 12, 15], ["TFC", "SIMPLE_CHEMICAL", 17, 20], ["TACN", "SIMPLE_CHEMICAL", 22, 26], ["FRAP", "SIMPLE_CHEMICAL", 28, 32], ["DPPH", "SIMPLE_CHEMICAL", 37, 41], ["radical", "SIMPLE_CHEMICAL", 42, 49], ["The highest TPC", "TEST", 0, 15], ["TFC", "TEST", 17, 20], ["TACN", "TREATMENT", 22, 26], ["FRAP", "TREATMENT", 28, 32], ["DPPH radical scavenging", "TREATMENT", 37, 60], ["highest TPC", "OBSERVATION", 4, 15]]], ["While, the lowest TPC and FRAP values were observed at run 5 (SAFA m 1:2.5, 30% additional water and 25 mL solvent), and the lowest DPPH radical scavenging at run 11 (SAFA m 1:2.5, 30% additional water and 25 mL solvent).", [["DPPH", "CHEMICAL", 132, 136], ["DPPH", "CHEMICAL", 132, 136], ["TPC", "SIMPLE_CHEMICAL", 18, 21], ["FRAP", "SIMPLE_CHEMICAL", 26, 30], ["DPPH", "SIMPLE_CHEMICAL", 132, 136], ["the lowest TPC", "TEST", 7, 21], ["FRAP values", "TEST", 26, 37], ["the lowest DPPH radical scavenging", "TREATMENT", 121, 155], ["SAFA", "TEST", 167, 171]]], ["Likewise, the lowest TFC and TACN values were detected in the run 4 (SAFA m 1:2.5, 60% additional water and 40 mL solvent) and run 14 (SAFA m 1:2.5, 30% additional water and 25 mL solvent).", [["TACN", "SIMPLE_CHEMICAL", 29, 33], ["the lowest TFC", "TEST", 10, 24], ["TACN values", "TEST", 29, 40]]], ["At these experimental points, the viscosity was very low, indicating that the DES might lose its intrinsic characteristics and become a simple aqueous solution.", [["DES", "CHEMICAL", 78, 81], ["DES", "CHEMICAL", 78, 81], ["the viscosity", "TEST", 30, 43], ["the DES", "PROBLEM", 74, 81], ["a simple aqueous solution", "TREATMENT", 134, 159], ["low", "OBSERVATION_MODIFIER", 53, 56]]], ["It has been reported that a very low viscosity induce less hydrogen-bonding and decrease the extraction yield of phytochemical compounds [37, 62] .", [["hydrogen", "CHEMICAL", 59, 67], ["a very low viscosity", "PROBLEM", 26, 46], ["phytochemical compounds", "PROBLEM", 113, 136], ["very", "OBSERVATION_MODIFIER", 28, 32], ["low viscosity", "OBSERVATION_MODIFIER", 33, 46], ["phytochemical compounds", "OBSERVATION", 113, 136]]], ["The highest values were detected in the runs where DES did not require additional water.", [["DES", "CHEMICAL", 51, 54], ["DES", "CHEMICAL", 51, 54], ["The highest values", "TEST", 0, 18], ["highest", "OBSERVATION_MODIFIER", 4, 11]]], ["These findings revealed the importance of introduction of water in DES and indicated that the optimum DES will not have too low or too high viscosity.", [["DES", "CHEMICAL", 67, 70], ["DES", "CHEMICAL", 102, 105], ["DES", "CHEMICAL", 67, 70], ["DES", "CHEMICAL", 102, 105], ["water", "SIMPLE_CHEMICAL", 58, 63], ["introduction of water in DES", "TREATMENT", 42, 70], ["the optimum DES", "TREATMENT", 90, 105], ["too high viscosity", "PROBLEM", 131, 149], ["high viscosity", "OBSERVATION_MODIFIER", 135, 149]]], ["Moreover, the highest responses were obtained with molarity ratio 1:4.", [["molarity", "SIMPLE_CHEMICAL", 51, 59], ["molarity ratio", "TEST", 51, 65]]], ["Coded Box-Behnken design with the analytical responses.RunCoded Values Analytical Responses X 1 (Molarity ratio); X 2 (Additional water, %) and X 3 (Solvent ratio, mL).", [["Additional water, %)", "TREATMENT", 119, 139]]], ["Y 1 (DPPH radical scavenging, mmol TE/g); Y 2 (TPC, mg GAE/g); Y 3 (FRAP, mmol ISE/g); Y 4 (TFC, mg ECE/g) and Y 5 (TACN, mg D3S/g).RunFor the analysis of the optimization models, the regression coefficients were indicated at the least square for the second-order quadratic polynomial models.", [["DPPH", "CHEMICAL", 5, 9], ["DPPH", "CHEMICAL", 5, 9], ["DPPH", "SIMPLE_CHEMICAL", 5, 9], ["Y 2", "SIMPLE_CHEMICAL", 42, 45], ["TPC", "SIMPLE_CHEMICAL", 47, 50], ["Y 3", "SIMPLE_CHEMICAL", 63, 66], ["FRAP", "SIMPLE_CHEMICAL", 68, 72], ["Y 4", "SIMPLE_CHEMICAL", 87, 90], ["Y 5", "SIMPLE_CHEMICAL", 111, 114], ["TACN", "SIMPLE_CHEMICAL", 116, 120], ["DPPH radical scavenging", "TEST", 5, 28], ["mmol TE/g", "TEST", 30, 39], ["Y", "TEST", 42, 43], ["TPC", "TEST", 47, 50], ["FRAP", "TEST", 68, 72], ["TFC", "TEST", 92, 95], ["TACN", "TREATMENT", 116, 120], ["the analysis", "TEST", 139, 151], ["the regression coefficients", "TEST", 180, 207]]], ["The stepwise option of response surface methodology was used to eliminate the non-significant parametric values [63] .", [["response surface methodology", "TREATMENT", 23, 51]]], ["The reduced second-order models in terms of actual factors for the responses such as TPC, TFC, TACN, FRAP and DPPH radical scavenging values of Roselle calyces as a function of molarity ratio (X 1 ), additional water (X 2 ) and solvent to solid ratio (X 3 ) were obtained as follows: These equations showed up the response patterns for individual measurement and intricacy of sceneries.", [["calyces", "ANATOMY", 152, 159], ["DPPH", "CHEMICAL", 110, 114], ["DPPH", "CHEMICAL", 110, 114], ["TPC", "SIMPLE_CHEMICAL", 85, 88], ["TACN", "SIMPLE_CHEMICAL", 95, 99], ["FRAP", "SIMPLE_CHEMICAL", 101, 105], ["DPPH", "SIMPLE_CHEMICAL", 110, 114], ["calyces", "MULTI-TISSUE_STRUCTURE", 152, 159], ["TPC", "TEST", 85, 88], ["TFC", "TEST", 90, 93], ["TACN", "TREATMENT", 95, 99], ["FRAP", "TREATMENT", 101, 105], ["DPPH radical scavenging values of Roselle calyces", "TREATMENT", 110, 159], ["molarity ratio", "PROBLEM", 177, 191], ["additional water (X 2 ) and solvent to solid ratio", "TREATMENT", 200, 250], ["These equations", "TEST", 284, 299], ["individual measurement", "TEST", 336, 358], ["reduced", "OBSERVATION_MODIFIER", 4, 11]]], ["The higher and positive parametric values translate the more significant the weight of the governing variable is [64] .", [["The higher and positive parametric values", "PROBLEM", 0, 41], ["higher", "OBSERVATION_MODIFIER", 4, 10], ["positive", "OBSERVATION_MODIFIER", 15, 23], ["parametric values", "OBSERVATION", 24, 41]]], ["The results of the ANOVA showing the effects of different parametric values on the responses along with R2, adjusted R2, predicted R2, adequate precision and coefficient of variance (CV) were assigned in Table 4 .", [["the ANOVA", "TEST", 15, 24]]], ["The model developed for TPC, which provided higher R 2 (0.9880) and adjusted R 2 (0.9725) was significant at p < 0.0001.", [["TPC", "TEST", 24, 27]]], ["The R 2 and adjusted R 2 values displayed a good closeness, indicating that there was strong conformity between the experimental findings and predicted values.", [["R 2", "GENE_OR_GENE_PRODUCT", 4, 7], ["R 2", "GENE_OR_GENE_PRODUCT", 21, 24], ["adjusted R 2 values", "TEST", 12, 31], ["good closeness", "OBSERVATION", 44, 58], ["strong", "OBSERVATION_MODIFIER", 86, 92], ["conformity", "OBSERVATION", 93, 103]]], ["The CV of 4.71% revealed that the model was better reproducible for TPC, as CV expresses the standard deviation in percentage.", [["The CV", "TEST", 0, 6], ["TPC", "TEST", 68, 71], ["the standard deviation in percentage", "PROBLEM", 89, 125], ["standard deviation", "OBSERVATION", 93, 111], ["percentage", "OBSERVATION_MODIFIER", 115, 125]]], ["The adequate precision ratio of 22.75 indicates that the model can be employed to explore the design because an adequate precision ratio higher than 4 is desirable.", [["The adequate precision ratio", "TEST", 0, 28], ["an adequate precision ratio", "TEST", 109, 136], ["adequate", "OBSERVATION_MODIFIER", 4, 12]]], ["The predicted R 2 of 0.8841 for TPC is in reasonable agreement with the adjusted R 2 of 0.9725; i.e., the difference is less than 0.2.", [["TPC", "TREATMENT", 32, 35]]], ["The model developed for TFC was significant at F value 30.84 (p < 0.0001) and had satisfactory R 2 (0.9655), adjusted R 2 (0.9211), CV (6.45%) and adequate precision (20.41) .", [["TFC", "TEST", 24, 27], ["CV", "TEST", 132, 134]]], ["Furthermore, the R 2 and adjusted R 2 of the model developed for the TFC were very close and higher which implicated there was great conformity between the experimental and predicted values.", [["R 2", "GENE_OR_GENE_PRODUCT", 17, 20], ["the TFC", "TEST", 65, 72], ["great", "OBSERVATION_MODIFIER", 127, 132], ["conformity", "OBSERVATION", 133, 143]]], ["For TACN, the model was significant at F value 21.77 (p < 0.0003) and had desirable R 2 (0.9655), adjusted R 2 (0.9211), CV (3.63%) and adequate precision (15.84) . nonetheless, the predicted R 2 of 0.6098 is not as close to the adjusted R 2 of 0.9211 as one might normally expect.", [["CV", "TEST", 121, 123]]], ["This may indicate a large block effect or a possible problem with the model and/or data.", [["a large block effect", "PROBLEM", 18, 38], ["large", "OBSERVATION_MODIFIER", 20, 25], ["block", "OBSERVATION", 26, 31]]], ["This model presented non-significant terms for lack of fit, indicating that the model was a good fit and adequate, since there was great conformity between the experimental and predicted values.RunIn relation to the model developed for DPPH radical scavenging, acceptable R 2 (0.9864), adjusted R 2 (0.9688), CV (2.57%) and adequate precision (21.06) with significant terms at F value 58.26 (p < 0.0001).", [["DPPH", "CHEMICAL", 236, 240], ["DPPH", "CHEMICAL", 236, 240], ["RunIn", "SIMPLE_CHEMICAL", 194, 199], ["DPPH radical", "SIMPLE_CHEMICAL", 236, 248], ["DPPH radical scavenging", "TEST", 236, 259], ["CV", "TEST", 309, 311], ["non-significant", "OBSERVATION_MODIFIER", 21, 36], ["great", "OBSERVATION_MODIFIER", 131, 136], ["conformity", "OBSERVATION", 137, 147]]], ["The predicted R 2 of 0.8163 for DPPH radical scavenging is in reasonable agreement with the adjusted R 2 of 0.9688 and a non-significant lack of fit approved the adequacy of the model.", [["DPPH", "CHEMICAL", 32, 36], ["DPPH", "CHEMICAL", 32, 36], ["DPPH radical", "SIMPLE_CHEMICAL", 32, 44], ["DPPH radical scavenging", "TREATMENT", 32, 55]]], ["With respect to the model generated for FRAP, significant terms were found at F value 32.78 (p < 0.0001) with higher R 2 (0.9768), adjusted R 2 (0.9470), CV (3.10%) and adequate precision (18.13) .", [["FRAP", "TEST", 40, 44], ["CV", "TEST", 154, 156]]], ["These results indicated that there was strong conformity between the experimental findings and predicted values, and the model adequate and reproducible for FRAP values of Roselle calyces.", [["calyces", "ANATOMY", 180, 187], ["Roselle calyces", "MULTI-TISSUE_STRUCTURE", 172, 187], ["strong", "OBSERVATION_MODIFIER", 39, 45], ["conformity", "OBSERVATION", 46, 56]]], ["These analytical findings proved that the parametric values for TPC, TFC, TACN, DPPH radical scavenging and FRAP values by response surface methodology can be used for the prediction and optimization stages [64]Effects of Independent Variables on the ResponsesThe linear, quadratic and interactions terms of the models on TPC, TFC, TACN, FRAP and DPPH radical scavenging of Roselle calyces were presented in Table 4 .", [["calyces", "ANATOMY", 382, 389], ["TACN", "CHEMICAL", 74, 78], ["DPPH", "CHEMICAL", 80, 84], ["TACN", "CHEMICAL", 332, 336], ["DPPH", "CHEMICAL", 347, 351], ["TACN", "CHEMICAL", 74, 78], ["DPPH", "CHEMICAL", 80, 84], ["TACN", "CHEMICAL", 332, 336], ["DPPH", "CHEMICAL", 347, 351], ["TPC", "SIMPLE_CHEMICAL", 64, 67], ["TFC", "SIMPLE_CHEMICAL", 69, 72], ["TACN", "SIMPLE_CHEMICAL", 74, 78], ["DPPH radical", "SIMPLE_CHEMICAL", 80, 92], ["FRAP", "SIMPLE_CHEMICAL", 108, 112], ["TPC", "SIMPLE_CHEMICAL", 322, 325], ["TFC", "SIMPLE_CHEMICAL", 327, 330], ["TACN", "SIMPLE_CHEMICAL", 332, 336], ["FRAP", "SIMPLE_CHEMICAL", 338, 342], ["DPPH", "SIMPLE_CHEMICAL", 347, 351], ["calyces", "ORGAN", 382, 389], ["the parametric values", "TEST", 38, 59], ["TPC", "TEST", 64, 67], ["TFC", "TEST", 69, 72], ["TACN", "TREATMENT", 74, 78], ["DPPH radical scavenging", "TREATMENT", 80, 103], ["FRAP values", "TEST", 108, 119], ["Independent Variables", "PROBLEM", 222, 243], ["TPC", "TEST", 322, 325], ["TFC", "TREATMENT", 327, 330], ["TACN", "TREATMENT", 332, 336], ["FRAP", "TREATMENT", 338, 342], ["DPPH radical scavenging of Roselle calyces", "TREATMENT", 347, 389]]], ["The linear and quadratic terms had significant effects on TPC.", [["TPC", "SIMPLE_CHEMICAL", 58, 61], ["TPC", "TREATMENT", 58, 61], ["linear", "OBSERVATION_MODIFIER", 4, 10], ["quadratic", "OBSERVATION_MODIFIER", 15, 24], ["significant", "OBSERVATION_MODIFIER", 35, 46], ["effects", "OBSERVATION", 47, 54]]], ["However, the interaction terms of additional water and liquid to solid ratio had no significant effects on TPC with F values of 9.43 (p < 0.0180).", [["water", "SIMPLE_CHEMICAL", 45, 50], ["TPC", "SIMPLE_CHEMICAL", 107, 110], ["additional water and liquid to solid ratio", "TREATMENT", 34, 76], ["F values", "TEST", 116, 124]]], ["The parametric value having the most impactful effects on TFC was linear term of liquid to solid ratio with F value of 97.35 (p < 0.0001), followed by the interaction terms of molarity ratio/liquid to ratio and additional water/liquid to solid ratio with F value of 10.86 (p < 0.0132), and the quadratic terms of additional water with F value 9.96 (p < 0.0160), and liquid to solid ratio with F value 85.42 (p < 0.0001), respectively.", [["molarity", "SIMPLE_CHEMICAL", 176, 184], ["The parametric value", "TEST", 0, 20], ["F value", "TEST", 108, 115], ["molarity ratio/liquid to ratio", "TREATMENT", 176, 206], ["additional water/liquid", "TREATMENT", 211, 234], ["F value", "TEST", 255, 262], ["F value", "TEST", 335, 342], ["F value", "TEST", 393, 400]]], ["All linear terms and quadratic effects on TACN.", [["TACN", "TREATMENT", 42, 46], ["linear", "OBSERVATION_MODIFIER", 4, 10], ["terms", "OBSERVATION_MODIFIER", 11, 16], ["quadratic effects", "OBSERVATION", 21, 38]]], ["Moreover, the interaction term of molarity ratio and additional water provided significant on TACN at F value 38.80 (p < 0.0004).", [["molarity ratio", "TEST", 34, 48]]], ["As shown in Table 4 , all the linear, interaction and quadratic units showed significant effects on DPPH radical scavenging values of Roselle calyces Likewise, the linear units having the most impactful effects on FRAP were found to be additional water at F value 82.80 (p < 0.0001), followed by liquid to solid ratio at F value 16.29 (p < 0.0050), while the most impactful quadratic units were additional water F value 100.05 (p < 0.0001), followed by molarity ratio F value 47.96 (p < 0.0002) and liquid to solid ratio F value 20.86 (p < 0.0026).", [["calyces", "ANATOMY", 142, 149], ["DPPH", "CHEMICAL", 100, 104], ["DPPH", "CHEMICAL", 100, 104], ["DPPH", "SIMPLE_CHEMICAL", 100, 104], ["FRAP", "SIMPLE_CHEMICAL", 214, 218], ["quadratic units", "TEST", 54, 69], ["significant effects", "PROBLEM", 77, 96], ["DPPH radical scavenging", "TREATMENT", 100, 123], ["FRAP", "TEST", 214, 218], ["solid ratio at F value", "TEST", 306, 328], ["additional water F value", "TEST", 395, 419], ["molarity ratio F value", "TEST", 453, 475], ["liquid to solid ratio F value", "TEST", 499, 528], ["significant", "OBSERVATION_MODIFIER", 77, 88]]], ["In addition, the interaction of molarity ratio and additional water displayed significant effect on FRAP F value 15.17 (p < 0.0059).Effects of Independent Variables on the ResponsesThe three-dimensional (3D) response surface plots of the models were used to interpret the effects of interactions between the variables on the responses (Figure 2 ).", [["molarity", "SIMPLE_CHEMICAL", 32, 40], ["molarity ratio", "TEST", 32, 46], ["FRAP F value", "TEST", 100, 112]]], ["The 3D response surface plots showed that the TPC, TFC, TACN, FRAP and DPPH radical scavenging values were strongly influenced by molarity ratio and additional water.", [["DPPH", "CHEMICAL", 71, 75], ["TACN", "CHEMICAL", 56, 60], ["DPPH", "CHEMICAL", 71, 75], ["TPC", "SIMPLE_CHEMICAL", 46, 49], ["TFC", "SIMPLE_CHEMICAL", 51, 54], ["TACN", "SIMPLE_CHEMICAL", 56, 60], ["FRAP", "SIMPLE_CHEMICAL", 62, 66], ["DPPH radical", "SIMPLE_CHEMICAL", 71, 83], ["molarity", "SIMPLE_CHEMICAL", 130, 138], ["The 3D response surface plots", "TEST", 0, 29], ["the TPC", "TEST", 42, 49], ["TFC", "TEST", 51, 54], ["TACN", "TREATMENT", 56, 60], ["FRAP", "TEST", 62, 66], ["DPPH radical scavenging values", "TEST", 71, 101]]], ["From the figures, it can be observed that an increase in molarity ratio induced a rapid increase in TPC, TFC, TACN, FRAP and DPPH radical scavenging values.", [["DPPH", "CHEMICAL", 125, 129], ["TACN", "CHEMICAL", 110, 114], ["DPPH", "CHEMICAL", 125, 129], ["TPC", "SIMPLE_CHEMICAL", 100, 103], ["TFC", "SIMPLE_CHEMICAL", 105, 108], ["TACN", "SIMPLE_CHEMICAL", 110, 114], ["FRAP", "SIMPLE_CHEMICAL", 116, 120], ["DPPH radical", "SIMPLE_CHEMICAL", 125, 137], ["an increase in molarity ratio", "PROBLEM", 42, 71], ["a rapid increase in TPC", "PROBLEM", 80, 103], ["TFC", "TREATMENT", 105, 108], ["TACN", "TREATMENT", 110, 114], ["FRAP", "TREATMENT", 116, 120], ["DPPH radical scavenging values", "TEST", 125, 155], ["increase", "OBSERVATION_MODIFIER", 45, 53], ["rapid", "OBSERVATION_MODIFIER", 82, 87], ["increase", "OBSERVATION_MODIFIER", 88, 96], ["scavenging values", "OBSERVATION", 138, 155]]], ["This can be explained because the carboxyl group (-COOH) and sodium cation (-Na + ) from sodium acetate would combine with the carboxyl group (-COOH) or the hydroxyl group (-OH) of formic acid.", [["sodium", "CHEMICAL", 61, 67], ["Na", "CHEMICAL", 77, 79], ["sodium acetate", "CHEMICAL", 89, 103], ["hydroxyl", "CHEMICAL", 157, 165], ["formic acid", "CHEMICAL", 181, 192], ["carboxyl", "CHEMICAL", 34, 42], ["COOH", "CHEMICAL", 51, 55], ["sodium", "CHEMICAL", 61, 67], ["Na + )", "CHEMICAL", 77, 83], ["sodium acetate", "CHEMICAL", 89, 103], ["carboxyl", "CHEMICAL", 127, 135], ["COOH", "CHEMICAL", 144, 148], ["hydroxyl", "CHEMICAL", 157, 165], ["OH", "CHEMICAL", 174, 176], ["formic acid", "CHEMICAL", 181, 192], ["-COOH", "SIMPLE_CHEMICAL", 50, 55], ["sodium cation", "SIMPLE_CHEMICAL", 61, 74], ["-Na +", "SIMPLE_CHEMICAL", 76, 81], ["sodium acetate", "SIMPLE_CHEMICAL", 89, 103], ["-COOH", "SIMPLE_CHEMICAL", 143, 148], ["hydroxyl", "SIMPLE_CHEMICAL", 157, 165], ["-OH", "SIMPLE_CHEMICAL", 173, 176], ["formic acid", "SIMPLE_CHEMICAL", 181, 192], ["sodium cation", "TREATMENT", 61, 74], ["sodium acetate", "TREATMENT", 89, 103], ["the carboxyl group (-COOH", "TREATMENT", 123, 148], ["the hydroxyl group", "TREATMENT", 153, 171], ["formic acid", "TREATMENT", 181, 192]]], ["With the lower molarity ratio of formic acid, there are many specific groups from HBA, which could not bond with the specific groups of HBD, leading to the precipitation of DESs [37, 53] .", [["formic acid", "CHEMICAL", 33, 44], ["HBA", "CHEMICAL", 82, 85], ["formic acid", "CHEMICAL", 33, 44], ["HBA", "CHEMICAL", 82, 85], ["formic acid", "SIMPLE_CHEMICAL", 33, 44], ["HBA", "SIMPLE_CHEMICAL", 82, 85], ["HBD", "GENE_OR_GENE_PRODUCT", 136, 139], ["HBD", "PROTEIN", 136, 139], ["formic acid", "TREATMENT", 33, 44], ["HBA", "TEST", 82, 85], ["HBD", "PROBLEM", 136, 139], ["lower molarity", "OBSERVATION_MODIFIER", 9, 23], ["formic acid", "OBSERVATION", 33, 44]]], ["Nonetheless, the effects of molarity ratio were moderate when compared to the effects of additional water.Effects of Independent Variables on the ResponsesAs demonstrated in Figure 2 , the addition of water led to a decrease in TPC, TFC, TACN, FRAP and DPPH radical scavenging values.", [["DPPH", "CHEMICAL", 253, 257], ["TACN", "CHEMICAL", 238, 242], ["DPPH", "CHEMICAL", 253, 257], ["molarity", "SIMPLE_CHEMICAL", 28, 36], ["TPC", "SIMPLE_CHEMICAL", 228, 231], ["TFC", "SIMPLE_CHEMICAL", 233, 236], ["TACN", "SIMPLE_CHEMICAL", 238, 242], ["FRAP", "SIMPLE_CHEMICAL", 244, 248], ["DPPH radical", "SIMPLE_CHEMICAL", 253, 265], ["molarity ratio", "PROBLEM", 28, 42], ["a decrease in TPC", "TREATMENT", 214, 231], ["TFC", "TREATMENT", 233, 236], ["TACN", "TREATMENT", 238, 242], ["FRAP", "TREATMENT", 244, 248], ["DPPH radical scavenging values", "TEST", 253, 283], ["moderate", "OBSERVATION_MODIFIER", 48, 56], ["scavenging values", "OBSERVATION", 266, 283]]], ["However, a slight increase in TACN was observed in 40-60% of additional water.", [["TACN", "CHEMICAL", 30, 34], ["TACN", "SIMPLE_CHEMICAL", 30, 34], ["TACN", "PROTEIN", 30, 34], ["a slight increase in TACN", "PROBLEM", 9, 34], ["slight", "OBSERVATION_MODIFIER", 11, 17], ["increase", "OBSERVATION_MODIFIER", 18, 26]]], ["0% additional water at the maximum response values might be explained because the DESs used in the present study were prepared as molarity terms.", [["the DESs", "TREATMENT", 78, 86]]], ["The hydrophilic DESs are greatly recommended for the isolation of bioactive compounds, facilitating their diffusion and solubility [61, 62] .", [["The hydrophilic DESs", "TREATMENT", 0, 20], ["the isolation of bioactive compounds", "TREATMENT", 49, 85], ["hydrophilic DESs", "OBSERVATION", 4, 20], ["bioactive compounds", "OBSERVATION", 66, 85]]], ["SAFA m was yet hydrophilic, implying that the further addition of water could be harmful to the DES and decrease the extraction performance.", [["DES", "CHEMICAL", 96, 99], ["DES", "CHEMICAL", 96, 99], ["SAFA", "SIMPLE_CHEMICAL", 0, 4], ["water", "SIMPLE_CHEMICAL", 66, 71], ["the DES", "TREATMENT", 92, 99], ["the extraction performance", "TREATMENT", 113, 139]]], ["The hydrophilic DESs are easy to use, reduce the viscosity and preparation cost and increase polyphenolic extraction yields, nonetheless, a certain of amount of water could not be overpassed [30, 33, 57, 65] .", [["DESs", "SIMPLE_CHEMICAL", 16, 20], ["polyphenolic", "SIMPLE_CHEMICAL", 93, 105], ["water", "SIMPLE_CHEMICAL", 161, 166], ["The hydrophilic DESs", "TREATMENT", 0, 20], ["the viscosity and preparation cost", "TREATMENT", 45, 79], ["increase polyphenolic extraction", "TREATMENT", 84, 116], ["hydrophilic DESs", "OBSERVATION", 4, 20], ["increase", "OBSERVATION_MODIFIER", 84, 92], ["polyphenolic extraction", "OBSERVATION", 93, 116]]], ["Adding more water weakens the interactions between the hydrogen-bonding of different components, affecting the extraction yield [37] .", [["hydrogen", "CHEMICAL", 55, 63], ["hydrogen", "SIMPLE_CHEMICAL", 55, 63], ["the hydrogen-bonding of different components", "TREATMENT", 51, 95]]], ["Molecules 2020, 25, x FOR PEER REVIEW 11 of 24Multi-Response of the Optimization ProcessThe response surface methodology was performed to optimize TPC, TFC, TACN, FRAP and DPPH radical scavenging values.", [["DPPH", "CHEMICAL", 172, 176], ["DPPH", "CHEMICAL", 172, 176], ["TPC", "SIMPLE_CHEMICAL", 147, 150], ["TFC", "SIMPLE_CHEMICAL", 152, 155], ["TACN", "SIMPLE_CHEMICAL", 157, 161], ["FRAP", "SIMPLE_CHEMICAL", 163, 167], ["DPPH radical", "SIMPLE_CHEMICAL", 172, 184], ["PEER REVIEW", "TEST", 26, 37], ["TPC", "TEST", 147, 150], ["TFC", "TEST", 152, 155], ["TACN", "TREATMENT", 157, 161], ["FRAP", "TREATMENT", 163, 167], ["DPPH radical scavenging values", "TEST", 172, 202], ["scavenging values", "OBSERVATION", 185, 202]]], ["The optimum conditions were 1:3.6 molarity ratio, 0% additional water and 10 mL solvent ratio.", [["The optimum conditions", "TEST", 0, 22]]], ["Under these optimum conditions, the predicted TPC, TFC, TACN, FRAP and DPPH radical scavenging values were 239.30 mg GAE/g, 10.45 mg ECE/g, 10.93 mg D3S/g, 503.83 mmol ISE/g and 355.42 mmol TE/g, respectively.", [["TACN", "CHEMICAL", 56, 60], ["DPPH", "CHEMICAL", 71, 75], ["TACN", "CHEMICAL", 56, 60], ["DPPH", "CHEMICAL", 71, 75], ["TPC", "SIMPLE_CHEMICAL", 46, 49], ["TFC", "SIMPLE_CHEMICAL", 51, 54], ["TACN", "SIMPLE_CHEMICAL", 56, 60], ["FRAP", "SIMPLE_CHEMICAL", 62, 66], ["DPPH radical", "SIMPLE_CHEMICAL", 71, 83], ["the predicted TPC", "TEST", 32, 49], ["TFC", "TEST", 51, 54], ["TACN", "TREATMENT", 56, 60], ["FRAP", "TEST", 62, 66], ["DPPH radical scavenging values", "TEST", 71, 101]]], ["For confirmation, further analyses were performed under optimum conditions.", [["confirmation", "TEST", 4, 16], ["further analyses", "TEST", 18, 34]]], ["The results were presented as 233.26 mg GAE/g, 10.14 mg ECE/g, 10.62 mg D3S/g, 493.45 mmol ISE/g and 343.41 mmol TE/g for TPC, TFC, TACN, FRAP and DPPH radical scavenging, respectively.Efficiency of Response Surface Methodology on Total AnthocyaninThe TACN of Roselle calyces in SAFA m increased from 6.90 to 10.93 mg D3S/g after the application of response surface methodology.", [["calyces", "ANATOMY", 268, 275], ["TPC", "CHEMICAL", 122, 125], ["TACN", "CHEMICAL", 132, 136], ["DPPH", "CHEMICAL", 147, 151], ["DPPH", "CHEMICAL", 147, 151], ["Anthocyanin", "CHEMICAL", 237, 248], ["TPC", "SIMPLE_CHEMICAL", 122, 125], ["TFC", "SIMPLE_CHEMICAL", 127, 130], ["TACN", "SIMPLE_CHEMICAL", 132, 136], ["FRAP", "SIMPLE_CHEMICAL", 138, 142], ["DPPH radical", "SIMPLE_CHEMICAL", 147, 159], ["Roselle calyces", "MULTI-TISSUE_STRUCTURE", 260, 275], ["mmol TE", "TEST", 108, 115], ["TPC", "TEST", 122, 125], ["TFC", "TEST", 127, 130], ["TACN", "TEST", 132, 136], ["FRAP", "TEST", 138, 142], ["DPPH radical scavenging", "TREATMENT", 147, 170], ["Total Anthocyanin", "TREATMENT", 231, 248], ["The TACN of Roselle calyces", "TREATMENT", 248, 275], ["response surface methodology", "TREATMENT", 349, 377], ["Response Surface", "OBSERVATION", 199, 215]]], ["These values were found to be higher than the total anthocyanin previously detected in Roselle calyces which has been ranged between 1.22 and 2.3 mg/g [16, 48] .", [["calyces", "ANATOMY", 95, 102], ["anthocyanin", "CHEMICAL", 52, 63], ["anthocyanin", "CHEMICAL", 52, 63], ["anthocyanin", "SIMPLE_CHEMICAL", 52, 63], ["Roselle calyces", "MULTI-TISSUE_STRUCTURE", 87, 102], ["These values", "TEST", 0, 12], ["the total anthocyanin", "TEST", 42, 63], ["higher", "OBSERVATION_MODIFIER", 30, 36]]], ["This is due not only to the origin and variety of the plant material but mostly to the use of DESs and UAE for the extraction.", [["DESs", "SIMPLE_CHEMICAL", 94, 98], ["UAE", "SIMPLE_CHEMICAL", 103, 106], ["DESs", "TREATMENT", 94, 98], ["the extraction", "TREATMENT", 111, 125], ["due not only", "UNCERTAINTY", 8, 20], ["plant material", "OBSERVATION", 54, 68]]], ["The DESs are natural and eco-friendly solvents which are prominent for the extraction of bioactive compounds including anthocyanins [41, 44, 53, 56, 58, 60, 66] .", [["anthocyanins", "CHEMICAL", 119, 131], ["anthocyanins", "CHEMICAL", 119, 131], ["DESs", "SIMPLE_CHEMICAL", 4, 8], ["anthocyanins", "SIMPLE_CHEMICAL", 119, 131], ["eco-friendly solvents", "TREATMENT", 25, 46], ["the extraction", "TREATMENT", 71, 85], ["anthocyanins", "TEST", 119, 131], ["prominent", "OBSERVATION_MODIFIER", 57, 66]]], ["The DES (sodium acetate:formic acid) used in the present study extracted better anthocyanin from Roselle calyces.", [["calyces", "ANATOMY", 105, 112], ["DES", "CHEMICAL", 4, 7], ["sodium acetate", "CHEMICAL", 9, 23], ["formic acid", "CHEMICAL", 24, 35], ["anthocyanin", "CHEMICAL", 80, 91], ["DES", "CHEMICAL", 4, 7], ["sodium acetate", "CHEMICAL", 9, 23], ["formic acid", "CHEMICAL", 24, 35], ["anthocyanin", "CHEMICAL", 80, 91], ["DES", "SIMPLE_CHEMICAL", 4, 7], ["sodium acetate", "SIMPLE_CHEMICAL", 9, 23], ["formic acid", "SIMPLE_CHEMICAL", 24, 35], ["anthocyanin", "SIMPLE_CHEMICAL", 80, 91], ["Roselle calyces", "MULTI-TISSUE_STRUCTURE", 97, 112], ["The DES (sodium acetate:formic acid)", "TREATMENT", 0, 36]]], ["Furthermore, the application of UAE combined with DESs is well-adapted and accelerates the mass transfer of the analytes [67] [68] [69] .", [["UAE", "CHEMICAL", 32, 35], ["DESs", "CHEMICAL", 50, 54], ["UAE", "SIMPLE_CHEMICAL", 32, 35], ["UAE", "TREATMENT", 32, 35], ["DESs", "TREATMENT", 50, 54], ["the mass", "PROBLEM", 87, 95], ["the analytes", "TEST", 108, 120], ["mass", "OBSERVATION", 91, 95]]], ["The effects of molarity ratio, additional water and solvent ratio on the response anthocyanin was well-represented by perturbation graphic generated using response surface methodology ( Figure 3 ).", [["anthocyanin", "CHEMICAL", 82, 93], ["anthocyanin", "CHEMICAL", 82, 93], ["molarity", "SIMPLE_CHEMICAL", 15, 23], ["water", "SIMPLE_CHEMICAL", 42, 47], ["anthocyanin", "SIMPLE_CHEMICAL", 82, 93], ["molarity ratio", "TREATMENT", 15, 29], ["additional water and solvent ratio", "TREATMENT", 31, 65], ["the response anthocyanin", "TREATMENT", 69, 93], ["molarity", "OBSERVATION_MODIFIER", 15, 23]]], ["As can be observed, the total anthocyanin of Roselle calyces behaved differently with variables.", [["calyces", "ANATOMY", 53, 60], ["anthocyanin", "CHEMICAL", 30, 41], ["anthocyanin", "CHEMICAL", 30, 41], ["anthocyanin", "SIMPLE_CHEMICAL", 30, 41], ["Roselle calyces", "MULTI-TISSUE_STRUCTURE", 45, 60], ["the total anthocyanin of Roselle calyces", "TREATMENT", 20, 60]]], ["The curvature observed indicated that TACN was sensitive to all the variables.", [["curvature", "OBSERVATION_MODIFIER", 4, 13]]], ["However, the TACN was mostly affected by molarity ratio and additional water, as these variables showed great variations (Figure 3 ).Efficiency of Response Surface Methodology on Total AnthocyaninThe TACN of Roselle calyces in SAFAm increased from 6.90 to 10.93 mg D3S/g after the application of response surface methodology.", [["calyces", "ANATOMY", 216, 223], ["SAFAm", "CHEMICAL", 227, 232], ["Anthocyanin", "CHEMICAL", 185, 196], ["TACN", "GENE_OR_GENE_PRODUCT", 13, 17], ["Roselle calyces", "MULTI-TISSUE_STRUCTURE", 208, 223], ["SAFAm", "SIMPLE_CHEMICAL", 227, 232], ["Total Anthocyanin", "TREATMENT", 179, 196], ["The TACN of Roselle calyces", "TREATMENT", 196, 223], ["response surface methodology", "TREATMENT", 296, 324], ["Response Surface", "OBSERVATION", 147, 163]]], ["These values were found to be higher than the total anthocyanin previously detected in Roselle calyces which has been ranged between 1.22 and 2.3 mg/g [16, 48] .", [["calyces", "ANATOMY", 95, 102], ["anthocyanin", "CHEMICAL", 52, 63], ["anthocyanin", "CHEMICAL", 52, 63], ["anthocyanin", "SIMPLE_CHEMICAL", 52, 63], ["Roselle calyces", "MULTI-TISSUE_STRUCTURE", 87, 102], ["These values", "TEST", 0, 12], ["the total anthocyanin", "TEST", 42, 63], ["higher", "OBSERVATION_MODIFIER", 30, 36]]], ["This is due not only to the origin and variety of the plant material but mostly to the use of DESs and UAE for the extraction.", [["DESs", "SIMPLE_CHEMICAL", 94, 98], ["UAE", "SIMPLE_CHEMICAL", 103, 106], ["DESs", "TREATMENT", 94, 98], ["the extraction", "TREATMENT", 111, 125], ["due not only", "UNCERTAINTY", 8, 20], ["plant material", "OBSERVATION", 54, 68]]], ["The DESs are natural and eco-friendly solvents which are prominent for the extraction of bioactive compounds including anthocyanins [41, 44, 53, 56, 58, 60, 66] .", [["anthocyanins", "CHEMICAL", 119, 131], ["anthocyanins", "CHEMICAL", 119, 131], ["DESs", "SIMPLE_CHEMICAL", 4, 8], ["anthocyanins", "SIMPLE_CHEMICAL", 119, 131], ["eco-friendly solvents", "TREATMENT", 25, 46], ["the extraction", "TREATMENT", 71, 85], ["anthocyanins", "TEST", 119, 131], ["prominent", "OBSERVATION_MODIFIER", 57, 66]]], ["The DES (sodium acetate:formic acid) used in the present study extracted better anthocyanin from Roselle calyces.", [["calyces", "ANATOMY", 105, 112], ["DES", "CHEMICAL", 4, 7], ["sodium acetate", "CHEMICAL", 9, 23], ["formic acid", "CHEMICAL", 24, 35], ["anthocyanin", "CHEMICAL", 80, 91], ["DES", "CHEMICAL", 4, 7], ["sodium acetate", "CHEMICAL", 9, 23], ["formic acid", "CHEMICAL", 24, 35], ["anthocyanin", "CHEMICAL", 80, 91], ["DES", "SIMPLE_CHEMICAL", 4, 7], ["sodium acetate", "SIMPLE_CHEMICAL", 9, 23], ["formic acid", "SIMPLE_CHEMICAL", 24, 35], ["anthocyanin", "SIMPLE_CHEMICAL", 80, 91], ["Roselle calyces", "MULTI-TISSUE_STRUCTURE", 97, 112], ["The DES (sodium acetate:formic acid)", "TREATMENT", 0, 36]]], ["Furthermore, the application of UAE combined with DESs is well-adapted and accelerates the mass transfer of the analytes [67] [68] [69] .", [["UAE", "CHEMICAL", 32, 35], ["DESs", "CHEMICAL", 50, 54], ["UAE", "SIMPLE_CHEMICAL", 32, 35], ["UAE", "TREATMENT", 32, 35], ["DESs", "TREATMENT", 50, 54], ["the mass", "PROBLEM", 87, 95], ["the analytes", "TEST", 108, 120], ["mass", "OBSERVATION", 91, 95]]], ["The effects of molarity ratio, additional water and solvent ratio on the response anthocyanin was well-represented by perturbation graphic generated using response surface methodology ( Figure 3 ).", [["anthocyanin", "CHEMICAL", 82, 93], ["anthocyanin", "CHEMICAL", 82, 93], ["molarity", "SIMPLE_CHEMICAL", 15, 23], ["water", "SIMPLE_CHEMICAL", 42, 47], ["anthocyanin", "SIMPLE_CHEMICAL", 82, 93], ["molarity ratio", "TREATMENT", 15, 29], ["additional water and solvent ratio", "TREATMENT", 31, 65], ["the response anthocyanin", "TREATMENT", 69, 93], ["molarity", "OBSERVATION_MODIFIER", 15, 23]]], ["As can be observed, the total anthocyanin of Roselle calyces behaved differently with variables.", [["calyces", "ANATOMY", 53, 60], ["anthocyanin", "CHEMICAL", 30, 41], ["anthocyanin", "CHEMICAL", 30, 41], ["anthocyanin", "SIMPLE_CHEMICAL", 30, 41], ["Roselle calyces", "MULTI-TISSUE_STRUCTURE", 45, 60], ["the total anthocyanin of Roselle calyces", "TREATMENT", 20, 60]]], ["The curvature observed indicated that TACN was sensitive to all the variables.", [["curvature", "OBSERVATION_MODIFIER", 4, 13]]], ["However, the TACN was mostly affected by molarity ratio and additional water, as these variables showed great variations (Figure 3) .Stability of Antioxidant Properties of Roselle in SAFAmThe polyphenols recovered from different natural sources find applications in foods [70] and cosmetics [71] where stability is a critical factor for their successful implementation.", [["polyphenols", "CHEMICAL", 192, 203], ["TACN", "GENE_OR_GENE_PRODUCT", 13, 17], ["Roselle", "SIMPLE_CHEMICAL", 172, 179], ["polyphenols", "SIMPLE_CHEMICAL", 192, 203], ["The polyphenols", "TREATMENT", 188, 203], ["Antioxidant Properties", "OBSERVATION", 146, 168]]], ["The optimum experimental conditions figured out with response surface methodology were used to evaluate the heat and storage stabilities of TPC, TFC, TACN, DPPH radical scavenging and FRAP of Roselle.Stability of Antioxidant Properties of Roselle in SAFA mThe polyphenols recovered from different natural sources find applications in foods [70] and cosmetics [71] where stability is a critical factor for their successful implementation.", [["TPC", "CHEMICAL", 140, 143], ["TACN", "CHEMICAL", 150, 154], ["DPPH", "CHEMICAL", 156, 160], ["Roselle", "CHEMICAL", 192, 199], ["TACN", "CHEMICAL", 150, 154], ["DPPH", "CHEMICAL", 156, 160], ["polyphenols", "CHEMICAL", 260, 271], ["TPC", "SIMPLE_CHEMICAL", 140, 143], ["TFC", "SIMPLE_CHEMICAL", 145, 148], ["TACN", "SIMPLE_CHEMICAL", 150, 154], ["DPPH radical", "SIMPLE_CHEMICAL", 156, 168], ["FRAP", "SIMPLE_CHEMICAL", 184, 188], ["Roselle", "SIMPLE_CHEMICAL", 192, 199], ["Roselle", "SIMPLE_CHEMICAL", 239, 246], ["SAFA m", "SIMPLE_CHEMICAL", 250, 256], ["polyphenols", "SIMPLE_CHEMICAL", 260, 271], ["The optimum experimental conditions", "PROBLEM", 0, 35], ["response surface methodology", "TREATMENT", 53, 81], ["TPC", "TEST", 140, 143], ["TFC", "TREATMENT", 145, 148], ["TACN", "TREATMENT", 150, 154], ["DPPH radical scavenging", "TREATMENT", 156, 179], ["The polyphenols", "TREATMENT", 256, 271], ["Antioxidant Properties", "OBSERVATION_MODIFIER", 213, 235]]], ["The optimum experimental conditions figured out with response surface methodology were used to evaluate the heat and storage stabilities of TPC, TFC, TACN, DPPH radical scavenging and FRAP of Roselle.", [["TPC", "CHEMICAL", 140, 143], ["TACN", "CHEMICAL", 150, 154], ["DPPH", "CHEMICAL", 156, 160], ["Roselle", "CHEMICAL", 192, 199], ["TACN", "CHEMICAL", 150, 154], ["DPPH", "CHEMICAL", 156, 160], ["TPC", "SIMPLE_CHEMICAL", 140, 143], ["TFC", "SIMPLE_CHEMICAL", 145, 148], ["TACN", "SIMPLE_CHEMICAL", 150, 154], ["DPPH radical", "SIMPLE_CHEMICAL", 156, 168], ["FRAP", "SIMPLE_CHEMICAL", 184, 188], ["Roselle", "SIMPLE_CHEMICAL", 192, 199], ["The optimum experimental conditions", "PROBLEM", 0, 35], ["response surface methodology", "TREATMENT", 53, 81], ["TPC", "TEST", 140, 143], ["TFC", "TREATMENT", 145, 148], ["TACN", "TREATMENT", 150, 154], ["DPPH radical scavenging", "TREATMENT", 156, 179]]], ["TACN was more stable at 40, 60 and 80 \u2022 C in SAFA m but decreased drastically at 100 \u2022 C. Similarly, the thermal degradation of anthocyanin in aqueous extracts of Roselle has been reported to be crucial between 60 and 90 \u2022 C [75, 76] .", [["aqueous extracts", "ANATOMY", 143, 159], ["anthocyanin", "CHEMICAL", 128, 139], ["Roselle", "CHEMICAL", 163, 170], ["anthocyanin", "CHEMICAL", 128, 139], ["TACN", "SIMPLE_CHEMICAL", 0, 4], ["anthocyanin", "SIMPLE_CHEMICAL", 128, 139], ["aqueous extracts", "ORGANISM_SUBSTANCE", 143, 159], ["Roselle", "SIMPLE_CHEMICAL", 163, 170], ["the thermal degradation of anthocyanin", "PROBLEM", 101, 139], ["stable", "OBSERVATION_MODIFIER", 14, 20]]], ["Generally, the phytochemical compounds with antioxidant properties in Roselle were found more stable in SAFA m .", [["Roselle", "SIMPLE_CHEMICAL", 70, 77], ["SAFA m", "GENE_OR_GENE_PRODUCT", 104, 110], ["stable", "OBSERVATION_MODIFIER", 94, 100]]], ["The strong thermal stability behavior of polyphenols in SAFA m could be associated with a strong hydrogen network between extracts and DESs components [58] .", [["extracts", "ANATOMY", 122, 130], ["polyphenols", "CHEMICAL", 41, 52], ["SAFA", "CHEMICAL", 56, 60], ["polyphenols", "CHEMICAL", 41, 52], ["hydrogen", "CHEMICAL", 97, 105], ["polyphenols", "SIMPLE_CHEMICAL", 41, 52], ["SAFA m", "SIMPLE_CHEMICAL", 56, 62], ["extracts", "ORGANISM_SUBSTANCE", 122, 130], ["polyphenols in SAFA m", "PROBLEM", 41, 62], ["strong", "OBSERVATION_MODIFIER", 4, 10], ["thermal", "OBSERVATION_MODIFIER", 11, 18], ["stability", "OBSERVATION_MODIFIER", 19, 28]]], ["However, the thermal degradation rate increased by augmenting both temperature and heat time.", [["the thermal degradation rate", "PROBLEM", 9, 37]]], ["The first-order reaction constant k and activation energy for isothermal kinetics of anthocyanin degradation were assigned in Table 5 .", [["anthocyanin", "CHEMICAL", 85, 96], ["anthocyanin", "CHEMICAL", 85, 96], ["anthocyanin", "SIMPLE_CHEMICAL", 85, 96], ["isothermal kinetics of anthocyanin degradation", "TREATMENT", 62, 108]]], ["The values k figured out in this study confirmed the influence of temperature and time on anthocyanin.", [["anthocyanin", "CHEMICAL", 90, 101], ["anthocyanin", "CHEMICAL", 90, 101], ["anthocyanin", "SIMPLE_CHEMICAL", 90, 101], ["The values k", "TEST", 0, 12], ["this study", "TEST", 28, 38], ["anthocyanin", "TREATMENT", 90, 101]]], ["It was observed that k values increased with augmenting temperature from 2.39 \u00d7 10 \u22125 at 40 \u2022 C to 49.96 \u00d7 10 \u22125 s \u22121 to 100 \u2022 C for times varying between 20 to 100 min.", [["k values", "TEST", 21, 29], ["augmenting temperature", "TEST", 45, 67]]], ["Other authors have also mentioned that k values increased with augmenting temperature and time [14, 58, [76] [77] [78] .", [["k values", "TEST", 39, 47], ["augmenting temperature", "TEST", 63, 85]]], ["The activation energy (Ea) was ranged from 36.78 to 49.13 kJ/mol and was slightly less than Ea values reported aqueous extracts of Roselle [75, 76] and in blackcurrant juice [78] . order reaction constant k and activation energy for isothermal kinetics of anthocyanin degradation were assigned in Table 5 .", [["extracts", "ANATOMY", 119, 127], ["Roselle", "CHEMICAL", 131, 138], ["anthocyanin", "CHEMICAL", 256, 267], ["anthocyanin", "CHEMICAL", 256, 267], ["aqueous extracts", "ORGANISM_SUBSTANCE", 111, 127], ["juice", "ORGANISM_SUBSTANCE", 168, 173], ["anthocyanin", "SIMPLE_CHEMICAL", 256, 267], ["Ea values", "TEST", 92, 101], ["blackcurrant juice", "TEST", 155, 173], ["activation energy", "TEST", 211, 228], ["anthocyanin degradation", "TREATMENT", 256, 279]]], ["The values k figured out in this study confirmed the influence of temperature and time on anthocyanin.", [["anthocyanin", "CHEMICAL", 90, 101], ["anthocyanin", "CHEMICAL", 90, 101], ["anthocyanin", "SIMPLE_CHEMICAL", 90, 101], ["The values k", "TEST", 0, 12], ["this study", "TEST", 28, 38], ["anthocyanin", "TREATMENT", 90, 101]]], ["It was observed that k values increased with augmenting temperature from 2.39 \u00d7 10 \u22125 at 40 \u00b0C to 49.96\u00d710 \u22125 s \u22121 to 100 \u00b0C for times varying between 20 to 100 min.", [["k values", "TEST", 21, 29], ["augmenting temperature", "TEST", 45, 67]]], ["Other authors have also mentioned that k values increased with augmenting temperature and time [14, 58, [76] [77] [78] .", [["k values", "TEST", 39, 47], ["augmenting temperature", "TEST", 63, 85]]], ["The activation energy (Ea) was ranged from 36.78 to 49.13 kJ/mol and was slightly less than Ea values reported aqueous extracts of Roselle [75, 76] and in blackcurrant juice [78] .Stability of Total Anthocyanin during StorageThe degradation of anthocyanin in SAFA m was investigated during eighteen days at room temperature (20 \u2022 C), 4 \u2022 and \u221220 \u2022 C, and the results were represented in Figure 5 .", [["extracts", "ANATOMY", 119, 127], ["Roselle", "CHEMICAL", 131, 138], ["Anthocyanin", "CHEMICAL", 199, 210], ["anthocyanin", "CHEMICAL", 244, 255], ["anthocyanin", "CHEMICAL", 244, 255], ["aqueous extracts", "ORGANISM_SUBSTANCE", 111, 127], ["juice", "ORGANISM_SUBSTANCE", 168, 173], ["Anthocyanin", "SIMPLE_CHEMICAL", 199, 210], ["anthocyanin", "SIMPLE_CHEMICAL", 244, 255], ["SAFA", "SIMPLE_CHEMICAL", 259, 263], ["Ea values", "TEST", 92, 101], ["blackcurrant juice", "TEST", 155, 173], ["Total Anthocyanin", "TREATMENT", 193, 210], ["anthocyanin", "TREATMENT", 244, 255], ["Total Anthocyanin", "OBSERVATION", 193, 210]]], ["The concentrations of anthocyanin decreased slowly in SAFA m with time at all temperatures.", [["anthocyanin", "CHEMICAL", 22, 33], ["anthocyanin", "CHEMICAL", 22, 33], ["anthocyanin", "SIMPLE_CHEMICAL", 22, 33], ["anthocyanin", "TREATMENT", 22, 33], ["concentrations", "OBSERVATION_MODIFIER", 4, 18], ["decreased", "OBSERVATION_MODIFIER", 34, 43], ["slowly", "OBSERVATION_MODIFIER", 44, 50]]], ["However, this decrease was steeper at higher temperature (20 \u2022 C).", [["decrease", "OBSERVATION_MODIFIER", 14, 22]]], ["The degradation rates were 40.10, 20.46 and 19.25% at 20 \u2022 C, 4 \u2022 C and \u221220 \u2022 C, respectively.", [["The degradation rates", "TEST", 0, 21], ["C", "TEST", 59, 60], ["C", "TEST", 66, 67], ["\u2212", "TEST", 72, 73]]], ["The linear relation between the logarithm of total anthocyanins and time indicated a first-order kinetic for Roselle anthocyanin degradation in SAFA m .", [["anthocyanins", "CHEMICAL", 51, 63], ["anthocyanin", "CHEMICAL", 117, 128], ["anthocyanins", "CHEMICAL", 51, 63], ["anthocyanin", "CHEMICAL", 117, 128], ["anthocyanins", "SIMPLE_CHEMICAL", 51, 63], ["anthocyanin", "SIMPLE_CHEMICAL", 117, 128], ["SAFA m", "GENE_OR_GENE_PRODUCT", 144, 150], ["total anthocyanins", "TREATMENT", 45, 63], ["Roselle anthocyanin degradation", "TREATMENT", 109, 140], ["linear", "OBSERVATION_MODIFIER", 4, 10]]], ["This is in agreement with the previous investigations in aqueous extracts of Roselle [14, 75] .", [["aqueous extracts", "ANATOMY", 57, 73], ["aqueous extracts", "ORGANISM_SUBSTANCE", 57, 73], ["the previous investigations", "TEST", 26, 53]]], ["The anthocyanin degradation was too slow in SAFA m , especially after 12 days, showing the strength of intramolecular and intermolecular reactions occurred between solute and SAFA m .", [["anthocyanin", "CHEMICAL", 4, 15], ["anthocyanin", "CHEMICAL", 4, 15], ["anthocyanin", "SIMPLE_CHEMICAL", 4, 15], ["solute", "SIMPLE_CHEMICAL", 164, 170], ["SAFA m", "GENE_OR_GENE_PRODUCT", 175, 181], ["The anthocyanin degradation", "PROBLEM", 0, 27], ["too slow in SAFA m", "PROBLEM", 32, 50], ["intramolecular and intermolecular reactions", "PROBLEM", 103, 146], ["anthocyanin degradation", "OBSERVATION", 4, 27], ["intermolecular reactions", "OBSERVATION", 122, 146]]], ["Nonetheless, the storage temperature had an influence on anthocyanin degradation ( Table 6 ).", [["anthocyanin", "CHEMICAL", 57, 68], ["anthocyanin", "SIMPLE_CHEMICAL", 57, 68], ["the storage temperature", "TEST", 13, 36], ["anthocyanin degradation", "TREATMENT", 57, 80]]], ["As can be seen, the values of k varied from 1.29 \u00d7 10 \u22127 to 2.52 \u00d7 10 \u22127 s \u22121 at \u221220 \u2022 C, from 1.47 \u00d7 10 \u22127 to 3.47 \u00d7 10 \u22127 s \u22121 at 4 \u2022 C and from 2.73 \u00d7 10 \u22127 to 7.41 \u00d7 10 \u22127 s \u22121 at 20 \u2022 C. During the storage, the values of the first-order rate constant (k) of the model increased 5.74-fold.", [["the values", "TEST", 16, 26], ["k", "TEST", 30, 31], ["C", "TEST", 87, 88], ["the values", "TEST", 212, 222], ["the model", "TEST", 263, 272]]], ["Furthermore, the values of t 1/2 were ranged 0.94 \u00d7 10 6 to 5.39 \u00d7 10 6 s and the highest t 1/2 values were found at \u221220 \u2022 C and 4 \u2022 C, respectively. k values detected in this study were low and t 1/2 values were higher when compared to k and t 1/2 values reported in previous studies [14, 76] .", [["the values", "TEST", 13, 23], ["C", "TEST", 123, 124], ["k values", "TEST", 150, 158], ["this study", "TEST", 171, 181], ["k", "TEST", 237, 238]]], ["This indicated that SAFA m was more anthocyanin-protective during the storage when compared to water.Stability of Total Anthocyanin during StorageThe degradation of anthocyanin in SAFAm was investigated during eighteen days at room temperature (20 \u00b0C), 4\u00b0 and \u221220 \u00b0C, and the results were represented in Figure 5 .", [["SAFA", "CHEMICAL", 20, 24], ["anthocyanin", "CHEMICAL", 36, 47], ["Anthocyanin", "CHEMICAL", 120, 131], ["anthocyanin", "CHEMICAL", 165, 176], ["SAFAm", "CHEMICAL", 180, 185], ["anthocyanin", "CHEMICAL", 36, 47], ["anthocyanin", "CHEMICAL", 165, 176], ["SAFA m", "GENE_OR_GENE_PRODUCT", 20, 26], ["anthocyanin", "SIMPLE_CHEMICAL", 36, 47], ["water", "SIMPLE_CHEMICAL", 95, 100], ["Anthocyanin", "SIMPLE_CHEMICAL", 120, 131], ["anthocyanin", "SIMPLE_CHEMICAL", 165, 176], ["SAFAm", "SIMPLE_CHEMICAL", 180, 185], ["Total Anthocyanin", "TREATMENT", 114, 131], ["anthocyanin", "TREATMENT", 165, 176], ["Total Anthocyanin", "OBSERVATION", 114, 131]]], ["The concentrations of anthocyanin decreased slowly in SAFAm with time at all temperatures.", [["anthocyanin", "CHEMICAL", 22, 33], ["anthocyanin", "CHEMICAL", 22, 33], ["anthocyanin", "SIMPLE_CHEMICAL", 22, 33], ["SAFAm", "SIMPLE_CHEMICAL", 54, 59], ["anthocyanin", "TREATMENT", 22, 33], ["concentrations", "OBSERVATION_MODIFIER", 4, 18], ["anthocyanin decreased", "OBSERVATION", 22, 43], ["slowly", "OBSERVATION_MODIFIER", 44, 50]]], ["However, this decrease was steeper at higher temperature (20 \u00b0C).", [["decrease", "OBSERVATION_MODIFIER", 14, 22]]], ["The degradation rates were 40.10, 20.46 and 19.25% at 20 \u00b0C, 4 \u00b0C and \u221220 \u00b0C, respectively.", [["The degradation rates", "TEST", 0, 21]]], ["The linear relation between the logarithm of total anthocyanins and time indicated a first-order kinetic for Roselle anthocyanin degradation in SAFAm.", [["anthocyanins", "CHEMICAL", 51, 63], ["Roselle anthocyanin", "CHEMICAL", 109, 128], ["SAFAm", "CHEMICAL", 144, 149], ["anthocyanins", "CHEMICAL", 51, 63], ["anthocyanin", "CHEMICAL", 117, 128], ["anthocyanins", "SIMPLE_CHEMICAL", 51, 63], ["Roselle", "SIMPLE_CHEMICAL", 109, 116], ["anthocyanin", "SIMPLE_CHEMICAL", 117, 128], ["SAFAm", "SIMPLE_CHEMICAL", 144, 149], ["total anthocyanins", "TREATMENT", 45, 63], ["Roselle anthocyanin degradation", "TREATMENT", 109, 140], ["linear", "OBSERVATION_MODIFIER", 4, 10], ["anthocyanin degradation", "OBSERVATION", 117, 140]]], ["This is in agreement with the previous investigations in aqueous extracts of Roselle [14, 75] .", [["aqueous extracts", "ANATOMY", 57, 73], ["aqueous extracts", "ORGANISM_SUBSTANCE", 57, 73], ["the previous investigations", "TEST", 26, 53]]], ["The anthocyanin degradation was too slow in SAFAm, especially after 12 days, showing the strength of intramolecular and intermolecular reactions occurred between solute and SAFAm.", [["anthocyanin", "CHEMICAL", 4, 15], ["SAFAm", "CHEMICAL", 44, 49], ["SAFAm", "CHEMICAL", 173, 178], ["anthocyanin", "CHEMICAL", 4, 15], ["SAFAm", "CHEMICAL", 173, 178], ["anthocyanin", "SIMPLE_CHEMICAL", 4, 15], ["SAFAm", "SIMPLE_CHEMICAL", 44, 49], ["solute", "SIMPLE_CHEMICAL", 162, 168], ["SAFAm", "SIMPLE_CHEMICAL", 173, 178], ["The anthocyanin degradation", "PROBLEM", 0, 27], ["too slow in SAFAm", "PROBLEM", 32, 49], ["intramolecular and intermolecular reactions", "PROBLEM", 101, 144], ["anthocyanin degradation", "OBSERVATION", 4, 27], ["intermolecular reactions", "OBSERVATION", 120, 144]]], ["Nonetheless, the storage temperature had an influence on anthocyanin degradation ( Table 6 ).", [["anthocyanin", "CHEMICAL", 57, 68], ["anthocyanin", "SIMPLE_CHEMICAL", 57, 68], ["the storage temperature", "TEST", 13, 36], ["anthocyanin degradation", "TREATMENT", 57, 80]]], ["As can be seen, the values of k varied from 1.29 \u00d7 10 \u22127 to 2.52 \u00d7 10 \u22127 s \u22121 at \u221220 \u00b0C, from 1.47 \u00d7 10 \u22127 to 3.47 \u00d7 10 \u22127 s \u22121 at 4 \u00b0C and from 2.73 \u00d7 10 \u22127 to 7.41 \u00d7 10 \u22127 s \u22121 at 20 \u00b0C. During the storage, the values of the first-order rate constant (k) of the model increased 5.74-fold.", [["the values", "TEST", 16, 26], ["k", "TEST", 30, 31], ["the values", "TEST", 209, 219], ["the model", "TEST", 260, 269], ["increased", "OBSERVATION_MODIFIER", 270, 279]]], ["Furthermore, the values of t1/2 were ranged 0.94 \u00d7 10 6 to 5.39 \u00d7 10 6 s and the highest t1/2 values were found at \u221220 \u00b0C and 4 \u00b0C, respectively. k values detected in this study were low and t1/2 values were higher when compared to k and t1/2 values reported in previous studies [14, 76] .", [["the values", "TEST", 13, 23], ["t1", "TEST", 27, 29], ["k values", "TEST", 146, 154], ["this study", "TEST", 167, 177], ["t1/2 values", "TEST", 191, 202], ["k", "TEST", 232, 233], ["t1", "TEST", 238, 240]]], ["This indicated that SAFAm was more anthocyanin-protective during the storage when compared to water.Plant MaterialRoselle collected from the experimental farms of the University of Agriculture of K\u00e9tou, located in K\u00e9tou province, Benin Republic.", [["SAFAm", "CHEMICAL", 20, 25], ["anthocyanin", "CHEMICAL", 35, 46], ["SAFAm", "CHEMICAL", 20, 25], ["anthocyanin", "CHEMICAL", 35, 46], ["SAFAm", "SIMPLE_CHEMICAL", 20, 25], ["anthocyanin", "SIMPLE_CHEMICAL", 35, 46], ["water", "SIMPLE_CHEMICAL", 94, 99], ["Plant MaterialRoselle", "TEST", 100, 121], ["MaterialRoselle", "OBSERVATION", 106, 121]]], ["The fresh Roselle calyces were sun-dried for 7 days.", [["calyces", "ANATOMY", 18, 25], ["Roselle calyces", "MULTI-TISSUE_STRUCTURE", 10, 25], ["The fresh Roselle calyces", "TREATMENT", 0, 25]]], ["The dried calyces were packed into cleaned and sterilized brown bottles and kept at 4 \u2022 C for further use.", [["calyces", "ANATOMY", 10, 17], ["calyces", "ORGAN", 10, 17], ["The dried calyces", "TREATMENT", 0, 17], ["sterilized brown bottles", "TREATMENT", 47, 71], ["calyces", "OBSERVATION_MODIFIER", 10, 17], ["packed", "OBSERVATION_MODIFIER", 23, 29]]], ["Prior analysis, the dried calyces were pulverized by a disintegrator (Sinbo, coffee and spice grinder, SCM 2934), sieved, and brown bottle at 4 \u2022 C.Chemicals and ReagentsDistilled water purified by a Millipore-Q system (Millipore Billerica, Massachusetts, USA).", [["calyces", "ANATOMY", 26, 33], ["SCM 2934", "CHEMICAL", 103, 111], ["calyces", "ORGANISM_SUBDIVISION", 26, 33], ["Prior analysis", "TEST", 0, 14], ["the dried calyces", "TREATMENT", 16, 33], ["a disintegrator (Sinbo, coffee", "TREATMENT", 53, 83]]], ["Methanol (\u226599,8%), 2,2-diphenyl-1-picrylhydrazyl (DPPH), 2,4,6-tris(2-pyridyl)-s-triazine (TPTZ, \u226599.0%), Trolox (97%), sodium nitrite (99-100.5%), hydrochloric acid (36.5-38%), (-)-epicatechin, gallic acid (\u226599.0) and sodium carbonate (99.5-100.5%) were bought from Sigma-Aldrich.", [["Methanol", "CHEMICAL", 0, 8], ["2,2-diphenyl-1-picrylhydrazyl", "CHEMICAL", 19, 48], ["DPPH", "CHEMICAL", 50, 54], ["2,4,6-tris(2-pyridyl)-s-triazine", "CHEMICAL", 57, 89], ["TPTZ", "CHEMICAL", 91, 95], ["Trolox", "CHEMICAL", 106, 112], ["sodium", "CHEMICAL", 120, 126], ["nitrite", "CHEMICAL", 127, 134], ["hydrochloric acid", "CHEMICAL", 148, 165], ["(-)-epicatechin", "CHEMICAL", 178, 193], ["gallic acid", "CHEMICAL", 195, 206], ["sodium carbonate", "CHEMICAL", 219, 235], ["Methanol", "CHEMICAL", 0, 8], ["2,2-diphenyl-1-picrylhydrazyl", "CHEMICAL", 19, 48], ["DPPH", "CHEMICAL", 50, 54], ["2,4,6-tris(2-pyridyl)-s-triazine", "CHEMICAL", 57, 89], ["TPTZ", "CHEMICAL", 91, 95], ["Trolox", "CHEMICAL", 106, 112], ["sodium nitrite", "CHEMICAL", 120, 134], ["hydrochloric acid", "CHEMICAL", 148, 165], ["(-)-epicatechin", "CHEMICAL", 178, 193], ["gallic acid", "CHEMICAL", 195, 206], ["sodium carbonate", "CHEMICAL", 219, 235], ["Methanol", "SIMPLE_CHEMICAL", 0, 8], ["2,2-diphenyl-1-picrylhydrazyl", "SIMPLE_CHEMICAL", 19, 48], ["DPPH", "SIMPLE_CHEMICAL", 50, 54], ["2,4,6-tris(2-pyridyl)-s-triazine", "SIMPLE_CHEMICAL", 57, 89], ["TPTZ", "SIMPLE_CHEMICAL", 91, 95], ["Trolox", "SIMPLE_CHEMICAL", 106, 112], ["sodium nitrite", "SIMPLE_CHEMICAL", 120, 134], ["hydrochloric acid", "SIMPLE_CHEMICAL", 148, 165], ["(-)-epicatechin", "SIMPLE_CHEMICAL", 178, 193], ["gallic acid", "SIMPLE_CHEMICAL", 195, 206], ["sodium carbonate", "SIMPLE_CHEMICAL", 219, 235], ["Sigma-Aldrich", "SIMPLE_CHEMICAL", 267, 280], ["Methanol", "TREATMENT", 0, 8], ["diphenyl", "TREATMENT", 23, 31], ["picrylhydrazyl", "TREATMENT", 34, 48], ["triazine (TPTZ", "TREATMENT", 81, 95], ["Trolox", "TEST", 106, 112], ["sodium nitrite", "TEST", 120, 134], ["hydrochloric acid", "TEST", 148, 165], ["epicatechin", "TREATMENT", 182, 193], ["gallic acid", "TREATMENT", 195, 206], ["sodium carbonate", "TREATMENT", 219, 235]]], ["Ethanol (\u226599.9%) purchased from Isolab.", [["Ethanol", "CHEMICAL", 0, 7], ["Ethanol", "CHEMICAL", 0, 7], ["Ethanol", "SIMPLE_CHEMICAL", 0, 7], ["Ethanol", "TREATMENT", 0, 7]]], ["Folin-Ciocalteu reagent, aluminum chloride, iron (III) chloride, iron sulfate heptahydrate (\u226599.5%) and formic acid (98-100%) brought from Merck.", [["Folin-Ciocalteu", "CHEMICAL", 0, 15], ["aluminum chloride", "CHEMICAL", 25, 42], ["iron (III) chloride", "CHEMICAL", 44, 63], ["iron sulfate heptahydrate", "CHEMICAL", 65, 90], ["formic acid", "CHEMICAL", 104, 115], ["Folin-Ciocalteu", "CHEMICAL", 0, 15], ["aluminum chloride", "CHEMICAL", 25, 42], ["iron (III) chloride", "CHEMICAL", 44, 63], ["iron sulfate heptahydrate", "CHEMICAL", 65, 90], ["formic acid", "CHEMICAL", 104, 115], ["Folin-Ciocalteu reagent", "SIMPLE_CHEMICAL", 0, 23], ["aluminum chloride", "SIMPLE_CHEMICAL", 25, 42], ["iron (III) chloride", "SIMPLE_CHEMICAL", 44, 63], ["iron sulfate heptahydrate", "SIMPLE_CHEMICAL", 65, 90], ["formic acid", "SIMPLE_CHEMICAL", 104, 115], ["Folin", "TEST", 0, 5], ["Ciocalteu reagent", "TREATMENT", 6, 23], ["aluminum chloride", "TREATMENT", 25, 42], ["iron (III) chloride", "TREATMENT", 44, 63], ["iron sulfate heptahydrate", "TREATMENT", 65, 90], ["formic acid", "TEST", 104, 115]]], ["Sodium acetate anhydrous (\u226599.0%), glacial acetic acid (99.5%), potassium chloride (\u226599.0%), and Sodium hydroxide (\u226597.0%) obtained from Carlo erba.Deep Eutectic Solvent PreparationThe Deep Eutectic Solvents (DESs) were prepared based on previously reported methodologies with some changes [55, 79] .", [["Sodium acetate", "CHEMICAL", 0, 14], ["anhydrous", "CHEMICAL", 15, 24], ["glacial acetic acid", "CHEMICAL", 35, 54], ["potassium chloride", "CHEMICAL", 64, 82], ["Sodium hydroxide", "CHEMICAL", 97, 113], ["Sodium acetate anhydrous", "CHEMICAL", 0, 24], ["glacial acetic acid", "CHEMICAL", 35, 54], ["potassium chloride", "CHEMICAL", 64, 82], ["Sodium hydroxide", "CHEMICAL", 97, 113], ["Sodium acetate anhydrous", "SIMPLE_CHEMICAL", 0, 24], ["glacial acetic acid", "SIMPLE_CHEMICAL", 35, 54], ["potassium chloride", "SIMPLE_CHEMICAL", 64, 82], ["Sodium hydroxide", "SIMPLE_CHEMICAL", 97, 113], ["Carlo erba", "SIMPLE_CHEMICAL", 137, 147], ["Sodium acetate anhydrous", "TREATMENT", 0, 24], ["glacial acetic acid", "TEST", 35, 54], ["potassium chloride", "TEST", 64, 82], ["Sodium hydroxide", "TREATMENT", 97, 113], ["Deep Eutectic Solvent Preparation", "TREATMENT", 148, 181], ["The Deep Eutectic Solvents (DESs", "TREATMENT", 181, 213], ["Eutectic Solvent", "OBSERVATION", 153, 169], ["Deep", "ANATOMY_MODIFIER", 185, 189], ["Eutectic Solvents", "OBSERVATION", 190, 207]]], ["The DESs made in a molar ratio of two different components consisting of hydrogen bond donor (HBD) and hydrogen bond acceptor (HBA), followed by the addition of 20, 40, 60, and 80% of distilled water (Table 1 ).", [["hydrogen", "CHEMICAL", 73, 81], ["hydrogen", "CHEMICAL", 103, 111], ["hydrogen bond donor", "SIMPLE_CHEMICAL", 73, 92], ["HBD", "SIMPLE_CHEMICAL", 94, 97], ["hydrogen bond acceptor", "SIMPLE_CHEMICAL", 103, 125], ["HBA", "SIMPLE_CHEMICAL", 127, 130], ["HBD", "PROTEIN", 94, 97], ["a molar ratio", "TEST", 17, 30], ["hydrogen bond donor (HBD)", "TREATMENT", 73, 98], ["hydrogen bond acceptor", "TREATMENT", 103, 125], ["hydrogen bond", "OBSERVATION", 73, 86]]], ["Sodium acetate used as HBA [79] and formic acid as HBD.", [["Sodium acetate", "CHEMICAL", 0, 14], ["HBA [79] and formic acid", "CHEMICAL", 23, 47], ["Sodium acetate", "CHEMICAL", 0, 14], ["HBA [79]", "CHEMICAL", 23, 31], ["formic acid", "CHEMICAL", 36, 47], ["Sodium acetate", "SIMPLE_CHEMICAL", 0, 14], ["HBA [79]", "SIMPLE_CHEMICAL", 23, 31], ["formic acid", "SIMPLE_CHEMICAL", 36, 47], ["HBD", "GENE_OR_GENE_PRODUCT", 51, 54], ["HBD", "PROTEIN", 51, 54], ["Sodium acetate", "TREATMENT", 0, 14], ["HBA", "TEST", 23, 26], ["formic acid as HBD", "PROBLEM", 36, 54]]], ["Another DES prepared in the molarity ratio of sodium acetate and formic acid (1:2).", [["DES", "CHEMICAL", 8, 11], ["sodium acetate", "CHEMICAL", 46, 60], ["formic acid", "CHEMICAL", 65, 76], ["DES", "CHEMICAL", 8, 11], ["sodium acetate", "CHEMICAL", 46, 60], ["formic acid", "CHEMICAL", 65, 76], ["sodium acetate", "SIMPLE_CHEMICAL", 46, 60], ["formic acid", "SIMPLE_CHEMICAL", 65, 76], ["Another DES", "TREATMENT", 0, 11], ["sodium acetate", "TREATMENT", 46, 60], ["formic acid", "TREATMENT", 65, 76]]], ["The molarity ratio-based DES formulated due to the fact that the anhydrous mixtures are very viscous, difficult to manipulate [55] , and unsuitable for polyphenolics extraction.", [["DES", "CHEMICAL", 25, 28], ["anhydrous", "CHEMICAL", 65, 74], ["polyphenolics", "CHEMICAL", 152, 165], ["polyphenolics", "SIMPLE_CHEMICAL", 152, 165], ["The molarity ratio-based DES", "TREATMENT", 0, 28], ["the anhydrous mixtures", "TREATMENT", 61, 83], ["very viscous", "PROBLEM", 88, 100], ["polyphenolics extraction", "TREATMENT", 152, 176]]], ["The molar ratio mixture prepared by mixing the molar mass of components as gram in appropriate ratios.", [["The molar ratio mixture", "TREATMENT", 0, 23], ["molar", "OBSERVATION_MODIFIER", 4, 9], ["molar", "OBSERVATION_MODIFIER", 47, 52], ["mass", "OBSERVATION", 53, 57]]], ["The molarity ratio mixture prepared by mixing ingredients as molarity in the proper ratios.", [["The molarity ratio mixture", "TREATMENT", 0, 26], ["molarity", "OBSERVATION_MODIFIER", 4, 12]]], ["In this work, DES components were placed in reaction flask at 75 \u2022 C with constant stirring for 2 h 30 min to obtain a homogeneous liquid.", [["DES", "CHEMICAL", 14, 17], ["DES", "CHEMICAL", 14, 17], ["DES components", "TREATMENT", 14, 28]]], ["The DESs prepared in molar and molarity ratios were encoded as SAFA 0 , and SAFA m , respectively.RheologyThe viscosity of DESs was measured using a Rheometer (Buchi, CH-9230 Flawil 1, Switzerland) fitted with a parallel geometry with 20 mm of diameter and gap 1 mm.", [["molarity ratios", "TEST", 31, 46], ["SAFA", "TEST", 63, 67], ["a Rheometer", "TEST", 147, 158], ["a parallel geometry", "TREATMENT", 210, 229], ["viscosity", "OBSERVATION_MODIFIER", 110, 119], ["20 mm", "OBSERVATION_MODIFIER", 235, 240], ["1 mm", "OBSERVATION_MODIFIER", 261, 265]]], ["The measurements carried out as described in [55] .Fourier Transformed Infrared (FTIR)FTIR analysis of DESs and extracts was carried out using a FTIR Spectrometer (Perkin Elmer, Spectrum-Two, USA, PEService 35).", [["extracts", "ANATOMY", 112, 120], ["DESs", "SIMPLE_CHEMICAL", 103, 107], ["extracts", "ORGANISM_SUBSTANCE", 112, 120], ["The measurements", "TEST", 0, 16], ["FTIR analysis", "TEST", 86, 99], ["DESs and extracts", "TREATMENT", 103, 120], ["a FTIR Spectrometer", "TEST", 143, 162]]], ["Diamond lens attenuated resistance was used.", [["Diamond lens attenuated resistance", "TREATMENT", 0, 34], ["lens", "OBSERVATION", 8, 12], ["attenuated resistance", "OBSERVATION", 13, 34]]], ["The spectrometer was adjusted in resolution 4 and by selecting the Norton-Beer (n-B) strong apodization function.", [["The spectrometer", "TREATMENT", 0, 16]]], ["The range of all spectra was between the wavenumbers of 4000 and 400 cm \u22121 .", [["the wavenumbers", "TEST", 37, 52], ["range", "OBSERVATION_MODIFIER", 4, 9], ["400 cm", "OBSERVATION_MODIFIER", 65, 71]]], ["Prior to every spectrum, a background reference was taken using an empty cell to ensure no interferences.", [["cell", "ANATOMY", 73, 77], ["cell", "CELL", 73, 77], ["an empty cell", "TREATMENT", 64, 77]]], ["Then, spectrum intensity was transformed into relative transmittance, %T.Extraction with DES and Conventional SolventsUltrasound-assisted extractions (UAE) performed in a sonication water bath (WUC-A03H, daihan scientific Co., Ltd.", [["DES", "CHEMICAL", 89, 92], ["%T.Extraction", "TREATMENT", 70, 83], ["DES", "TREATMENT", 89, 92], ["Conventional SolventsUltrasound-assisted extractions", "TREATMENT", 97, 149], ["a sonication water bath", "TREATMENT", 169, 192]]], ["Distilled water, 70% ethanol, and methanol were used as conventional solvents as they have exhibited high extraction performance of anthocyanins from Roselle [6, 14, 16, 17] .", [["ethanol", "CHEMICAL", 21, 28], ["methanol", "CHEMICAL", 34, 42], ["anthocyanins", "CHEMICAL", 132, 144], ["ethanol", "CHEMICAL", 21, 28], ["methanol", "CHEMICAL", 34, 42], ["anthocyanins", "CHEMICAL", 132, 144], ["ethanol", "SIMPLE_CHEMICAL", 21, 28], ["methanol", "SIMPLE_CHEMICAL", 34, 42], ["anthocyanins", "SIMPLE_CHEMICAL", 132, 144], ["methanol", "TREATMENT", 34, 42], ["conventional solvents", "TREATMENT", 56, 77]]], ["0.5 g of comminuted Roselle calyces added with 20 mL of conventional solvents and DESs.", [["calyces", "ANATOMY", 28, 35], ["comminuted Roselle calyces", "TREATMENT", 9, 35], ["conventional solvents", "TREATMENT", 56, 77], ["DESs", "TREATMENT", 82, 86]]], ["The mixture was ultrasonicated in an ultrasonic bath at room temperature (25 \u2022 C) for 20 min.", [["an ultrasonic bath", "TREATMENT", 34, 52]]], ["The samples were left to cool and then filtered.Optimization Parameters of DES and Extraction with Response Surface MethodologyThe polyphenolic yield is affected by different operational factors such as temperature, time, liquid-solid ratio, the molar ratio of DES, speed of agitator and particle size.", [["samples", "ANATOMY", 4, 11], ["DES", "CHEMICAL", 75, 78], ["DES", "CHEMICAL", 261, 264], ["DES", "CHEMICAL", 261, 264], ["The samples", "TEST", 0, 11], ["DES and Extraction", "TREATMENT", 75, 93], ["temperature", "TEST", 203, 214], ["left", "ANATOMY_MODIFIER", 17, 21], ["polyphenolic yield", "OBSERVATION", 131, 149], ["particle", "OBSERVATION_MODIFIER", 288, 296], ["size", "OBSERVATION_MODIFIER", 297, 301]]], ["Herein, only three of them examined: Liquid-to-solid ratio, molarity ratio, and additional water content.", [["molarity", "SIMPLE_CHEMICAL", 60, 68], ["water", "SIMPLE_CHEMICAL", 91, 96], ["water content", "OBSERVATION", 91, 104]]], ["The DES that provides the highest yield of anthocyanin was selected for the optimization process.Optimization Parameters of DES and Extraction with Response Surface MethodologyThe optimization parameters of the DES examined systematically using response surface methodology based on the three-level Box-Behnken design (Design expert software 9.0).", [["DES", "CHEMICAL", 4, 7], ["anthocyanin", "CHEMICAL", 43, 54], ["DES", "CHEMICAL", 124, 127], ["DES", "CHEMICAL", 211, 214], ["DES", "CHEMICAL", 4, 7], ["anthocyanin", "CHEMICAL", 43, 54], ["anthocyanin", "SIMPLE_CHEMICAL", 43, 54], ["The DES", "TREATMENT", 0, 7], ["anthocyanin", "TREATMENT", 43, 54], ["DES and Extraction", "TREATMENT", 124, 142], ["the DES", "TREATMENT", 207, 214], ["response surface methodology", "TEST", 245, 273], ["Design expert software", "TEST", 319, 341]]], ["The combinations of the molarity ratio of sodium acetate (1) to formic acid (1, 2.5 and 4), additional water (0%, 30% and 60%) and solvent to solid ratio (10:0.5, 25:0.5 and 40:0.5 mL/g) were independent variables chosen for UAE.", [["sodium acetate", "CHEMICAL", 42, 56], ["formic acid", "CHEMICAL", 64, 75], ["sodium acetate", "CHEMICAL", 42, 56], ["formic acid", "CHEMICAL", 64, 75], ["sodium acetate", "SIMPLE_CHEMICAL", 42, 56], ["formic acid", "SIMPLE_CHEMICAL", 64, 75], ["the molarity ratio of sodium acetate", "TREATMENT", 20, 56], ["formic acid", "TEST", 64, 75]]], ["These variables regrouped in 17 experimental points, including five replicates at the central point.", [["These variables", "TEST", 0, 15], ["17 experimental", "OBSERVATION_MODIFIER", 29, 44], ["central", "ANATOMY_MODIFIER", 86, 93]]], ["Total anthocyanin, total phenolic content, FRAP, DPPH radical scavenging activity, and total flavonoid values investigated as the responses (Y) for the design experiment.", [["anthocyanin", "CHEMICAL", 6, 17], ["DPPH", "CHEMICAL", 49, 53], ["flavonoid", "CHEMICAL", 93, 102], ["anthocyanin", "CHEMICAL", 6, 17], ["DPPH", "CHEMICAL", 49, 53], ["flavonoid", "CHEMICAL", 93, 102], ["anthocyanin", "SIMPLE_CHEMICAL", 6, 17], ["phenolic", "SIMPLE_CHEMICAL", 25, 33], ["FRAP", "SIMPLE_CHEMICAL", 43, 47], ["DPPH", "SIMPLE_CHEMICAL", 49, 53], ["flavonoid", "SIMPLE_CHEMICAL", 93, 102], ["Total anthocyanin", "TREATMENT", 0, 17], ["total phenolic content", "TEST", 19, 41], ["FRAP", "TREATMENT", 43, 47], ["DPPH radical scavenging activity", "TREATMENT", 49, 81], ["total flavonoid values", "TEST", 87, 109], ["phenolic content", "OBSERVATION", 25, 41], ["scavenging activity", "OBSERVATION", 62, 81]]], ["The experimental data fitted to the following quadratic polynomial model:Determination of Total Phenolic Content (TPC)The TPC of Roselle extracts was determined using the Folin-Ciocalteu method [51, 60] .", [["extracts", "ANATOMY", 137, 145], ["TPC", "SIMPLE_CHEMICAL", 122, 125], ["Roselle extracts", "ORGANISM_SUBSTANCE", 129, 145], ["Total Phenolic Content (TPC", "TREATMENT", 90, 117], ["The TPC of Roselle extracts", "TREATMENT", 118, 145], ["Phenolic Content", "OBSERVATION", 96, 112]]], ["A UV-spectrophotometer (Thermo Spectronic) used to read absorbance at 760 nm, and the TPC in each extract was calculated from a calibration curve (Y = 0.0009x \u2212 0.0125; R 2 = 0.9977), using gallic acid as a standard.", [["extract", "ANATOMY", 98, 105], ["TPC", "CHEMICAL", 86, 89], ["gallic acid", "CHEMICAL", 190, 201], ["gallic acid", "CHEMICAL", 190, 201], ["TPC", "SIMPLE_CHEMICAL", 86, 89], ["gallic acid", "SIMPLE_CHEMICAL", 190, 201], ["A UV-spectrophotometer (Thermo Spectronic)", "TREATMENT", 0, 42], ["the TPC in each extract", "TREATMENT", 82, 105], ["a calibration curve", "TEST", 126, 145], ["Y", "TEST", 147, 148], ["gallic acid", "TREATMENT", 190, 201], ["TPC", "OBSERVATION_MODIFIER", 86, 89]]], ["The results were given as mg gallic acid equivalent (GAE) g \u22121 dw.Determination of Total Flavonoid (TFC)The total flavonoid was determined using a modified protocol [51, 57, 80] .", [["gallic acid", "CHEMICAL", 29, 40], ["flavonoid", "CHEMICAL", 114, 123], ["gallic acid", "CHEMICAL", 29, 40], ["Flavonoid", "CHEMICAL", 89, 98], ["flavonoid", "CHEMICAL", 114, 123], ["gallic acid", "SIMPLE_CHEMICAL", 29, 40], ["Flavonoid", "SIMPLE_CHEMICAL", 89, 98], ["TFC", "SIMPLE_CHEMICAL", 100, 103], ["flavonoid", "SIMPLE_CHEMICAL", 114, 123], ["Total Flavonoid (TFC)", "TREATMENT", 83, 104], ["The total flavonoid", "TREATMENT", 104, 123], ["a modified protocol", "TREATMENT", 145, 164]]], ["The absorbance was measured at 510 nm after 10 min in the dark at room temperature.", [["The absorbance", "TEST", 0, 14], ["absorbance", "OBSERVATION_MODIFIER", 4, 14]]], ["The TFC was calculated from a calibration curve using epicatechin as standard (Y = 17.062x + 0.0152; R 2 = 0.9994).", [["epicatechin", "CHEMICAL", 54, 65], ["epicatechin", "CHEMICAL", 54, 65], ["epicatechin", "SIMPLE_CHEMICAL", 54, 65], ["The TFC", "TEST", 0, 7], ["a calibration curve", "TEST", 28, 47], ["epicatechin", "TEST", 54, 65]]], ["The results estimated as mg epicatechin equivalents (ECE) g \u22121 dw.Determination of Total Anthocyanin (TACN)A modified pH differential method [48] was employed to quantify the total anthocyanin of Roselle calyces.", [["calyces", "ANATOMY", 204, 211], ["epicatechin", "CHEMICAL", 28, 39], ["epicatechin", "CHEMICAL", 28, 39], ["anthocyanin", "CHEMICAL", 181, 192], ["epicatechin", "SIMPLE_CHEMICAL", 28, 39], ["Anthocyanin", "SIMPLE_CHEMICAL", 89, 100], ["TACN", "SIMPLE_CHEMICAL", 102, 106], ["anthocyanin", "SIMPLE_CHEMICAL", 181, 192], ["Roselle calyces", "MULTI-TISSUE_STRUCTURE", 196, 211], ["Total Anthocyanin (TACN)", "TREATMENT", 83, 107]]], ["Briefly, 0.05 mL aliquot of the extract diluted with 1.95 mL of buffer (consisting of 1.86 g of KCl, 980 mL of distilled water and 6.3 mL HCl), pH 1.0 and another 0.05 mL aliquot of the extract diluted with 1.95 mL of buffer, (consisting of 54.43 g of sodium acetate, 960 mL distilled water and 20 mL HCl) solution pH 4.5.", [["extract", "ANATOMY", 32, 39], ["extract", "ANATOMY", 186, 193], ["KCl", "CHEMICAL", 96, 99], ["sodium acetate", "CHEMICAL", 252, 266], ["KCl", "CHEMICAL", 96, 99], ["HCl", "CHEMICAL", 138, 141], ["sodium acetate", "CHEMICAL", 252, 266], ["HCl", "CHEMICAL", 301, 304], ["sodium acetate", "SIMPLE_CHEMICAL", 252, 266], ["the extract", "TREATMENT", 28, 39], ["KCl", "TREATMENT", 96, 99], ["pH", "TEST", 144, 146], ["sodium acetate", "TREATMENT", 252, 266], ["pH", "TEST", 315, 317]]], ["The buffer solutions completed up to 1 L with distilled water.", [["The buffer solutions", "TREATMENT", 0, 20]]], ["Afterward, the absorbance measured at 518 nm, and the total anthocyanin content was calculated in function of mg delphinidin-3-sambubioside equivalent (D3S E) g \u22121 with the following equation,Determination of Total Anthocyanin (TACN)where A = (Absorbance 518 nm \u2212 Absorbance 700 nm ) pH 1.0 \u2212 (Absorbance 518 nm \u2212 Absorbance 700 nm ) pH 4.5; M W (molecular weight) = 571 g\u00b7mol \u22121 for D3S, DF = dilution factor established in D, l = pathlength in cm and \u03b5 = 26,900 molar extinction coefficient, in L \u00d7 mol \u22121 \u00d7 cm \u22121 , for delphinidin-3-sambubioside.Determination of Ferric Reducing Antioxidant Power (FRAP)FRAP assay performed according to the procedure of [62, 80] .", [["anthocyanin", "CHEMICAL", 60, 71], ["delphinidin-3-sambubioside", "CHEMICAL", 113, 139], ["Anthocyanin", "CHEMICAL", 215, 226], ["delphinidin-3-sambubioside", "CHEMICAL", 522, 548], ["Ferric", "CHEMICAL", 566, 572], ["anthocyanin", "CHEMICAL", 60, 71], ["delphinidin-3-sambubioside", "CHEMICAL", 113, 139], ["Anthocyanin", "CHEMICAL", 215, 226], ["delphinidin-3-sambubioside", "CHEMICAL", 522, 548], ["Ferric", "CHEMICAL", 566, 572], ["anthocyanin", "SIMPLE_CHEMICAL", 60, 71], ["delphinidin-3-sambubioside", "SIMPLE_CHEMICAL", 113, 139], ["Anthocyanin", "SIMPLE_CHEMICAL", 215, 226], ["TACN", "SIMPLE_CHEMICAL", 228, 232], ["delphinidin-3-sambubioside", "SIMPLE_CHEMICAL", 522, 548], ["Ferric", "SIMPLE_CHEMICAL", 566, 572], ["FRAP", "SIMPLE_CHEMICAL", 601, 605], ["the absorbance", "TEST", 11, 25], ["the total anthocyanin content", "TEST", 50, 79], ["mg delphinidin", "TREATMENT", 110, 124], ["sambubioside equivalent (D3S E)", "TREATMENT", 127, 158], ["Total Anthocyanin (TACN", "TREATMENT", 209, 232], ["Absorbance", "TEST", 244, 254], ["Absorbance", "TEST", 264, 274], ["pH", "TEST", 284, 286], ["Absorbance", "TEST", 294, 304], ["nm", "TEST", 309, 311], ["Absorbance", "TEST", 314, 324], ["pH", "TEST", 334, 336], ["M W", "TEST", 342, 345], ["molecular weight", "TEST", 347, 363], ["g\u00b7mol", "TEST", 371, 376], ["D3S", "TEST", 384, 387], ["DF", "PROBLEM", 389, 391], ["dilution factor", "TEST", 394, 409], ["pathlength in cm", "TEST", 432, 448], ["\u03b5", "TEST", 453, 454], ["molar extinction coefficient", "TEST", 464, 492], ["delphinidin", "TEST", 522, 533], ["sambubioside", "TREATMENT", 536, 548], ["Ferric Reducing Antioxidant Power (FRAP)", "TREATMENT", 566, 606], ["FRAP assay", "TEST", 606, 616]]], ["The FRAP values of the extracts were calculated from the calibration curve (Y = 0.8325 \u2212 0.0936; R 2 = 0.9966) using FeSO 4 as a standard.", [["extracts", "ANATOMY", 23, 31], ["extracts", "ORGANISM_SUBSTANCE", 23, 31], ["The FRAP values", "TEST", 0, 15], ["the calibration curve", "TEST", 53, 74], ["Y", "TEST", 76, 77], ["FeSO", "TREATMENT", 117, 121]]], ["The results were given as mmol FeSO 4 equivalents (mmol ISE g \u22121 dw) [81] .Determination of the DPPH Radical Scavenging ActivityDPPH radical scavenging activity determined according to previous studies [51, 82, 83 ].", [["DPPH", "CHEMICAL", 96, 100], ["ActivityDPPH", "CHEMICAL", 120, 132], ["FeSO 4", "CHEMICAL", 31, 37], ["DPPH", "CHEMICAL", 96, 100], ["ActivityDPPH", "CHEMICAL", 120, 132], ["DPPH", "SIMPLE_CHEMICAL", 96, 100], ["ActivityDPPH", "SIMPLE_CHEMICAL", 120, 132], ["mmol FeSO", "TREATMENT", 26, 35], ["the DPPH Radical", "TREATMENT", 92, 108], ["radical scavenging activity", "TEST", 133, 160], ["previous studies", "TEST", 185, 201]]], ["An aliquot of 50 \u00b5L of the sample added with 1 mL DPPH solution (0.06 mM in 80% methanol).", [["sample", "ANATOMY", 27, 33], ["DPPH", "CHEMICAL", 50, 54], ["DPPH", "CHEMICAL", 50, 54], ["methanol", "CHEMICAL", 80, 88], ["DPPH", "SIMPLE_CHEMICAL", 50, 54], ["methanol", "SIMPLE_CHEMICAL", 80, 88], ["1 mL DPPH solution", "TREATMENT", 45, 63]]], ["The absorbance at 517 nm was recorded.", [["The absorbance", "TEST", 0, 14], ["absorbance", "OBSERVATION_MODIFIER", 4, 14]]], ["The DPPH solution used as control.", [["DPPH", "CHEMICAL", 4, 8], ["DPPH", "CHEMICAL", 4, 8], ["DPPH", "SIMPLE_CHEMICAL", 4, 8], ["The DPPH solution", "TREATMENT", 0, 17]]], ["The reduction ratio of DPPH determined with the following equation,Determination of the DPPH Radical Scavenging Activitywhere Ac = Absorbance of control and As = Absorbance of extract.", [["DPPH", "CHEMICAL", 23, 27], ["DPPH", "CHEMICAL", 88, 92], ["DPPH", "CHEMICAL", 23, 27], ["DPPH", "CHEMICAL", 88, 92], ["DPPH", "SIMPLE_CHEMICAL", 23, 27], ["DPPH", "SIMPLE_CHEMICAL", 88, 92], ["DPPH", "TEST", 23, 27], ["the DPPH Radical", "TREATMENT", 84, 100], ["Ac = Absorbance of control", "TREATMENT", 126, 152], ["reduction", "OBSERVATION_MODIFIER", 4, 13]]], ["The DPPH radical scavenging activity in each extract was calculated from a calibration curve (Y = 149.11x \u2212 0.7773; R 2 = 0.9977) considering the reduction ratio as Y and using Trolox as a standard.", [["extract", "ANATOMY", 45, 52], ["DPPH", "CHEMICAL", 4, 8], ["Trolox", "CHEMICAL", 177, 183], ["DPPH", "CHEMICAL", 4, 8], ["Trolox", "CHEMICAL", 177, 183], ["DPPH", "SIMPLE_CHEMICAL", 4, 8], ["Trolox", "SIMPLE_CHEMICAL", 177, 183], ["The DPPH radical scavenging activity", "TREATMENT", 0, 36], ["a calibration curve", "TEST", 73, 92], ["the reduction ratio", "TREATMENT", 142, 161], ["Trolox", "TREATMENT", 177, 183], ["DPPH", "OBSERVATION", 4, 8], ["radical", "OBSERVATION_MODIFIER", 9, 16], ["scavenging", "OBSERVATION_MODIFIER", 17, 27], ["activity", "OBSERVATION_MODIFIER", 28, 36]]], ["The results were given as mmol Trolox equivalent (TE) g \u22121 dw [84] .Thermal StabilityFor the thermal stability, 10 mL of Roselle extracts were put in the brown bottles with screw caps and placed in a preheated water bath at 100, 80, 60 and 40 \u2022 C. Three bottles of each group were removed from the water bath after 20, 40, 60, 80 and 100 min and cooled to room temperature.", [["extracts", "ANATOMY", 129, 137], ["Trolox", "CHEMICAL", 31, 37], ["Trolox", "CHEMICAL", 31, 37], ["Trolox", "SIMPLE_CHEMICAL", 31, 37], ["extracts", "ORGANISM_SUBSTANCE", 129, 137], ["mmol Trolox equivalent (TE)", "TREATMENT", 26, 53], ["Roselle extracts", "TREATMENT", 121, 137], ["screw caps", "TREATMENT", 173, 183], ["a preheated water bath", "TREATMENT", 198, 220], ["the water bath", "TREATMENT", 294, 308], ["Stability", "OBSERVATION", 76, 85], ["thermal", "OBSERVATION_MODIFIER", 93, 100], ["stability", "OBSERVATION_MODIFIER", 101, 110], ["brown", "ANATOMY", 154, 159], ["screw caps", "OBSERVATION", 173, 183]]], ["To evaluate the kinetic modeling of TPC, TFC, TACN, DPPH radical scavenging and FRAP values of DES extracts of Roselle, the first-order reaction rate constant (k) calculated [58, 85] ,Thermal Stabilitywhere k is the constant rate (s \u22121 ), C 0 is the initial concentration and C t is the concentration after the heating time (t) at a given temperature.", [["extracts", "ANATOMY", 99, 107], ["TACN", "CHEMICAL", 46, 50], ["DPPH", "CHEMICAL", 52, 56], ["DES", "CHEMICAL", 95, 98], ["TACN", "CHEMICAL", 46, 50], ["DPPH", "CHEMICAL", 52, 56], ["DES", "CHEMICAL", 95, 98], ["TPC", "SIMPLE_CHEMICAL", 36, 39], ["TFC", "SIMPLE_CHEMICAL", 41, 44], ["TACN", "SIMPLE_CHEMICAL", 46, 50], ["DPPH", "SIMPLE_CHEMICAL", 52, 56], ["FRAP", "SIMPLE_CHEMICAL", 80, 84], ["TPC", "TEST", 36, 39], ["TFC", "TEST", 41, 44], ["TACN", "TREATMENT", 46, 50], ["DPPH radical scavenging", "TREATMENT", 52, 75], ["FRAP values", "TEST", 80, 91], ["DES extracts", "TEST", 95, 107], ["Thermal Stabilitywhere k", "TEST", 184, 208], ["the constant rate", "TEST", 212, 229]]], ["The kinetics of thermal degradation of anthocyanin of Roselle was evaluated with parameter activation energy (Ea) which was determined as described in [74] ,Thermal Stabilitywhere k is the constant rate (s \u22121 ), k ref is the constant rate (s \u22121 ) of a reference temperature T ref (K) .", [["anthocyanin", "CHEMICAL", 39, 50], ["Roselle", "CHEMICAL", 54, 61], ["anthocyanin", "CHEMICAL", 39, 50], ["anthocyanin", "SIMPLE_CHEMICAL", 39, 50], ["Roselle", "SIMPLE_CHEMICAL", 54, 61], ["anthocyanin of Roselle", "TREATMENT", 39, 61], ["Thermal Stabilitywhere k", "TEST", 157, 181], ["the constant rate", "TEST", 185, 202], ["k ref", "TEST", 212, 217], ["the constant rate", "TEST", 221, 238]]], ["40 \u2022 C considered as reference temperature in the present study.", [["reference temperature", "TEST", 21, 42], ["the present study", "TEST", 46, 63]]], ["Ea is the activation energy (J mol \u22121 ) and R is the universal gas constant (8.32 J mol \u22121 K \u22121 ).Storage StabilityThe effect of storage time was investigated at \u221220 \u2022 C, 4 \u2022 C, and ambient conditions in the dark.", [["the universal gas", "TEST", 49, 66], ["Stability", "OBSERVATION_MODIFIER", 106, 115]]], ["10 mL of Roselle extracts were put in brown bottles and placed in the dark at \u221220 \u2022 C, 4 \u2022 C and ambient temperature (20 \u2022 C).", [["extracts", "ANATOMY", 17, 25], ["Roselle", "CHEMICAL", 9, 16], ["extracts", "ORGANISM_SUBSTANCE", 17, 25], ["Roselle extracts", "TREATMENT", 9, 25], ["ambient temperature", "TREATMENT", 97, 116]]], ["The first-order rate constant (k) and half-life time (t 1/2 ) used to determine the kinetic modeling of anthocyanin degradation during the storage [14, 58] :Data and Statistical AnalysesAll studies were performed in triplicates and the mean values were determined.", [["anthocyanin", "CHEMICAL", 104, 115], ["anthocyanin", "CHEMICAL", 104, 115], ["anthocyanin", "SIMPLE_CHEMICAL", 104, 115], ["anthocyanin degradation", "PROBLEM", 104, 127], ["Statistical Analyses", "TEST", 166, 186], ["All studies", "TEST", 186, 197], ["the mean values", "TEST", 232, 247]]], ["The software Design Expert 9.0 (Trial version, Stat-Ease Inc., Mineapolis, MN USA) was used to design the experimentation along with data analysis.", [["Trial version", "TEST", 32, 45], ["Mineapolis", "TREATMENT", 63, 73], ["data analysis", "TEST", 133, 146]]], ["The adequacy of the models obtained was ascertained by screening the R 2 , adjusted R 2 , coefficient of variation (CV) and the value of Fisher's test (F-value).", [["Fisher's test", "TEST", 137, 150]]], ["The significance of the models and regression coefficients were measured at p < 0.05.", [["regression coefficients", "TEST", 35, 58]]], ["One-way statistical analyses were carried out by ANOVA with post-hoc Duncan's test using SPSS (version 21).", [["Duncan's test", "TEST", 69, 82]]], ["The significance of the results was assessed at p \u2264 0.05.ConclusionsThe analysis of the effect of water addition revealed that the viscosity and DES nanostructure decreased upon water addition.", [["DES", "CHEMICAL", 145, 148], ["DES", "CHEMICAL", 145, 148], ["water", "SIMPLE_CHEMICAL", 98, 103], ["DES", "SIMPLE_CHEMICAL", 145, 148], ["water", "SIMPLE_CHEMICAL", 178, 183], ["The analysis", "TEST", 68, 80], ["the viscosity and DES nanostructure", "TREATMENT", 127, 162]]], ["However, the extraction of phytochemical compounds and the antioxidant properties of Roselle increased considerably after the water introduction.", [["Roselle", "CHEMICAL", 85, 92], ["Roselle", "SIMPLE_CHEMICAL", 85, 92], ["phytochemical compounds", "PROBLEM", 27, 50], ["the water introduction", "TREATMENT", 122, 144], ["phytochemical compounds", "OBSERVATION", 27, 50], ["increased", "OBSERVATION_MODIFIER", 93, 102]]], ["SAFA m with 1:2 molarity ratio was revealed to be the most efficient for the extraction of anthocyanins and polyphenol antioxidants from Roselle calyces when compared to SAFA 0 , SAFA 20 , SAFA 40 , SAFA 60 , SAFA 80 and conventional solvents.", [["calyces", "ANATOMY", 145, 152], ["anthocyanins", "CHEMICAL", 91, 103], ["polyphenol", "CHEMICAL", 108, 118], ["SAFA 20 , SAFA 40 , SAFA 60 , SAFA 80", "CHEMICAL", 179, 216], ["anthocyanins", "CHEMICAL", 91, 103], ["polyphenol", "CHEMICAL", 108, 118], ["SAFA", "CHEMICAL", 170, 174], ["SAFA", "SIMPLE_CHEMICAL", 0, 4], ["anthocyanins", "SIMPLE_CHEMICAL", 91, 103], ["polyphenol", "SIMPLE_CHEMICAL", 108, 118], ["Roselle calyces", "MULTI-TISSUE_STRUCTURE", 137, 152], ["1:2 molarity ratio", "TEST", 12, 30], ["the extraction", "TREATMENT", 73, 87], ["anthocyanins", "TREATMENT", 91, 103], ["polyphenol antioxidants", "TREATMENT", 108, 131], ["Roselle calyces", "TREATMENT", 137, 152], ["SAFA", "TEST", 170, 174], ["SAFA", "TEST", 179, 183], ["SAFA", "TEST", 189, 193], ["SAFA", "TEST", 199, 203], ["SAFA", "TEST", 209, 213], ["conventional solvents", "TREATMENT", 221, 242]]], ["Subsequently, this DES was selected for the optimization using a Box-Behnken design paired with response surface methodology to determine the optimum point for the extraction of maximum anthocyanins from Roselle.", [["DES", "CHEMICAL", 19, 22], ["anthocyanins", "CHEMICAL", 186, 198], ["Roselle", "CHEMICAL", 204, 211], ["DES", "CHEMICAL", 19, 22], ["anthocyanins", "CHEMICAL", 186, 198], ["anthocyanins", "SIMPLE_CHEMICAL", 186, 198], ["Roselle", "SIMPLE_CHEMICAL", 204, 211], ["this DES", "TREATMENT", 14, 22], ["response surface methodology", "TREATMENT", 96, 124], ["the extraction", "TREATMENT", 160, 174], ["maximum anthocyanins", "TREATMENT", 178, 198]]], ["Under these optimum conditions, TPC, TFC, TACN, FRAP and DPPH radical scavenging were found to be 233.26 mg GAE/g, 10.14 mg ECE/g, 10.62 mg D3S/g, 493.45 mmol ISE/g, and 343.41 mmol TE/g, respectively.", [["TPC", "CHEMICAL", 32, 35], ["TACN", "CHEMICAL", 42, 46], ["FRAP", "CHEMICAL", 48, 52], ["DPPH", "CHEMICAL", 57, 61], ["TACN", "CHEMICAL", 42, 46], ["DPPH", "CHEMICAL", 57, 61], ["TPC", "SIMPLE_CHEMICAL", 32, 35], ["TFC", "SIMPLE_CHEMICAL", 37, 40], ["TACN", "SIMPLE_CHEMICAL", 42, 46], ["FRAP", "SIMPLE_CHEMICAL", 48, 52], ["DPPH radical", "SIMPLE_CHEMICAL", 57, 69], ["TPC", "TEST", 32, 35], ["TFC", "TREATMENT", 37, 40], ["TACN", "TREATMENT", 42, 46], ["FRAP", "TREATMENT", 48, 52], ["DPPH radical scavenging", "TREATMENT", 57, 80]]], ["The thermal and storage tests performed on Roselle extracts showed that the phytochemical compounds mainly anthocyanins were more stable in SAFA m .", [["extracts", "ANATOMY", 51, 59], ["anthocyanins", "CHEMICAL", 107, 119], ["anthocyanins", "CHEMICAL", 107, 119], ["Roselle extracts", "ORGANISM_SUBSTANCE", 43, 59], ["anthocyanins", "SIMPLE_CHEMICAL", 107, 119], ["SAFA m", "GENE_OR_GENE_PRODUCT", 140, 146], ["The thermal and storage tests", "TEST", 0, 29], ["Roselle extracts", "TEST", 43, 59], ["the phytochemical compounds", "PROBLEM", 72, 99], ["stable", "OBSERVATION_MODIFIER", 130, 136]]], ["This novel DES represented a green and sustainable solvent for the extraction of bioactive compounds.Conflicts of Interest:The authors declare that there is no conflict of interest.", [["DES", "CHEMICAL", 11, 14], ["DES", "CHEMICAL", 11, 14], ["This novel DES", "TREATMENT", 0, 14], ["the extraction of bioactive compounds", "TREATMENT", 63, 100], ["green", "OBSERVATION_MODIFIER", 29, 34], ["bioactive compounds", "OBSERVATION", 81, 100], ["no", "UNCERTAINTY", 157, 159]]]], "PMC7280583": [["INTRODUCTIONBoth its high pathogenicity and easy person\u2010to\u2010person transmission have allowed SARS\u2010CoV\u20102 to spread rapidly worldwide.1Moreover, asymptomatic and paucisymptomatic patients, which represent up to four fifths of cases, facilitate silent transmission.2The identification and isolation of these patients is therefore essential to slow down the chain of infection.", [["SARS", "DISEASE", 92, 96], ["infection", "DISEASE", 362, 371], ["patients", "ORGANISM", 176, 184], ["patients", "ORGANISM", 304, 312], ["patients", "SPECIES", 176, 184], ["patients", "SPECIES", 304, 312], ["its high pathogenicity", "PROBLEM", 17, 39], ["SARS", "PROBLEM", 92, 96], ["asymptomatic", "PROBLEM", 142, 154], ["The identification", "TEST", 262, 280], ["infection", "PROBLEM", 362, 371], ["high", "OBSERVATION_MODIFIER", 21, 25], ["asymptomatic", "OBSERVATION_MODIFIER", 142, 154], ["infection", "OBSERVATION", 362, 371]]], ["To achieve this goal, it is mandatory to establish what the most frequent signs and symptoms may be in the early stages of the disease or in paucisymptomatic patients.INTRODUCTIONOlfactory and gustatory disturbances were reported as a rare clinical finding in Chinese case series on COVID\u201019, affecting only 5% of the patients.3On the contrary, since the first outbreaks of the epidemic in Europe, we realized that these disorders were reported by many more COVID\u201019 patients.4In the past few weeks, several authors have reported similar findings.5, 6, 7, 8, 9, 10 In particular, these symptoms seem to be common in the early stages of the disease and in paucisymptomatic patients.11However, all these reports are anamnestic or observational while the literature lacks objective studies that evaluate the gustatory and olfactory function in these patients.", [["gustatory", "ANATOMY", 193, 202], ["gustatory", "ANATOMY", 805, 814], ["olfactory", "ANATOMY", 819, 828], ["gustatory disturbances", "DISEASE", 193, 215], ["patients", "ORGANISM", 158, 166], ["patients", "ORGANISM", 318, 326], ["patients", "ORGANISM", 467, 475], ["patients", "ORGANISM", 672, 680], ["gustatory", "ANATOMICAL_SYSTEM", 805, 814], ["olfactory", "ANATOMICAL_SYSTEM", 819, 828], ["patients", "ORGANISM", 847, 855], ["patients", "SPECIES", 158, 166], ["patients", "SPECIES", 318, 326], ["patients", "SPECIES", 467, 475], ["patients", "SPECIES", 672, 680], ["patients", "SPECIES", 847, 855], ["the most frequent signs and symptoms", "PROBLEM", 56, 92], ["the disease", "PROBLEM", 123, 134], ["gustatory disturbances", "PROBLEM", 193, 215], ["these disorders", "PROBLEM", 415, 430], ["these symptoms", "PROBLEM", 580, 594], ["the disease", "PROBLEM", 636, 647], ["objective studies", "TEST", 769, 786], ["disease", "OBSERVATION", 127, 134], ["disease", "OBSERVATION", 640, 647]]], ["Objective evaluation with validated, repeatable and standardized tests is crucial to establish exactly what the frequency, extent, clinical characteristics of these disorders are and then monitor their course over time.", [["Objective evaluation", "TEST", 0, 20], ["standardized tests", "TEST", 52, 70], ["these disorders", "PROBLEM", 159, 174]]], ["Moreover, understanding mechanisms of sensorineural olfactory and gustatory loss with SARS\u2010CoV\u20102 infections might provide novel insights into aspects of viral pathogenesis.INTRODUCTIONPsychophysical tests represent one of the cornerstone in the evaluation of chemosensitive functions.12Using this test methodology, we recently published a preliminary study on a restricted series of hospitalized patients objectively assessed at the University Hospital of Sassari.13However, the majority of tests currently reported in the literature can only be administered in person during the patient's visit and have limited availability.", [["olfactory", "ANATOMY", 52, 61], ["gustatory", "ANATOMY", 66, 75], ["sensorineural olfactory and gustatory loss", "DISEASE", 38, 80], ["SARS", "DISEASE", 86, 90], ["infections", "DISEASE", 97, 107], ["olfactory", "ORGAN", 52, 61], ["gustatory", "ANATOMICAL_SYSTEM", 66, 75], ["CoV\u20102", "GENE_OR_GENE_PRODUCT", 91, 96], ["patients", "ORGANISM", 396, 404], ["patient", "ORGANISM", 580, 587], ["patients", "SPECIES", 396, 404], ["person", "SPECIES", 562, 568], ["patient", "SPECIES", 580, 587], ["sensorineural olfactory", "PROBLEM", 38, 61], ["gustatory loss", "PROBLEM", 66, 80], ["SARS", "PROBLEM", 86, 90], ["CoV\u20102 infections", "PROBLEM", 91, 107], ["viral pathogenesis", "PROBLEM", 153, 171], ["INTRODUCTIONPsychophysical tests", "TEST", 172, 204], ["the evaluation", "TEST", 241, 255], ["chemosensitive functions", "PROBLEM", 259, 283], ["this test methodology", "TEST", 292, 313], ["a preliminary study", "TEST", 337, 356], ["tests", "TEST", 491, 496], ["sensorineural", "OBSERVATION", 38, 51], ["viral", "OBSERVATION", 153, 158], ["chemosensitive functions", "OBSERVATION", 259, 283]]], ["This limitation does not allow assessment of all cases in home quarantine, excluding from the objective evaluation the majority of patients in the initial stages of the disease, paucisymptomatic or with mild and moderate forms of COVID\u201019.", [["COVID", "DISEASE", 230, 235], ["patients", "ORGANISM", 131, 139], ["patients", "SPECIES", 131, 139], ["assessment", "TEST", 31, 41], ["the objective evaluation", "TEST", 90, 114], ["the disease", "PROBLEM", 165, 176], ["paucisymptomatic", "PROBLEM", 178, 194], ["mild and moderate forms of COVID\u2010", "PROBLEM", 203, 236], ["disease", "OBSERVATION", 169, 176], ["mild", "OBSERVATION_MODIFIER", 203, 207], ["moderate", "OBSERVATION_MODIFIER", 212, 220]]], ["To overcome this limitation, we have recently proposed and validated a new psychophysical test that can be self\u2010administered by the patient at home.14The scoring system of this new test, can produce scores on a scale of values equal to that provided by the operator\u2010administered test.", [["patient", "ORGANISM", 132, 139], ["patient", "SPECIES", 132, 139], ["a new psychophysical test", "TEST", 69, 94], ["this new test", "TEST", 172, 185], ["the operator\u2010administered test", "TEST", 253, 283]]], ["For this reason, the results of the two tests are directly comparable.INTRODUCTIONIn this study, we report and analyze the results of a large Italian multicenter study that objectively investigated chemoreceptive disorders in COVID\u201019 patients.Group quarantined functional assessment ::: MATERIALS AND METHODSThe patient cohort was composed of health personnel (doctors, paramedics, nurses, auxiliary staff) in home quarantine, after positivity for SARS\u2010CoV\u20102 confirmed to the nasopharyngeal swab.", [["nasopharyngeal swab", "ANATOMY", 477, 496], ["chemoreceptive disorders", "DISEASE", 198, 222], ["SARS", "DISEASE", 449, 453], ["patients", "ORGANISM", 235, 243], ["patient", "ORGANISM", 313, 320], ["nasopharyngeal swab", "MULTI-TISSUE_STRUCTURE", 477, 496], ["patients", "SPECIES", 235, 243], ["patient", "SPECIES", 313, 320], ["SARS\u2010CoV", "SPECIES", 449, 457], ["the two tests", "TEST", 32, 45], ["this study", "TEST", 85, 95], ["chemoreceptive disorders", "PROBLEM", 198, 222], ["SARS", "PROBLEM", 449, 453], ["the nasopharyngeal swab", "TEST", 473, 496], ["nasopharyngeal swab", "ANATOMY", 477, 496]]], ["This group of patients was composed both of cases in which the swab was performed following the onset of suspicious symptoms, and of asymptomatic patients with positivity detected incidentally to the routine swab.Group quarantined functional assessment ::: MATERIALS AND METHODSThe patients were contacted by phone, the operator explained the study methodology and asked the subjects to collect all the materials necessary for its correct execution, thus contacting the operator again to perform the telephone test.", [["swab", "ANATOMY", 63, 67], ["swab", "ANATOMY", 208, 212], ["patients", "ORGANISM", 14, 22], ["patients", "ORGANISM", 146, 154], ["patients", "ORGANISM", 282, 290], ["patients", "SPECIES", 14, 22], ["patients", "SPECIES", 146, 154], ["patients", "SPECIES", 282, 290], ["the swab", "TEST", 59, 67], ["suspicious symptoms", "PROBLEM", 105, 124], ["positivity", "PROBLEM", 160, 170], ["the routine swab", "TEST", 196, 212], ["the study methodology", "TEST", 339, 360], ["the telephone test", "TEST", 496, 514]]], ["The olfactory threshold was determined using nine solutions with increasing concentration of denatured ethyl\u2010alcohol.", [["olfactory", "ANATOMY", 4, 13], ["ethyl\u2010alcohol", "CHEMICAL", 103, 116], ["ethyl\u2010alcohol", "CHEMICAL", 103, 116], ["olfactory", "ORGAN", 4, 13], ["ethyl\u2010alcohol", "SIMPLE_CHEMICAL", 103, 116], ["nine solutions", "TREATMENT", 45, 59], ["denatured ethyl\u2010alcohol", "PROBLEM", 93, 116], ["denatured ethyl\u2010alcohol", "OBSERVATION", 93, 116]]], ["The olfactory discriminative capability was instead tested by means of seven groups of odorants, for each of which the patient expressed an evaluation from 0 (no discrimination) to 10 (normal discrimination).", [["olfactory", "ANATOMY", 4, 13], ["olfactory", "MULTI-TISSUE_STRUCTURE", 4, 13], ["patient", "ORGANISM", 119, 126], ["patient", "SPECIES", 119, 126], ["an evaluation", "TEST", 137, 150]]], ["Finally, the gustatory function was assessed for each of the primary tastes by means of solutions prepared by the patient.16The evaluation methodology and the scoring system have been previously described in detail in the paper in which this test has been validated.14", [["gustatory", "ANATOMY", 13, 22], ["patient", "ORGANISM", 114, 121], ["patient", "SPECIES", 114, 121], ["the gustatory function", "TEST", 9, 31], ["The evaluation methodology", "TEST", 124, 150]]]], "PMC2908148": [["IntroductionThe public health response to an emerging influenza pandemic, particularly whether to initiate aggressive community mitigation strategies such as school closure, depends in part on the severity of illness caused by the potentially pandemic strain: whether it has a more severe disease rate or higher mortality than usually seen with seasonal influenza [1].", [["influenza", "DISEASE", 54, 63], ["illness", "DISEASE", 209, 216], ["influenza", "DISEASE", 354, 363], ["an emerging influenza pandemic", "PROBLEM", 42, 72], ["aggressive community mitigation strategies", "TREATMENT", 107, 149], ["school closure", "TREATMENT", 158, 172], ["illness", "PROBLEM", 209, 216], ["a more severe disease rate", "PROBLEM", 275, 301], ["seasonal influenza", "PROBLEM", 345, 363], ["severe", "OBSERVATION_MODIFIER", 282, 288], ["disease", "OBSERVATION", 289, 296]]], ["Determining severity of illness as soon as possible after a potentially pandemic influenza strain is recognized is thus one of the highest priorities for public health authorities.IntroductionIn the United States, a key measure for categorizing the potential severity of a pandemic strain is the case-fatality rate (CFR) among those infected [1].", [["influenza", "DISEASE", 81, 90], ["illness", "PROBLEM", 24, 31], ["a potentially pandemic influenza strain", "PROBLEM", 58, 97], ["a pandemic strain", "PROBLEM", 271, 288], ["illness", "OBSERVATION", 24, 31]]], ["The major challenge to directly calculating the CFR rate is specifying the denominator of how many people have been infected, given that most disease does not require hospital care, many persons do not and are advised not to seek medical attention, and strain-specific diagnostic testing capacity is likely to be limited.IntroductionPopulation-based telephone surveys can be a useful way to quickly assess and monitor the prevalence and distribution of influenza-like illness (ILI) in the community.", [["influenza-like illness", "DISEASE", 453, 475], ["ILI", "DISEASE", 477, 480], ["people", "ORGANISM", 99, 105], ["persons", "ORGANISM", 187, 194], ["people", "SPECIES", 99, 105], ["persons", "SPECIES", 187, 194], ["influenza-", "SPECIES", 453, 463], ["diagnostic testing capacity", "TEST", 269, 296], ["influenza", "PROBLEM", 453, 462], ["infected", "OBSERVATION", 116, 124], ["influenza", "OBSERVATION", 453, 462]]], ["However, they do not distinguish between influenza and other causes of ILI (e.g., respiratory syncytial virus, rhinoviruses, coronaviruses, parainfluenza viruses) and their use to rapidly estimate the prevalence of influenza is challenging.IntroductionOn April 24, 2009, New York City (NYC) became the third geographic area of the US in one week to document the presence of novel H1N1 (nH1N1), later declared pandemic influenza (H1N1) 2009 [2], [3].", [["influenza", "DISEASE", 41, 50], ["ILI", "DISEASE", 71, 74], ["respiratory syncytial virus", "DISEASE", 82, 109], ["rhinoviruses", "DISEASE", 111, 123], ["coronaviruses", "DISEASE", 125, 138], ["parainfluenza viruses", "DISEASE", 140, 161], ["influenza", "DISEASE", 215, 224], ["influenza", "DISEASE", 418, 427], ["respiratory syncytial virus", "ORGANISM", 82, 109], ["rhinoviruses", "ORGANISM", 111, 123], ["parainfluenza viruses", "ORGANISM", 140, 161], ["nH1N1", "ORGANISM", 386, 391], ["parainfluenza", "SPECIES", 140, 153], ["pandemic influenza", "SPECIES", 409, 427], ["respiratory syncytial virus", "SPECIES", 82, 109], ["influenza", "PROBLEM", 41, 50], ["ILI", "PROBLEM", 71, 74], ["respiratory syncytial virus", "PROBLEM", 82, 109], ["rhinoviruses", "PROBLEM", 111, 123], ["coronaviruses", "PROBLEM", 125, 138], ["parainfluenza viruses", "PROBLEM", 140, 161], ["influenza", "PROBLEM", 215, 224], ["the US", "TEST", 327, 333], ["novel H1N1 (nH1N1)", "PROBLEM", 374, 392], ["pandemic influenza (H1N1", "PROBLEM", 409, 433], ["respiratory syncytial", "ANATOMY", 82, 103], ["influenza", "OBSERVATION", 215, 224], ["H1N1", "OBSERVATION", 380, 384]]], ["The first confirmed NYC cases occurred in students attending a high school in Queens, where approximately a third of the 2,700 students developed ILI during the course of a week [4].", [["ILI", "DISEASE", 146, 149], ["ILI", "PROBLEM", 146, 149]]], ["In response, the NYC Department of Health and Mental Hygiene (DOHMH) implemented a multifaceted surveillance approach to understand the severity of illness, and the scope, distribution, and impact of nH1N1 in NYC [3], [5].", [["illness", "DISEASE", 148, 155], ["H1N1", "DISEASE", 201, 205], ["a multifaceted surveillance approach", "TREATMENT", 81, 117], ["illness", "PROBLEM", 148, 155], ["H1N1", "OBSERVATION", 201, 205]]], ["In addition to establishing surveillance for more severe illness including deaths and hospitalizations due to nH1N1, we used rapid, population-based telephone surveys to estimate the total burden of ILI and nH1N1 in NYC and, thus, enable rapid estimation of case-fatality and hospitalization rates.IntroductionThis paper presents our estimates of the prevalence of nH1N1 during the 50 days of peak circulation of nH1N1 in NYC, the methods used to derive them, and the resulting case-fatality, hospitalization and intensive care unit (ICU) admission rates.", [["illness", "DISEASE", 57, 64], ["deaths", "DISEASE", 75, 81], ["ILI", "DISEASE", 199, 202], ["more severe illness", "PROBLEM", 45, 64], ["ILI", "PROBLEM", 199, 202], ["hospitalization rates", "TEST", 276, 297]]], ["To our knowledge, NYC was the only area of the country to directly obtain population-level ILI or nH1N1 prevalence during the initial spring 2009 wave of the pandemic.Ethics ::: MethodsThe investigation of this novel strain of influenza in April/May, 2009, including the population-based telephone surveys, was deemed public health practice and not human subjects research by both the General Counsel and the Institutional Review Board Chair of the New York City Department of Health and Mental Hygiene, and therefore did not require Institutional Review Board review.Population Surveys ::: MethodsDOHMH employed rapid telephone polling methods typically used in public opinion research to assess ILI prevalence among both adults and children during two overlapping periods in May and June 2009.", [["ILI", "DISEASE", 91, 94], ["influenza", "DISEASE", 227, 236], ["ILI", "DISEASE", 697, 700], ["human", "ORGANISM", 349, 354], ["children", "ORGANISM", 734, 742], ["human", "SPECIES", 349, 354], ["children", "SPECIES", 734, 742], ["human", "SPECIES", 349, 354], ["the pandemic", "PROBLEM", 154, 166], ["Methods", "TREATMENT", 178, 185], ["influenza", "PROBLEM", 227, 236]]], ["This size sample was adequate to generate a reliable citywide prevalence estimate yet still be conducted quickly.", [["This size sample", "TEST", 0, 16], ["size", "OBSERVATION_MODIFIER", 5, 9]]], ["Household samples of 1000 would typically yield data on more than 2500 persons.", [["persons", "SPECIES", 71, 78]]], ["The predicted 95% margin of error around an estimated prevalence of 50% in such a sample is less than +/\u2212 2%, even after adjusting for non-response weighting.", [["error", "TEST", 28, 33], ["an estimated prevalence", "TEST", 41, 64], ["non-response weighting", "TEST", 135, 157], ["margin", "OBSERVATION_MODIFIER", 18, 24]]], ["Sampled numbers were dialed between five and six times to contact and interview a household, or until the sampled number was determined to be non-working.", [["Sampled numbers", "TEST", 0, 15]]], ["For the first survey, the Council of American Survey Research Organizations (CASRO) response rate 3 (RR3) was 8.4% with a cooperation rate of 31.2% [6].", [["response rate", "TEST", 84, 97], ["RR3", "TEST", 101, 104], ["a cooperation rate", "TEST", 120, 138]]], ["For the second survey, the RR3 was 8.4% with a cooperation rate of 27.9%.Population Surveys ::: MethodsFor each survey, the analysis dataset contained a record for every enumerated household member.", [["the RR3", "TEST", 23, 30], ["a cooperation rate", "TEST", 45, 63], ["the analysis dataset", "TEST", 120, 140]]], ["Respondents were weighted to the 2007 ACS head of household distribution by borough (NYC has five boroughs), age group (0\u201317 years, 18\u201364 years, 65+ years), gender, number of persons in the household and race/ethnicity.", [["ACS", "DISEASE", 38, 41], ["head", "ORGANISM_SUBDIVISION", 42, 46], ["persons", "ORGANISM", 175, 182], ["persons", "SPECIES", 175, 182]]], ["Other household members were weighted to the non-head of household population by borough, age-group, household composition, and respondent's race/ethnicity to generate population estimates of ILI by age group.Population Surveys ::: MethodsILI was defined as having fever and either cough or sore throat during the specified time period.", [["ILI", "DISEASE", 192, 195], ["fever", "DISEASE", 265, 270], ["cough", "DISEASE", 282, 287], ["sore throat", "DISEASE", 291, 302], ["fever", "PROBLEM", 265, 270], ["cough", "PROBLEM", 282, 287], ["sore throat", "PROBLEM", 291, 302], ["cough", "OBSERVATION", 282, 287]]], ["In the first survey, respondents were asked whether they or other household members had experienced fever and either cough or sore throat between May first and the date of the interview (May 20\u201327).", [["fever", "DISEASE", 100, 105], ["cough", "DISEASE", 117, 122], ["sore throat", "DISEASE", 126, 137], ["fever", "PROBLEM", 100, 105], ["cough", "PROBLEM", 117, 122], ["sore throat", "PROBLEM", 126, 137]]], ["In the second survey, the same procedures were used, but the time frame was changed to the past 30 days (May 15\u201319 to June 15\u201319).Population Surveys ::: MethodsThe surveys included two overlapping time periods with different estimates of ILI prevalence.", [["ILI", "DISEASE", 238, 241], ["Methods", "TREATMENT", 153, 160], ["ILI prevalence", "OBSERVATION", 238, 252]]], ["To combine the surveys, an estimate was needed of the proportion of ILI cases reported in each survey that occurred in the 13 day overlapping time period, May 15\u201327.", [["ILI", "DISEASE", 68, 71], ["ILI cases", "PROBLEM", 68, 77]]], ["Ideally, this should reflect the underlying epidemic curve for ILI in NYC during this time.", [["ILI", "DISEASE", 63, 66], ["the underlying epidemic curve", "PROBLEM", 29, 58], ["ILI", "PROBLEM", 63, 66]]], ["Chief complaints are used to classify visits into syndrome categories, including an ILI category that utilizes a definition similar to the survey question, but which can also include the word \u201cflu\u201d [8], [9].Population Surveys ::: MethodsFor each survey, the number of ED ILI visits occurring during the non-overlap and overlap periods was calculated by age, sex, and borough.", [["ILI", "DISEASE", 271, 274]]], ["Assuming that the ILI prevalence reported in the survey followed the same distribution as the ED visits (Figure 1), the proportion of ILI from each survey that was in the overlap period could be estimated.", [["ILI", "DISEASE", 18, 21], ["ILI", "DISEASE", 134, 137], ["ILI", "PROBLEM", 134, 137]]], ["The ILI prevalence estimates during each non-overlap survey period plus the overlap period were then combined.Method 1: Using geographic differences in nH1N1 activity to estimate background ILI ::: Adjustment for background ILI ::: MethodsDuring the reporting period of the May survey, results from ongoing enhanced surveillance of laboratory-confirmed hospitalized nH1N1 cases and of emergency department visits for ILI suggested that community transmission of nH1N1 was occurring primarily in certain parts of the city.", [["nH1N1", "DISEASE", 366, 371], ["ILI", "DISEASE", 417, 420], ["nH1N1", "DISEASE", 462, 467], ["nH1N1", "GENE_OR_GENE_PRODUCT", 152, 157], ["nH1N1", "ORGANISM", 462, 467], ["nH1N1", "DNA", 152, 157], ["ILI", "PROBLEM", 417, 420]]], ["Assuming no geographic variability in the ratios of nH1N1 hospitalizations to nH1N1 prevalence and of nH1N1 prevalence to ILI prevalence, we hypothesized that ILI prevalence in the less affected areas would be largely attributable to causes other than nH1N1.", [["ILI", "DISEASE", 122, 125], ["ILI", "DISEASE", 159, 162], ["nH1N1", "GENE_OR_GENE_PRODUCT", 52, 57], ["geographic variability", "PROBLEM", 12, 34], ["ILI prevalence", "PROBLEM", 159, 173], ["no", "UNCERTAINTY", 9, 11], ["geographic", "OBSERVATION_MODIFIER", 12, 22], ["variability", "OBSERVATION_MODIFIER", 23, 34], ["less affected", "OBSERVATION_MODIFIER", 181, 194]]], ["Following this logic, we defined background ILI prevalence as the average prevalence from the initially less affected boroughs, Bronx, Manhattan and Staten Island from the first survey, overall and by age group, and assumed the same background rate for the entire survey period.", [["background ILI prevalence", "PROBLEM", 33, 58]]], ["We then subtracted our estimates of background ILI from the combined ILI prevalence estimates to produce estimates of nH1N1 prevalence for the period May 1\u2013June 19, 2009.Method 2: Using auxiliary data from previous years to estimate background ILI ::: Adjustment for background ILI ::: MethodsThe second method used data from the ED syndromic surveillance system to adjust for background ILI.", [["ILI", "DISEASE", 388, 391], ["background ILI", "PROBLEM", 36, 50], ["Methods", "TREATMENT", 286, 293], ["background ILI", "PROBLEM", 377, 391]]], ["Using data from EDs reporting consistently over the preceding 5 years, we constructed an age group-specific Serfling model, similar to what is used for estimating excess mortality due to influenza.", [["influenza", "DISEASE", 187, 196], ["estimating excess mortality", "PROBLEM", 152, 179], ["influenza", "PROBLEM", 187, 196], ["influenza", "OBSERVATION", 187, 196]]], ["The Serfling models estimated the expected number of ILI visits in the absence of any type of influenza and were fit separately by age group and included seasonal terms, linear and quadratic trends, and day of week effects to adjust for differential health seeking behavior.", [["ILI", "DISEASE", 53, 56], ["influenza", "DISEASE", 94, 103], ["influenza", "PROBLEM", 94, 103], ["influenza", "OBSERVATION", 94, 103]]], ["This provided a baseline estimate of daily ILI visits in the absence of influenza for the period May 1st to June 19th.", [["influenza", "DISEASE", 72, 81], ["influenza", "PROBLEM", 72, 81]]], ["Daily ED ILI visit data from 2009 were then used to reflect combined background ILI and nH1N1 activity and excess visits due to nH1N1 were calculated by subtracting the expected visits from observed values.", [["ILI", "DISEASE", 80, 83], ["combined background ILI", "PROBLEM", 60, 83]]], ["The daily proportion of ED visits for ILI attributable to nH1N1 were then combined and applied to the ILI estimates for the three survey periods, the two non-overlapping periods and the overlap period, to estimate the prevalence of ILI due to nH1N1.Deaths, hospitalization and ICU admission surveillance ::: MethodsDuring this time period, active surveillance for the first 3 weeks followed by enhanced surveillance was conducted for deaths through all NYC hospitals and the medical examiner's office, including nH1N1 specific testing.", [["ILI", "DISEASE", 38, 41], ["ILI", "DISEASE", 232, 235], ["deaths", "DISEASE", 434, 440], ["ILI", "PROBLEM", 38, 41], ["nH1N1", "TREATMENT", 58, 63], ["ILI", "PROBLEM", 232, 235], ["nH1N1", "TREATMENT", 243, 248], ["enhanced surveillance", "TEST", 394, 415], ["H1N1 specific testing", "TEST", 513, 534]]], ["For most of the period, enhanced surveillance for hospitalizations and ICU admissions due to nH1N1 was also conducted, including nH1N1 specific testing on persons hospitalized who tested influenza A positive and on all persons admitted to the ICU with acute respiratory illness, including ILI.", [["respiratory", "ANATOMY", 258, 269], ["influenza A positive", "DISEASE", 187, 207], ["acute respiratory illness", "DISEASE", 252, 277], ["ILI", "DISEASE", 289, 292], ["persons", "ORGANISM", 155, 162], ["persons", "ORGANISM", 219, 226], ["persons", "SPECIES", 155, 162], ["persons", "SPECIES", 219, 226], ["influenza", "PROBLEM", 187, 196], ["acute respiratory illness", "PROBLEM", 252, 277], ["ILI", "PROBLEM", 289, 292], ["acute", "OBSERVATION_MODIFIER", 252, 257], ["respiratory", "ANATOMY", 258, 269], ["illness", "OBSERVATION", 270, 277]]], ["Eligible cases were persons who died or were hospitalized with laboratory-confirmed or probable (confirmed influenza A, not subtyped) nH1N1 infection with either onset of symptoms between May 1\u2013June 19, 2009 inclusive or, in the absence of an onset date, first came to medical attention during this time period.Calculation of case-fatality, hospitalization and ICU admission rates ::: MethodsTwo sets of case-fatality, hospitalization and ICU admission rates were calculated using numerators obtained through population-based nH1N1 death and hospitalization surveillance and each of the two sets of denominators of persons estimated to have had ILI due to nH1N1 from the population surveys after adjustment for background ILI.", [["influenza A, not subtyped) nH1N1 infection", "DISEASE", 107, 149], ["death", "DISEASE", 532, 537], ["ILI", "DISEASE", 645, 648], ["ILI", "DISEASE", 722, 725], ["persons", "ORGANISM", 20, 27], ["persons", "ORGANISM", 615, 622], ["persons", "SPECIES", 20, 27], ["persons", "SPECIES", 615, 622], ["influenza A", "PROBLEM", 107, 118], ["nH1N1 infection", "PROBLEM", 134, 149], ["symptoms", "PROBLEM", 171, 179], ["ICU admission rates", "TEST", 439, 458], ["hospitalization surveillance", "TEST", 542, 570], ["ILI", "PROBLEM", 645, 648], ["background ILI", "PROBLEM", 711, 725], ["infection", "OBSERVATION", 140, 149]]], ["Compound estimates such as the combined survey estimate of nH1N1 prevalence attributable ILI were generated using Monte Carlo methods with the R statistical package.ILI prevalence estimates ::: Results", [["ILI", "DISEASE", 89, 92], ["ILI", "PROBLEM", 89, 92], ["the R statistical package", "TREATMENT", 139, 164]]]], "1bcdafb2f3e1dbbc5df7d4892bb61df8a964d31d": [["has increased in recent years due to its association and frequent mention within the context of US politics especially as it pertains to Donald Trump's former and current political campaign agenda in forging coalitions and targeting the Mid-West and so-called \"blue-collar regions\" of the United States, well known for their manufacturing industries (Douthat 2018; Trip 2019) .", [["increased", "OBSERVATION_MODIFIER", 4, 13]]]], "ba8645e8c394ad2d10e3d914d9c9ffaa0e4c50f2": [["Affinity chromatography purified antibody from sera of rabbits immunised against HDOA (Fig 1) Enzyme linked immunosorbent assay Heat-denatured ovalbumin High performance liquid chromatography Affinity chromatography purified antibody from sera of rabbits immunised against NOA (Fig 1) Native ovalbumin[NTRODUCTIONThe detection of added proteins in food has been widely approached in the industry by immunochemical techniques (Griffiths et a1 1981 (Griffiths et a1 , 1984 Skerrit and Smith 1985; Breton et a1 1988a) .", [["sera", "ANATOMY", 47, 51], ["sera", "ANATOMY", 239, 243], ["sera", "ORGANISM_SUBSTANCE", 47, 51], ["rabbits", "ORGANISM", 55, 62], ["sera", "ORGANISM_SUBSTANCE", 239, 243], ["rabbits", "ORGANISM", 247, 254], ["Affinity chromatography purified antibody", "PROTEIN", 0, 41], ["rabbits", "SPECIES", 55, 62], ["rabbits", "SPECIES", 247, 254], ["rabbits", "SPECIES", 55, 62], ["rabbits", "SPECIES", 247, 254], ["Affinity chromatography", "TEST", 0, 23], ["antibody", "TEST", 33, 41], ["sera", "TEST", 47, 51], ["rabbits", "TEST", 55, 62], ["HDOA", "TEST", 81, 85], ["Enzyme", "TEST", 94, 100], ["immunosorbent assay", "TEST", 108, 127], ["Heat", "TEST", 128, 132], ["denatured ovalbumin", "TREATMENT", 133, 152], ["High performance liquid chromatography", "TEST", 153, 191], ["Affinity chromatography", "TEST", 192, 215], ["purified antibody", "TEST", 216, 233], ["sera of rabbits", "TREATMENT", 239, 254], ["Native ovalbumin", "TREATMENT", 285, 301]]], ["However, these techniques have so far been limited for a number of different reasons. (a) Proteins in foods are mostly denatured because of the physical, chemical and enzymic transformations undergone during food processing; thus, epitopes found on native molecules are often modified or destroyed. (b) Depending upon the type of immunoassay used, different conclusions can be drawn when a given antigen is present (Breton et a1 1988a (Breton et a1 , 1989 ; native ovalbumin is fully precipitated by polyclonal antibodies whereas the latter will not bind NOA-coated plates.[NTRODUCTIONIt is becoming important to study epitopes transformed during food processing to identify and quantify components, and also additives, and thus provide for improved quality control.", [["ovalbumin", "GENE_OR_GENE_PRODUCT", 465, 474], ["NOA", "SIMPLE_CHEMICAL", 555, 558], ["epitopes", "PROTEIN", 231, 239], ["polyclonal antibodies", "PROTEIN", 500, 521], ["epitopes", "PROTEIN", 619, 627], ["chemical and enzymic transformations", "TREATMENT", 154, 190], ["immunoassay", "TEST", 330, 341], ["native ovalbumin", "PROBLEM", 458, 474], ["polyclonal antibodies", "PROBLEM", 500, 521], ["NOA-coated plates", "TREATMENT", 555, 572], ["NTRODUCTIONIt", "TREATMENT", 574, 587], ["mostly", "OBSERVATION_MODIFIER", 112, 118], ["denatured", "OBSERVATION", 119, 128]]], ["The utilisation of proteins in food is largely determined by their functional properties such as emulsifying, stabilising, foaming and gelforming properties.", [["proteins in food", "PROBLEM", 19, 35], ["proteins", "OBSERVATION", 19, 27]]], ["Egg albumin is one of the most important proteins in food products.", [["Egg albumin", "GENE_OR_GENE_PRODUCT", 0, 11], ["Egg albumin", "PROTEIN", 0, 11], ["Egg albumin", "TEST", 0, 11], ["albumin", "OBSERVATION", 4, 11], ["one of the most important", "OBSERVATION_MODIFIER", 15, 40], ["proteins", "OBSERVATION", 41, 49], ["food products", "OBSERVATION", 53, 66]]], ["As reported by Shimada and Matsushita (1980) , heat coagulation of ovalbumin results from the formation of disulphide links and the exposure of hydrophobic groups.", [["disulphide", "CHEMICAL", 107, 117], ["heat coagulation of ovalbumin", "TREATMENT", 47, 76], ["disulphide links", "PROBLEM", 107, 123]]], ["Ovalbumin is a good model for such studies because the presence of disulphide bridges limits the extent of denaturation.", [["Ovalbumin", "CHEMICAL", 0, 9], ["Ovalbumin", "CHEMICAL", 0, 9], ["disulphide", "CHEMICAL", 67, 77], ["Ovalbumin", "SIMPLE_CHEMICAL", 0, 9], ["disulphide bridges", "SIMPLE_CHEMICAL", 67, 85], ["Ovalbumin", "TREATMENT", 0, 9], ["such studies", "TEST", 30, 42], ["disulphide bridges", "PROBLEM", 67, 85], ["denaturation", "PROBLEM", 107, 119], ["good model", "OBSERVATION_MODIFIER", 15, 25], ["disulphide bridges", "OBSERVATION", 67, 85], ["extent", "OBSERVATION_MODIFIER", 97, 103], ["denaturation", "OBSERVATION", 107, 119]]], ["This might explain why common epitopes were found in this work to both the native (NOA) and the heat denatured (HDOA) molecules (Breton et a1 1989) .", [["heat denatured (HDOA) molecules", "PROTEIN", 96, 127], ["common epitopes", "PROBLEM", 23, 38], ["the heat denatured (HDOA) molecules", "PROBLEM", 92, 127]]], ["Similarly, human antiovalbumin IgE antibodies were found to bind both the native and the denatured forms of ovalbumin after digestion (Elsayed et a1 1986) .", [["human", "ORGANISM", 11, 16], ["antiovalbumin IgE antibodies", "GENE_OR_GENE_PRODUCT", 17, 45], ["ovalbumin", "GENE_OR_GENE_PRODUCT", 108, 117], ["human antiovalbumin IgE antibodies", "PROTEIN", 11, 45], ["human", "SPECIES", 11, 16], ["human", "SPECIES", 11, 16], ["human antiovalbumin IgE antibodies", "TEST", 11, 45]]], ["Kilshaw et a1 (1986), by using monoclonal antibodies of the IgGl subclass, concluded that important differences characterised epitopes of NOA compared with those of HDOA; however, only four monoclonals were used to reach this conclusion.", [["IgGl", "GENE_OR_GENE_PRODUCT", 60, 64], ["monoclonal antibodies", "PROTEIN", 31, 52], ["IgGl subclass", "PROTEIN", 60, 73], ["epitopes", "PROTEIN", 126, 134], ["NOA", "PROBLEM", 138, 141], ["four monoclonals", "TREATMENT", 185, 201]]], ["Some thermal treatments, including extrusion cooking, are likely to modify completely epitopes found on the native molecule.", [["epitopes", "PROTEIN", 86, 94], ["Some thermal treatments", "TREATMENT", 0, 23], ["extrusion cooking", "TREATMENT", 35, 52], ["completely epitopes", "PROBLEM", 75, 94], ["thermal", "OBSERVATION_MODIFIER", 5, 12]]], ["It is thus necessary to investigate specific epitopes for the denatured form of the molecule.", [["epitopes", "PROTEIN", 45, 53]]], ["It was shown, for instance, that glycosylation of ovalbumin through the Maillard reaction takes place by heat treatment at low temperature, leading to a loss of immunogenic properties (Kato et a1 1985) .[NTRODUCTIONIt is also important to evaluate the accuracy of different immunochemical methods to quantify NOA and HDOA, in order to control or to identify ovalbumin in heat-processed foods containing egg.", [["egg", "ANATOMY", 403, 406], ["HDOA", "CHEMICAL", 317, 321], ["ovalbumin", "GENE_OR_GENE_PRODUCT", 50, 59], ["NOA", "SIMPLE_CHEMICAL", 309, 312], ["HDOA", "SIMPLE_CHEMICAL", 317, 321], ["ovalbumin", "GENE_OR_GENE_PRODUCT", 358, 367], ["egg", "ORGANISM_SUBSTANCE", 403, 406], ["glycosylation of ovalbumin", "TREATMENT", 33, 59], ["the Maillard reaction", "TREATMENT", 68, 89], ["low temperature", "PROBLEM", 123, 138], ["a loss of immunogenic properties", "PROBLEM", 151, 183], ["different immunochemical methods", "TEST", 264, 296], ["NOA", "PROBLEM", 309, 312], ["HDOA", "TREATMENT", 317, 321], ["Maillard reaction", "OBSERVATION", 72, 89], ["low temperature", "OBSERVATION_MODIFIER", 123, 138]]], ["In this presentation we shall describe different antibodies obtained from rabbits immunised against either NOA or HDOA and purified by affinity chromatography.", [["HDOA", "CHEMICAL", 114, 118], ["rabbits", "ORGANISM", 74, 81], ["HDOA", "SIMPLE_CHEMICAL", 114, 118], ["antibodies", "PROTEIN", 49, 59], ["rabbits", "SPECIES", 74, 81], ["rabbits", "SPECIES", 74, 81], ["different antibodies", "PROBLEM", 39, 59], ["affinity chromatography", "TEST", 135, 158]]], ["It is shown that, in sandwich ELISA, such antibodies can distinguish NOA from HDOA and can be used for the recognition of the temperature at which canned mushrooms have been heated.", [["NOA", "DISEASE", 69, 72], ["HDOA", "CHEMICAL", 78, 82], ["HDOA", "SIMPLE_CHEMICAL", 78, 82], ["antibodies", "PROTEIN", 42, 52], ["sandwich ELISA", "TEST", 21, 35], ["such antibodies", "PROBLEM", 37, 52], ["NOA", "PROBLEM", 69, 72], ["HDOA", "TREATMENT", 78, 82], ["the temperature", "PROBLEM", 122, 137]]], ["This new approach may be helpful in characterising and quantifying proteinaceous components in food, with a possible assessment of the temperature range at which the food has been heated.EXPERIMENTALHen egg albumin (ovalbumin fraction VII) was purchased from Sigma Chemicals (St Louis, MO, USA).", [["albumin", "GENE_OR_GENE_PRODUCT", 207, 214], ["ovalbumin fraction VII", "GENE_OR_GENE_PRODUCT", 216, 238], ["St Louis", "ORGANISM", 276, 284], ["ovalbumin fraction VII", "PROTEIN", 216, 238], ["EXPERIMENTALHen egg albumin", "TEST", 187, 214]]], ["Ultrogel ACA-22 was obtained from IBF Reactifs (Villeneuve la Garenne).", [["Ultrogel", "CHEMICAL", 0, 8], ["ACA-22", "CHEMICAL", 9, 15], ["ACA-22", "CHEMICAL", 9, 15], ["Ultrogel ACA", "TEST", 0, 12]]], ["Immunoplates for ELISA were from Nunc (Intermed, Noisy le Grand).", [["Immunoplates", "TEST", 0, 12], ["ELISA", "TEST", 17, 22]]], ["Peroxidecoupled goat anti-rabbit IgG was obtained from Bio-Rad Laboratories (Paris) and peroxidase substrate ABTS (2,2-azino-di-(3-ethylbenzthiazoline-6-sulphonate)) was from Boehringer Mannheim, Mannheim, FRG).", [["ABTS", "CHEMICAL", 109, 113], ["2,2-azino-di-(3-ethylbenzthiazoline-6-sulphonate", "CHEMICAL", 115, 163], ["ABTS", "CHEMICAL", 109, 113], ["2,2-azino-di-(3-ethylbenzthiazoline-6-sulphonate)", "CHEMICAL", 115, 164], ["peroxidase substrate ABTS", "SIMPLE_CHEMICAL", 88, 113], ["2,2-azino-di-(3-ethylbenzthiazoline-6-sulphonate", "SIMPLE_CHEMICAL", 115, 163], ["Peroxidecoupled goat anti-rabbit IgG", "PROTEIN", 0, 36], ["goat", "SPECIES", 16, 20], ["anti-rabbit", "SPECIES", 21, 32], ["goat", "SPECIES", 16, 20], ["anti-rabbit", "SPECIES", 21, 32], ["Peroxidecoupled goat anti-rabbit IgG", "TEST", 0, 36], ["peroxidase substrate ABTS", "TEST", 88, 113], ["azino-di", "TREATMENT", 119, 127], ["ethylbenzthiazoline", "TREATMENT", 131, 150]]], ["Canned mushrooms with 20 g kg-' additive ovalbumin, treated at different temperatures (50, 65, 85 and 100\u00b0C) for lOmin, were provided by M. Duclos (ANICC, Saint-Paterne).Unlabelled and labelled ovalbuminNative and heat-denatured ovalbumin were prepared according to the method described earlier (Breton et aZ1989) .", [["ovalbuminNative", "SIMPLE_CHEMICAL", 194, 209], ["ovalbumin", "GENE_OR_GENE_PRODUCT", 229, 238], ["' additive ovalbumin", "TREATMENT", 30, 50], ["heat-denatured ovalbumin", "TREATMENT", 214, 238]]], ["NOA and HDOA were labelled with ' * ' I using Bolton-Hunter reagent.", [["HDOA", "CHEMICAL", 8, 12], ["HDOA", "CHEMICAL", 8, 12], ["NOA", "SIMPLE_CHEMICAL", 0, 3], ["HDOA", "SIMPLE_CHEMICAL", 8, 12]]], ["Specific activities were 11.1 kBq pg-' NOA and 3.1 kBq pg-' HDOA.ImmunisationRabbits (3 months old) were immunised by multiple intradermal injections of antigen (either NOA or HDOA) in Freund's complete adjuvant.", [["intradermal", "ANATOMY", 127, 138], ["HDOA", "CHEMICAL", 176, 180], ["HDOA", "SIMPLE_CHEMICAL", 176, 180], ["Freund", "ORGANISM", 185, 191], ["Specific activities", "TEST", 0, 19], ["ImmunisationRabbits", "TEST", 65, 84], ["multiple intradermal injections of antigen", "TREATMENT", 118, 160], ["HDOA", "TREATMENT", 176, 180], ["Freund's complete adjuvant", "TREATMENT", 185, 211]]], ["Each rabbit received 1 mg antigen per injection.", [["rabbit", "ORGANISM", 5, 11], ["rabbit", "SPECIES", 5, 11], ["rabbit", "SPECIES", 5, 11]]], ["Two weeks later the procedure was repeated with incomplete adjuvant.", [["the procedure", "TREATMENT", 16, 29], ["incomplete adjuvant", "TREATMENT", 48, 67]]], ["Animals were bled 5 to 7 days after the last injection.", [["Animals", "ORGANISM", 0, 7], ["the last injection", "TREATMENT", 36, 54]]], ["Hyperimmunisation took place once a month by intravenous injection of 1 mg antigen in 0.5 ml saline followed by bleeds on days 5, 10 and 15.", [["intravenous", "ANATOMY", 45, 56], ["bleeds", "DISEASE", 112, 118], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 45, 56], ["0.5 ml saline", "TREATMENT", 86, 99], ["bleeds", "PROBLEM", 112, 118], ["bleeds", "OBSERVATION", 112, 118]]], ["Mice were immunised with HDOA as described above except that antigen doses were adjusted at 30 pg per injection.Preparation of affinity purified antibodies(a) Afinity columns NOA and HDOA was coupled to Ultrogel ACA-22 as previously reported (Breton et al 1989) .( b ) Antibody purificationA 2-ml aliquot of either rabbit anti-NOA or anti-HDOA was loaded successively on to NOA and HDOA columns, or vice versa according to Antibodies were eluted with 0 .", [["HDOA", "CHEMICAL", 25, 29], ["HDOA", "CHEMICAL", 183, 187], ["HDOA", "CHEMICAL", 25, 29], ["Ultrogel ACA-22", "CHEMICAL", 203, 218], ["Mice", "ORGANISM", 0, 4], ["HDOA", "SIMPLE_CHEMICAL", 25, 29], ["HDOA", "SIMPLE_CHEMICAL", 183, 187], ["rabbit", "ORGANISM", 315, 321], ["anti-NOA", "GENE_OR_GENE_PRODUCT", 322, 330], ["anti-HDOA", "SIMPLE_CHEMICAL", 334, 343], ["affinity purified antibodies", "PROTEIN", 127, 155], ["rabbit anti-NOA", "PROTEIN", 315, 330], ["anti-HDOA", "PROTEIN", 334, 343], ["Antibodies", "PROTEIN", 423, 433], ["Mice", "SPECIES", 0, 4], ["rabbit", "SPECIES", 315, 321], ["Mice", "SPECIES", 0, 4], ["rabbit", "SPECIES", 315, 321], ["HDOA", "TREATMENT", 25, 29], ["antigen doses", "TREATMENT", 61, 74], ["affinity purified antibodies", "TEST", 127, 155], ["a) Afinity columns NOA", "PROBLEM", 156, 178], ["HDOA", "TEST", 183, 187], ["Ultrogel ACA", "TEST", 203, 215], ["Antibody purificationA", "TEST", 269, 291], ["rabbit anti-NOA", "TREATMENT", 315, 330], ["anti-HDOA", "TREATMENT", 334, 343], ["HDOA columns", "TREATMENT", 382, 394], ["Antibodies", "TEST", 423, 433]]], ["2~ glycine-HC1 buffer pH 2.3 containing 10% dioxane, immediately neutralised with crystallised Tris and then dialysed against cold phosphate buffer saline (PBS).Enzyme linked immunosorbent assays (ELISA)These were performed as previously described (Breton et a1 1989) .Direct ELISAMicrotitre plates (Nunc) were incubated with 0.2 ml (200 ng m1-l) of antigen (NOA, HDOA or mushrooms treated at different temperatures), and a 50 g litre-' solution of dry skim milk was used for plate saturation.", [["milk", "ANATOMY", 458, 462], ["glycine", "CHEMICAL", 3, 10], ["phosphate", "CHEMICAL", 131, 140], ["HDOA", "CHEMICAL", 364, 368], ["glycine", "CHEMICAL", 3, 10], ["dioxane", "CHEMICAL", 44, 51], ["Tris", "CHEMICAL", 95, 99], ["phosphate", "CHEMICAL", 131, 140], ["glycine-HC1", "SIMPLE_CHEMICAL", 3, 14], ["dioxane", "SIMPLE_CHEMICAL", 44, 51], ["phosphate buffer saline", "SIMPLE_CHEMICAL", 131, 154], ["HDOA", "SIMPLE_CHEMICAL", 364, 368], ["skim", "ORGANISM", 453, 457], ["milk", "ORGANISM_SUBSTANCE", 458, 462], ["glycine", "TEST", 3, 10], ["HC1 buffer pH", "TREATMENT", 11, 24], ["10% dioxane", "TREATMENT", 40, 51], ["crystallised Tris", "TREATMENT", 82, 99], ["cold phosphate buffer saline (PBS", "TREATMENT", 126, 159], ["Enzyme linked immunosorbent assays", "TEST", 161, 195], ["ELISA", "TEST", 197, 202], ["Direct ELISAMicrotitre plates", "TREATMENT", 269, 298], ["antigen (NOA", "TREATMENT", 350, 362], ["HDOA", "TREATMENT", 364, 368], ["mushrooms", "TREATMENT", 372, 381], ["a 50 g litre-' solution of dry skim milk", "TREATMENT", 422, 462], ["plate saturation", "TEST", 476, 492]]], ["Plates were incubated with affinity purified antibodies WAC,-NAC, or DAC,-DAC,) for 2 h at 37\u00b0C or overnight at 4\u00b0C.Sandwich ELZSAIn brief, the first incubation was made with 0-2 ml (200 ng m1-l) of affinity purified antibodies (NAC1-NAC, or DAC,-DAC,).", [["NAC", "CHEMICAL", 61, 64], ["DAC", "CHEMICAL", 69, 72], ["DAC", "CHEMICAL", 74, 77], ["NAC1-NAC", "CHEMICAL", 229, 237], ["DAC", "CHEMICAL", 242, 245], ["DAC", "CHEMICAL", 247, 250], ["NAC", "CHEMICAL", 61, 64], ["DAC", "CHEMICAL", 69, 72], ["DAC", "CHEMICAL", 74, 77], ["NAC", "CHEMICAL", 234, 237], ["DAC,-DAC", "CHEMICAL", 242, 250], ["WAC", "SIMPLE_CHEMICAL", 56, 59], ["NAC", "SIMPLE_CHEMICAL", 61, 64], ["DAC", "SIMPLE_CHEMICAL", 69, 72], ["-DAC", "SIMPLE_CHEMICAL", 73, 77], ["NAC1-NAC", "SIMPLE_CHEMICAL", 229, 237], ["DAC", "SIMPLE_CHEMICAL", 242, 245], ["affinity purified antibodies", "PROTEIN", 199, 227], ["NAC1", "PROTEIN", 229, 233], ["affinity purified antibodies", "TEST", 27, 55], ["WAC", "TEST", 56, 59], ["NAC", "TREATMENT", 61, 64], ["DAC", "TREATMENT", 69, 72], ["affinity purified antibodies", "TEST", 199, 227], ["NAC1", "TEST", 229, 233], ["NAC", "TREATMENT", 234, 237], ["DAC", "TREATMENT", 242, 245]]], ["After antigen fixation, plates were incubated with the second antibody made by 1 + 999 dilution of mouse antiserum against either NOA or HDOA.", [["HDOA", "CHEMICAL", 137, 141], ["mouse", "ORGANISM", 99, 104], ["antiserum", "ORGANISM_SUBSTANCE", 105, 114], ["HDOA", "SIMPLE_CHEMICAL", 137, 141], ["mouse", "SPECIES", 99, 104], ["mouse", "SPECIES", 99, 104], ["antigen fixation", "TREATMENT", 6, 22], ["plates", "TREATMENT", 24, 30], ["mouse antiserum", "TREATMENT", 99, 114], ["fixation", "OBSERVATION", 14, 22]]], ["The third antibody was a goat peroxidase-labelled anti-mouse serum.", [["serum", "ANATOMY", 61, 66], ["goat", "ORGANISM", 25, 29], ["peroxidase", "GENE_OR_GENE_PRODUCT", 30, 40], ["serum", "ORGANISM_SUBSTANCE", 61, 66], ["goat peroxidase", "PROTEIN", 25, 40], ["goat", "SPECIES", 25, 29], ["anti-mouse", "SPECIES", 50, 60], ["goat", "SPECIES", 25, 29], ["The third antibody", "TEST", 0, 18], ["a goat peroxidase", "TEST", 23, 40], ["labelled anti-mouse serum", "TEST", 41, 66]]], ["The presence of enzyme was revealed with ABTS.Immunocapture of lZ5I-NOA and 1251-HDOA by affinity purified polyclonal antibodiesMicrotitre plates were coated with 0.2 ml of a solution of 1 pg of affinity purified polyclonal antibodies (NACI-NAC4 or DAC,-DAC4) in 1 ml pH 9-6, 0.05 M carbonate buffer at 37\u00b0C for 2 h.", [["ABTS", "CHEMICAL", 41, 45], ["NACI-NAC4", "CHEMICAL", 236, 245], ["DAC", "CHEMICAL", 249, 252], ["ABTS", "CHEMICAL", 41, 45], ["DAC", "CHEMICAL", 249, 252], ["carbonate", "CHEMICAL", 283, 292], ["ABTS", "SIMPLE_CHEMICAL", 41, 45], ["1251-HDOA", "SIMPLE_CHEMICAL", 76, 85], ["NACI-NAC4", "SIMPLE_CHEMICAL", 236, 245], ["DAC", "SIMPLE_CHEMICAL", 249, 252], ["-DAC4", "SIMPLE_CHEMICAL", 253, 258], ["carbonate", "SIMPLE_CHEMICAL", 283, 292], ["lZ5I-NOA and 1251-HDOA", "DNA", 63, 85], ["affinity purified polyclonal antibodies", "PROTEIN", 195, 234], ["NACI", "PROTEIN", 236, 240], ["NAC4", "PROTEIN", 241, 245], ["DAC4", "PROTEIN", 254, 258], ["enzyme", "TEST", 16, 22], ["ABTS", "TEST", 41, 45], ["Immunocapture", "TEST", 46, 59], ["lZ5I", "TEST", 63, 67], ["NOA", "PROBLEM", 68, 71], ["affinity", "TEST", 89, 97], ["polyclonal antibodiesMicrotitre plates", "TREATMENT", 107, 145], ["a solution", "TREATMENT", 173, 183], ["affinity purified polyclonal antibodies", "TREATMENT", 195, 234], ["NACI", "TEST", 236, 240], ["DAC,-DAC4)", "TREATMENT", 249, 259], ["0.05 M carbonate buffer", "TREATMENT", 276, 299]]], ["After washing, plates were incubated with 0 2 ml of radiolabelled antigen '251-NOA or 12'I-HDOA (1 pg m1-' in PBS) overnight at 4\u00b0C. Wells were washed four times with PBS-Tween 20, cut and counted, and the amount of antigen captured was calculated.Quantitative immunoprecipitationThe standard procedure as described previously (Breton et a1 1989) was employed.Quantitative immunoprecipitationIn brief, fixed amounts of purified NAC,, DAC, or DAC, were mixed with increasing concentrations of either NOA or HDOA (1&200 pg) to a final volume of 1 ml PBS.", [["12'I-HDOA", "CHEMICAL", 86, 95], ["NAC", "CHEMICAL", 428, 431], ["DAC", "CHEMICAL", 434, 437], ["DAC", "CHEMICAL", 442, 445], ["HDOA", "CHEMICAL", 506, 510], ["12'I-HDOA", "CHEMICAL", 86, 95], ["NAC", "CHEMICAL", 428, 431], ["DAC", "CHEMICAL", 434, 437], ["DAC", "CHEMICAL", 442, 445], ["HDOA", "CHEMICAL", 506, 510], ["251-NOA", "SIMPLE_CHEMICAL", 75, 82], ["12'I-HDOA", "SIMPLE_CHEMICAL", 86, 95], ["NAC", "SIMPLE_CHEMICAL", 428, 431], ["DAC", "SIMPLE_CHEMICAL", 434, 437], ["DAC", "SIMPLE_CHEMICAL", 442, 445], ["NOA", "SIMPLE_CHEMICAL", 499, 502], ["HDOA", "SIMPLE_CHEMICAL", 506, 510], ["plates", "TEST", 15, 21], ["radiolabelled antigen", "TEST", 52, 73], ["HDOA", "TEST", 91, 95], ["PBS", "TEST", 110, 113], ["PBS", "TEST", 167, 170], ["Quantitative immunoprecipitation", "TEST", 248, 280], ["The standard procedure", "TREATMENT", 280, 302], ["purified NAC", "TREATMENT", 419, 431], ["DAC", "TREATMENT", 434, 437], ["DAC", "TREATMENT", 442, 445], ["HDOA", "TREATMENT", 506, 510], ["immunoprecipitation", "OBSERVATION", 261, 280]]], ["Succeeding steps were as described previously.High performance liquid chromatography (HPLC)A gel filtration HPLC column TSK 4000 SW (600 x 7.5 mm) was used with a Spectra Physics model 8700 liquid chromatograph equipped with a UV/visible SP 8440 variable wavelight detector connected to a 4200 computing integrator (Gilson, Villiers Le Bel).", [["High performance liquid chromatography", "TEST", 46, 84], ["HPLC", "TEST", 86, 90], ["A gel filtration HPLC", "TEST", 91, 112], ["liquid chromatograph", "TEST", 190, 210], ["a UV", "TREATMENT", 225, 229]]], ["Samples (200 pl) were injected on to the column.", [["Samples", "ANATOMY", 0, 7], ["Samples", "TEST", 0, 7], ["column", "ANATOMY", 41, 47]]], ["The elution was effected with phosphate buffer (pH 7) containing 0-175 M NaCl at a rate of 1 ml min-'.", [["phosphate", "CHEMICAL", 30, 39], ["NaCl", "CHEMICAL", 73, 77], ["phosphate", "CHEMICAL", 30, 39], ["NaCl", "CHEMICAL", 73, 77], ["phosphate", "SIMPLE_CHEMICAL", 30, 39], ["phosphate buffer (pH", "TREATMENT", 30, 50], ["NaCl", "TREATMENT", 73, 77]]], ["The eluates were monitored at 220 mm.Identification of heat-treated ovalbumin in canned mushroomsOvalbumin (20 g kg-') was added to experimental canned mushrooms and the procedure was as described previously (Breton et a1 1988b) .", [["mushrooms", "ANATOMY", 152, 161], ["Ovalbumin", "CHEMICAL", 97, 106], ["Ovalbumin", "CHEMICAL", 97, 106], ["Ovalbumin", "SIMPLE_CHEMICAL", 97, 106], ["The eluates", "TEST", 0, 11], ["heat", "PROBLEM", 55, 59], ["ovalbumin", "TREATMENT", 68, 77], ["Ovalbumin", "TREATMENT", 97, 106], ["experimental canned mushrooms", "TREATMENT", 132, 161], ["the procedure", "TREATMENT", 166, 179]]], ["Heat treatment of these cans was carried out at 50,65, 85 and 100\u00b0C for 10 min.", [["Heat treatment", "TREATMENT", 0, 14]]], ["Ovalbumin coagulated at either 85 or 100\u00b0C was solubilised as in Breton et al (1989) .", [["Ovalbumin", "CHEMICAL", 0, 9], ["Ovalbumin", "CHEMICAL", 0, 9], ["Ovalbumin", "SIMPLE_CHEMICAL", 0, 9], ["Ovalbumin coagulated", "TREATMENT", 0, 20], ["coagulated", "OBSERVATION", 10, 20]]], ["Affinity purified polyclonal antibodies of different specificities (200 pi of 0.2 mg ml-solutions) were first coated on plates.", [["Affinity purified polyclonal antibodies", "PROTEIN", 0, 39], ["Affinity purified polyclonal antibodies of different specificities", "PROBLEM", 0, 66], ["polyclonal antibodies", "OBSERVATION", 18, 39]]], ["After incubating either with pure ovalbumin solutions or mushroom extracts, the presence of ovalbumin was detected by antibodies as described in the section headed 'Direct ELISA'.Protein estimationProtein concentrations were determined either spectrophotometrically using extinction coefficient E;amm = 0.72 for ovalbumin and 1.4 for antibody or colorirnetrically by the Bradford method (Bradford 1976) .(1) Antibody analysis by afinity chromatographyThe preparation of eight different antibodies by affinity chromatography is shown in Fig I and Table 1 .", [["extracts", "ANATOMY", 66, 74], ["mushroom extracts", "ORGANISM_SUBSTANCE", 57, 74], ["ovalbumin", "GENE_OR_GENE_PRODUCT", 92, 101], ["ovalbumin", "PROTEIN", 92, 101], ["antibodies", "PROTEIN", 118, 128], ["antibodies", "PROTEIN", 486, 496], ["pure ovalbumin solutions", "TREATMENT", 29, 53], ["mushroom extracts", "TREATMENT", 57, 74], ["ovalbumin", "PROBLEM", 92, 101], ["Protein estimation", "TEST", 179, 197], ["Protein concentrations", "TEST", 197, 219], ["extinction coefficient E", "TEST", 272, 296], ["amm", "TEST", 297, 300], ["ovalbumin", "TEST", 312, 321], ["antibody", "TEST", 334, 342], ["Antibody analysis", "TEST", 408, 425], ["chromatography", "TEST", 437, 451], ["affinity chromatography", "TEST", 500, 523], ["ovalbumin", "OBSERVATION", 92, 101]]], ["The controls were when (1) sera from non-immunised rabbits were applied to either NOA or HDOA columns, no immunoglobulin bound to these columns; (2) no detectable antibodies were found in tke flow-through fluids after passing immune sera through both columns.", [["sera", "ANATOMY", 27, 31], ["sera", "ANATOMY", 233, 237], ["sera", "ORGANISM_SUBSTANCE", 27, 31], ["rabbits", "ORGANISM", 51, 58], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 106, 120], ["tke", "SIMPLE_CHEMICAL", 188, 191], ["sera", "ORGANISM_SUBSTANCE", 233, 237], ["immunoglobulin", "PROTEIN", 106, 120], ["antibodies", "PROTEIN", 163, 173], ["rabbits", "SPECIES", 51, 58], ["rabbits", "SPECIES", 51, 58], ["non-immunised rabbits", "TREATMENT", 37, 58], ["HDOA columns", "TEST", 89, 101], ["immunoglobulin bound", "PROBLEM", 106, 126], ["these columns", "TEST", 130, 143], ["detectable antibodies", "PROBLEM", 152, 173]]], ["In anti-NOA serum, NAC, were considered as specific for NOA and NAC, specific for HDOA, and the total antibody concentration was 1.70 mg ml-(NAC, +NAC4/NAC, +NAC3).", [["serum", "ANATOMY", 12, 17], ["NAC", "CHEMICAL", 19, 22], ["NAC", "CHEMICAL", 64, 67], ["NAC", "CHEMICAL", 141, 144], ["NAC", "CHEMICAL", 152, 155], ["NAC", "CHEMICAL", 19, 22], ["NAC", "CHEMICAL", 64, 67], ["NAC", "CHEMICAL", 141, 144], ["NAC4", "CHEMICAL", 147, 151], ["NAC", "CHEMICAL", 152, 155], ["serum", "ORGANISM_SUBSTANCE", 12, 17], ["NAC", "SIMPLE_CHEMICAL", 19, 22], ["NOA", "SIMPLE_CHEMICAL", 56, 59], ["NAC", "SIMPLE_CHEMICAL", 64, 67], ["HDOA", "SIMPLE_CHEMICAL", 82, 86], ["NAC", "SIMPLE_CHEMICAL", 141, 144], ["NAC", "SIMPLE_CHEMICAL", 152, 155], ["anti-NOA serum", "TEST", 3, 17], ["NAC", "TREATMENT", 19, 22], ["NOA", "PROBLEM", 56, 59], ["NAC", "TREATMENT", 64, 67], ["HDOA", "TEST", 82, 86], ["the total antibody concentration", "TEST", 92, 124], ["NAC", "TEST", 141, 144], ["NAC4", "TEST", 147, 151], ["NAC", "TREATMENT", 152, 155]]], ["Thus, as judged by affinity chromatography, anti-NOA sera contained antibodies mainly directed against NOA, namely NAC, (85 %) and antibodies directed against DOA, namely NAC, (7%).", [["sera", "ANATOMY", 53, 57], ["NAC", "CHEMICAL", 115, 118], ["NAC", "CHEMICAL", 171, 174], ["NAC", "CHEMICAL", 115, 118], ["NAC", "CHEMICAL", 171, 174], ["sera", "ORGANISM_SUBSTANCE", 53, 57], ["NAC", "SIMPLE_CHEMICAL", 115, 118], ["DOA", "SIMPLE_CHEMICAL", 159, 162], ["NAC", "SIMPLE_CHEMICAL", 171, 174], ["antibodies", "PROTEIN", 68, 78], ["antibodies", "PROTEIN", 131, 141], ["affinity chromatography", "TEST", 19, 42], ["anti-NOA sera", "TEST", 44, 57], ["antibodies", "TEST", 68, 78], ["NAC", "TEST", 115, 118], ["antibodies", "TEST", 131, 141], ["DOA", "PROBLEM", 159, 162], ["NAC", "TEST", 171, 174]]], ["Antibodies against both forms represented only a small fraction of the total.", [["Antibodies", "TEST", 0, 10], ["small", "OBSERVATION_MODIFIER", 49, 54]]], ["In anti-HDOA serum, DAC, were specific for NOA and DAC, were specific for HDOA, and the total antibody concentration was 1.35 mg ml-' (DAC, +DAC,/DAC2 +DAC,).", [["anti-HDOA serum", "ANATOMY", 3, 18], ["DAC", "CHEMICAL", 20, 23], ["DAC", "CHEMICAL", 51, 54], ["DAC", "CHEMICAL", 135, 138], ["DAC", "CHEMICAL", 141, 144], ["DAC", "CHEMICAL", 152, 155], ["DAC", "CHEMICAL", 20, 23], ["DAC", "CHEMICAL", 51, 54], ["DAC", "CHEMICAL", 135, 138], ["DAC", "CHEMICAL", 141, 144], ["DAC", "CHEMICAL", 152, 155], ["anti-HDOA", "ORGANISM_SUBSTANCE", 3, 12], ["serum", "ORGANISM_SUBSTANCE", 13, 18], ["DAC", "SIMPLE_CHEMICAL", 20, 23], ["NOA", "SIMPLE_CHEMICAL", 43, 46], ["DAC", "SIMPLE_CHEMICAL", 51, 54], ["HDOA", "SIMPLE_CHEMICAL", 74, 78], ["anti-HDOA serum", "TEST", 3, 18], ["DAC", "TEST", 20, 23], ["NOA", "PROBLEM", 43, 46], ["DAC", "TEST", 51, 54], ["HDOA", "TEST", 74, 78], ["the total antibody concentration", "TEST", 84, 116], ["DAC", "TEST", 135, 138], ["DAC", "TREATMENT", 141, 144]]], ["Thus in the anti-HDOA antisera, 50% of antibodies (DAC,-DAC,) were directed against common epitopes to NOA and HDOA while only 22% were specific for HDOA (DAC,) and 28 % for NOA(1) Antibody analysis by afinity chromatography(2) Antibody analysis by immunoprecipitation in solution followed by ELISA and HPLC(1) Antibody analysis by afinity chromatographyThe addition of any amount (up to 200 pg) of DAC, antibody to NOA gave rise to a small amount of immunoprecipitate, while an increased precipitation was observed with HDOA (Fig 2a) .", [["DAC,-DAC", "CHEMICAL", 51, 59], ["DAC", "CHEMICAL", 155, 158], ["DAC", "CHEMICAL", 399, 402], ["DAC", "CHEMICAL", 56, 59], ["DAC", "CHEMICAL", 399, 402], ["HDOA", "CHEMICAL", 521, 525], ["DAC", "SIMPLE_CHEMICAL", 51, 54], ["-DAC", "SIMPLE_CHEMICAL", 55, 59], ["HDOA", "SIMPLE_CHEMICAL", 111, 115], ["HDOA", "SIMPLE_CHEMICAL", 149, 153], ["DAC", "SIMPLE_CHEMICAL", 155, 158], ["DAC", "SIMPLE_CHEMICAL", 399, 402], ["HDOA", "SIMPLE_CHEMICAL", 521, 525], ["antibodies", "PROTEIN", 39, 49], ["the anti-HDOA antisera", "TREATMENT", 8, 30], ["antibodies (DAC", "TREATMENT", 39, 54], ["DAC", "TREATMENT", 56, 59], ["HDOA", "TEST", 111, 115], ["HDOA", "TEST", 149, 153], ["DAC", "TEST", 155, 158], ["NOA", "TEST", 174, 177], ["Antibody analysis", "TEST", 181, 198], ["afinity chromatography", "TEST", 202, 224], ["Antibody analysis", "TEST", 228, 245], ["immunoprecipitation", "TEST", 249, 268], ["ELISA", "TEST", 293, 298], ["HPLC", "TEST", 303, 307], ["Antibody analysis", "TEST", 311, 328], ["chromatography", "TEST", 340, 354], ["DAC", "TREATMENT", 399, 402], ["antibody to NOA", "PROBLEM", 404, 419], ["a small amount of immunoprecipitate", "PROBLEM", 433, 468], ["an increased precipitation", "PROBLEM", 476, 502], ["small amount", "OBSERVATION_MODIFIER", 435, 447], ["increased", "OBSERVATION_MODIFIER", 479, 488], ["precipitation", "OBSERVATION", 489, 502]]], ["After removal of immunoprecipitates by high speed centrifugation, supernates were shown by direct ELISA to contain mainly antibodies directed against HDOA.", [["HDOA", "GENE_OR_GENE_PRODUCT", 150, 154], ["antibodies", "PROTEIN", 122, 132], ["HDOA", "PROTEIN", 150, 154], ["removal of immunoprecipitates", "TREATMENT", 6, 35], ["high speed centrifugation", "TREATMENT", 39, 64], ["direct ELISA", "TEST", 91, 103]]], ["This is shown by the slope obtained against NOA as compared with that of HDOA (Fig 2b) on HDOA-sensitised plates.", [["HDOA", "CHEMICAL", 90, 94], ["HDOA", "CHEMICAL", 73, 77], ["HDOA", "CHEMICAL", 90, 94], ["NOA", "SIMPLE_CHEMICAL", 44, 47], ["HDOA", "SIMPLE_CHEMICAL", 73, 77], ["HDOA", "SIMPLE_CHEMICAL", 90, 94], ["NOA", "PROBLEM", 44, 47], ["HDOA", "TEST", 73, 77], ["HDOA-sensitised plates", "TREATMENT", 90, 112], ["sensitised plates", "OBSERVATION", 95, 112]]], ["(NOAsensitised plates were not suitable for analysis, since fixed NOA underwent drastic conformational change as reported by Breton et al(1989) .)", [["(NOAsensitised plates", "TEST", 0, 21], ["analysis", "TEST", 44, 52], ["fixed NOA", "PROBLEM", 60, 69], ["drastic conformational change", "PROBLEM", 80, 109]]], ["Whereas the addition of 40 pg of HDOA was enough to inhibit 85 % of the ELISA response, the addition of 200 pg of NOA inhibited only 35 %.", [["HDOA", "CHEMICAL", 33, 37], ["HDOA", "CHEMICAL", 33, 37], ["HDOA", "SIMPLE_CHEMICAL", 33, 37], ["the ELISA response", "TEST", 68, 86], ["NOA", "TREATMENT", 114, 117]]], ["When those supernates were studied by HPLC (Fig 3) , at low dose (20 pg m1-I) of either NOA (Fig 3a) or HDOA (Fig 3c) as antigen, a large peak of free antibody was seen (20.1) in both cases.", [["HDOA", "CHEMICAL", 104, 108], ["HDOA", "SIMPLE_CHEMICAL", 104, 108], ["HPLC", "TEST", 38, 42], ["HDOA", "TEST", 104, 108], ["antigen", "TEST", 121, 128], ["a large peak of free antibody", "TEST", 130, 159], ["large", "OBSERVATION_MODIFIER", 132, 137], ["peak", "OBSERVATION_MODIFIER", 138, 142], ["free antibody", "OBSERVATION", 146, 159]]], ["This fitted the above observation that the immunoprecipitation did not take place with NOA whereas it was incomplete with HDOA at 20 pg m1-l.", [["HDOA", "CHEMICAL", 122, 126], ["HDOA", "CHEMICAL", 122, 126], ["HDOA", "SIMPLE_CHEMICAL", 122, 126], ["the immunoprecipitation", "TREATMENT", 39, 62], ["HDOA", "TREATMENT", 122, 126]]], ["At high dose of antigen (200 pg ml-') a large increase of NOA was seen (20.8) (Fig 3b) whereas with HDOA only a small amount of free antibody (20.1) and free antigen (9.5) can be seen (Fig 3d) .", [["HDOA", "CHEMICAL", 100, 104], ["HDOA", "SIMPLE_CHEMICAL", 100, 104], ["antigen", "TREATMENT", 16, 23], ["a large increase of NOA", "PROBLEM", 38, 61], ["HDOA", "TEST", 100, 104], ["free antibody", "TEST", 128, 141], ["free antigen", "TEST", 153, 165], ["large", "OBSERVATION_MODIFIER", 40, 45], ["increase", "OBSERVATION_MODIFIER", 46, 54], ["small", "OBSERVATION_MODIFIER", 112, 117], ["amount", "OBSERVATION_MODIFIER", 118, 124]]], ["This was in accordance with the observation that a very small amount of precipitate was recovered in the presence of NOA whereas a large amount of precipitate was recovered with HDOA.", [["HDOA", "CHEMICAL", 178, 182], ["HDOA", "CHEMICAL", 178, 182], ["NOA", "SIMPLE_CHEMICAL", 117, 120], ["HDOA", "SIMPLE_CHEMICAL", 178, 182], ["a very small amount of precipitate", "PROBLEM", 49, 83], ["NOA", "PROBLEM", 117, 120], ["small", "OBSERVATION_MODIFIER", 56, 61], ["amount", "OBSERVATION_MODIFIER", 62, 68], ["NOA", "OBSERVATION", 117, 120], ["large", "OBSERVATION_MODIFIER", 131, 136], ["amount", "OBSERVATION_MODIFIER", 137, 143]]], ["Thus DAC, binds both NOA and HDOA but binds HDOA more strongly than NOA in solution.", [["DAC", "CHEMICAL", 5, 8], ["HDOA", "CHEMICAL", 29, 33], ["DAC", "CHEMICAL", 5, 8], ["HDOA", "CHEMICAL", 29, 33], ["DAC", "SIMPLE_CHEMICAL", 5, 8], ["HDOA", "SIMPLE_CHEMICAL", 29, 33], ["HDOA", "SIMPLE_CHEMICAL", 44, 48], ["NOA", "SIMPLE_CHEMICAL", 68, 71], ["DAC", "TREATMENT", 5, 8]]], ["In Fig 3b, concentration or with HDOA at low (c) or high (d) concentration; 9.5 peak represents HDOA (elution time in minutes); 10.2 peak represents IgM-NOA complexes; 17.5 peak represents IgG-NOA complexes; 20.1 peak represents free antibodies; 20.8 peak represents NOA.(1) Antibody analysis by afinity chromatographyA similar study of NAC2 and DAC2 by immunoprecipitation (Figs 4a and 4b) , ELISA (Figs 4c and 4d) and HPLC (Figs 5a-5d) showed that both antibodies were essentially directed against HDOA.", [["HDOA", "CHEMICAL", 33, 37], ["HDOA", "CHEMICAL", 33, 37], ["HDOA", "SIMPLE_CHEMICAL", 33, 37], ["HDOA", "SIMPLE_CHEMICAL", 96, 100], ["NAC2", "GENE_OR_GENE_PRODUCT", 337, 341], ["DAC2", "SIMPLE_CHEMICAL", 346, 350], ["HDOA", "SIMPLE_CHEMICAL", 500, 504], ["IgM", "PROTEIN", 149, 152], ["NOA complexes", "PROTEIN", 153, 166], ["IgG", "PROTEIN", 189, 192], ["NOA complexes", "PROTEIN", 193, 206], ["NAC2", "PROTEIN", 337, 341], ["DAC2", "PROTEIN", 346, 350], ["antibodies", "PROTEIN", 455, 465], ["HDOA", "PROTEIN", 500, 504], ["HDOA", "TEST", 33, 37], ["high (d) concentration", "TREATMENT", 52, 74], ["IgM", "TEST", 149, 152], ["NOA complexes", "PROBLEM", 153, 166], ["IgG", "TEST", 189, 192], ["NOA complexes", "TEST", 193, 206], ["free antibodies", "TEST", 229, 244], ["NOA", "PROBLEM", 267, 270], ["Antibody analysis", "TEST", 275, 292], ["afinity chromatography", "TEST", 296, 318], ["NAC2", "TEST", 337, 341], ["DAC2", "TEST", 346, 350], ["immunoprecipitation", "TEST", 354, 373], ["Figs", "TEST", 375, 379], ["ELISA", "TEST", 393, 398], ["HPLC", "TEST", 420, 424], ["both antibodies", "PROBLEM", 450, 465]]], ["For NAC,, HPLC analysis (Fig 5a) showed that, with a small amount of added NOA, free antibodies (20.1) with immune complexes at 10.2 (IgM) and at 17.5 (IgG) were present.", [["NAC", "CHEMICAL", 4, 7], ["NAC", "CHEMICAL", 4, 7], ["NAC", "SIMPLE_CHEMICAL", 4, 7], ["NOA", "SIMPLE_CHEMICAL", 75, 78], ["immune complexes", "PROTEIN", 108, 124], ["IgM", "PROTEIN", 134, 137], ["IgG", "PROTEIN", 152, 155], ["NAC", "TREATMENT", 4, 7], ["HPLC analysis", "TEST", 10, 23], ["Fig 5a", "TEST", 25, 31], ["added NOA", "PROBLEM", 69, 78], ["free antibodies", "TEST", 80, 95], ["immune complexes", "TEST", 108, 124], ["IgM", "TEST", 134, 137], ["IgG", "TEST", 152, 155], ["small", "OBSERVATION_MODIFIER", 53, 58]]], ["At a high dose of NOA the two peaks of immune complexes increased along with free NOA (20.8).", [["immune complexes", "PROTEIN", 39, 55], ["a high dose of NOA", "TREATMENT", 3, 21], ["immune complexes", "PROBLEM", 39, 55], ["free NOA", "TEST", 77, 85], ["immune complexes", "OBSERVATION", 39, 55]]], ["In contrast, with HDOA at low dose only, a small peak of free antibodies was detected whereas at a high dose a peak of HDOA was detected (9.5).", [["HDOA", "CHEMICAL", 18, 22], ["HDOA", "CHEMICAL", 18, 22], ["HDOA", "SIMPLE_CHEMICAL", 18, 22], ["HDOA", "SIMPLE_CHEMICAL", 119, 123], ["HDOA", "TREATMENT", 18, 22], ["a small peak of free antibodies", "PROBLEM", 41, 72], ["HDOA", "TEST", 119, 123], ["small", "OBSERVATION_MODIFIER", 43, 48], ["peak", "OBSERVATION_MODIFIER", 49, 53], ["free antibodies", "OBSERVATION", 57, 72]]], ["For DAC2 the profile was quite different: in the presence of small amounts of NOA only free antibodies were found (20.1) whereas an excess of NOA gave a large peak of free NOA (20.8) with an important shoulder of free antibodies (20.1).", [["DAC2", "GENE_OR_GENE_PRODUCT", 4, 8], ["NOA", "SIMPLE_CHEMICAL", 78, 81], ["shoulder", "ORGANISM_SUBDIVISION", 201, 209], ["DAC2", "PROTEIN", 4, 8], ["antibodies", "PROTEIN", 92, 102], ["small amounts of NOA", "PROBLEM", 61, 81], ["free antibodies", "TEST", 87, 102], ["an excess of NOA", "PROBLEM", 129, 145], ["a large peak of free NOA", "PROBLEM", 151, 175], ["free antibodies", "TEST", 213, 228], ["small", "OBSERVATION_MODIFIER", 61, 66], ["amounts", "OBSERVATION_MODIFIER", 67, 74], ["large", "OBSERVATION_MODIFIER", 153, 158], ["peak", "OBSERVATION_MODIFIER", 159, 163], ["shoulder", "ANATOMY", 201, 209]]], ["Supernate of DAC, with a low dose of HDOA showed a small amount of free antibody, and a small peak of free antigen was found with a large dose of HDOA.(1) Antibody analysis by afinity chromatographyThus NAC, bound but did not precipitate NOA (as evidenced by immune soluble complexes) while precipitating HDOA.", [["DAC", "CHEMICAL", 13, 16], ["HDOA", "CHEMICAL", 37, 41], ["HDOA", "CHEMICAL", 146, 150], ["NAC", "CHEMICAL", 203, 206], ["DAC", "CHEMICAL", 13, 16], ["HDOA", "CHEMICAL", 146, 150], ["NAC", "CHEMICAL", 203, 206], ["DAC", "SIMPLE_CHEMICAL", 13, 16], ["HDOA", "SIMPLE_CHEMICAL", 37, 41], ["HDOA", "SIMPLE_CHEMICAL", 146, 150], ["NAC", "SIMPLE_CHEMICAL", 203, 206], ["NOA", "SIMPLE_CHEMICAL", 238, 241], ["HDOA", "SIMPLE_CHEMICAL", 305, 309], ["immune soluble complexes", "PROTEIN", 259, 283], ["HDOA", "PROTEIN", 305, 309], ["DAC", "TREATMENT", 13, 16], ["a low dose of HDOA", "TREATMENT", 23, 41], ["a small amount of free antibody", "PROBLEM", 49, 80], ["a small peak of free antigen", "PROBLEM", 86, 114], ["Antibody analysis", "TEST", 155, 172], ["afinity chromatography", "TEST", 176, 198], ["NAC", "TREATMENT", 203, 206], ["NOA", "PROBLEM", 238, 241], ["immune soluble complexes", "TREATMENT", 259, 283], ["DAC", "ANATOMY", 13, 16], ["small", "OBSERVATION_MODIFIER", 51, 56], ["amount", "OBSERVATION_MODIFIER", 57, 63], ["free antibody", "OBSERVATION", 67, 80], ["small", "OBSERVATION_MODIFIER", 88, 93], ["peak", "OBSERVATION_MODIFIER", 94, 98]]], ["Similar studies cannot be done with NAC, as ELISA could not be used to measure free antibodies (see Table 2 ) or with NAC, (due to poor recovery).", [["NAC", "CHEMICAL", 36, 39], ["NAC", "CHEMICAL", 118, 121], ["NAC", "CHEMICAL", 36, 39], ["NAC", "CHEMICAL", 118, 121], ["NAC", "SIMPLE_CHEMICAL", 36, 39], ["NAC", "SIMPLE_CHEMICAL", 118, 121], ["free antibodies", "PROTEIN", 79, 94], ["Similar studies", "TEST", 0, 15], ["NAC", "TREATMENT", 36, 39], ["ELISA", "TEST", 44, 49], ["NAC", "TREATMENT", 118, 121]]], ["(3) Comparison of affinity purified polyclonal antibodies by ELISAIt can be seen ( Table 2 ) that NAC, did not bind either NOA or HDOA on plates.3) Comparison of affinity purified polyclonal antibodies by ELISAOnly NAC, seemed to be perfectly specific for HDOA.", [["NAC", "CHEMICAL", 98, 101], ["HDOA", "CHEMICAL", 130, 134], ["NAC", "CHEMICAL", 215, 218], ["NAC", "CHEMICAL", 98, 101], ["HDOA", "CHEMICAL", 130, 134], ["NAC", "CHEMICAL", 215, 218], ["NAC", "SIMPLE_CHEMICAL", 98, 101], ["HDOA", "SIMPLE_CHEMICAL", 130, 134], ["NAC", "SIMPLE_CHEMICAL", 215, 218], ["HDOA", "SIMPLE_CHEMICAL", 256, 260], ["affinity purified polyclonal antibodies", "PROTEIN", 18, 57], ["affinity purified polyclonal antibodies", "PROTEIN", 162, 201], ["affinity purified polyclonal antibodies", "PROBLEM", 18, 57], ["NAC", "TREATMENT", 98, 101], ["HDOA on plates", "PROBLEM", 130, 144], ["affinity purified polyclonal antibodies", "TREATMENT", 162, 201], ["ELISAOnly NAC", "TREATMENT", 205, 218], ["HDOA", "PROBLEM", 256, 260]]], ["All DAC antibodies were non-specific, recognising both NOA and HDOA.", [["DAC", "CHEMICAL", 4, 7], ["DAC", "CHEMICAL", 4, 7], ["DAC antibodies", "GENE_OR_GENE_PRODUCT", 4, 18], ["HDOA", "SIMPLE_CHEMICAL", 63, 67], ["DAC antibodies", "PROTEIN", 4, 18], ["All DAC antibodies", "TEST", 0, 18]]], ["Table 3 shows that NOA was captured best by NAC, and NAC, (3.7 and 2.6 ng respectively) as expected, but these antibodies (and especially NAC,) also captured HDOA.", [["NAC", "CHEMICAL", 44, 47], ["NAC", "CHEMICAL", 53, 56], ["NAC", "CHEMICAL", 138, 141], ["NAC", "CHEMICAL", 44, 47], ["NAC", "CHEMICAL", 53, 56], ["NAC", "CHEMICAL", 138, 141], ["NOA", "SIMPLE_CHEMICAL", 19, 22], ["NAC", "SIMPLE_CHEMICAL", 44, 47], ["NAC", "SIMPLE_CHEMICAL", 53, 56], ["NAC", "SIMPLE_CHEMICAL", 138, 141], ["HDOA", "SIMPLE_CHEMICAL", 158, 162], ["antibodies", "PROTEIN", 111, 121], ["HDOA", "PROTEIN", 158, 162], ["NAC", "TEST", 53, 56], ["these antibodies", "TEST", 105, 121], ["NAC", "TREATMENT", 138, 141]]], ["The largest amounts of HDOA captured were by NAC,, NAC,, DAC,, DAC,, NAC, and DAC,, in decreasing order of importance.", [["NAC", "CHEMICAL", 45, 48], ["NAC", "CHEMICAL", 51, 54], ["DAC", "CHEMICAL", 57, 60], ["DAC", "CHEMICAL", 63, 66], ["NAC", "CHEMICAL", 69, 72], ["DAC", "CHEMICAL", 78, 81], ["HDOA", "CHEMICAL", 23, 27], ["NAC", "CHEMICAL", 45, 48], ["NAC", "CHEMICAL", 51, 54], ["DAC", "CHEMICAL", 57, 60], ["DAC", "CHEMICAL", 63, 66], ["NAC", "CHEMICAL", 69, 72], ["DAC", "CHEMICAL", 78, 81], ["HDOA", "SIMPLE_CHEMICAL", 23, 27], ["NAC", "SIMPLE_CHEMICAL", 45, 48], ["NAC", "SIMPLE_CHEMICAL", 51, 54], ["DAC", "SIMPLE_CHEMICAL", 57, 60], ["DAC", "SIMPLE_CHEMICAL", 63, 66], ["NAC", "SIMPLE_CHEMICAL", 69, 72], ["DAC", "SIMPLE_CHEMICAL", 78, 81], ["HDOA", "TREATMENT", 23, 27], ["NAC", "TREATMENT", 45, 48], ["NAC", "TREATMENT", 51, 54], ["DAC", "TREATMENT", 57, 60], ["DAC", "TREATMENT", 63, 66], ["NAC", "TREATMENT", 69, 72], ["DAC", "TREATMENT", 78, 81], ["largest", "OBSERVATION_MODIFIER", 4, 11], ["amounts", "OBSERVATION_MODIFIER", 12, 19]]], ["Most important is the fact that NAC, is the most specific for NOA whereas DAC, is completely specific for HDOA.", [["NAC", "CHEMICAL", 32, 35], ["DAC", "CHEMICAL", 74, 77], ["NAC", "CHEMICAL", 32, 35], ["DAC", "CHEMICAL", 74, 77], ["NAC", "SIMPLE_CHEMICAL", 32, 35], ["DAC", "SIMPLE_CHEMICAL", 74, 77], ["HDOA", "SIMPLE_CHEMICAL", 106, 110], ["NAC", "TREATMENT", 32, 35], ["NOA", "PROBLEM", 62, 65], ["HDOA", "PROBLEM", 106, 110]]], ["These results were confirmed by sandwich ELISA (Table 3) mouse anti-HDOA was shown to be more suitable for discrimination between captured NOA and HDOA.(5) Recognition of ovalbumin in canned mushroom as a function of heat treatment depending upon polyclonal antibodies usedEither NAC, (mostly specific for NOA) or DAC, (specific for HDOA) was coated on a plate at 200 ng rn1-I.", [["mushroom", "ANATOMY", 191, 199], ["NAC", "CHEMICAL", 280, 283], ["DAC", "CHEMICAL", 314, 317], ["NAC", "CHEMICAL", 280, 283], ["DAC", "CHEMICAL", 314, 317], ["mouse", "ORGANISM", 57, 62], ["ovalbumin", "GENE_OR_GENE_PRODUCT", 171, 180], ["NAC", "SIMPLE_CHEMICAL", 280, 283], ["DAC", "SIMPLE_CHEMICAL", 314, 317], ["HDOA", "SIMPLE_CHEMICAL", 333, 337], ["ovalbumin", "PROTEIN", 171, 180], ["polyclonal antibodies", "PROTEIN", 247, 268], ["mouse", "SPECIES", 57, 62], ["mouse", "SPECIES", 57, 62], ["mouse anti-HDOA", "TREATMENT", 57, 72], ["ovalbumin in canned mushroom", "TREATMENT", 171, 199], ["heat treatment", "TREATMENT", 217, 231], ["polyclonal antibodies", "TREATMENT", 247, 268], ["NAC", "TREATMENT", 280, 283], ["NOA", "PROBLEM", 306, 309], ["DAC", "TREATMENT", 314, 317], ["a plate", "TREATMENT", 353, 360]]], ["Juices from canned mushroom (with 2 % ovalbumin used as additive) which had been heated at different temperatures were used as antigens on each plate.", [["Juices", "ANATOMY", 0, 6], ["mushroom", "ANATOMY", 19, 27], ["Juices", "CHEMICAL", 0, 6], ["Juices", "SIMPLE_CHEMICAL", 0, 6], ["canned mushroom", "TREATMENT", 12, 27], ["2 % ovalbumin", "TREATMENT", 34, 47], ["canned mushroom", "OBSERVATION", 12, 27]]], ["Mouse anti-HDOA antibodies were used to reveal the presence of captured ovalbumin.", [["Mouse", "ORGANISM", 0, 5], ["anti-HDOA antibodies", "GENE_OR_GENE_PRODUCT", 6, 26], ["ovalbumin", "GENE_OR_GENE_PRODUCT", 72, 81], ["Mouse anti-HDOA antibodies", "PROTEIN", 0, 26], ["ovalbumin", "PROTEIN", 72, 81], ["Mouse", "SPECIES", 0, 5], ["Mouse", "SPECIES", 0, 5], ["Mouse anti-HDOA antibodies", "TEST", 0, 26]]], ["All controls (canned mushrooms without added ovalbumin) were negative; it can be seen in Table 4 that drastic changes of NOA conformation occurred between 65 and 85\u00b0C. In that temperature range, by using NAC, for immunocapture it was possible to detect the presence of native OA heated up to 65\"C, whereas with DAC, antibodies it was possible to recognise the ovalbumin that had been heated at 85\u00b0C or 100\u00b0C. Thus heat treatment of food could be detected by this method.DISCUSSIONImmunochemical analysis of food products is becoming more and more useful for a variety of purposes.", [["NAC", "CHEMICAL", 204, 207], ["DAC", "CHEMICAL", 311, 314], ["NAC", "CHEMICAL", 204, 207], ["DAC", "CHEMICAL", 311, 314], ["NAC", "SIMPLE_CHEMICAL", 204, 207], ["DAC", "SIMPLE_CHEMICAL", 311, 314], ["antibodies", "PROTEIN", 316, 326], ["All controls (canned mushrooms", "TREATMENT", 0, 30], ["added ovalbumin", "TREATMENT", 39, 54], ["drastic changes of NOA conformation", "PROBLEM", 102, 137], ["NAC", "TREATMENT", 204, 207], ["immunocapture", "TREATMENT", 213, 226], ["native OA", "PROBLEM", 269, 278], ["DAC", "TREATMENT", 311, 314], ["antibodies", "TREATMENT", 316, 326], ["the ovalbumin", "TREATMENT", 356, 369], ["heat treatment of food", "TREATMENT", 414, 436], ["DISCUSSIONImmunochemical analysis", "TEST", 470, 503], ["NOA conformation", "OBSERVATION", 121, 137]]], ["In this presentation it has been shown that antibodies with different specificities Identification of heat-treated ovalbumin in canned mushrooms based on optical densities from ELISA procedure using mouse anti-HDOA antiserum (1 :1000) as revealing antibody present in an anti-serum can be separated by affinity chromatography.", [["anti-serum", "ANATOMY", 271, 281], ["mouse", "ORGANISM", 199, 204], ["anti-serum", "CANCER", 271, 281], ["antibodies", "PROTEIN", 44, 54], ["mouse", "SPECIES", 199, 204], ["mouse", "SPECIES", 199, 204], ["ovalbumin in canned mushrooms", "TREATMENT", 115, 144], ["ELISA procedure", "TREATMENT", 177, 192], ["mouse anti-HDOA antiserum", "TREATMENT", 199, 224], ["antibody", "PROBLEM", 248, 256], ["affinity chromatography", "TEST", 302, 325]]], ["However, the final specificity will be dependent upon the technique used.", [["the technique", "TREATMENT", 54, 67]]], ["Several reports have shown that ovalbumin in heated food can be detected (Janssen et a1 1987) and quantified (Breton et a1 1988b) by immunochemical methods, but until now no experiment has been reported where an immunochemical test could be used to determine whether the product has been heated in the range 'native or heated to below 65\u00b0C' or 'heated at 85 to 100\u00b0C'.", [["ovalbumin", "GENE_OR_GENE_PRODUCT", 32, 41], ["ovalbumin in heated food", "PROBLEM", 32, 56], ["immunochemical methods", "TEST", 133, 155], ["an immunochemical test", "TEST", 209, 231]]], ["We have designed a method by which several polyclonal antibodies could be used by immunising rabbits and mice with either native or heat-denatured ovalbumin and by selecting specific polyclonal antibodies by affinity chromatography on either NOA or HDOA columns.", [["rabbits", "ORGANISM", 93, 100], ["mice", "ORGANISM", 105, 109], ["ovalbumin", "GENE_OR_GENE_PRODUCT", 147, 156], ["polyclonal antibodies", "PROTEIN", 43, 64], ["polyclonal antibodies", "PROTEIN", 183, 204], ["rabbits", "SPECIES", 93, 100], ["mice", "SPECIES", 105, 109], ["rabbits", "SPECIES", 93, 100], ["mice", "SPECIES", 105, 109], ["a method", "TREATMENT", 17, 25], ["several polyclonal antibodies", "TREATMENT", 35, 64], ["denatured ovalbumin", "TREATMENT", 137, 156], ["specific polyclonal antibodies", "TEST", 174, 204], ["affinity chromatography", "TEST", 208, 231], ["HDOA columns", "PROBLEM", 249, 261]]], ["NOA is a monomer of MW 43 kDa and HDOA is a polymer or aggregates of 17 000-18 000 kDa as judged by HPLC (Breton et al 1989) .", [["NOA", "DISEASE", 0, 3], ["HDOA", "CHEMICAL", 34, 38], ["NOA", "SIMPLE_CHEMICAL", 0, 3], ["HDOA", "SIMPLE_CHEMICAL", 34, 38], ["HDOA", "PROTEIN", 34, 38]]], ["Such an observation has been made previously showing that heatdenatured OA aggregates exhibited an MW of 2700kDa at 78\u00b0C; 6000kDa at 80\u00b0C and 9700kDa at 82\u00b0C (Kato and Takagi 1987) .DISCUSSIONThese antigens induced different antibody subpopulations: as judged by affinity chromatography, anti-NOA antisera contained 87 % anti-NOA specific antibodies, 7 % anti-DOA specific antibodies and 8 % antibodies binding both NOA and DOA.", [["NOA", "GENE_OR_GENE_PRODUCT", 326, 329], ["anti-DOA", "SIMPLE_CHEMICAL", 355, 363], ["NOA specific antibodies", "PROTEIN", 326, 349], ["anti-DOA specific antibodies", "PROTEIN", 355, 383], ["antibodies", "PROTEIN", 392, 402], ["different antibody subpopulations", "PROBLEM", 215, 248], ["affinity chromatography", "TEST", 263, 286], ["anti-NOA antisera", "TEST", 288, 305], ["anti-NOA specific antibodies", "TEST", 321, 349], ["specific antibodies", "TEST", 364, 383], ["8 % antibodies binding both NOA", "PROBLEM", 388, 419], ["DOA", "PROBLEM", 424, 427]]], ["Anti-DOA antisera contained only 22 % antibodies specific for DOA, 28 % specific for NOA and 50% binding both NOA and DOA.", [["antibodies", "PROTEIN", 38, 48], ["Anti-DOA antisera", "TEST", 0, 17], ["DOA", "TEST", 62, 65], ["NOA", "PROBLEM", 85, 88], ["DOA", "PROBLEM", 118, 121]]], ["However, by direct ELISA, the eight different antibody subpopulations behaved quite differently: as shown previously (Breton et a1 1989) , when fixed to plastic plates, NOA was extremely denatured by interaction with the plastic, and most antibodies (Table 2 ) reacted with NOA on plates, even those supposed to be specific for HDOA (such as DAC,) with the exception of NAC, (specific for NOA) and DAC, (specific for HDOA); most antibodies reacted even better against HDOA.", [["HDOA", "CHEMICAL", 328, 332], ["DAC", "CHEMICAL", 342, 345], ["NAC", "CHEMICAL", 370, 373], ["DAC", "CHEMICAL", 398, 401], ["HDOA", "CHEMICAL", 328, 332], ["DAC", "CHEMICAL", 342, 345], ["NAC", "CHEMICAL", 370, 373], ["DAC", "CHEMICAL", 398, 401], ["NOA", "SIMPLE_CHEMICAL", 169, 172], ["NOA", "SIMPLE_CHEMICAL", 274, 277], ["HDOA", "SIMPLE_CHEMICAL", 328, 332], ["DAC", "SIMPLE_CHEMICAL", 342, 345], ["NAC", "SIMPLE_CHEMICAL", 370, 373], ["DAC", "SIMPLE_CHEMICAL", 398, 401], ["HDOA", "SIMPLE_CHEMICAL", 417, 421], ["HDOA", "SIMPLE_CHEMICAL", 468, 472], ["antibodies", "PROTEIN", 239, 249], ["HDOA", "PROTEIN", 417, 421], ["antibodies", "PROTEIN", 429, 439], ["direct ELISA", "TEST", 12, 24], ["the eight different antibody subpopulations", "PROBLEM", 26, 69], ["NOA on plates", "PROBLEM", 274, 287], ["HDOA", "PROBLEM", 328, 332], ["DAC", "TREATMENT", 342, 345], ["NAC", "TREATMENT", 370, 373], ["NOA", "PROBLEM", 389, 392], ["DAC", "TREATMENT", 398, 401], ["HDOA", "TEST", 417, 421], ["most antibodies", "PROBLEM", 424, 439], ["denatured", "OBSERVATION", 187, 196]]], ["Thus it can be concluded that direct ELISA should not be used to detect changes in antigenic properties of proteins which occurred during food processing.", [["direct ELISA", "TEST", 30, 42], ["changes in antigenic properties of proteins", "PROBLEM", 72, 115]]], ["Indeed, on the one hand, though still of general use, direct ELISA fails to detect monoclonal antibodies, leaving these to be identified by other immunochemical tests (Friguet et a1 1984) .", [["monoclonal antibodies", "PROTEIN", 83, 104], ["direct ELISA", "TEST", 54, 66], ["monoclonal antibodies", "PROBLEM", 83, 104], ["other immunochemical tests", "TEST", 140, 166]]], ["The present observation with polyclonal antibodies emphasises the high percentage (85 %) of antibodies which would not be detected by direct ELISA (Table 1) .", [["polyclonal antibodies", "PROTEIN", 29, 50], ["antibodies", "PROTEIN", 92, 102], ["polyclonal antibodies", "TEST", 29, 50], ["antibodies", "PROBLEM", 92, 102]]], ["Moreover, none of the anti-HDOA antibodies was truly specific (ie recognising only HDOA) ( Table 2) .", [["anti-HDOA antibodies", "GENE_OR_GENE_PRODUCT", 22, 42], ["anti-HDOA antibodies", "PROTEIN", 22, 42], ["the anti-HDOA antibodies", "TEST", 18, 42]]], ["On the other hand, immunoprecipitation is not likely to be of use in the agrofood industries.", [["immunoprecipitation", "TEST", 19, 38], ["not likely to be", "UNCERTAINTY", 42, 58]]], ["As we have seen, whereas NAC, was specific for NOA (Breton et a1 1989) , DAC,, NAC, and DAC, were unable to precipitate NOA and were mainly directed against HDOA though not fully specific for it (Figs 2 and 4) .", [["NAC", "CHEMICAL", 25, 28], ["DAC", "CHEMICAL", 73, 76], ["NAC", "CHEMICAL", 79, 82], ["DAC", "CHEMICAL", 88, 91], ["NAC", "CHEMICAL", 25, 28], ["DAC", "CHEMICAL", 73, 76], ["NAC", "CHEMICAL", 79, 82], ["DAC", "CHEMICAL", 88, 91], ["NAC", "SIMPLE_CHEMICAL", 25, 28], ["DAC", "SIMPLE_CHEMICAL", 73, 76], ["NAC", "SIMPLE_CHEMICAL", 79, 82], ["DAC", "SIMPLE_CHEMICAL", 88, 91], ["NOA", "SIMPLE_CHEMICAL", 120, 123], ["HDOA", "SIMPLE_CHEMICAL", 157, 161], ["NAC", "TREATMENT", 25, 28], ["NOA", "PROBLEM", 47, 50], ["DAC", "TREATMENT", 73, 76], ["NAC", "TREATMENT", 79, 82], ["DAC", "TREATMENT", 88, 91], ["NOA", "PROBLEM", 120, 123], ["Figs", "TEST", 196, 200], ["NAC", "ANATOMY", 79, 82]]], ["These results were confirmed by HPLC analysis of supernates after immunoprecipitation (Figs 3 and 5).", [["HPLC analysis", "TEST", 32, 45], ["immunoprecipitation", "TEST", 66, 85], ["Figs", "TEST", 87, 91]]], ["Thus sandwich ELISA can be considered as the best technique for unambiguous identification of either NOA or HDOA, as shown by immunocapture of radioactive ovalbumin followed by sandwich ELISA (Table 3) .", [["NOA", "SIMPLE_CHEMICAL", 101, 104], ["HDOA", "SIMPLE_CHEMICAL", 108, 112], ["sandwich ELISA", "TEST", 5, 19], ["radioactive ovalbumin", "TREATMENT", 143, 164]]], ["For instance, by comparing seven different procedures, A1 Moudallal (1984) showed that the apparent binding specificity of monoclonal antibodies depended upon the kind of ELISA test used.", [["monoclonal antibodies", "PROTEIN", 123, 144], ["monoclonal antibodies", "PROBLEM", 123, 144], ["ELISA test", "TEST", 171, 181], ["monoclonal antibodies", "OBSERVATION", 123, 144]]], ["Direct ELISA with antigencoated plates was the least powerful technique, but several different sandwich ELISA tests were found to be much better for specificity and sensitivity for the identification of tobacco mosaic virus.", [["tobacco mosaic virus", "DISEASE", 203, 223], ["tobacco mosaic virus", "ORGANISM", 203, 223], ["tobacco mosaic virus", "SPECIES", 203, 223], ["tobacco mosaic virus", "SPECIES", 203, 223], ["Direct ELISA", "TEST", 0, 12], ["antigencoated plates", "TREATMENT", 18, 38], ["several different sandwich ELISA tests", "TEST", 77, 115], ["tobacco mosaic virus", "PROBLEM", 203, 223], ["tobacco mosaic virus", "OBSERVATION", 203, 223]]], ["It was also shown that the specific binding of monoclonal antibodies to the native form of rat brain hexokinase was possible if the enzyme had been immobilised by polyclonal antibodies (Smith and Wilson 1986).", [["brain", "ANATOMY", 95, 100], ["rat", "ORGANISM", 91, 94], ["brain", "ORGAN", 95, 100], ["hexokinase", "GENE_OR_GENE_PRODUCT", 101, 111], ["monoclonal antibodies", "PROTEIN", 47, 68], ["rat brain hexokinase", "PROTEIN", 91, 111], ["polyclonal antibodies", "PROTEIN", 163, 184], ["rat", "SPECIES", 91, 94], ["rat", "SPECIES", 91, 94], ["monoclonal antibodies", "TEST", 47, 68], ["rat brain hexokinase", "PROBLEM", 91, 111], ["the enzyme", "TEST", 128, 138], ["polyclonal antibodies", "TEST", 163, 184]]], ["Conversely immunocapture of a coronavirus by monoclonal antibodies increased the sensitivity of an ELISA assay (Bernard et al 1986) .", [["coronavirus", "DISEASE", 30, 41], ["coronavirus", "ORGANISM", 30, 41], ["monoclonal antibodies", "PROTEIN", 45, 66], ["coronavirus", "SPECIES", 30, 41], ["coronavirus", "SPECIES", 30, 41], ["a coronavirus", "PROBLEM", 28, 41], ["monoclonal antibodies", "TEST", 45, 66], ["an ELISA assay", "TEST", 96, 110], ["coronavirus", "OBSERVATION", 30, 41]]], ["In the case of ovalbumin the molecules underwent an extensive conformational change due to the adsorption of the protein on to polyvinylchloride microtitre plates, as tested with monoclonal (Kilshaw et a1 1986) or polyclonal (Breton et a1 1989) antibodies.DISCUSSIONWhen used as capture antibodies, NAC, was not fully specific for NOA by immunocapture (Table 3) , however, when a mouse anti-HDOA antiserum was used in a sandwich ELISA, NAC, was specific for NOA (OD = 0.4) as compared to HDOA (OD = 0), NAC, could also be used.", [["NAC", "CHEMICAL", 299, 302], ["NAC", "CHEMICAL", 436, 439], ["HDOA", "CHEMICAL", 488, 492], ["NAC", "CHEMICAL", 503, 506], ["polyvinylchloride", "CHEMICAL", 127, 144], ["NAC", "CHEMICAL", 299, 302], ["NAC", "CHEMICAL", 436, 439], ["HDOA", "CHEMICAL", 488, 492], ["NAC", "CHEMICAL", 503, 506], ["NAC", "SIMPLE_CHEMICAL", 299, 302], ["mouse", "ORGANISM", 380, 385], ["NAC", "SIMPLE_CHEMICAL", 436, 439], ["HDOA", "SIMPLE_CHEMICAL", 488, 492], ["NAC", "SIMPLE_CHEMICAL", 503, 506], ["polyclonal (Breton et a1 1989) antibodies", "PROTEIN", 214, 255], ["mouse", "SPECIES", 380, 385], ["mouse", "SPECIES", 380, 385], ["anti-HDOA", "SPECIES", 386, 395], ["an extensive conformational change", "PROBLEM", 49, 83], ["polyvinylchloride microtitre plates", "TREATMENT", 127, 162], ["polyclonal (Breton et", "TEST", 214, 235], ["NAC", "TREATMENT", 299, 302], ["NOA", "PROBLEM", 331, 334], ["immunocapture", "TEST", 338, 351], ["a mouse anti-HDOA antiserum", "TREATMENT", 378, 405], ["a sandwich ELISA", "TEST", 418, 434], ["NAC", "TREATMENT", 436, 439], ["NOA", "PROBLEM", 458, 461], ["HDOA", "TEST", 488, 492], ["NAC", "TREATMENT", 503, 506]]], ["The most likely explanation is that, due to the highly aggregated state of HDOA (MW 18 000 kDa), a NAC, molecule binds much more HDOA than NOA even though the affinity should be much lower.DISCUSSIONSimilarly, DAC, was apparently fully specific for HDOA as measured by immunocapture of radiolabelled antigens (Table 3) .", [["HDOA", "CHEMICAL", 75, 79], ["NAC", "CHEMICAL", 99, 102], ["DAC", "CHEMICAL", 210, 213], ["HDOA", "CHEMICAL", 75, 79], ["NAC", "CHEMICAL", 99, 102], ["HDOA", "CHEMICAL", 129, 133], ["DAC", "CHEMICAL", 210, 213], ["HDOA", "SIMPLE_CHEMICAL", 75, 79], ["NAC", "SIMPLE_CHEMICAL", 99, 102], ["HDOA", "SIMPLE_CHEMICAL", 129, 133], ["DAC", "SIMPLE_CHEMICAL", 210, 213], ["HDOA", "SIMPLE_CHEMICAL", 249, 253], ["HDOA", "PROTEIN", 75, 79], ["HDOA", "PROTEIN", 249, 253], ["radiolabelled antigens", "PROTEIN", 286, 308], ["a NAC", "TREATMENT", 97, 102], ["HDOA", "PROBLEM", 249, 253], ["most likely", "UNCERTAINTY", 4, 15]]], ["However, this was not the case by sandwich ELISA unless a mouse anti-HDOA antiserum was used as second antibody (Table 3) .", [["mouse", "ORGANISM", 58, 63], ["mouse", "SPECIES", 58, 63], ["mouse", "SPECIES", 58, 63], ["sandwich ELISA", "TEST", 34, 48], ["a mouse anti-HDOA antiserum", "TREATMENT", 56, 83]]], ["Thus sandwich ELISA using NAC, or DAC, as capture antibodies permitted identification when ovalbumin was either native or heated to below 65\"C, as compared with ovalbumin heated at 85 to 100\u00b0C (Table 4 ).", [["NAC", "CHEMICAL", 26, 29], ["DAC", "CHEMICAL", 34, 37], ["NAC", "CHEMICAL", 26, 29], ["DAC", "CHEMICAL", 34, 37], ["NAC", "SIMPLE_CHEMICAL", 26, 29], ["DAC", "SIMPLE_CHEMICAL", 34, 37], ["NAC", "TREATMENT", 26, 29], ["DAC", "TREATMENT", 34, 37], ["capture antibodies", "TEST", 42, 60], ["ovalbumin", "PROBLEM", 91, 100], ["ovalbumin", "TEST", 161, 170]]], ["This observation holds for pure solutions of ovalbumin or canned mushroom juices with 20 g litre-' of ovalbumin as additive.DISCUSSIONIt is becoming important to confirm adequate processing of food, particularly thermal treatment for ensuring the absence of living pathogens, most of which are destroyed by heat treatment at 75\u00b0C. However, new technologies in meat processing involve long-term heating between 56 and 85\u00b0C or short-term heating between 57 and 63\"C, known as aseptic processing.", [["mushroom juices", "ANATOMY", 65, 80], ["meat", "ANATOMY", 360, 364], ["ovalbumin", "SIMPLE_CHEMICAL", 45, 54], ["juices", "ORGANISM_SUBSTANCE", 74, 80], ["meat", "ORGANISM_SUBDIVISION", 360, 364], ["pure solutions of ovalbumin", "TREATMENT", 27, 54], ["ovalbumin", "TREATMENT", 102, 111], ["thermal treatment", "TREATMENT", 212, 229], ["living pathogens", "PROBLEM", 258, 274], ["heat treatment", "TREATMENT", 307, 321], ["aseptic processing", "PROBLEM", 474, 492], ["aseptic", "OBSERVATION", 474, 481]]], ["The results reported above have to be related to those given by differential scanning calorimetry, which shows a steady increase of denaturation between 62 and 77\u00b0C (Hegg et a1 1979) .DISCUSSIONFrom these results we can speculate that a drastic change occurred during heat treatment between 65 and 85\u00b0C. If means are required to control for time/ temperature processing of food, a more precise technique is needed.", [["differential scanning calorimetry", "TEST", 64, 97], ["a steady increase of denaturation", "PROBLEM", 111, 144], ["a drastic change", "PROBLEM", 235, 251], ["heat treatment", "TREATMENT", 268, 282], ["a more precise technique", "TREATMENT", 379, 403], ["steady", "OBSERVATION_MODIFIER", 113, 119], ["increase", "OBSERVATION_MODIFIER", 120, 128], ["drastic", "OBSERVATION", 237, 244]]], ["Thus more specific antibodies for immunocapture have to be developed.", [["specific antibodies", "TEST", 10, 29], ["immunocapture", "PROBLEM", 34, 47]]], ["The technique itself should be based on the assumption that, for a given protein, different conformations might be representative of different heat treatments, provided the duration of heat treatment is long enough to obtain a stabilised form of the molecule.", [["different heat treatments", "TREATMENT", 133, 158], ["heat treatment", "TREATMENT", 185, 199]]], ["Then only monoclonal antibodies would be specific enough to distinguish, by immunocapture, different ovalbumins that have been heated a t various temperatures.", [["ovalbumins", "SIMPLE_CHEMICAL", 101, 111], ["monoclonal antibodies", "PROTEIN", 10, 31], ["monoclonal antibodies", "TEST", 10, 31], ["immunocapture", "TEST", 76, 89]]]], "5f755349a4535a95766758f0e7d3a80d30c54ac0": [], "21bc72381784b06599a8fcfd2ccb9c018499bf61": [["BackgroundSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease 2019 (COVID-19) [1] have resulted in a World Health Organization (WHO)classified pandemic [2] .", [["acute respiratory syndrome coronavirus", "DISEASE", 17, 55], ["coronavirus disease", "DISEASE", 75, 94], ["BackgroundSevere acute respiratory syndrome coronavirus 2", "ORGANISM", 0, 57], ["SARS-CoV-2", "ORGANISM", 59, 69], ["coronavirus", "SPECIES", 75, 86], ["BackgroundSevere acute respiratory syndrome coronavirus", "SPECIES", 0, 55], ["SARS-CoV-2", "SPECIES", 59, 69], ["BackgroundSevere acute respiratory syndrome coronavirus", "PROBLEM", 0, 55], ["SARS", "TEST", 59, 63], ["CoV", "TEST", 64, 67], ["coronavirus disease", "PROBLEM", 75, 94], ["COVID", "TEST", 101, 106], ["acute", "OBSERVATION_MODIFIER", 17, 22], ["respiratory syndrome", "OBSERVATION", 23, 43], ["coronavirus", "ANATOMY", 75, 86]]], ["Most patients with SARS-CoV-2 infection are asymptomatic or exhibit mild-to-moderate symptoms, but approximately 15% progress to severe pneumonia, and 5% require intensive care unit (ICU) management due to acute respiratory distress syndrome, septic shock and/or multiple organ failure.", [["respiratory", "ANATOMY", 212, 223], ["organ", "ANATOMY", 272, 277], ["SARS-CoV-2 infection", "DISEASE", 19, 39], ["pneumonia", "DISEASE", 136, 145], ["respiratory distress syndrome", "DISEASE", 212, 241], ["septic shock", "DISEASE", 243, 255], ["organ failure", "DISEASE", 272, 285], ["patients", "ORGANISM", 5, 13], ["SARS-CoV-2", "ORGANISM", 19, 29], ["organ", "ORGAN", 272, 277], ["patients", "SPECIES", 5, 13], ["CoV-", "SPECIES", 24, 28], ["SARS", "PROBLEM", 19, 23], ["CoV-2 infection", "PROBLEM", 24, 39], ["asymptomatic", "PROBLEM", 44, 56], ["mild-to-moderate symptoms", "PROBLEM", 68, 93], ["severe pneumonia", "PROBLEM", 129, 145], ["ICU) management", "TREATMENT", 183, 198], ["acute respiratory distress syndrome", "PROBLEM", 206, 241], ["septic shock", "PROBLEM", 243, 255], ["multiple organ failure", "PROBLEM", 263, 285], ["mild", "OBSERVATION_MODIFIER", 68, 72], ["moderate", "OBSERVATION_MODIFIER", 76, 84], ["symptoms", "OBSERVATION", 85, 93], ["severe", "OBSERVATION_MODIFIER", 129, 135], ["pneumonia", "OBSERVATION", 136, 145], ["acute", "OBSERVATION_MODIFIER", 206, 211], ["respiratory", "ANATOMY", 212, 223], ["distress syndrome", "OBSERVATION", 224, 241], ["septic shock", "OBSERVATION", 243, 255], ["multiple", "OBSERVATION_MODIFIER", 263, 271], ["organ", "ANATOMY", 272, 277], ["failure", "OBSERVATION", 278, 285]]], ["As of July 29, 2020, 16,708,920 cases of COVID-19 have been reported, including 660,123 deaths [3] .", [["deaths", "DISEASE", 88, 94], ["COVID", "TEST", 41, 46]]], ["Case fatality is reported at 3.95% [3] , but this varies widely by location [3] .BackgroundPoor-risk factors for outcome in COVID-19 patients include old age, hypertension, cardiovascular disease and diabetes [4] .", [["cardiovascular", "ANATOMY", 173, 187], ["hypertension", "DISEASE", 159, 171], ["cardiovascular disease", "DISEASE", 173, 195], ["diabetes", "DISEASE", 200, 208], ["patients", "ORGANISM", 133, 141], ["patients", "SPECIES", 133, 141], ["Poor-risk factors", "PROBLEM", 91, 108], ["hypertension", "PROBLEM", 159, 171], ["cardiovascular disease", "PROBLEM", 173, 195], ["diabetes", "PROBLEM", 200, 208], ["hypertension", "OBSERVATION", 159, 171], ["cardiovascular", "ANATOMY", 173, 187], ["disease", "OBSERVATION", 188, 195]]], ["Cancer patients also appear to have a worse prognosis [5] .", [["Cancer", "ANATOMY", 0, 6], ["Cancer", "DISEASE", 0, 6], ["Cancer", "CANCER", 0, 6], ["patients", "ORGANISM", 7, 15], ["patients", "SPECIES", 7, 15]]], ["A meta-analysis found that cancer prevalence in people with COVID-19 was 2% [6] .", [["cancer", "ANATOMY", 27, 33], ["cancer", "DISEASE", 27, 33], ["cancer", "CANCER", 27, 33], ["people", "ORGANISM", 48, 54], ["people", "SPECIES", 48, 54], ["A meta-analysis", "TEST", 0, 15], ["COVID", "TEST", 60, 65], ["cancer", "OBSERVATION", 27, 33]]], ["More importantly, patients with cancer had a higher risk of severe events (admission to an ICU requiring invasive ventilation, or death) compared to those without cancer (11-39% vs 5.8-7.6%) [7, 8] .", [["cancer", "ANATOMY", 32, 38], ["cancer", "ANATOMY", 163, 169], ["cancer", "DISEASE", 32, 38], ["death", "DISEASE", 130, 135], ["cancer", "DISEASE", 163, 169], ["patients", "ORGANISM", 18, 26], ["cancer", "CANCER", 32, 38], ["cancer", "CANCER", 163, 169], ["patients", "SPECIES", 18, 26], ["cancer", "PROBLEM", 32, 38], ["severe events", "PROBLEM", 60, 73], ["invasive ventilation", "TREATMENT", 105, 125], ["death", "PROBLEM", 130, 135], ["cancer", "PROBLEM", 163, 169], ["cancer", "OBSERVATION", 32, 38], ["severe", "OBSERVATION_MODIFIER", 60, 66], ["cancer", "OBSERVATION", 163, 169]]], ["A large-scale study using UK Coronavirus Cancer Monitoring Project data gave consistent findings [9] .BackgroundPatients with hematologic malignancies usually have higher levels of immunosuppression and may develop more severe respiratory viral infections than patients with solid tumors [10] .", [["Cancer", "ANATOMY", 41, 47], ["hematologic malignancies", "ANATOMY", 126, 150], ["respiratory", "ANATOMY", 227, 238], ["solid tumors", "ANATOMY", 275, 287], ["Cancer", "DISEASE", 41, 47], ["hematologic malignancies", "DISEASE", 126, 150], ["respiratory viral infections", "DISEASE", 227, 255], ["tumors", "DISEASE", 281, 287], ["Patients", "ORGANISM", 112, 120], ["hematologic malignancies", "CANCER", 126, 150], ["patients", "ORGANISM", 261, 269], ["solid tumors", "CANCER", 275, 287], ["Patients", "SPECIES", 112, 120], ["patients", "SPECIES", 261, 269], ["A large-scale study", "TEST", 0, 19], ["UK Coronavirus Cancer", "PROBLEM", 26, 47], ["hematologic malignancies", "PROBLEM", 126, 150], ["immunosuppression", "TREATMENT", 181, 198], ["more severe respiratory viral infections", "PROBLEM", 215, 255], ["solid tumors", "PROBLEM", 275, 287], ["large", "OBSERVATION_MODIFIER", 2, 7], ["hematologic malignancies", "OBSERVATION", 126, 150], ["severe", "OBSERVATION_MODIFIER", 220, 226], ["respiratory", "ANATOMY", 227, 238], ["viral infections", "OBSERVATION", 239, 255]]], ["In Europe and the USA, hematologic malignancies comprise the fourth most common cancer site [11, 12] .", [["hematologic malignancies", "ANATOMY", 23, 47], ["cancer", "ANATOMY", 80, 86], ["hematologic malignancies", "DISEASE", 23, 47], ["cancer", "DISEASE", 80, 86], ["hematologic malignancies", "CANCER", 23, 47], ["cancer", "CANCER", 80, 86], ["hematologic malignancies", "PROBLEM", 23, 47], ["hematologic malignancies", "OBSERVATION", 23, 47], ["fourth", "OBSERVATION_MODIFIER", 61, 67], ["most", "OBSERVATION_MODIFIER", 68, 72], ["common", "OBSERVATION_MODIFIER", 73, 79], ["cancer", "OBSERVATION", 80, 86]]], ["The use of new antineoplastic agents, particularly novel targeted therapies, has improved overall survival.", [["antineoplastic", "ANATOMY", 15, 29], ["new antineoplastic agents", "TREATMENT", 11, 36], ["novel targeted therapies", "TREATMENT", 51, 75]]], ["However, these therapies have side effects on humoral and cell-mediated immunity, increasing the risk of infections caused by viral agents [13] .", [["cell", "ANATOMY", 58, 62], ["infections", "DISEASE", 105, 115], ["cell", "CELL", 58, 62], ["these therapies", "TREATMENT", 9, 24], ["side effects", "PROBLEM", 30, 42], ["humoral and cell-mediated immunity", "TREATMENT", 46, 80], ["infections", "PROBLEM", 105, 115], ["viral agents", "TREATMENT", 126, 138], ["infections", "OBSERVATION", 105, 115]]], ["To date, few data are available on COVID-19 in patients with hematologic malignancies.", [["hematologic malignancies", "ANATOMY", 61, 85], ["hematologic malignancies", "DISEASE", 61, 85], ["COVID-19", "GENE_OR_GENE_PRODUCT", 35, 43], ["patients", "ORGANISM", 47, 55], ["hematologic malignancies", "CANCER", 61, 85], ["patients", "SPECIES", 47, 55], ["COVID", "TEST", 35, 40], ["hematologic malignancies", "PROBLEM", 61, 85], ["malignancies", "OBSERVATION", 73, 85]]], ["Reported studies have focused on hospitalized patients.", [["patients", "ORGANISM", 46, 54], ["patients", "SPECIES", 46, 54]]], ["One showed very high mortality (40% at 1 month) among 25 patients in France [14] .", [["patients", "ORGANISM", 57, 65], ["patients", "SPECIES", 57, 65], ["very high mortality", "PROBLEM", 11, 30], ["very", "OBSERVATION_MODIFIER", 11, 15], ["high", "OBSERVATION_MODIFIER", 16, 20]]], ["A second suggested that hospitalized patients with hematologic malignancies have a higher mortality rate than patients without hematologic malignancies (62% vs 8%) [15] .", [["hematologic malignancies", "ANATOMY", 51, 75], ["hematologic malignancies", "ANATOMY", 127, 151], ["hematologic malignancies", "DISEASE", 51, 75], ["malignancies", "DISEASE", 139, 151], ["patients", "ORGANISM", 37, 45], ["hematologic malignancies", "CANCER", 51, 75], ["patients", "ORGANISM", 110, 118], ["hematologic malignancies", "CANCER", 127, 151], ["patients", "SPECIES", 37, 45], ["patients", "SPECIES", 110, 118], ["hematologic malignancies", "PROBLEM", 51, 75], ["hematologic malignancies", "PROBLEM", 127, 151]]], ["However, these were small patient series; the clinical impact of COVID-19 in this population remains unclear.", [["COVID-19", "CHEMICAL", 65, 73], ["COVID-19", "CHEMICAL", 65, 73], ["patient", "ORGANISM", 26, 33], ["COVID-19", "GENE_OR_GENE_PRODUCT", 65, 73], ["patient", "SPECIES", 26, 33], ["COVID", "TEST", 65, 70], ["small", "OBSERVATION_MODIFIER", 20, 25]]], ["Therefore, real-time collection, analysis, and dissemination of data about COVID-19 in patients with hematologic malignancies and their outcomes are needed.", [["hematologic malignancies", "ANATOMY", 101, 125], ["hematologic malignancies", "DISEASE", 101, 125], ["patients", "ORGANISM", 87, 95], ["hematologic malignancies", "CANCER", 101, 125], ["patients", "SPECIES", 87, 95], ["analysis", "TEST", 33, 41], ["COVID", "TEST", 75, 80], ["hematologic malignancies", "PROBLEM", 101, 125]]], ["Meanwhile, impactful decisions are being suggested on the basis of expert opinion [16, 17] .BackgroundThe Madrid region was the epicenter of Spain's COVID-19 crisis.", [["Spain's COVID", "TEST", 141, 154], ["crisis", "PROBLEM", 158, 164]]], ["As of 29 July, 78,807 patients had been diagnosed with COVID-19 and 15,199 fatalities reported in the Madrid region [18] .", [["COVID", "DISEASE", 55, 60], ["fatalities", "DISEASE", 75, 85], ["patients", "ORGANISM", 22, 30], ["patients", "SPECIES", 22, 30], ["COVID", "TEST", 55, 60]]], ["We considered it critical to collect clinical data in patients with hematologic malignancies within a defined geographical area with high excess mortality in order to understand the epidemiology of COVID-19.", [["hematologic malignancies", "ANATOMY", 68, 92], ["hematologic malignancies", "DISEASE", 68, 92], ["patients", "ORGANISM", 54, 62], ["hematologic malignancies", "CANCER", 68, 92], ["patients", "SPECIES", 54, 62], ["clinical data", "TEST", 37, 50], ["hematologic malignancies", "PROBLEM", 68, 92], ["high excess mortality", "PROBLEM", 133, 154], ["COVID", "TEST", 198, 203], ["high", "OBSERVATION_MODIFIER", 133, 137], ["excess mortality", "OBSERVATION", 138, 154]]], ["We aimed to identify independent prognostic factors for mortality that could support recommendations for managing patients with hematologic malignancies in healthcare emergency situations such as the COVID-19 pandemic.Study design and participantsThis was a multicenter, registry-based study with prospective data collection sponsored by the Madrid Society of Hematology (Asociaci\u00f3n Madrile\u00f1a de Hematolog\u00eda y Hemoterapia, AMHH).", [["hematologic malignancies", "ANATOMY", 128, 152], ["hematologic malignancies", "DISEASE", 128, 152], ["patients", "ORGANISM", 114, 122], ["hematologic malignancies", "CANCER", 128, 152], ["participants", "ORGANISM", 235, 247], ["patients", "SPECIES", 114, 122], ["participants", "SPECIES", 235, 247], ["hematologic malignancies", "PROBLEM", 128, 152], ["the COVID", "TEST", 196, 205], ["pandemic", "PROBLEM", 209, 217], ["based study", "TEST", 280, 291]]], ["AHMM established the registry on March 13 by contacting all members to register patients with hematologic malignancies who had microbiological confirmation of SARS-CoV-2 infection.", [["hematologic malignancies", "ANATOMY", 94, 118], ["hematologic malignancies", "DISEASE", 94, 118], ["SARS-CoV-2 infection", "DISEASE", 159, 179], ["patients", "ORGANISM", 80, 88], ["hematologic malignancies", "CANCER", 94, 118], ["SARS-CoV-2", "ORGANISM", 159, 169], ["patients", "SPECIES", 80, 88], ["SARS-CoV-2", "SPECIES", 159, 169], ["hematologic malignancies", "PROBLEM", 94, 118], ["microbiological confirmation", "TEST", 127, 155], ["SARS", "PROBLEM", 159, 163], ["CoV", "PROBLEM", 164, 167], ["2 infection", "PROBLEM", 168, 179], ["infection", "OBSERVATION", 170, 179]]], ["Health care for patients with hematologic malignancies in the Madrid region is provided at 26 hospitals affiliated with the Madrid regional health service (Servicio Madrile\u00f1o de Salud, SERMAS), covering a population of 6.6 million inhabitants.", [["hematologic malignancies", "ANATOMY", 30, 54], ["hematologic malignancies", "DISEASE", 30, 54], ["patients", "ORGANISM", 16, 24], ["hematologic malignancies", "CANCER", 30, 54], ["patients", "SPECIES", 16, 24], ["hematologic malignancies", "PROBLEM", 30, 54], ["malignancies", "OBSERVATION", 42, 54]]], ["Additionally, patients are seen at six private non-SERMAS-affiliated healthcare centers.", [["patients", "ORGANISM", 14, 22], ["patients", "SPECIES", 14, 22]]], ["This case series included consecutive patients with hematologic malignancies aged \u2265 18 years who received a confirmed diagnosis of COVID-19 in the emergency departments, hospital wards (patients infected while hospitalized) or outpatient clinics of these Madrid hospitals up to May 25, 2020.", [["hematologic malignancies", "ANATOMY", 52, 76], ["hematologic malignancies", "DISEASE", 52, 76], ["patients", "ORGANISM", 38, 46], ["hematologic malignancies", "CANCER", 52, 76], ["patients", "ORGANISM", 186, 194], ["patients", "SPECIES", 38, 46], ["patients", "SPECIES", 186, 194], ["hematologic malignancies", "PROBLEM", 52, 76], ["COVID", "TEST", 131, 136]]], ["Clinical specimens for diagnosis confirmation were obtained by nasopharyngeal swab collection in accordance with Spanish disease control and prevention guidelines.", [["specimens", "ANATOMY", 9, 18], ["nasopharyngeal swab", "ANATOMY", 63, 82], ["nasopharyngeal swab", "MULTI-TISSUE_STRUCTURE", 63, 82], ["Clinical specimens", "TEST", 0, 18], ["diagnosis confirmation", "TEST", 23, 45], ["nasopharyngeal swab collection", "TEST", 63, 93], ["Spanish disease control", "TREATMENT", 113, 136], ["nasopharyngeal", "ANATOMY", 63, 77]]], ["Samples were processed at local microbiology laboratories, and SARS-CoV-2 one-step real-time reverse transcriptase PCR diagnostic assay was performed [19] .Study design and participantsThe study was approved by the Institutional Review Board (IRB) of University Hospital 12 de Octubre (n 20/189) and then by the IRBs of all participating centers.", [["Samples", "ANATOMY", 0, 7], ["participants", "ORGANISM", 173, 185], ["reverse transcriptase", "PROTEIN", 93, 114], ["participants", "SPECIES", 173, 185], ["SARS-CoV", "SPECIES", 63, 71], ["Samples", "TEST", 0, 7], ["SARS", "TEST", 63, 67], ["CoV", "TEST", 68, 71], ["diagnostic assay", "TEST", 119, 135], ["The study", "TEST", 185, 194]]], ["The study was performed in accordance with the principles of the Declaration of Helsinki and the International Conference on Harmonization Good Clinical Practice guidelines.ProceduresData were prospectively extracted locally from electronic health records by hospital hematology department study coordinators and uploaded to a secure web platform (HEMATO-MADRID COVID-19), which utilized RED-Cap data capture tools and was supported by AMHH.", [["RED", "PROTEIN", 388, 391], ["AMHH", "PROTEIN", 436, 440], ["The study", "TEST", 0, 9]]], ["Clinical management decisions were made according to local protocols at each center; national guidelines for COVID-19 treatment issued by the Spanish Ministry of Health, National Health System, and National Medicine Agency were widely implemented.", [["Clinical management", "TREATMENT", 0, 19], ["COVID-19 treatment", "TREATMENT", 109, 127]]], ["Decisions about hospital/ICU admissions were made locally based on daily updated criteria during the healthcare emergency period.ProceduresPotential prognostic factors were collected including pre-infection patient characteristics (age, sex, comorbidities, type of hematologic malignancy and therapy), COVID-19 clinical severity, treatments and care setting. '", [["malignancy", "DISEASE", 277, 287], ["patient", "ORGANISM", 207, 214], ["patient", "SPECIES", 207, 214], ["Potential prognostic factors", "PROBLEM", 139, 167], ["hematologic malignancy", "PROBLEM", 265, 287], ["therapy", "TREATMENT", 292, 299], ["COVID", "TEST", 302, 307], ["treatments", "TREATMENT", 330, 340]]], ["Active antineoplastic treatment' was defined as having received anticancer therapy within 30 days prior to COVID-19 diagnosis.", [["antineoplastic", "ANATOMY", 7, 21], ["anticancer", "ANATOMY", 64, 74], ["anticancer", "CANCER", 64, 74], ["Active antineoplastic treatment", "TREATMENT", 0, 31], ["anticancer therapy", "TREATMENT", 64, 82], ["COVID", "TEST", 107, 112], ["antineoplastic treatment", "OBSERVATION", 7, 31]]], ["Therapies were classified as 'conventional chemotherapy, ' 'low-intensity chemotherapy, ' hypomethylating agents, monoclonal antibodies, immunomodulatory drugs, 'molecular targeted therapies, ' or supportive care (Table 1) .", [["hypomethylating agents", "SIMPLE_CHEMICAL", 90, 112], ["monoclonal antibodies", "PROTEIN", 114, 135], ["Therapies", "TREATMENT", 0, 9], ["conventional chemotherapy", "TREATMENT", 30, 55], ["' 'low-intensity chemotherapy", "TREATMENT", 57, 86], ["' hypomethylating agents", "TREATMENT", 88, 112], ["monoclonal antibodies", "TREATMENT", 114, 135], ["immunomodulatory drugs", "TREATMENT", 137, 159], ["'molecular targeted therapies", "TREATMENT", 161, 190], ["supportive care", "TREATMENT", 197, 212]]], ["Patients who were receiving monoclonal antibodies in combination with cytotoxic chemotherapy were classified into the category of 'conventional chemotherapy. '", [["Patients", "ORGANISM", 0, 8], ["monoclonal antibodies", "PROTEIN", 28, 49], ["Patients", "SPECIES", 0, 8], ["monoclonal antibodies", "TREATMENT", 28, 49], ["cytotoxic chemotherapy", "TREATMENT", 70, 92], ["'conventional chemotherapy", "TREATMENT", 130, 156]]], ["COVID-19 severity classification followed WHO guidelines [20] .", [["COVID", "TEST", 0, 5]]], ["No data on symptoms, laboratory findings, respiratory support, or viral kinetics were available for analyses as standardization was not achieved.OutcomesParticipant vital status (death from any cause vs alive) was the main study outcome.", [["respiratory", "ANATOMY", 42, 53], ["death", "DISEASE", 179, 184], ["symptoms", "PROBLEM", 11, 19], ["laboratory findings", "TEST", 21, 40], ["respiratory support", "TREATMENT", 42, 61], ["viral kinetics", "PROBLEM", 66, 80], ["analyses", "TEST", 100, 108]]], ["Study centers could update patient status through data cutoff (May 25, 2020).", [["patient", "ORGANISM", 27, 34], ["patient", "SPECIES", 27, 34]]], ["Observation time for individual patients was calculated from the date of SARS-CoV-2 positivity to the date of death or last information update.Statistical analysisPotential pre-infection prognostic factors for mortality were analyzed in three steps: unadjusted, partially adjusted and adjusted analyses.", [["death", "DISEASE", 110, 115], ["patients", "ORGANISM", 32, 40], ["patients", "SPECIES", 32, 40], ["CoV", "TEST", 78, 81], ["Statistical analysisPotential pre-infection prognostic factors", "PROBLEM", 143, 205]]], ["The associations between mortality and therapies received for COVID-19 were determined according to clinical severity (dichotomized as mild/moderate or severe/critical).", [["therapies", "TREATMENT", 39, 48], ["COVID", "TEST", 62, 67], ["mild/moderate or severe/critical)", "PROBLEM", 135, 168], ["mild", "OBSERVATION_MODIFIER", 135, 139], ["moderate", "OBSERVATION_MODIFIER", 140, 148]]], ["Hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated with Cox regression analyses.", [["Hazard ratios", "TEST", 0, 13], ["CIs", "TEST", 50, 53], ["Cox regression analyses", "TEST", 75, 98]]], ["Variables included in the models were pre-specified and restricted in number to limit model overfitting.", [["limit model", "OBSERVATION_MODIFIER", 80, 91], ["overfitting", "OBSERVATION", 92, 103]]], ["Analyses were generated using SAS/ STAT software, Version 9.4, SAS Institute Inc.ResultsOf 833 patients reported to the HEMATO-MADRID COVID-19 registry by 27/32 healthcare providers, 697 were included in the present analyses (Fig. 1) .", [["patients", "ORGANISM", 95, 103], ["patients", "SPECIES", 95, 103], ["Analyses", "TEST", 0, 8], ["Version", "TEST", 50, 57]]], ["The earliest PCR confirmation date in registered patients was February 28, 2020; during the 12-week reporting period, 5% of cases were reported in the 2 weeks prior to the start of lockdown, 75% in the following 4 weeks and the remaining 20% in the last 6 weeks.ResultsOf the 697 patients, 479 (69%) had a lymphoid malignancy, including 187 (27%) with non-Hodgkin lymphoma and 137 (20%) with multiple myeloma, and 218 (31%) had a myeloid malignancy, including 78 (11%) with myelodysplastic syndrome (MDS), 61 (9%) with acute myeloid leukemia (AML) and 63 (9%) with Philadelphia chromosome (Ph)-negative myeloproliferative neoplasms (Table 1) .", [["lymphoid malignancy", "ANATOMY", 306, 325], ["non-Hodgkin lymphoma", "ANATOMY", 352, 372], ["myeloma", "ANATOMY", 401, 408], ["myeloid malignancy", "ANATOMY", 430, 448], ["acute myeloid leukemia", "ANATOMY", 519, 541], ["AML", "ANATOMY", 543, 546], ["myeloproliferative neoplasms", "ANATOMY", 603, 631], ["lymphoid malignancy", "DISEASE", 306, 325], ["non-Hodgkin lymphoma", "DISEASE", 352, 372], ["multiple myeloma", "DISEASE", 392, 408], ["myeloid malignancy", "DISEASE", 430, 448], ["myelodysplastic syndrome", "DISEASE", 474, 498], ["MDS", "DISEASE", 500, 503], ["acute myeloid leukemia", "DISEASE", 519, 541], ["AML", "DISEASE", 543, 546], ["myeloproliferative neoplasms", "DISEASE", 603, 631], ["patients", "ORGANISM", 49, 57], ["patients", "ORGANISM", 280, 288], ["lymphoid malignancy", "CANCER", 306, 325], ["non-Hodgkin lymphoma", "CANCER", 352, 372], ["myeloma", "CANCER", 401, 408], ["myeloid malignancy", "CANCER", 430, 448], ["acute myeloid leukemia", "CANCER", 519, 541], ["AML", "CANCER", 543, 546], ["Philadelphia chromosome (Ph)", "GENE_OR_GENE_PRODUCT", 565, 593], ["myeloproliferative neoplasms", "CANCER", 603, 631], ["patients", "SPECIES", 49, 57], ["patients", "SPECIES", 280, 288], ["The earliest PCR confirmation", "TEST", 0, 29], ["a lymphoid malignancy", "PROBLEM", 304, 325], ["non-Hodgkin lymphoma", "PROBLEM", 352, 372], ["multiple myeloma", "PROBLEM", 392, 408], ["a myeloid malignancy", "PROBLEM", 428, 448], ["myelodysplastic syndrome", "PROBLEM", 474, 498], ["MDS", "TEST", 500, 503], ["acute myeloid leukemia", "PROBLEM", 519, 541], ["AML", "TEST", 543, 546], ["Philadelphia chromosome", "TEST", 565, 588], ["Ph", "TEST", 590, 592], ["myeloproliferative neoplasms", "PROBLEM", 603, 631], ["lymphoid malignancy", "OBSERVATION", 306, 325], ["non-Hodgkin lymphoma", "OBSERVATION", 352, 372], ["multiple", "OBSERVATION_MODIFIER", 392, 400], ["myeloma", "OBSERVATION", 401, 408], ["myeloid malignancy", "OBSERVATION", 430, 448], ["myelodysplastic syndrome", "OBSERVATION", 474, 498], ["acute", "OBSERVATION_MODIFIER", 519, 524], ["myeloid leukemia", "OBSERVATION", 525, 541], ["myeloproliferative neoplasms", "OBSERVATION", 603, 631]]], ["Overall median age of patients was 72 years (IQR 60-79), and 413/690 (60%) were male.", [["patients", "ORGANISM", 22, 30], ["patients", "SPECIES", 22, 30], ["IQR", "TEST", 45, 48]]], ["Comorbidities were present in 80% of patients, the commonest being hypertension (40%), cardiac disease (20%) and diabetes (17%) ( Table 1 ).ResultsIn total, 405 (59%) patients were receiving active antineoplastic treatment, including at least 75% of patients with multiple myeloma, AML, chronic myeloid leukemia (CML), and Philadelphia chromosome (Ph)-negative myeloproliferative neoplasms (MPNs).", [["cardiac", "ANATOMY", 87, 94], ["antineoplastic", "ANATOMY", 198, 212], ["myeloma", "ANATOMY", 273, 280], ["AML", "ANATOMY", 282, 285], ["chronic myeloid leukemia", "ANATOMY", 287, 311], ["CML", "ANATOMY", 313, 316], ["myeloproliferative neoplasms", "ANATOMY", 361, 389], ["MPNs", "ANATOMY", 391, 395], ["hypertension", "DISEASE", 67, 79], ["cardiac disease", "DISEASE", 87, 102], ["diabetes", "DISEASE", 113, 121], ["multiple myeloma", "DISEASE", 264, 280], ["AML", "DISEASE", 282, 285], ["chronic myeloid leukemia", "DISEASE", 287, 311], ["CML", "DISEASE", 313, 316], ["myeloproliferative neoplasms", "DISEASE", 361, 389], ["MPNs", "DISEASE", 391, 395], ["patients", "ORGANISM", 37, 45], ["cardiac", "ORGAN", 87, 94], ["patients", "ORGANISM", 167, 175], ["patients", "ORGANISM", 250, 258], ["myeloma", "CANCER", 273, 280], ["AML", "CANCER", 282, 285], ["chronic myeloid leukemia", "CANCER", 287, 311], ["CML", "CANCER", 313, 316], ["Philadelphia chromosome", "GENE_OR_GENE_PRODUCT", 323, 346], ["myeloproliferative neoplasms", "CANCER", 361, 389], ["MPNs", "CANCER", 391, 395], ["patients", "SPECIES", 37, 45], ["patients", "SPECIES", 167, 175], ["patients", "SPECIES", 250, 258], ["Comorbidities", "PROBLEM", 0, 13], ["hypertension", "PROBLEM", 67, 79], ["cardiac disease", "PROBLEM", 87, 102], ["diabetes", "PROBLEM", 113, 121], ["active antineoplastic treatment", "TREATMENT", 191, 222], ["multiple myeloma", "PROBLEM", 264, 280], ["AML", "PROBLEM", 282, 285], ["chronic myeloid leukemia", "PROBLEM", 287, 311], ["CML)", "PROBLEM", 313, 317], ["Philadelphia chromosome (Ph)", "PROBLEM", 323, 351], ["myeloproliferative neoplasms", "PROBLEM", 361, 389], ["hypertension", "OBSERVATION", 67, 79], ["cardiac", "ANATOMY", 87, 94], ["disease", "OBSERVATION", 95, 102], ["antineoplastic treatment", "OBSERVATION", 198, 222], ["multiple", "OBSERVATION_MODIFIER", 264, 272], ["myeloma", "OBSERVATION", 273, 280], ["AML", "ANATOMY", 282, 285], ["chronic", "OBSERVATION_MODIFIER", 287, 294], ["myeloid leukemia", "OBSERVATION", 295, 311], ["Philadelphia chromosome", "OBSERVATION", 323, 346], ["negative", "UNCERTAINTY", 352, 360], ["myeloproliferative neoplasms", "OBSERVATION", 361, 389]]], ["The rate was 31% in patients with chronic lymphocytic leukemia or (27) 137 (20) 109 (15) 33 (5) 13 (2) 78 (11) 61 (9) 16 (2) 63 (9) Age, yearsResultsCardiac disease 138 (20) 33 (18) 30 (22) 20 (18) 8 (24) 1 (8) 22 (28) 7 (11) 3 (13) 14 (22) Pulmonary disease 90 (13) 21 (11) 20 (15) 16 (15) 2 (6) 1 (8) 14 (18) 6 (10) 4 (25) 6 (10)ResultsRenal disease 77 (11) 11 (6) 32 (23) 8 (7) 4 (12) 1 (8) 9 (12) 22 (36) 4 (25) 9 (14) Hypertension 277 (40) 64 (34) 63 (46) 44 (40) 13 (39) 2 (15) 35 (45) 1 (2) 2 (13) 30 (48) Diabetes 121 (17) 29 (16) 29 (21) 20 (18) 7 (21) 0 18 (23) 5 (8) 3 (19) 10 (16) Other cancer 79 (11) 19 (10) 14 (10) 13 (12) 1 (3) 2 (15) 16 (21) 2 (3) 1 (6) 11 (17) Active antineoplastic treatment \u2020 % shown as proportion of all patients with that malignancy 92 (49) 27 (20) 75 (69) 14 (44) 4 (33) 54 (69) 15 (25) 0(8)Care setting % shown as proportion of all patients with that malignancy Ambulatory 89 (13) 24 (13) 16 (12) 15 (14) 4 (12) 3 (23) 6 (8) 9 (15) 6 (37)(14)Hospital 608 (87) 163 (87) 121 (88) 97 (89) 29 (88) 10 (77) 72 (92) 52 (85) 10 (63) 54 (86) Outcome Survivors 467 (67) 128 (68) 90 (66) 70 (64) 24 (73) 11 (85) 45 (58) 34 (56) 14 (87) 51 (81) Non-survivors 230 (33) 59 (32) 47 (34) 39 (36) 9 (27) 2 (15) 33 (42) 27 (44) 2 (13) 12 (19) myelodysplastic syndrome (Table 1) COVID-19 clinical severity was classified as severe/ critical in 62% of patients, moderate in 23% and mild in 15% ( Table 2) ; 46% of transplant recipients had severe/ critical disease.", [["chronic lymphocytic leukemia", "ANATOMY", 34, 62], ["cancer", "ANATOMY", 599, 605], ["chronic lymphocytic leukemia", "DISEASE", 34, 62], ["Cardiac disease", "DISEASE", 149, 164], ["Pulmonary disease", "DISEASE", 241, 258], ["Renal disease", "DISEASE", 338, 351], ["Hypertension", "DISEASE", 423, 435], ["Diabetes", "DISEASE", 513, 521], ["cancer", "DISEASE", 599, 605], ["malignancy", "DISEASE", 761, 771], ["malignancy", "DISEASE", 892, 902], ["myelodysplastic syndrome", "DISEASE", 1267, 1291], ["patients", "ORGANISM", 20, 28], ["chronic lymphocytic leukemia", "CANCER", 34, 62], ["patients", "ORGANISM", 742, 750], ["patients", "ORGANISM", 873, 881], ["patients", "ORGANISM", 1374, 1382], ["recipients", "ORGANISM", 1447, 1457], ["patients", "SPECIES", 20, 28], ["patients", "SPECIES", 742, 750], ["patients", "SPECIES", 873, 881], ["patients", "SPECIES", 1374, 1382], ["The rate", "TEST", 0, 8], ["chronic lymphocytic leukemia", "PROBLEM", 34, 62], ["Cardiac disease", "TEST", 149, 164], ["Pulmonary disease", "TEST", 241, 258], ["Renal disease", "TEST", 338, 351], ["Hypertension", "TEST", 423, 435], ["Diabetes", "TEST", 513, 521], ["Other cancer", "TEST", 593, 605], ["Active antineoplastic treatment", "TREATMENT", 679, 710], ["malignancy", "TEST", 761, 771], ["that malignancy", "PROBLEM", 887, 902], ["Ambulatory", "TEST", 903, 913], ["Survivors", "TEST", 1083, 1092], ["Non-survivors", "TEST", 1175, 1188], ["myelodysplastic syndrome", "PROBLEM", 1267, 1291], ["COVID", "TEST", 1302, 1307], ["clinical severity", "TEST", 1311, 1328], ["moderate in 23%", "PROBLEM", 1384, 1399], ["transplant recipients", "TREATMENT", 1436, 1457], ["severe/ critical disease", "PROBLEM", 1462, 1486], ["chronic", "OBSERVATION_MODIFIER", 34, 41], ["lymphocytic leukemia", "OBSERVATION", 42, 62], ["Cardiac", "ANATOMY", 149, 156], ["disease", "OBSERVATION", 157, 164], ["Pulmonary", "ANATOMY", 241, 250], ["disease", "OBSERVATION", 251, 258], ["Renal", "ANATOMY", 338, 343], ["disease", "OBSERVATION", 344, 351], ["malignancy", "OBSERVATION", 761, 771], ["malignancy", "OBSERVATION", 892, 902], ["myelodysplastic syndrome", "OBSERVATION", 1267, 1291], ["severe", "OBSERVATION_MODIFIER", 1347, 1353], ["moderate", "OBSERVATION_MODIFIER", 1384, 1392], ["mild", "OBSERVATION_MODIFIER", 1404, 1408], ["severe", "OBSERVATION_MODIFIER", 1462, 1468], ["critical disease", "OBSERVATION", 1470, 1486]]], ["Patients with severe/critical disease were older and more likely (51%/22%) to have \u2265 3 comorbidities than those with mild COVID-19 (9%) ( Table 2) .", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["severe/critical disease", "PROBLEM", 14, 37], ["\u2265 3 comorbidities", "PROBLEM", 83, 100], ["mild COVID", "PROBLEM", 117, 127], ["severe", "OBSERVATION_MODIFIER", 14, 20], ["critical", "OBSERVATION_MODIFIER", 21, 29], ["disease", "OBSERVATION", 30, 37], ["mild", "OBSERVATION_MODIFIER", 117, 121]]], ["Overall, 87% of patients required hospitalization, and 13% received ambulatory management (Table 1) ; 55 (8%) were admitted to an ICU ( Table 2 ), most of whom had organ function damage, including 40/55 (73%) with acute respiratory distress syndrome and 2 (4%) with sepsis.", [["organ", "ANATOMY", 164, 169], ["respiratory", "ANATOMY", 220, 231], ["organ function damage", "DISEASE", 164, 185], ["acute respiratory distress syndrome", "DISEASE", 214, 249], ["sepsis", "DISEASE", 266, 272], ["patients", "ORGANISM", 16, 24], ["organ", "ORGAN", 164, 169], ["patients", "SPECIES", 16, 24], ["ambulatory management", "TREATMENT", 68, 89], ["organ function damage", "PROBLEM", 164, 185], ["acute respiratory distress syndrome", "PROBLEM", 214, 249], ["sepsis", "PROBLEM", 266, 272], ["acute", "OBSERVATION_MODIFIER", 214, 219], ["respiratory distress", "OBSERVATION", 220, 240], ["sepsis", "OBSERVATION", 266, 272]]], ["(Table 3) were increasing age > 60 years, > 2 comorbidities (HR 1.4, 95% CI 1.05-1.90, vs \u2264 2 comorbidities), AML (vs non-Hodgkin lymphoma), and active antineoplastic treatment with monoclonal antibodies vs no active therapy; there was 50% increased mortality in patients receiving conventional chemotherapy vs no active therapy (HR 1.50, 0.99-2.29, p value 0.0561).", [["AML", "ANATOMY", 110, 113], ["non-Hodgkin lymphoma", "ANATOMY", 118, 138], ["AML", "DISEASE", 110, 113], ["non-Hodgkin lymphoma", "DISEASE", 118, 138], ["AML", "CANCER", 110, 113], ["non-Hodgkin lymphoma", "CANCER", 118, 138], ["patients", "ORGANISM", 263, 271], ["monoclonal antibodies", "PROTEIN", 182, 203], ["patients", "SPECIES", 263, 271], ["HR", "TEST", 61, 63], ["CI", "TEST", 73, 75], ["\u2264 2 comorbidities", "PROBLEM", 90, 107], ["AML", "PROBLEM", 110, 113], ["non-Hodgkin lymphoma", "PROBLEM", 118, 138], ["active antineoplastic treatment", "TREATMENT", 145, 176], ["monoclonal antibodies", "TREATMENT", 182, 203], ["active therapy", "TREATMENT", 210, 224], ["50% increased mortality", "PROBLEM", 236, 259], ["conventional chemotherapy", "TREATMENT", 282, 307], ["active therapy", "TREATMENT", 314, 328], ["HR", "TEST", 330, 332], ["p value", "TEST", 350, 357], ["AML", "OBSERVATION", 110, 113], ["non-Hodgkin lymphoma", "OBSERVATION", 118, 138], ["active", "OBSERVATION_MODIFIER", 145, 151], ["antineoplastic", "OBSERVATION_MODIFIER", 152, 166], ["increased", "OBSERVATION_MODIFIER", 240, 249], ["mortality", "OBSERVATION_MODIFIER", 250, 259]]], ["Prognostic variables associated with lower mortality included Ph-negative MPNs (HR 0.33 vs non-Hodgkin lymphoma) and active treatment with hypomethylating agents (HR 0.47 vs no active treatment).", [["non-Hodgkin lymphoma", "ANATOMY", 91, 111], ["MPNs", "DISEASE", 74, 78], ["non-Hodgkin lymphoma", "DISEASE", 91, 111], ["non-Hodgkin lymphoma", "CANCER", 91, 111], ["Prognostic variables", "PROBLEM", 0, 20], ["lower mortality", "PROBLEM", 37, 52], ["Ph-negative MPNs", "PROBLEM", 62, 78], ["HR", "TEST", 80, 82], ["non-Hodgkin lymphoma", "PROBLEM", 91, 111], ["active treatment", "TREATMENT", 117, 133], ["hypomethylating agents", "TREATMENT", 139, 161], ["HR", "TEST", 163, 165], ["active treatment", "TREATMENT", 177, 193], ["Ph-negative MPNs", "OBSERVATION", 62, 78], ["non-Hodgkin lymphoma", "OBSERVATION", 91, 111]]], ["Mortality rate among patients who underwent transplantation was 18%.(14)Overall, 574 (82%) patients received antiviral therapy (with \u03b2-interferon in 50 patients as an immunity booster), the most common being hydroxychloroquine in combination with antiretrovirals, azithromycin, or both (Table 4 ).", [["\u03b2-interferon", "CHEMICAL", 133, 145], ["hydroxychloroquine", "CHEMICAL", 208, 226], ["azithromycin", "CHEMICAL", 264, 276], ["hydroxychloroquine", "CHEMICAL", 208, 226], ["azithromycin", "CHEMICAL", 264, 276], ["patients", "ORGANISM", 21, 29], ["patients", "ORGANISM", 91, 99], ["\u03b2-interferon", "GENE_OR_GENE_PRODUCT", 133, 145], ["patients", "ORGANISM", 152, 160], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 208, 226], ["azithromycin", "SIMPLE_CHEMICAL", 264, 276], ["interferon", "PROTEIN", 135, 145], ["patients", "SPECIES", 21, 29], ["patients", "SPECIES", 91, 99], ["patients", "SPECIES", 152, 160], ["transplantation", "TREATMENT", 44, 59], ["antiviral therapy", "TREATMENT", 109, 126], ["interferon", "TREATMENT", 135, 145], ["an immunity booster", "TREATMENT", 164, 183], ["hydroxychloroquine", "TREATMENT", 208, 226], ["antiretrovirals", "TREATMENT", 247, 262], ["azithromycin", "TREATMENT", 264, 276]]], ["Additionally, 346 (50%), 318 (46%) and 132 (19%) patients received empirical antibiotics, systemic corticosteroids (mainly methylprednisolone and prednisone) and off-label tocilizumab, respectively.", [["methylprednisolone", "CHEMICAL", 123, 141], ["prednisone", "CHEMICAL", 146, 156], ["methylprednisolone", "CHEMICAL", 123, 141], ["prednisone", "CHEMICAL", 146, 156], ["patients", "ORGANISM", 49, 57], ["methylprednisolone", "SIMPLE_CHEMICAL", 123, 141], ["prednisone", "SIMPLE_CHEMICAL", 146, 156], ["off-label tocilizumab", "SIMPLE_CHEMICAL", 162, 183], ["patients", "SPECIES", 49, 57], ["empirical antibiotics", "TREATMENT", 67, 88], ["systemic corticosteroids", "TREATMENT", 90, 114], ["methylprednisolone", "TREATMENT", 123, 141], ["prednisone", "TREATMENT", 146, 156], ["label tocilizumab", "TREATMENT", 166, 183]]], ["Patients with severe/critical COVID-19 who did not receive antiviral therapy had a higher risk of death than patients receiving any antiviral combination therapy (HR 2.20, 95% CI 1.44-3.35) on multivariable analysis (Table 4) .", [["death", "DISEASE", 98, 103], ["Patients", "ORGANISM", 0, 8], ["patients", "ORGANISM", 109, 117], ["Patients", "SPECIES", 0, 8], ["patients", "SPECIES", 109, 117], ["severe/critical COVID", "PROBLEM", 14, 35], ["antiviral therapy", "TREATMENT", 59, 76], ["death", "PROBLEM", 98, 103], ["any antiviral combination therapy", "TREATMENT", 128, 161], ["HR", "TEST", 163, 165], ["CI", "TEST", 176, 178], ["multivariable analysis", "TEST", 193, 215], ["severe", "OBSERVATION_MODIFIER", 14, 20]]], ["Mortality in patients treated with tocilizumab differed according to clinical severity of COVID-19 (test for strata homogeneity, p < 0.0001), with a higher risk in patients with mild/moderate COVID-19 treated vs not treated with tocilizumab (HR 5.94).DiscussionTo our knowledge, this is the first large-scale case series describing the epidemiology and outcome of COVID-19 in patients with hematologic malignancies.", [["hematologic malignancies", "ANATOMY", 390, 414], ["tocilizumab", "CHEMICAL", 35, 46], ["tocilizumab", "CHEMICAL", 229, 240], ["COVID-19", "CHEMICAL", 364, 372], ["hematologic malignancies", "DISEASE", 390, 414], ["patients", "ORGANISM", 13, 21], ["tocilizumab", "SIMPLE_CHEMICAL", 35, 46], ["patients", "ORGANISM", 164, 172], ["tocilizumab", "SIMPLE_CHEMICAL", 229, 240], ["patients", "ORGANISM", 376, 384], ["hematologic malignancies", "CANCER", 390, 414], ["patients", "SPECIES", 13, 21], ["patients", "SPECIES", 164, 172], ["patients", "SPECIES", 376, 384], ["tocilizumab", "TREATMENT", 35, 46], ["COVID", "TEST", 90, 95], ["strata homogeneity", "PROBLEM", 109, 127], ["mild/moderate COVID", "PROBLEM", 178, 197], ["tocilizumab", "TREATMENT", 229, 240], ["HR", "TEST", 242, 244], ["COVID", "TEST", 364, 369], ["hematologic malignancies", "PROBLEM", 390, 414], ["mild", "OBSERVATION_MODIFIER", 178, 182], ["moderate", "OBSERVATION_MODIFIER", 183, 191], ["malignancies", "OBSERVATION", 402, 414]]], ["To date, only small case series in this setting have been reported [14, 15, 21, 22] in mainly hospitalized patients, whereas our study included both inpatients and outpatients.", [["patients", "ORGANISM", 107, 115], ["outpatients", "ORGANISM", 164, 175], ["patients", "SPECIES", 107, 115], ["our study", "TEST", 125, 134], ["small", "OBSERVATION_MODIFIER", 14, 19]]], ["Our findings show that patients with hematologic malignancies and COVID-19 have threefold-fourfold higher rates of severe/critical disease (62% vs 15%) and mortality (33% vs 10%) compared to COVID-19 cases in the general population [23] [24] [25] .", [["hematologic malignancies", "ANATOMY", 37, 61], ["hematologic malignancies", "DISEASE", 37, 61], ["patients", "ORGANISM", 23, 31], ["hematologic malignancies", "CANCER", 37, 61], ["patients", "SPECIES", 23, 31], ["hematologic malignancies", "PROBLEM", 37, 61], ["COVID", "TEST", 66, 71], ["severe/critical disease", "PROBLEM", 115, 138], ["mortality", "TEST", 156, 165], ["COVID", "TEST", 191, 196], ["severe", "OBSERVATION_MODIFIER", 115, 121], ["critical disease", "OBSERVATION", 122, 138]]], ["Clinical severity of COVID-19 was worse, and mortality rates were higher among older patients and those with a greater number of comorbidities and varied by type of hematologic malignancy and active antineoplastic treatment.", [["hematologic malignancy", "ANATOMY", 165, 187], ["antineoplastic", "ANATOMY", 199, 213], ["malignancy", "DISEASE", 177, 187], ["patients", "ORGANISM", 85, 93], ["patients", "SPECIES", 85, 93], ["COVID", "TEST", 21, 26], ["mortality rates", "PROBLEM", 45, 60], ["hematologic malignancy", "PROBLEM", 165, 187], ["active antineoplastic treatment", "TREATMENT", 192, 223], ["hematologic malignancy", "OBSERVATION", 165, 187], ["active", "OBSERVATION_MODIFIER", 192, 198], ["antineoplastic treatment", "OBSERVATION", 199, 223]]], ["Rates of severe/critical COVID-19 and mortality in our study were higher than reported in patients with solid tumors (26-43% and 13-28%; respectively) [9] .DiscussionDespite the high societal impact of COVID-19 in Spain, the ENE-COVID nation-wide, population-based study reported a SARS-CoV-2 seroprevalence of 11.5% for the Madrid region [26] , which is clearly insufficient to provide herd immunity.", [["solid tumors", "ANATOMY", 104, 116], ["tumors", "DISEASE", 110, 116], ["patients", "ORGANISM", 90, 98], ["solid tumors", "CANCER", 104, 116], ["patients", "SPECIES", 90, 98], ["severe/critical COVID", "PROBLEM", 9, 30], ["our study", "TEST", 51, 60], ["solid tumors", "PROBLEM", 104, 116], ["COVID", "TEST", 202, 207], ["based study", "TEST", 259, 270], ["a SARS", "TEST", 280, 286], ["CoV", "TEST", 287, 290], ["severe", "OBSERVATION_MODIFIER", 9, 15], ["tumors", "OBSERVATION", 110, 116]]], ["Together with our study, these findings have important policy implications, including the need for increased surveillance for SARS-CoV-2 in patients with hematologic malignancies.DiscussionAmong the strengths of this study are the prospective and comprehensive collection of clinical and outcome data, and the use of multivariable analysis to identify independent risk factors for death.", [["hematologic malignancies", "ANATOMY", 154, 178], ["SARS", "DISEASE", 126, 130], ["hematologic malignancies", "DISEASE", 154, 178], ["death", "DISEASE", 381, 386], ["SARS-CoV-2", "ORGANISM", 126, 136], ["patients", "ORGANISM", 140, 148], ["hematologic malignancies", "CANCER", 154, 178], ["patients", "SPECIES", 140, 148], ["SARS-CoV", "SPECIES", 126, 134], ["our study", "TEST", 14, 23], ["increased surveillance", "TEST", 99, 121], ["SARS", "PROBLEM", 126, 130], ["CoV", "TEST", 131, 134], ["hematologic malignancies", "PROBLEM", 154, 178], ["this study", "TEST", 212, 222], ["multivariable analysis", "TEST", 317, 339], ["death", "PROBLEM", 381, 386], ["hematologic malignancies", "OBSERVATION", 154, 178]]], ["Our patient series is highly representative of this population as, in Spain, COVID-19 severity classification followed WHO guidelines (20) .", [["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11]]], ["Severe disease was defined as: bilateral lung infiltrates on chest imaging that were not fully explained by congestive heart failure or other forms of volume overload; tachypnea (\u2265 30 breaths/min); oxygen saturation \u2264 90% at rest; and/or PaO 2 /FIO 2 ratio < 300 mmHg.", [["lung", "ANATOMY", 41, 45], ["chest", "ANATOMY", 61, 66], ["heart", "ANATOMY", 119, 124], ["congestive heart failure", "DISEASE", 108, 132], ["volume overload", "DISEASE", 151, 166], ["tachypnea", "DISEASE", 168, 177], ["oxygen", "CHEMICAL", 198, 204], ["oxygen", "CHEMICAL", 198, 204], ["lung", "ORGAN", 41, 45], ["chest", "ORGAN", 61, 66], ["heart", "ORGAN", 119, 124], ["oxygen", "SIMPLE_CHEMICAL", 198, 204], ["Severe disease", "PROBLEM", 0, 14], ["bilateral lung infiltrates", "PROBLEM", 31, 57], ["chest imaging", "TEST", 61, 74], ["congestive heart failure", "PROBLEM", 108, 132], ["volume overload", "PROBLEM", 151, 166], ["tachypnea", "PROBLEM", 168, 177], ["oxygen saturation", "TEST", 198, 215], ["PaO", "TEST", 238, 241], ["FIO", "TEST", 245, 248], ["disease", "OBSERVATION", 7, 14], ["bilateral", "ANATOMY_MODIFIER", 31, 40], ["lung", "ANATOMY", 41, 45], ["infiltrates", "OBSERVATION", 46, 57], ["chest", "ANATOMY", 61, 66], ["congestive", "OBSERVATION", 108, 118], ["heart", "ANATOMY", 119, 124], ["failure", "OBSERVATION", 125, 132], ["volume overload", "OBSERVATION", 151, 166], ["tachypnea", "OBSERVATION", 168, 177]]], ["'Critical' severity was defined as patients presenting with sepsis/septic shock, acute respiratory distress syndrome or multiple organ dysfunction/failure health care for all patients with hematologic malignancies is centralized in hospitals.", [["respiratory", "ANATOMY", 87, 98], ["organ", "ANATOMY", 129, 134], ["hematologic malignancies", "ANATOMY", 189, 213], ["sepsis", "DISEASE", 60, 66], ["septic shock", "DISEASE", 67, 79], ["acute respiratory distress syndrome", "DISEASE", 81, 116], ["organ dysfunction", "DISEASE", 129, 146], ["malignancies", "DISEASE", 201, 213], ["patients", "ORGANISM", 35, 43], ["organ", "ORGAN", 129, 134], ["patients", "ORGANISM", 175, 183], ["hematologic malignancies", "CANCER", 189, 213], ["patients", "SPECIES", 35, 43], ["patients", "SPECIES", 175, 183], ["Critical' severity", "PROBLEM", 1, 19], ["sepsis", "PROBLEM", 60, 66], ["septic shock", "PROBLEM", 67, 79], ["acute respiratory distress syndrome", "PROBLEM", 81, 116], ["multiple organ dysfunction", "PROBLEM", 120, 146], ["failure health care", "TREATMENT", 147, 166], ["hematologic malignancies", "PROBLEM", 189, 213], ["sepsis", "OBSERVATION", 60, 66], ["septic shock", "OBSERVATION", 67, 79], ["acute", "OBSERVATION_MODIFIER", 81, 86], ["respiratory distress", "OBSERVATION", 87, 107], ["syndrome", "OBSERVATION", 108, 116], ["multiple", "OBSERVATION_MODIFIER", 120, 128], ["organ", "ANATOMY", 129, 134], ["dysfunction", "OBSERVATION", 135, 146], ["failure", "OBSERVATION", 147, 154], ["malignancies", "OBSERVATION", 201, 213]]], ["We therefore believe that the mortality rate in our study reflects the true mortality rate in patients with hematologic malignancies and COVID-19 that contacted the healthcare system during the growth phase of the pandemic.", [["hematologic malignancies", "ANATOMY", 108, 132], ["hematologic malignancies", "DISEASE", 108, 132], ["patients", "ORGANISM", 94, 102], ["hematologic malignancies", "CANCER", 108, 132], ["patients", "SPECIES", 94, 102], ["the mortality rate", "TEST", 26, 44], ["our study", "TEST", 48, 57], ["hematologic malignancies", "PROBLEM", 108, 132], ["COVID", "TEST", 137, 142], ["the pandemic", "PROBLEM", 210, 222]]], ["Another strength was the selection of a restricted number of prognostic factors based on clinical features for determining associations with mortality rate.", [["prognostic factors", "PROBLEM", 61, 79], ["mortality rate", "TEST", 141, 155]]], ["These factors could be utilized in a prognostic model to stratify patients with hematologic malignancies and to implement preventive strategies for future healthcare crises.", [["hematologic malignancies", "ANATOMY", 80, 104], ["hematologic malignancies", "DISEASE", 80, 104], ["patients", "ORGANISM", 66, 74], ["hematologic malignancies", "CANCER", 80, 104], ["patients", "SPECIES", 66, 74], ["hematologic malignancies", "PROBLEM", 80, 104], ["preventive strategies", "TREATMENT", 122, 143], ["future healthcare crises", "PROBLEM", 148, 172]]], ["Key risk factors for clinical severity and mortality previously reported in the general population (e.g., older age, higher number of comorbidities) were validated in our study.", [["Key risk factors", "PROBLEM", 0, 16], ["clinical severity", "PROBLEM", 21, 38], ["mortality", "PROBLEM", 43, 52], ["our study", "TEST", 167, 176]]], ["Notably, the median age of patients in our series was higher than in the general population with COVID-19 (72 vs 60 years), with 32% of cases occurring in patients aged 70-79 years; in the general population, COVID-19 cases were more uniformly distributed across age groups [23] .", [["patients", "ORGANISM", 27, 35], ["patients", "ORGANISM", 155, 163], ["patients", "SPECIES", 27, 35], ["patients", "SPECIES", 155, 163], ["COVID", "TEST", 209, 214]]], ["Additionally, our findings highlight that the type of hematologic malignancy was associated with COVID-19 mortality.", [["hematologic malignancy", "ANATOMY", 54, 76], ["malignancy", "DISEASE", 66, 76], ["hematologic malignancy", "PROBLEM", 54, 76], ["COVID", "TEST", 97, 102], ["hematologic", "OBSERVATION_MODIFIER", 54, 65], ["malignancy", "OBSERVATION", 66, 76]]], ["Our study showed relatively higher mortality rates in patients with AML (44%) and myelodysplastic syndrome (42%) and relatively lower rates in patients with Ph-negative MPNs (19%) and CML (13%), consistent with a Chinese study of 5 patients with CML receiving tyrosine kinase inhibitor (TKI) therapy [27] .DiscussionThe differential outcomes from COVID-19 between patients with different hematologic malignancies could be associated with multiple factors.", [["AML", "ANATOMY", 68, 71], ["CML", "ANATOMY", 184, 187], ["CML", "ANATOMY", 246, 249], ["hematologic malignancies", "ANATOMY", 388, 412], ["AML", "DISEASE", 68, 71], ["myelodysplastic syndrome", "DISEASE", 82, 106], ["MPNs", "DISEASE", 169, 173], ["CML", "DISEASE", 184, 187], ["CML", "DISEASE", 246, 249], ["tyrosine", "CHEMICAL", 260, 268], ["TKI", "CHEMICAL", 287, 290], ["hematologic malignancies", "DISEASE", 388, 412], ["tyrosine", "CHEMICAL", 260, 268], ["patients", "ORGANISM", 54, 62], ["AML", "CANCER", 68, 71], ["patients", "ORGANISM", 143, 151], ["CML", "CANCER", 184, 187], ["patients", "ORGANISM", 232, 240], ["CML", "CANCER", 246, 249], ["tyrosine kinase inhibitor", "SIMPLE_CHEMICAL", 260, 285], ["TKI", "SIMPLE_CHEMICAL", 287, 290], ["patients", "ORGANISM", 364, 372], ["malignancies", "CANCER", 400, 412], ["COVID-19", "DNA", 347, 355], ["patients", "SPECIES", 54, 62], ["patients", "SPECIES", 143, 151], ["patients", "SPECIES", 232, 240], ["patients", "SPECIES", 364, 372], ["Our study", "TEST", 0, 9], ["AML", "PROBLEM", 68, 71], ["myelodysplastic syndrome", "PROBLEM", 82, 106], ["Ph-negative MPNs", "PROBLEM", 157, 173], ["CML", "TEST", 184, 187], ["a Chinese study", "TEST", 211, 226], ["CML", "PROBLEM", 246, 249], ["tyrosine kinase inhibitor", "TREATMENT", 260, 285], ["TKI) therapy", "TREATMENT", 287, 299], ["COVID", "TEST", 347, 352], ["different hematologic malignancies", "PROBLEM", 378, 412], ["relatively", "OBSERVATION_MODIFIER", 17, 27], ["higher", "OBSERVATION_MODIFIER", 28, 34], ["AML", "OBSERVATION", 68, 71], ["myelodysplastic syndrome", "OBSERVATION", 82, 106], ["lower", "OBSERVATION_MODIFIER", 128, 133], ["MPNs", "OBSERVATION", 169, 173], ["consistent with", "UNCERTAINTY", 195, 210], ["hematologic malignancies", "OBSERVATION", 388, 412]]], ["On multivariate analysis, we found that type of active antineoplastic treatment appeared associated with mortality from COVID-19.", [["antineoplastic", "ANATOMY", 55, 69], ["COVID-19", "CHEMICAL", 120, 128], ["antineoplastic", "CANCER", 55, 69], ["multivariate analysis", "TEST", 3, 24], ["active antineoplastic treatment", "TREATMENT", 48, 79], ["COVID", "TEST", 120, 125], ["active", "OBSERVATION_MODIFIER", 48, 54], ["antineoplastic treatment", "OBSERVATION", 55, 79]]], ["Patients receiving monoclonal antibody-based therapy had a significantly greater (HR 2.02) risk of death vs those not receiving active antineoplastic treatment, while those receiving active conventional chemotherapy were 50% more likely to die from COVID-19.", [["antineoplastic", "ANATOMY", 135, 149], ["death", "DISEASE", 99, 104], ["COVID-19", "CHEMICAL", 249, 257], ["Patients", "ORGANISM", 0, 8], ["monoclonal antibody", "PROTEIN", 19, 38], ["Patients", "SPECIES", 0, 8], ["monoclonal antibody", "TREATMENT", 19, 38], ["based therapy", "TREATMENT", 39, 52], ["death", "PROBLEM", 99, 104], ["active antineoplastic treatment", "TREATMENT", 128, 159], ["active conventional chemotherapy", "TREATMENT", 183, 215], ["COVID", "TEST", 249, 254]]], ["By contrast, there was a significant 53% lower mortality among patients receiving hypomethylating agents (HMA).", [["HMA", "CHEMICAL", 106, 109], ["patients", "ORGANISM", 63, 71], ["hypomethylating agents", "SIMPLE_CHEMICAL", 82, 104], ["HMA", "SIMPLE_CHEMICAL", 106, 109], ["patients", "SPECIES", 63, 71], ["a significant 53% lower mortality", "PROBLEM", 23, 56], ["hypomethylating agents", "TREATMENT", 82, 104], ["significant", "OBSERVATION_MODIFIER", 25, 36]]], ["Among the 33 patients treated with HMA, 45% were MDS and 52% were AML; 23% of patients with MDS or AML were treated with HMAs.Table 4 COVID-19 pharmacological therapies and association with mortality in patients with hematologic malignancies and COVID-19, according to clinical severity of COVID-19: time-to-event analysisCI confidence interval, COVID-19 coronavirus disease 2019, HR hazard ratio * Multivariable analyses for the mild/moderate severity group are adjusted for age only, due to the limited number of events. \u2020 Multivariable analyses for the severe/ critical severity group are adjusted for age (years), sex and comorbidity count, except for the analysis of \u03b2-interferon, which was adjusted for age only. \u2021 HRs and 95% CI were estimated with Cox regression analyses The association between low-intensity chemotherapy and lower COVID-19 mortality in our partially adjusted analysis could be in part because nearly half of patients with Ph-negative MPNs were receiving this chemotherapy.", [["AML", "ANATOMY", 66, 69], ["AML", "ANATOMY", 99, 102], ["hematologic malignancies", "ANATOMY", 217, 241], ["HMA", "CHEMICAL", 35, 38], ["MDS", "DISEASE", 49, 52], ["AML", "DISEASE", 66, 69], ["MDS", "DISEASE", 92, 95], ["AML", "DISEASE", 99, 102], ["hematologic malignancies", "DISEASE", 217, 241], ["coronavirus disease", "DISEASE", 355, 374], ["MPNs", "DISEASE", 961, 965], ["HMA", "CHEMICAL", 35, 38], ["patients", "ORGANISM", 13, 21], ["AML", "CANCER", 66, 69], ["patients", "ORGANISM", 78, 86], ["AML", "CANCER", 99, 102], ["patients", "ORGANISM", 203, 211], ["hematologic malignancies", "CANCER", 217, 241], ["\u03b2-interferon", "GENE_OR_GENE_PRODUCT", 672, 684], ["patients", "ORGANISM", 935, 943], ["MPNs", "CANCER", 961, 965], ["\u03b2-interferon", "PROTEIN", 672, 684], ["patients", "SPECIES", 13, 21], ["patients", "SPECIES", 78, 86], ["patients", "SPECIES", 203, 211], ["patients", "SPECIES", 935, 943], ["HMA", "TREATMENT", 35, 38], ["MDS", "TEST", 49, 52], ["AML", "PROBLEM", 66, 69], ["MDS", "PROBLEM", 92, 95], ["AML", "PROBLEM", 99, 102], ["HMAs", "TREATMENT", 121, 125], ["pharmacological therapies", "TREATMENT", 143, 168], ["hematologic malignancies", "PROBLEM", 217, 241], ["COVID", "TEST", 246, 251], ["COVID", "TEST", 290, 295], ["interval", "TEST", 336, 344], ["COVID", "TEST", 346, 351], ["coronavirus disease", "PROBLEM", 355, 374], ["HR hazard ratio", "TEST", 381, 396], ["Multivariable analyses", "TEST", 399, 421], ["the mild/moderate severity group", "PROBLEM", 426, 458], ["Multivariable analyses", "TEST", 525, 547], ["the severe/ critical severity group", "PROBLEM", 552, 587], ["comorbidity count", "TEST", 626, 643], ["the analysis", "TEST", 656, 668], ["\u03b2-interferon", "TREATMENT", 672, 684], ["HRs", "TEST", 721, 724], ["CI", "TEST", 733, 735], ["Cox regression analyses", "TEST", 756, 779], ["low-intensity chemotherapy", "TREATMENT", 804, 830], ["lower COVID", "TREATMENT", 835, 846], ["Ph-negative MPNs", "PROBLEM", 949, 965], ["this chemotherapy", "TREATMENT", 981, 998], ["AML", "OBSERVATION", 99, 102], ["mild", "OBSERVATION_MODIFIER", 430, 434], ["moderate", "OBSERVATION_MODIFIER", 435, 443], ["Ph-negative MPNs", "OBSERVATION", 949, 965]]], ["Interestingly, acknowledging that the number of patients with CML was low, 88% were receiving molecular targeted therapies (TKI therapy), and mortality rate was only 13%.", [["CML", "ANATOMY", 62, 65], ["CML", "DISEASE", 62, 65], ["patients", "ORGANISM", 48, 56], ["CML", "CANCER", 62, 65], ["patients", "SPECIES", 48, 56], ["CML", "PROBLEM", 62, 65], ["molecular targeted therapies", "TREATMENT", 94, 122], ["TKI therapy", "TREATMENT", 124, 135], ["mortality rate", "TEST", 142, 156], ["CML", "OBSERVATION", 62, 65]]], ["Kinase inhibitor-targeted therapy was demonstrated to block dissemination of SARS-CoV and Middle East respiratory syndrome coronavirus and is being investigated as a potential therapeutic approach against SARS-CoV-2 [28] .", [["SARS-CoV", "DISEASE", 77, 85], ["Middle East respiratory syndrome coronavirus", "DISEASE", 90, 134], ["SARS", "DISEASE", 205, 209], ["Kinase", "GENE_OR_GENE_PRODUCT", 0, 6], ["SARS-CoV", "ORGANISM", 77, 85], ["Middle East respiratory syndrome coronavirus", "ORGANISM", 90, 134], ["SARS-CoV-2", "ORGANISM", 205, 215], ["SARS-CoV", "SPECIES", 77, 85], ["Middle East respiratory syndrome coronavirus", "SPECIES", 90, 134], ["SARS-CoV", "SPECIES", 205, 213], ["Kinase inhibitor", "TREATMENT", 0, 16], ["targeted therapy", "TREATMENT", 17, 33], ["SARS", "PROBLEM", 77, 81], ["CoV", "PROBLEM", 82, 85], ["Middle East respiratory syndrome coronavirus", "PROBLEM", 90, 134], ["SARS", "PROBLEM", 205, 209], ["CoV", "TEST", 210, 213], ["Middle", "ANATOMY_MODIFIER", 90, 96], ["respiratory syndrome", "OBSERVATION", 102, 122]]], ["Our findings suggest that patients with CML may even garner some protection against poor outcomes with COVID-19 due to their TKI therapy; discontinuing such therapy out of fear of COVID-19 might not be warranted.N (%), patients n, events Clinical severity of COVID-The clinical characteristics, management and outcome of COVID-19 in patients undergoing HSCT remain unknown; guidelines are being generated by various organizations [29, 30] .", [["CML", "ANATOMY", 40, 43], ["CML", "DISEASE", 40, 43], ["COVID-19", "CHEMICAL", 321, 329], ["COVID-19", "CHEMICAL", 180, 188], ["COVID-19", "CHEMICAL", 321, 329], ["patients", "ORGANISM", 26, 34], ["CML", "CANCER", 40, 43], ["TKI", "SIMPLE_CHEMICAL", 125, 128], ["patients", "ORGANISM", 219, 227], ["patients", "ORGANISM", 333, 341], ["patients", "SPECIES", 26, 34], ["patients", "SPECIES", 219, 227], ["patients", "SPECIES", 333, 341], ["CML", "PROBLEM", 40, 43], ["COVID", "TEST", 103, 108], ["their TKI therapy", "TREATMENT", 119, 136], ["such therapy", "TREATMENT", 152, 164], ["COVID", "TEST", 180, 185], ["COVID", "PROBLEM", 259, 264], ["COVID", "TEST", 321, 326], ["HSCT", "TREATMENT", 353, 357]]], ["Our real-world data showed a mortality rate of 18%.", [["a mortality rate", "TEST", 27, 43]]], ["However, this figure should be interpreted with caution as both type of transplant and time from transplant (IQR 8-56 months) were heterogeneous.", [["transplant", "TREATMENT", 72, 82], ["transplant", "TREATMENT", 97, 107], ["transplant", "OBSERVATION", 72, 82], ["heterogeneous", "OBSERVATION_MODIFIER", 131, 144]]], ["Our data suggest that life-saving transplantation should not be delayed in patients with hematologic malignancies, although close monitoring is of paramount importance.N (%), patients n, events Clinical severity of COVID-Although the majority of the 230 deaths in our case series occurred during hospitalization, only 55 (8%) patients were admitted to an ICU.", [["hematologic malignancies", "ANATOMY", 89, 113], ["hematologic malignancies", "DISEASE", 89, 113], ["deaths", "DISEASE", 254, 260], ["patients", "ORGANISM", 75, 83], ["hematologic malignancies", "CANCER", 89, 113], ["patients", "ORGANISM", 175, 183], ["patients", "ORGANISM", 326, 334], ["patients", "SPECIES", 75, 83], ["patients", "SPECIES", 175, 183], ["patients", "SPECIES", 326, 334], ["Our data", "TEST", 0, 8], ["life-saving transplantation", "TREATMENT", 22, 49], ["hematologic malignancies", "PROBLEM", 89, 113], ["close monitoring", "TEST", 124, 140], ["COVID", "TEST", 215, 220]]], ["This rate is consistent with reports from the UK [9] and USA [31] , in which the incidence of ICU admission among patients with all types of cancer and COVID-19 was 6-14%.", [["cancer", "ANATOMY", 141, 147], ["cancer", "DISEASE", 141, 147], ["patients", "ORGANISM", 114, 122], ["cancer", "CANCER", 141, 147], ["patients", "SPECIES", 114, 122], ["This rate", "TEST", 0, 9], ["cancer", "PROBLEM", 141, 147], ["COVID", "TEST", 152, 157], ["cancer", "OBSERVATION", 141, 147]]], ["We were not able to determine from our dataset whether a diagnosis of a hematologic malignancy decreases a patient's chances of accessing such intensive support, for example due to equipment and/or personnel shortages.", [["hematologic malignancy", "ANATOMY", 72, 94], ["malignancy", "DISEASE", 84, 94], ["hematologic malignancy", "CANCER", 72, 94], ["patient", "ORGANISM", 107, 114], ["patient", "SPECIES", 107, 114], ["a hematologic malignancy", "PROBLEM", 70, 94], ["accessing such intensive support", "TREATMENT", 128, 160], ["hematologic", "OBSERVATION_MODIFIER", 72, 83], ["malignancy", "OBSERVATION", 84, 94]]], ["In our cohort, overall mortality rate in patients admitted to an ICU was 51%, suggesting that many patients with hematologic malignancy can survive COVID-19 and require equivalent access to ICU care.N (%), patients n, events Clinical severity of COVID-There are currently no approved treatment options for patients with COVID-19 in Europe, and no clear recommendations can be made regarding specific therapies due to limited data and unknown risk: benefit profiles.", [["hematologic malignancy", "ANATOMY", 113, 135], ["malignancy", "DISEASE", 125, 135], ["patients", "ORGANISM", 41, 49], ["patients", "ORGANISM", 99, 107], ["hematologic malignancy", "CANCER", 113, 135], ["patients", "ORGANISM", 206, 214], ["patients", "ORGANISM", 306, 314], ["patients", "SPECIES", 41, 49], ["patients", "SPECIES", 99, 107], ["patients", "SPECIES", 206, 214], ["patients", "SPECIES", 306, 314], ["hematologic malignancy", "PROBLEM", 113, 135], ["ICU care", "TREATMENT", 190, 198], ["treatment options", "TREATMENT", 284, 301], ["COVID", "TEST", 320, 325], ["specific therapies", "TREATMENT", 391, 409]]], ["Even fewer such data are available for patients with hematologic malignancies.", [["hematologic malignancies", "ANATOMY", 53, 77], ["hematologic malignancies", "DISEASE", 53, 77], ["patients", "ORGANISM", 39, 47], ["hematologic malignancies", "CANCER", 53, 77], ["patients", "SPECIES", 39, 47], ["hematologic malignancies", "PROBLEM", 53, 77]]], ["Our study is the first in which the effect of COVID-19 treatments has been studied in such patients with different degrees of clinical severity of COVID-19.", [["COVID-19", "CHEMICAL", 46, 54], ["COVID-19", "CHEMICAL", 46, 54], ["COVID-19", "CHEMICAL", 147, 155], ["patients", "ORGANISM", 91, 99], ["patients", "SPECIES", 91, 99], ["Our study", "TEST", 0, 9], ["COVID-19 treatments", "TREATMENT", 46, 65], ["COVID", "TEST", 147, 152]]], ["Interestingly, our findings showed that in patients with severe/critical COVID-19, not receiving any antiviral therapy was associated with higher mortality than being treated with any antiviral combination therapy.", [["patients", "ORGANISM", 43, 51], ["patients", "SPECIES", 43, 51], ["severe/critical COVID", "PROBLEM", 57, 78], ["any antiviral therapy", "TREATMENT", 97, 118], ["any antiviral combination therapy", "TREATMENT", 180, 213]]], ["However, this was a non-randomized study and residual confounding by indication may explain this finding.", [["a non-randomized study", "TEST", 18, 40]]], ["These data provide a rationale for including patients with hematologic malignancies in investigational strategies of antiviral therapy.", [["hematologic malignancies", "ANATOMY", 59, 83], ["hematologic malignancies", "DISEASE", 59, 83], ["patients", "ORGANISM", 45, 53], ["hematologic malignancies", "CANCER", 59, 83], ["patients", "SPECIES", 45, 53], ["hematologic malignancies", "PROBLEM", 59, 83], ["investigational strategies", "TREATMENT", 87, 113], ["antiviral therapy", "TREATMENT", 117, 134], ["antiviral therapy", "OBSERVATION", 117, 134]]], ["Regarding the effect of corticoids, although some clinical trials have showed that corticoids have a survival benefit, in patients with hematological malignancies, we have not seen this effect.", [["hematological malignancies", "ANATOMY", 136, 162], ["hematological malignancies", "DISEASE", 136, 162], ["corticoids", "SIMPLE_CHEMICAL", 24, 34], ["corticoids", "SIMPLE_CHEMICAL", 83, 93], ["patients", "ORGANISM", 122, 130], ["hematological malignancies", "CANCER", 136, 162], ["patients", "SPECIES", 122, 130], ["corticoids", "TREATMENT", 24, 34], ["corticoids", "TREATMENT", 83, 93], ["hematological malignancies", "PROBLEM", 136, 162], ["corticoids", "OBSERVATION", 24, 34]]], ["Notably, we also observed that the mortality rate in patients with mild/moderate COVID-19 was nearly sixfold higher among those treated with, vs not receiving, tocilizumab.", [["patients", "ORGANISM", 53, 61], ["tocilizumab", "SIMPLE_CHEMICAL", 160, 171], ["patients", "SPECIES", 53, 61], ["the mortality rate", "TEST", 31, 49], ["mild/moderate COVID", "PROBLEM", 67, 86], ["tocilizumab", "TREATMENT", 160, 171], ["mild", "OBSERVATION_MODIFIER", 67, 71], ["moderate", "OBSERVATION_MODIFIER", 72, 80]]], ["Further, tocilizumab was not associated with any benefit in patients with severe/ critical COVID-19.", [["tocilizumab", "CHEMICAL", 9, 20], ["tocilizumab", "SIMPLE_CHEMICAL", 9, 20], ["patients", "ORGANISM", 60, 68], ["patients", "SPECIES", 60, 68], ["tocilizumab", "TREATMENT", 9, 20], ["severe/ critical COVID", "PROBLEM", 74, 96]]], ["As no reference guidelines were available, these results may be related to the expected high variability in the criteria used for prescribing tocilizumab, doses administered and clinical severity of the disease at the time of drug administration.", [["tocilizumab", "CHEMICAL", 142, 153], ["tocilizumab", "SIMPLE_CHEMICAL", 142, 153], ["prescribing tocilizumab", "TREATMENT", 130, 153], ["the disease", "PROBLEM", 199, 210], ["drug administration", "TREATMENT", 226, 245], ["high variability", "OBSERVATION", 88, 104], ["disease", "OBSERVATION", 203, 210]]], ["These findings call for optimizing precision medicine strategies when designing controlled studies on the use of tocilizumab.LimitationsOur study has some limitations.", [["tocilizumab", "CHEMICAL", 113, 124], ["tocilizumab", "SIMPLE_CHEMICAL", 113, 124], ["optimizing precision medicine strategies", "TREATMENT", 24, 64], ["tocilizumab", "TREATMENT", 113, 124], ["Our study", "TEST", 136, 145]]], ["First, this was primarily an observational cohort study designed for rapid patient accrual during the nonlinear growth phase of the COVID-19 outbreak.", [["patient", "ORGANISM", 75, 82], ["patient", "SPECIES", 75, 82], ["an observational cohort study", "TEST", 26, 55], ["the COVID", "TEST", 128, 137]]], ["For this reason, our study introduces uncertainty into the exact timing of therapeutic intervals, as required to meet IRB regulatory requirements.", [["our study", "TEST", 17, 26]]], ["Second, although to the best of our knowledge we included all patients with hematologic malignancies and COVID-19, the true number of such patients might have been higher because of the low rate of testing or misdiagnoses at the beginning of the pandemic and including only patients who contacted the healthcare system.", [["hematologic malignancies", "ANATOMY", 76, 100], ["hematologic malignancies", "DISEASE", 76, 100], ["patients", "ORGANISM", 62, 70], ["hematologic malignancies", "CANCER", 76, 100], ["patients", "ORGANISM", 139, 147], ["patients", "ORGANISM", 274, 282], ["patients", "SPECIES", 62, 70], ["patients", "SPECIES", 139, 147], ["patients", "SPECIES", 274, 282], ["hematologic malignancies", "PROBLEM", 76, 100], ["COVID", "TEST", 105, 110], ["the low rate of testing", "PROBLEM", 182, 205], ["misdiagnoses", "PROBLEM", 209, 221]]], ["More data on the prevalence and outcomes of COVID-19 in asymptomatic patients with hematologic malignancies could emerge as hospital systems implement more comprehensive testing of all patients seeking care.", [["hematologic malignancies", "ANATOMY", 83, 107], ["hematologic malignancies", "DISEASE", 83, 107], ["patients", "ORGANISM", 69, 77], ["hematologic malignancies", "CANCER", 83, 107], ["patients", "ORGANISM", 185, 193], ["patients", "SPECIES", 69, 77], ["patients", "SPECIES", 185, 193], ["COVID", "TEST", 44, 49], ["hematologic malignancies", "PROBLEM", 83, 107], ["comprehensive testing", "TEST", 156, 177]]], ["Third, data on clinical symptoms, laboratory findings, disease status and details on therapy were missing.", [["clinical symptoms", "PROBLEM", 15, 32], ["laboratory findings", "TEST", 34, 53], ["disease status", "PROBLEM", 55, 69], ["therapy", "TREATMENT", 85, 92]]], ["We did not collect data on contacts although during the first wave of the COVID-19 pandemic in Madrid, we expected most patients to be infected by community transmission.", [["patients", "ORGANISM", 120, 128], ["patients", "SPECIES", 120, 128], ["the COVID", "TEST", 70, 79], ["infected", "OBSERVATION", 135, 143]]], ["Finally, our case series incorporates a heterogeneous patient population with multiple different hematologic malignancies; further studies in patients with specific malignancies [32] are needed, as it is possible that type of malignancy and disease status may affect the clinical course of COVID-19.", [["hematologic malignancies", "ANATOMY", 97, 121], ["malignancies", "ANATOMY", 165, 177], ["hematologic malignancies", "DISEASE", 97, 121], ["malignancies", "DISEASE", 165, 177], ["malignancy", "DISEASE", 226, 236], ["COVID-19", "CHEMICAL", 290, 298], ["patient", "ORGANISM", 54, 61], ["hematologic malignancies", "CANCER", 97, 121], ["patients", "ORGANISM", 142, 150], ["malignancies", "CANCER", 165, 177], ["malignancy", "CANCER", 226, 236], ["patient", "SPECIES", 54, 61], ["patients", "SPECIES", 142, 150], ["a heterogeneous patient population", "PROBLEM", 38, 72], ["multiple different hematologic malignancies", "PROBLEM", 78, 121], ["further studies", "TEST", 123, 138], ["specific malignancies", "PROBLEM", 156, 177], ["malignancy", "PROBLEM", 226, 236], ["disease status", "PROBLEM", 241, 255], ["COVID", "TEST", 290, 295], ["heterogeneous", "OBSERVATION_MODIFIER", 40, 53], ["multiple", "OBSERVATION_MODIFIER", 78, 86], ["different", "OBSERVATION_MODIFIER", 87, 96], ["hematologic malignancies", "OBSERVATION", 97, 121], ["malignancy", "OBSERVATION", 226, 236]]], ["Nevertheless, our study included a large number of patients with some malignancies, which could overcome in part this perceived limitation.Learn more biomedcentral.com/submissionsReady to submit your research Ready to submit your research ?", [["malignancies", "ANATOMY", 70, 82], ["malignancies", "DISEASE", 70, 82], ["patients", "ORGANISM", 51, 59], ["malignancies", "CANCER", 70, 82], ["patients", "SPECIES", 51, 59], ["our study", "TEST", 14, 23], ["some malignancies", "PROBLEM", 65, 82], ["large", "OBSERVATION_MODIFIER", 35, 40], ["malignancies", "OBSERVATION", 70, 82]]], ["Choose BMC and benefit from:Learn more biomedcentral.com/submissions?", [["BMC", "ANATOMY", 7, 10], ["BMC", "CANCER", 7, 10]]], ["Choose BMC and benefit from:", [["BMC", "ANATOMY", 7, 10], ["BMC", "CANCER", 7, 10]]]], "dbeffe6225d5cd7bbe869b29d529ed7673950aaa": [["IntroductionPersonality influences many aspects of human behaviour, e.g. made decisions, propensity for communication with other people, way of writing or listened music [22] .", [["human", "ORGANISM", 51, 56], ["human", "SPECIES", 51, 56], ["people", "SPECIES", 129, 135], ["human", "SPECIES", 51, 56]]], ["In the context of computer science, personality may influence organization of created source code, or a choice of a software project a person takes part in.IntroductionWhile automatic personality recognition from text attained remarkable attention [37] , personality recognition from source code is still a scarcely explored problem.IntroductionAutomatic personality recognition can be useful to customize learning process or to assess cultural fit in a company.", [["person", "SPECIES", 135, 141], ["IntroductionAutomatic personality recognition", "PROBLEM", 333, 378]]], ["Each company has a different culture [26] -there are places where programmers are supposed to often contact clients and conversely where they talk only to their supervisors.", [["a different culture", "TEST", 17, 36]]], ["If a person fits in his company, he is more involved in what he is doing, more satisfied with things he has accomplished during his work time and more productive, which is beneficial both for him and his employer.", [["person", "SPECIES", 5, 11]]], ["Cultural fit depends on one's personality, thus an automatic personality recognition system that detects whether a person fits into the company's environment based on programming assessment completed during a recruitment phase could save both employee's and employer's time and stress.", [["person", "SPECIES", 115, 121], ["programming assessment", "TEST", 167, 189], ["stress", "PROBLEM", 278, 284]]], ["Both in academia and industry, psychological and sociological predispositions of programmers could be examined to better recognize their soft skills and choose job.IntroductionThis paper proposes personality recognition from source code with random tree forest on the basis of 35 handcrafted features based on lexical, syntactic and semantic properties of source code.", [["lexical", "TREATMENT", 310, 317], ["academia", "OBSERVATION", 8, 16]]], ["We compare above features with n-gram features serving as baseline features and present results arising from joint usage of both handcrafted and baseline features.", [["joint", "ANATOMY", 109, 114]]], ["Finally, we compare our results with scores obtained within Personality Recognition in SOurce COde (PR-SOCO) track during Forum for Information Retrieval Evaluation (PAN@FIRE 2016).IntroductionAs a model of personality, we adopt Big Five -a five-factor model of personality [27, 28] .", [["PR", "PROTEIN", 100, 102], ["Retrieval Evaluation", "TEST", 144, 164]]], ["The Big Five model assumes that personality can be described by the following five personality traits:Introduction-Conscientiousness (C) -consistency, persistence, good organizational skills.Introduction-Agreeableness (A) -attitude towards others (whether a person is suspicious or trustful, modest, willing to compromise). -Neuroticism (N) -impulsiveness, susceptibility to stress and anxiety. -Openness to experience (O) -intellectual curiosity, willingness to explore, rich imagination of examined person, searching original solutions rather than following in someone's footsteps. -Extroversion (E) -assertiveness, building relationship at ease.IntroductionEach personality trait can be divided further into six facets, but facets are out of scope of our work.Related WorkDeep learning personality predictors require no feature engineering, no preprocessing, scanning, nor parsing of source codes.", [["Neuroticism", "DISEASE", 325, 336], ["impulsiveness", "DISEASE", 342, 355], ["anxiety", "DISEASE", 386, 393], ["person", "SPECIES", 258, 264], ["person", "SPECIES", 501, 507], ["Neuroticism", "PROBLEM", 325, 336], ["impulsiveness", "PROBLEM", 342, 355], ["stress", "PROBLEM", 375, 381], ["anxiety", "PROBLEM", 386, 393], ["IntroductionEach personality trait", "TREATMENT", 648, 682], ["scanning", "TEST", 862, 870]]], ["An example of such an approach is an LSTM neural network which reads source code byte by byte [12] .", [["LSTM neural network", "ANATOMY", 37, 56], ["neural network", "MULTI-TISSUE_STRUCTURE", 42, 56]]], ["Low amount of learning data is, however, especially problematic for this approach, as not only the correct predictor (a classifier or a regressor), but also the relevant features should be learned from data.Related WorkFeatures designed for personality recognition from source code were based mainly on source code, but also on structure of the project, content of comments, or code complexity.", [["personality recognition", "PROBLEM", 241, 264], ["amount", "OBSERVATION_MODIFIER", 4, 10]]], ["In the PR-SOCO task, the following features were taken into account [33] :Related Work-number of files submitted by each programmer, -mean number of lines in programs, -mean length of variables, -mean number of classes, -mean length of classes (computed on the basis of the number of lines of code), -mean number of attributes, methods in a class, -number of programs implementing the same class, -number of errors, -Halstead complexity measures (e.g. difficulty and time needed for implementation and understanding), -duplicated fragments of source code, -cyclomatic complexity, -frequency of occurrence of comments and their length, -occurrence of comments written exclusively in capital letters, -number of comments in classes, -number of words inside comments, -usage of punctuation marks inside comments, -number of lines with missing white characters inside arithmetic expressions, -number of import declarations, which import the whole content of module (usage of * instead of concrete classes), -used white characters, -ways of indentation and formatting used by the programmer, -number of empty lines between methods, blocks of code and number of white characters between parentheses, -occurrence of digits, capital and small letters and symbol in names, as well as length of names.Related WorkIn [3] , frequency distribution of different types of nodes in an abstract syntax tree was examined, yielding however low results, little above baseline approaches.", [["nodes", "ANATOMY", 1357, 1362], ["nodes", "MULTI-TISSUE_STRUCTURE", 1357, 1362], ["PR", "PROTEIN", 7, 9], ["missing white characters", "PROBLEM", 832, 856], ["indentation", "PROBLEM", 1036, 1047], ["different types of nodes", "PROBLEM", 1338, 1362], ["empty lines", "OBSERVATION", 1098, 1109], ["digits", "ANATOMY", 1209, 1215], ["small", "OBSERVATION_MODIFIER", 1229, 1234], ["different types", "OBSERVATION_MODIFIER", 1338, 1353], ["nodes", "OBSERVATION", 1357, 1362], ["abstract syntax", "OBSERVATION", 1369, 1384]]], ["Another type of features are character n-grams -versatile, easy to implement features, which are language independent and have a wide range of applications in classification tasks, including authorship attribution [14, 35] , author profiling [2] , authorship verification [9, 20] and plagiarism detection [23] .", [["authorship verification", "TEST", 248, 271], ["plagiarism detection", "TEST", 284, 304]]], ["They may also provide convenient features for a baseline solution of PR-SOCO.", [["PR-SOCO", "GENE_OR_GENE_PRODUCT", 69, 76], ["PR", "PROTEIN", 69, 71], ["SOCO", "PROTEIN", 72, 76]]], ["In the context of personality recognition from source code, character n-grams were used in [17, 32] .Related WorkThe choice of a predictor (a regressor or a classifier) is a more standard procedure and includes mainly: linear regression [16, 25, 32] , support vector regression [7, 11] , decision trees [11] , nearest neighbours [25, 36] and neural networks [12, 36] .Related WorkThe research concerning personality recognition from source code is scarce and extraction of novel features will likely extend possiblities of distinguishing traits.", [["neural networks", "ANATOMY", 342, 357], ["a more standard procedure", "TREATMENT", 172, 197], ["novel features", "PROBLEM", 473, 487]]], ["Table 1 shows proposed handcrafted lexical, syntactic and semantic features for automatic personality recognition from source code.", [["automatic personality recognition", "PROBLEM", 80, 113]]], ["Consistecy in using curly brackets around one-line branches of code is implemented in two variants so it gives rise to two features.", [["curly brackets", "TREATMENT", 20, 34], ["curly brackets", "OBSERVATION", 20, 34], ["line", "ANATOMY_MODIFIER", 46, 50], ["branches", "ANATOMY_MODIFIER", 51, 59]]], ["Number of consecutive lines with aligned characters represents four features, as it is computed separately for four groups of characters.", [["lines", "CELL", 22, 27], ["consecutive lines", "TREATMENT", 10, 27], ["consecutive lines", "OBSERVATION", 10, 27], ["aligned", "OBSERVATION_MODIFIER", 33, 40], ["four features", "OBSERVATION_MODIFIER", 63, 76]]], ["Thus, in total there are 35 proposed features.Proposed FeaturesProposed features are grounded in the extension of lexical hypothesis to programming languages.", [["lexical hypothesis", "OBSERVATION", 114, 132]]], ["We suppose that in the domain of programming code a conscientious person will likely apply consistent indentation throught the code; a person high in openness might use richer vocabulary while an extrovert might use longer names for variables, methods and classes.", [["person", "SPECIES", 66, 72], ["person", "SPECIES", 135, 141]]], ["Additionaly, corellation between personality traits and programming style has been found in [10] , according to which persons high in openness prefer breadth-first programming style, while persons low in openness prefer depth-first programming style.Proposed FeaturesWe describe in detail three features, most complicated due to their involved implementation: the number of code duplications, length of comments in characters and the level of indentation.Proposed FeaturesDetection of code duplication is quite a complex task, which could be even cast as another machine learning problem, provided suitable learning data would be available or generated [24] .", [["persons", "ORGANISM", 118, 125], ["persons", "SPECIES", 118, 125], ["persons", "SPECIES", 189, 196], ["personality traits", "PROBLEM", 33, 51], ["code duplication", "PROBLEM", 485, 501], ["code duplication", "OBSERVATION", 485, 501]]], ["We adopted a simpler solution consuming less computing resources -syntax tree rewriting [30] .", [["a simpler solution consuming", "TREATMENT", 11, 39]]], ["Two pieces of code, one being a duplicate of another, exhibit the same structure but differ in names of constants, variables or methods.Proposed FeaturesThe syntax tree generated with the javalang parser is transformed to a topologically equivalent syntax tree, where tree nodes are simplified, to only reflect the structure of the code and discard irrelevant data.", [["tree nodes", "ANATOMY", 268, 278], ["tree nodes", "MULTI-TISSUE_STRUCTURE", 268, 278], ["the javalang parser", "TREATMENT", 184, 203], ["tree nodes", "OBSERVATION", 268, 278]]], ["For instance, a name of declared method has been discarded, but structure of its body, type of formal parameters and returned type have been retained.", [["body", "ANATOMY", 81, 85], ["body", "ORGANISM_SUBDIVISION", 81, 85]]], ["Detection of code duplication in one block is performed on the basis of such a simplified tree.", [["code duplication in one block", "TREATMENT", 13, 42]]], ["A list of all subtrees in the block is created and subtrees which serialize to the same expression are treated as duplications.Proposed FeaturesComputing length of comment, otherwise simple, requires detection whether a comment contains parts of source code.", [["the block", "TREATMENT", 26, 35], ["length", "OBSERVATION_MODIFIER", 154, 160], ["simple", "OBSERVATION_MODIFIER", 183, 189]]], ["Parsing a comment with a parser of Java would end up with a failure, as programmers usually comment a few lines of code or methods rather than entire programs.", [["a failure", "PROBLEM", 58, 67], ["failure", "OBSERVATION", 60, 67]]], ["To solve this problem, besides the main parser of the whole program, parsers of smaller grammatical units of a program are used.Proposed FeaturesAs white characters are discarded during lexical analysis and even less information is passed to the parser, the level of indentation feature was implemented as a state machine (separate from the used parser), which reads tokens, one by one, and tracks the level of indentation.", [["a program", "TREATMENT", 109, 118], ["Proposed FeaturesAs white characters", "PROBLEM", 128, 164], ["lexical analysis", "TEST", 186, 202], ["indentation", "OBSERVATION", 267, 278], ["indentation", "OBSERVATION", 411, 422]]], ["One difficulty in implementing this feature lies in distinguishing between a correct and wrong indentation after a sequence of empty lines of code.", [["wrong indentation", "PROBLEM", 89, 106], ["empty lines", "OBSERVATION", 127, 138]]], ["Although based only on finite automata formalism, the state machine has to roughly understand the syntax of Javait tracks the number of opening parentheses or curly brackets, closing an open block at the correct indentation level, reopening a block of code at a wrong indentation level.", [["curly brackets", "PROBLEM", 159, 173], ["an open block", "TREATMENT", 183, 196]]], ["Additional difficulty arises from one-line bodies of if and for instructions, where curly brackets are not required.", [["curly brackets", "TREATMENT", 84, 98]]], ["This seemingly simple task becomes a complex programming problem due to the great number of cases which should be considered.", [["a complex programming problem", "PROBLEM", 35, 64]]], ["Due to above difficulties, the implementation of the discussed feature ignores checking the level of indentation in conditional instructions and loops whose bodies contain only one line of code; and in switch instructions.", [["above difficulties", "PROBLEM", 7, 25]]], ["For the switch instruction, it is even impossible to determine which notation is correct, as the flat form was used by programmers mainly in the past, while switch instruction in the indented form is predominant currently.Choice of a ParserAs many proposed features were based on the syntactic structure of source code, choice of a parser of Java was an important part of the feature engineering.", [["predominant", "OBSERVATION_MODIFIER", 200, 211]]], ["Table 2 presents measured time of parsing source code with above parsers for the Hello world program (Listing 1.1) and the PR-SOCO corpus.", [["PR", "PROTEIN", 123, 125]]], ["The parser generated by ANTLR was incorrect as it was not able to parse all source code from the training corpus.", [["corpus", "CANCER", 106, 112], ["ANTLR", "PROTEIN", 24, 29]]], ["It was also very slow.", [["very", "OBSERVATION_MODIFIER", 12, 16], ["slow", "OBSERVATION_MODIFIER", 17, 21]]], ["Although JavaParser turned out faster than javalang on the PR-SOCO corpus, we chose the latter, as it was implemented in Python, which was the language of the whole project.DataAs a learning and evaluation data we used the corpus of source codes, released for the PR-SOCO track [33] , which accompanied PAN@FIRE 2016.", [["PR", "PROTEIN", 59, 61], ["PR", "PROTEIN", 264, 266], ["JavaParser", "PROBLEM", 9, 19], ["evaluation data", "TEST", 195, 210], ["SOCO corpus", "ANATOMY", 62, 73]]], ["In the PR-SOCO corpus, personality was modelled with Big Five, and each trait was given a value from [20, 80] .", [["PR", "PROTEIN", 7, 9], ["SOCO corpus", "ANATOMY", 10, 21]]], ["Values of personality traits were found on the basis of 25-item BFI questionnaire called Big Five locator which was completed by students.", [["personality traits", "TEST", 10, 28]]], ["The judge system does not have tools for style correction.", [["style correction", "TREATMENT", 41, 57]]], ["However, it is not known whether students used an IDE before the submission or not.", [["IDE", "PROTEIN", 50, 53], ["an IDE", "TREATMENT", 47, 53]]], ["The training and test set contain source codes of 49 and 21 programmers, respectively.", [["test set", "TEST", 17, 25], ["source codes", "TEST", 34, 46]]], ["During the PR-SOCO contest, personalities of 21 persons from the test set were concealed from participating teams.", [["persons", "ORGANISM", 48, 55], ["PR", "PROTEIN", 11, 13], ["persons", "SPECIES", 48, 55]]], ["A single solution predicted five traits for each of 21 persons from the test set.", [["persons", "ORGANISM", 55, 62], ["persons", "SPECIES", 55, 62], ["A single solution", "TREATMENT", 0, 17], ["the test set", "TEST", 68, 80]]], ["Values from range [0, 20) and [80, 100] are never taken by any trait.DataWe followed the PR-SOCO track and used two measures to assess our solution and compare with existing personality predictors: Root Mean Square Error (RMSE ) and Pearson Product-Moment Correlation coefficient (PCC ).DataRMSE measures the effectiveness of a regressor.", [["PR", "PROTEIN", 89, 91], ["Values", "TEST", 0, 6], ["RMSE", "TEST", 222, 226], ["DataRMSE", "TREATMENT", 287, 295], ["a regressor", "TREATMENT", 326, 337]]], ["For each personality trait t, root mean square error is defined as: where x i denotes true value of trait t for i-th instance (programmer), y i is a value of trait t predicted by a personality predictor, and N is the number of instances (programmers).", [["root", "ANATOMY", 30, 34]]], ["The lower RMSE the better.", [["lower", "ANATOMY_MODIFIER", 4, 9], ["better", "OBSERVATION_MODIFIER", 19, 25]]], ["Pearson Product-Moment Correlation is defined as:Datawithx,\u0233 denoting mean values of samples (x i ) N i=1 and (y i ) N i=1 , respectively.", [["Datawithx", "TEST", 49, 58], ["samples", "TEST", 85, 92]]], ["PCC indicates whether obtained RMSE is a random artifact or there is a correlation between actual and guessed values of traits.", [["a random artifact", "PROBLEM", 39, 56]]], ["The larger the absolute value of PCC the better.Experiments and ResultsIn the experiments we took the profile-based approach, i.e., all source codes of a programmer were treated as one learning instance.", [["larger", "OBSERVATION_MODIFIER", 4, 10], ["absolute value", "OBSERVATION_MODIFIER", 15, 29]]], ["Since personality traits take continuous values, personality recognition was cast as a regression problem with random forest regression [4] from scikit-learn package [31] as the prediction module.", [["a regression problem", "PROBLEM", 85, 105], ["random forest regression", "PROBLEM", 111, 135]]], ["Random forest regressors were trained on 85% of the original training set, remaining 15% of the training set was reserved for the model selection procedure.", [["Random forest regressors", "TREATMENT", 0, 24], ["the training set", "TREATMENT", 92, 108], ["the model selection procedure", "TREATMENT", 126, 155]]], ["We examined the random forest regression with the number of decision trees varying from 64 to 128 and their depth varying from 2 to 6.", [["the random forest regression", "PROBLEM", 12, 40]]], ["Optimal values of the above hyperparameters were selected separately for each personality trait with grid search [8] .", [["Optimal values", "TEST", 0, 14], ["the above hyperparameters", "TEST", 18, 43]]], ["Mean Square Error (MSE ) was used as the function measuring the quality of a split.Experiments and ResultsBeside regression with 35 handcrafted features, we used N = 1500 n-gram features as our baseline: N 1 = 1000 most frequent character trigrams (n-grams with n = 3) and N 2 = 500 most frequent token trigrams.", [["35 handcrafted features", "PROBLEM", 129, 152], ["gram features", "TEST", 173, 186], ["n-grams", "TEST", 249, 256], ["n", "TEST", 262, 263]]], ["Table 3 presents results of personality recognition we obtained with 3 sets of features: proposed handcrafted features, n-grams and handcrafted features together with n-grams.", [["personality recognition", "TEST", 28, 51]]], ["For comparison, best results, medians and mean results of FIRE competitors are given in Table 4 (summary of FIRE competition [33] shows also first, second and third quantiles, all extreme values, and detailed results of all participating teams).", [["FIRE competitors", "TREATMENT", 58, 74]]], ["Additionally we computed confidence intervals with the pairs bootstrap method [13] .ResultsFor conscientiousness personality trait, the model with handcrafted features obtained RMSE equal 8.17 (with 95% confidence interval [6.00, 9.", [["conscientiousness personality trait", "PROBLEM", 95, 130], ["RMSE", "TEST", 177, 181]]], ["98]) which is lower than the minimum error achieved in the competition.", [["lower", "OBSERVATION_MODIFIER", 14, 19]]], ["For the model predicting conscientiousness with handcrafted features, the following features were the most important (more important features come first): The effect of joint usage of handcrafted features and n-grams is the reduced error (in comparison to usage of only one type of features) for extroversion and agreeableness, although it does not set up new state-of-the-art results.ResultsFinally, we examined statistical significance of obtained trait predictions (RMSE s).", [["joint", "ANATOMY", 169, 174], ["handcrafted features", "PROBLEM", 48, 68], ["handcrafted features", "PROBLEM", 184, 204], ["the reduced error", "PROBLEM", 220, 237], ["extroversion", "PROBLEM", 296, 308], ["joint", "ANATOMY", 169, 174]]], ["Statistical tests, conducted on the STAC platform [34] , were computed for 14 algorithms (11 solutions from the PR-SOCO task and our three solutions: with handcrafted features, n-grams and all features) and five datasets (predictions for each of five traits were counted as a separate dataset).", [["PR", "PROTEIN", 112, 114], ["Statistical tests", "TEST", 0, 17], ["the STAC platform", "TEST", 32, 49], ["the PR", "TEST", 108, 114], ["handcrafted features", "PROBLEM", 155, 175]]], ["For solution from the PR-SOCO task we always chose the best shot.", [["PR", "PROTEIN", 22, 24]]], ["As the omnibus test we used Friedman F-test [15] for testing hypothesis H 0 that the means of the results of two or more algorithms are the same, followed by Nemenyi test [29] as the post-hoc test for pairwise comparison of predictors.", [["the omnibus test", "TEST", 3, 19], ["Friedman F-test", "TEST", 28, 43], ["the post-hoc test", "TEST", 179, 196]]], ["At the significance level \u03b1 = 0.05, hypothesis H 0 should be rejected but pairwise comparison revealed no pair of algorithms with a statistical difference in results.ConclusionsIn this work we proposed new features for automatic personality recognition from source code.", [["pair of algorithms", "PROBLEM", 106, 124], ["automatic personality recognition", "PROBLEM", 219, 252]]], ["These features, despite their low number, achieved the state-of-the-art-results for conscientiousness.", [["conscientiousness", "PROBLEM", 84, 101]]], ["The lowest error in conscientiousness prediction is in line with the fact, that conscientiousness (and extroversion) are easily inferred from even slices of behaviour [6, 18] .ConclusionsN-gram features are surprisingly good predictors of personality, at the same time they are easy to implement and language independent.ConclusionsWhile the programmers' personalities may be connected with the code they write, we could not capture the relation between them.", [["ConclusionsN", "TEST", 176, 188]]], ["The results we achieved in neuroticism and conscientiousness recognition are state-of-the-art in personality recognition from source code, yet still insufficient to state that such a correlation exists.ConclusionsLarge confidence intervals of RMSE s and PCC s, and conducted statistical tests prove that larger datasets are needed to increase statistical strength of our results as well as other methods proposed so far.", [["conscientiousness recognition", "TEST", 43, 72], ["RMSE s", "TEST", 243, 249], ["PCC s", "PROBLEM", 254, 259], ["conducted statistical tests", "TEST", 265, 292], ["larger datasets", "PROBLEM", 304, 319], ["Large", "OBSERVATION_MODIFIER", 213, 218]]]], "PMC7125626": [["IntroductionPorcine reproductive and respiratory syndrome virus (PRRSV) is an enveloped, single-strand positive-sense RNA virus belonging to the family Arteriviridae, order Nidovirales (Collins et al., 1992, Conzelmann et al., 1993, Wensvoort et al., 1991).", [["IntroductionPorcine reproductive and respiratory syndrome", "DISEASE", 0, 57], ["IntroductionPorcine reproductive and respiratory syndrome virus", "ORGANISM", 0, 63], ["PRRSV", "ORGANISM", 65, 70], ["PRRSV", "SPECIES", 65, 70], ["PRRSV", "SPECIES", 65, 70], ["IntroductionPorcine reproductive", "PROBLEM", 0, 32], ["respiratory syndrome virus", "PROBLEM", 37, 63], ["respiratory syndrome", "OBSERVATION", 37, 57]]], ["Its genome is approximately 15.4-kb containing a 5\u2032- and a 3\u2032-untranslated region (UTR) and 10 open reading frames (Conzelmann et al., 1993, Johnson et al., 2011, Meng et al., 1994, Meulenberg et al., 1993).", [["5\u2032- and a 3\u2032-untranslated region", "DNA", 49, 81], ["UTR", "DNA", 83, 86], ["open reading frames", "DNA", 95, 114], ["a 3\u2032-untranslated region (UTR)", "TREATMENT", 57, 87], ["genome", "OBSERVATION_MODIFIER", 4, 10], ["approximately", "OBSERVATION_MODIFIER", 14, 27], ["15.4-kb", "OBSERVATION_MODIFIER", 28, 35]]], ["It encodes at least 16 non-structural proteins involved in the processing of viral proteolysis, genome replication, transcription and evading host immune responses, which include four proteases (Nsp1\u03b1, Nsp1\u03b2, Nsp2, and Nsp4), the RNA-dependent RNA polymerase (Nsp9), a helicase (Nsp10), and an endonuclease (Nsp11) (Dokland, 2010, Fang et al., 2012, Snijder and Meulenberg, 1998, Ziebuhr et al., 2000).", [["Nsp1\u03b1", "GENE_OR_GENE_PRODUCT", 195, 200], ["Nsp1\u03b2", "GENE_OR_GENE_PRODUCT", 202, 207], ["Nsp2", "GENE_OR_GENE_PRODUCT", 209, 213], ["Nsp4", "GENE_OR_GENE_PRODUCT", 219, 223], ["RNA-dependent RNA polymerase", "GENE_OR_GENE_PRODUCT", 230, 258], ["Nsp9", "GENE_OR_GENE_PRODUCT", 260, 264], ["Nsp10", "GENE_OR_GENE_PRODUCT", 279, 284], ["Nsp11", "GENE_OR_GENE_PRODUCT", 308, 313], ["structural proteins", "PROTEIN", 27, 46], ["proteases", "PROTEIN", 184, 193], ["Nsp1\u03b1", "PROTEIN", 195, 200], ["Nsp1\u03b2", "PROTEIN", 202, 207], ["Nsp2", "PROTEIN", 209, 213], ["Nsp4", "PROTEIN", 219, 223], ["RNA-dependent RNA polymerase", "PROTEIN", 230, 258], ["Nsp9", "PROTEIN", 260, 264], ["helicase", "PROTEIN", 269, 277], ["Nsp10", "PROTEIN", 279, 284], ["endonuclease", "PROTEIN", 294, 306], ["Nsp11", "PROTEIN", 308, 313], ["viral proteolysis", "PROBLEM", 77, 94], ["genome replication", "TREATMENT", 96, 114], ["four proteases", "TEST", 179, 193], ["Nsp1", "TEST", 195, 199], ["Nsp1", "TEST", 202, 206], ["Nsp2", "TEST", 209, 213], ["Nsp4", "TEST", 219, 223], ["the RNA", "TEST", 226, 233], ["a helicase (Nsp10", "TREATMENT", 267, 284], ["viral proteolysis", "OBSERVATION", 77, 94]]], ["It also encodes eight structural proteins including the membrane glycoproteins Gp2a, Gp2b, Gp3, Gp4, Gp5, and Gp5a, the matrix protein (M), and the nucleocapsid protein (N) involved in the process of viral entry, assembling, and release (Dea et al., 2000, Johnson et al., 2011, Meulenberg et al., 1995).", [["membrane", "ANATOMY", 56, 64], ["membrane", "CELLULAR_COMPONENT", 56, 64], ["Gp2a", "GENE_OR_GENE_PRODUCT", 79, 83], ["Gp2b", "GENE_OR_GENE_PRODUCT", 85, 89], ["Gp3", "GENE_OR_GENE_PRODUCT", 91, 94], ["Gp4", "GENE_OR_GENE_PRODUCT", 96, 99], ["Gp5", "GENE_OR_GENE_PRODUCT", 101, 104], ["Gp5a", "GENE_OR_GENE_PRODUCT", 110, 114], ["matrix", "CELLULAR_COMPONENT", 120, 126], ["nucleocapsid protein (N)", "GENE_OR_GENE_PRODUCT", 148, 172], ["structural proteins", "PROTEIN", 22, 41], ["membrane glycoproteins", "PROTEIN", 56, 78], ["Gp2a", "PROTEIN", 79, 83], ["Gp2b", "PROTEIN", 85, 89], ["Gp3", "PROTEIN", 91, 94], ["Gp4", "PROTEIN", 96, 99], ["Gp5", "PROTEIN", 101, 104], ["Gp5a", "PROTEIN", 110, 114], ["matrix protein", "PROTEIN", 120, 134], ["M", "PROTEIN", 136, 137], ["nucleocapsid protein", "PROTEIN", 148, 168], ["N", "PROTEIN", 170, 171], ["the membrane glycoproteins", "TEST", 52, 78], ["Gp2a", "TEST", 79, 83], ["Gp2b", "TEST", 85, 89], ["Gp3", "TEST", 91, 94], ["Gp4", "TEST", 96, 99], ["Gp5", "TEST", 101, 104], ["Gp5a", "TEST", 110, 114], ["the matrix protein", "TEST", 116, 134], ["the nucleocapsid protein", "TEST", 144, 168], ["eight", "OBSERVATION_MODIFIER", 16, 21], ["structural proteins", "OBSERVATION", 22, 41], ["membrane", "ANATOMY_MODIFIER", 56, 64], ["glycoproteins", "ANATOMY_MODIFIER", 65, 78], ["viral entry", "OBSERVATION", 200, 211]]], ["These viral proteins are associated with certain host factors to control the whole process of PRRSV infection.IntroductionPRRSV has two major genotypes, the European genotype (type 1) and the North American genotype (type 2) (Forsberg, 2005, Hanada et al., 2005).", [["PRRSV infection", "DISEASE", 94, 109], ["IntroductionPRRSV", "CHEMICAL", 110, 127], ["PRRSV", "ORGANISM", 94, 99], ["viral proteins", "PROTEIN", 6, 20], ["PRRSV", "SPECIES", 94, 99], ["These viral proteins", "PROBLEM", 0, 20], ["certain host factors", "PROBLEM", 41, 61], ["PRRSV infection", "PROBLEM", 94, 109], ["viral proteins", "OBSERVATION", 6, 20], ["PRRSV infection", "OBSERVATION", 94, 109]]], ["Recently, there have been devastating outbreaks of atypical PRRS caused by a highly pathogenic PRRSV (HP-PRRSV) strain in China, which is characterized by high fever, high morbidity, and high mortality in all age pigs (Zhou and Yang, 2010).", [["PRRS", "DISEASE", 60, 64], ["fever", "DISEASE", 160, 165], ["PRRS", "ORGANISM", 60, 64], ["PRRSV", "ORGANISM", 95, 100], ["HP-PRRSV", "ORGANISM", 102, 110], ["pigs", "ORGANISM", 213, 217], ["PRRS", "SPECIES", 60, 64], ["PRRSV", "SPECIES", 95, 100], ["pigs", "SPECIES", 213, 217], ["PRRS", "SPECIES", 60, 64], ["PRRSV", "SPECIES", 95, 100], ["PRRSV", "SPECIES", 105, 110], ["atypical PRRS", "PROBLEM", 51, 64], ["a highly pathogenic PRRSV (HP-PRRSV) strain in China", "PROBLEM", 75, 127], ["high fever", "PROBLEM", 155, 165], ["high morbidity", "PROBLEM", 167, 181], ["devastating", "OBSERVATION_MODIFIER", 26, 37], ["outbreaks", "OBSERVATION_MODIFIER", 38, 47], ["atypical PRRS", "OBSERVATION", 51, 64], ["highly", "OBSERVATION_MODIFIER", 77, 83], ["pathogenic", "OBSERVATION_MODIFIER", 84, 94], ["PRRSV", "OBSERVATION", 95, 100], ["high", "OBSERVATION_MODIFIER", 155, 159], ["fever", "OBSERVATION", 160, 165], ["high", "OBSERVATION_MODIFIER", 167, 171], ["morbidity", "OBSERVATION_MODIFIER", 172, 181]]], ["PRRSV has a very narrow cell tropism, showing a preference for cells of the monocyte/macrophage lineage in vivo (Duan et al., 1997).", [["cell", "ANATOMY", 24, 28], ["cells", "ANATOMY", 63, 68], ["monocyte", "ANATOMY", 76, 84], ["macrophage lineage", "ANATOMY", 85, 103], ["PRRSV", "ORGANISM", 0, 5], ["cell", "CELL", 24, 28], ["cells", "CELL", 63, 68], ["monocyte", "CELL", 76, 84], ["macrophage lineage", "CELL", 85, 103], ["monocyte/macrophage lineage", "CELL_TYPE", 76, 103], ["PRRSV", "SPECIES", 0, 5], ["PRRSV", "SPECIES", 0, 5], ["PRRSV", "PROBLEM", 0, 5], ["a very narrow cell tropism", "PROBLEM", 10, 36], ["very", "OBSERVATION_MODIFIER", 12, 16], ["narrow cell tropism", "OBSERVATION", 17, 36], ["monocyte", "ANATOMY", 76, 84], ["macrophage lineage", "OBSERVATION", 85, 103]]], ["PRSSV is also sustained by MA-104 cell line derived from African green monkey kidney and its derivatives (MARC-145 and CL2621) in vitro (Kim et al., 1993).", [["MA-104 cell line", "ANATOMY", 27, 43], ["kidney", "ANATOMY", 78, 84], ["MARC-145", "CHEMICAL", 106, 114], ["PRSSV", "GENE_OR_GENE_PRODUCT", 0, 5], ["MA-104 cell line", "CELL", 27, 43], ["monkey", "ORGANISM", 71, 77], ["kidney", "ORGAN", 78, 84], ["MARC-145", "CELL", 106, 114], ["CL2621", "CELL", 119, 125], ["PRSSV", "PROTEIN", 0, 5], ["MA-104 cell line", "CELL_LINE", 27, 43], ["green monkey", "SPECIES", 65, 77], ["PRSSV", "SPECIES", 0, 5], ["African green monkey", "SPECIES", 57, 77], ["cell line", "OBSERVATION", 34, 43], ["kidney", "ANATOMY", 78, 84]]], ["This cell tropism is mainly determined by the presence or absence of specific receptors in the target cells.", [["cell", "ANATOMY", 5, 9], ["cells", "ANATOMY", 102, 107], ["cell", "CELL", 5, 9], ["cells", "CELL", 102, 107], ["specific receptors", "PROTEIN", 69, 87], ["target cells", "CELL_TYPE", 95, 107], ["This cell tropism", "PROBLEM", 0, 17], ["cell tropism", "OBSERVATION", 5, 17], ["target cells", "OBSERVATION", 95, 107]]], ["PRRSV enters cells via receptor-mediated endocytosis, and heparan sulfate, sialoadhesin, and CD163 are known as the main PRRSV receptors (Van Breedam et al., 2010a).", [["cells", "ANATOMY", 13, 18], ["heparan sulfate", "CHEMICAL", 58, 73], ["PRRSV", "ORGANISM", 0, 5], ["cells", "CELL", 13, 18], ["heparan sulfate", "SIMPLE_CHEMICAL", 58, 73], ["sialoadhesin", "GENE_OR_GENE_PRODUCT", 75, 87], ["CD163", "GENE_OR_GENE_PRODUCT", 93, 98], ["PRRSV", "ORGANISM", 121, 126], ["sialoadhesin", "PROTEIN", 75, 87], ["CD163", "PROTEIN", 93, 98], ["PRRSV receptors", "PROTEIN", 121, 136], ["PRRSV", "SPECIES", 0, 5], ["receptor-mediated endocytosis", "TREATMENT", 23, 52], ["heparan sulfate", "TREATMENT", 58, 73], ["sialoadhesin", "TREATMENT", 75, 87], ["CD163", "TREATMENT", 93, 98]]], ["CD163, a macrophage differentiation membrane antigen belonging to the scavenger receptor cysteine-rich (SRCR) family, is shown to be capable of mediating PRRSV infection in non-permissive cells (Calvert et al., 2007).IntroductionThe plasma membrane is proposed not to be a homogeneously passive solvent, but a heterogeneous structure, displaying a tremendous complexity of lipids and proteins (Lingwood and Simons, 2010).", [["cells", "ANATOMY", 188, 193], ["plasma membrane", "ANATOMY", 233, 248], ["PRRSV infection", "DISEASE", 154, 169], ["cysteine", "CHEMICAL", 89, 97], ["CD163", "GENE_OR_GENE_PRODUCT", 0, 5], ["macrophage differentiation membrane antigen", "GENE_OR_GENE_PRODUCT", 9, 52], ["SRCR", "GENE_OR_GENE_PRODUCT", 104, 108], ["PRRSV", "ORGANISM", 154, 159], ["cells", "CELL", 188, 193], ["plasma", "ORGANISM_SUBSTANCE", 233, 239], ["membrane", "CELLULAR_COMPONENT", 240, 248], ["lipids", "SIMPLE_CHEMICAL", 373, 379], ["CD163", "PROTEIN", 0, 5], ["macrophage differentiation membrane antigen", "PROTEIN", 9, 52], ["scavenger receptor cysteine-rich (SRCR) family", "PROTEIN", 70, 116], ["non-permissive cells", "CELL_TYPE", 173, 193], ["PRRSV", "SPECIES", 154, 159], ["CD163", "TEST", 0, 5], ["a macrophage differentiation membrane antigen", "TEST", 7, 52], ["PRRSV infection", "PROBLEM", 154, 169], ["The plasma membrane", "TREATMENT", 229, 248], ["a homogeneously passive solvent", "PROBLEM", 271, 302], ["a heterogeneous structure", "PROBLEM", 308, 333], ["macrophage", "OBSERVATION_MODIFIER", 9, 19], ["infection", "OBSERVATION", 160, 169], ["plasma membrane", "OBSERVATION", 233, 248], ["not to be", "UNCERTAINTY", 261, 270], ["homogeneously", "OBSERVATION_MODIFIER", 273, 286], ["passive", "OBSERVATION_MODIFIER", 287, 294], ["solvent", "OBSERVATION", 295, 302], ["heterogeneous", "OBSERVATION_MODIFIER", 310, 323], ["structure", "OBSERVATION", 324, 333], ["tremendous", "OBSERVATION_MODIFIER", 348, 358]]], ["The strong evidence for this theory is the presence of lipid rafts that are specialized lipid domains enriched in sphingolipid, cholesterol, and a subclass of membrane proteins (Munro, 2003, Simons and Ikonen, 1997).", [["lipid rafts", "ANATOMY", 55, 66], ["membrane", "ANATOMY", 159, 167], ["cholesterol", "CHEMICAL", 128, 139], ["sphingolipid", "CHEMICAL", 114, 126], ["cholesterol", "CHEMICAL", 128, 139], ["lipid rafts", "CELLULAR_COMPONENT", 55, 66], ["lipid domains", "CELLULAR_COMPONENT", 88, 101], ["sphingolipid", "SIMPLE_CHEMICAL", 114, 126], ["cholesterol", "SIMPLE_CHEMICAL", 128, 139], ["membrane", "CELLULAR_COMPONENT", 159, 167], ["lipid domains", "PROTEIN", 88, 101], ["membrane proteins", "PROTEIN", 159, 176], ["lipid rafts", "TREATMENT", 55, 66], ["cholesterol", "TEST", 128, 139], ["strong evidence for", "UNCERTAINTY", 4, 23], ["lipid rafts", "OBSERVATION", 55, 66]]], ["Rafts can incorporate or exclude proteins selectively and coalesce into large domains to form platforms that function in many cellular processes including signal transduction, membrane trafficking, cytoskeletal organization, and pathogen infection (Brown and London, 2000, Simons and Toomre, 2000).", [["cellular", "ANATOMY", 126, 134], ["membrane", "ANATOMY", 176, 184], ["cytoskeletal", "ANATOMY", 198, 210], ["pathogen infection", "DISEASE", 229, 247], ["cellular", "CELL", 126, 134], ["membrane", "CELLULAR_COMPONENT", 176, 184], ["cytoskeletal", "CELLULAR_COMPONENT", 198, 210], ["proteins selectively", "PROBLEM", 33, 53], ["many cellular processes", "PROBLEM", 121, 144], ["signal transduction", "TEST", 155, 174], ["cytoskeletal organization", "PROBLEM", 198, 223], ["pathogen infection", "PROBLEM", 229, 247], ["cellular processes", "OBSERVATION", 126, 144], ["membrane trafficking", "OBSERVATION", 176, 196], ["cytoskeletal organization", "OBSERVATION", 198, 223], ["pathogen", "OBSERVATION_MODIFIER", 229, 237], ["infection", "OBSERVATION", 238, 247]]], ["Since lipid rafts are rich in sphingolipid and cholesterol, its resistance to cold detergent extraction has been widely used as an index (Harder et al., 1998).IntroductionLipid rafts are utilized in the lifecycle of numerous enveloped viruses.", [["lipid rafts", "ANATOMY", 6, 17], ["cholesterol", "CHEMICAL", 47, 58], ["sphingolipid", "CHEMICAL", 30, 42], ["cholesterol", "CHEMICAL", 47, 58], ["lipid rafts", "CELLULAR_COMPONENT", 6, 17], ["sphingolipid", "SIMPLE_CHEMICAL", 30, 42], ["cholesterol", "SIMPLE_CHEMICAL", 47, 58], ["lipid rafts", "TREATMENT", 6, 17], ["cold detergent extraction", "TREATMENT", 78, 103], ["IntroductionLipid rafts", "TREATMENT", 159, 182], ["lipid rafts", "OBSERVATION", 6, 17], ["cholesterol", "ANATOMY", 47, 58], ["numerous", "OBSERVATION_MODIFIER", 216, 224], ["enveloped", "OBSERVATION_MODIFIER", 225, 234], ["viruses", "OBSERVATION", 235, 242]]], ["Many enveloped viruses exploit lipid rafts for their entry stages, in which the viral enveloped glycoproteins probably insert into lipid rafts to interact with the raft-located receptors or convert from their native state to activated form to initiate or facilitate viral internalization and/or fusion (Ahn et al., 2002, Bender et al., 2003, Popik et al., 2002).", [["lipid rafts", "ANATOMY", 31, 42], ["lipid rafts", "ANATOMY", 131, 142], ["raft", "ANATOMY", 164, 168], ["lipid rafts", "CELLULAR_COMPONENT", 31, 42], ["lipid rafts", "CELLULAR_COMPONENT", 131, 142], ["raft", "CELLULAR_COMPONENT", 164, 168], ["viral enveloped glycoproteins", "PROTEIN", 80, 109], ["raft-located receptors", "PROTEIN", 164, 186], ["lipid rafts", "TREATMENT", 31, 42], ["the viral enveloped glycoproteins", "TREATMENT", 76, 109], ["lipid rafts", "TREATMENT", 131, 142], ["viral internalization", "TREATMENT", 266, 287], ["enveloped", "OBSERVATION_MODIFIER", 5, 14], ["viruses", "OBSERVATION", 15, 22]]], ["Lipid rafts are also found in the intracellular structures and many special proteins such as arrays of signal transduction proteins and some viral non-structural proteins are found in lipid rafts on plasma membrane and intracellular membranes, which contribute to efficient trafficking, replication, assembly, and budding (Aizaki et al., 2004, Barman and Nayak, 2007, Bhattacharya et al., 2006, Ono and Freed, 2001).", [["Lipid rafts", "ANATOMY", 0, 11], ["intracellular structures", "ANATOMY", 34, 58], ["lipid rafts", "ANATOMY", 184, 195], ["plasma membrane", "ANATOMY", 199, 214], ["intracellular membranes", "ANATOMY", 219, 242], ["Lipid", "SIMPLE_CHEMICAL", 0, 5], ["intracellular structures", "CELLULAR_COMPONENT", 34, 58], ["lipid rafts", "CELLULAR_COMPONENT", 184, 195], ["plasma membrane", "CELLULAR_COMPONENT", 199, 214], ["intracellular membranes", "CELLULAR_COMPONENT", 219, 242], ["signal transduction proteins", "PROTEIN", 103, 131], ["viral non-structural proteins", "PROTEIN", 141, 170], ["Lipid rafts", "TEST", 0, 11], ["many special proteins", "PROBLEM", 63, 84], ["signal transduction proteins", "PROBLEM", 103, 131], ["some viral non-structural proteins", "PROBLEM", 136, 170], ["intracellular membranes", "PROBLEM", 219, 242], ["intracellular", "ANATOMY_MODIFIER", 34, 47], ["viral non-structural proteins", "OBSERVATION", 141, 170], ["lipid rafts", "OBSERVATION", 184, 195], ["plasma membrane", "OBSERVATION", 199, 214], ["intracellular membranes", "OBSERVATION", 219, 242]]], ["In addition, for certain viruses, the viral membrane shows similar structure to lipid raft in cell membrane, and is critical for their efficient infections (Brugger et al., 2006, Graham et al., 2003).", [["membrane", "ANATOMY", 44, 52], ["lipid raft", "ANATOMY", 80, 90], ["cell membrane", "ANATOMY", 94, 107], ["infections", "DISEASE", 145, 155], ["lipid raft", "CELLULAR_COMPONENT", 80, 90], ["cell membrane", "CELLULAR_COMPONENT", 94, 107], ["certain viruses", "PROBLEM", 17, 32], ["the viral membrane", "TEST", 34, 52], ["their efficient infections", "PROBLEM", 129, 155], ["viruses", "OBSERVATION", 25, 32], ["viral membrane", "OBSERVATION", 38, 52], ["similar structure", "OBSERVATION", 59, 76], ["lipid raft", "OBSERVATION", 80, 90], ["cell membrane", "OBSERVATION", 94, 107], ["infections", "OBSERVATION", 145, 155]]], ["Recently, it was reported that cholesterol-depletion drugs could inhibit PRRSV infection and influence PRRSV entry to Marc-145 cells (Huang et al., 2011).", [["Marc-145 cells", "ANATOMY", 118, 132], ["cholesterol", "CHEMICAL", 31, 42], ["PRRSV infection", "DISEASE", 73, 88], ["cholesterol", "CHEMICAL", 31, 42], ["cholesterol", "SIMPLE_CHEMICAL", 31, 42], ["PRRSV", "ORGANISM", 73, 78], ["PRRSV", "ORGANISM", 103, 108], ["Marc-145 cells", "CELL", 118, 132], ["Marc-145 cells", "CELL_LINE", 118, 132], ["PRRSV", "SPECIES", 73, 78], ["PRRSV", "SPECIES", 103, 108], ["cholesterol-depletion drugs", "TREATMENT", 31, 58], ["PRRSV infection", "PROBLEM", 73, 88]]], ["However, there is a lack of detailed and direct evidence to prove whether lipid rafts function in PRRSV entry process.", [["lipid rafts", "ANATOMY", 74, 85], ["lipid rafts", "CELLULAR_COMPONENT", 74, 85], ["PRRSV", "ORGANISM", 98, 103], ["PRRSV", "SPECIES", 98, 103], ["lipid rafts function", "PROBLEM", 74, 94], ["PRRSV entry", "OBSERVATION", 98, 109]]], ["Moreover, we still have little information about whether lipid rafts are required in PRRSV infection and how PRRSV utilizes lipid rafts.", [["lipid rafts", "ANATOMY", 57, 68], ["lipid rafts", "ANATOMY", 124, 135], ["infection", "DISEASE", 91, 100], ["lipid rafts", "CELLULAR_COMPONENT", 57, 68], ["PRRSV", "ORGANISM", 85, 90], ["PRRSV", "ORGANISM", 109, 114], ["lipid rafts", "CELLULAR_COMPONENT", 124, 135], ["PRRSV", "SPECIES", 85, 90], ["PRRSV", "SPECIES", 109, 114], ["lipid rafts", "TREATMENT", 57, 68], ["PRRSV infection", "PROBLEM", 85, 100], ["lipid rafts", "TREATMENT", 124, 135], ["PRRSV infection", "OBSERVATION", 85, 100]]], ["Here, we provide more evidence to verify that PRRSV entry is associated with lipid rafts.", [["lipid rafts", "ANATOMY", 77, 88], ["PRRSV", "ORGANISM", 46, 51], ["lipid rafts", "CELLULAR_COMPONENT", 77, 88], ["PRRSV", "SPECIES", 46, 51], ["PRRSV entry", "PROBLEM", 46, 57], ["lipid rafts", "PROBLEM", 77, 88], ["PRRSV", "OBSERVATION", 46, 51], ["lipid rafts", "OBSERVATION", 77, 88]]], ["In addition, we show that lipid rafts in cell membrane play an important role in PRRSV replication and release, and lipid rafts in PRRSV envelope are also critical for its infection.Depletion of cellular cholesterol inhibits PRRSV infection ::: ResultTo assess whether PRRSV infection is sensitive to intact lipid rafts, we tested the impact of Methyl-\u03b2-cyclodextrin (M\u03b2CD), a drug widely used to sequester cholesterol (Ilangumaran and Hoessli, 1998), on the infection of different PRRSV strains.", [["lipid rafts", "ANATOMY", 26, 37], ["cell membrane", "ANATOMY", 41, 54], ["lipid rafts", "ANATOMY", 116, 127], ["cellular", "ANATOMY", 195, 203], ["lipid rafts", "ANATOMY", 308, 319], ["infection", "DISEASE", 172, 181], ["cholesterol", "CHEMICAL", 204, 215], ["PRRSV infection", "DISEASE", 225, 240], ["PRRSV infection", "DISEASE", 269, 284], ["Methyl-\u03b2-cyclodextrin", "CHEMICAL", 345, 366], ["M\u03b2CD", "CHEMICAL", 368, 372], ["cholesterol", "CHEMICAL", 407, 418], ["Ilangumaran", "CHEMICAL", 420, 431], ["infection", "DISEASE", 459, 468], ["cholesterol", "CHEMICAL", 204, 215], ["Methyl-\u03b2-cyclodextrin", "CHEMICAL", 345, 366], ["M\u03b2CD", "CHEMICAL", 368, 372], ["cholesterol", "CHEMICAL", 407, 418], ["Ilangumaran", "CHEMICAL", 420, 431], ["lipid rafts", "CELLULAR_COMPONENT", 26, 37], ["cell membrane", "CELLULAR_COMPONENT", 41, 54], ["PRRSV", "ORGANISM", 81, 86], ["lipid rafts", "CELLULAR_COMPONENT", 116, 127], ["PRRSV", "ORGANISM", 131, 136], ["cellular", "CELL", 195, 203], ["cholesterol", "SIMPLE_CHEMICAL", 204, 215], ["PRRSV", "ORGANISM", 225, 230], ["PRRSV", "ORGANISM", 269, 274], ["lipid rafts", "CELLULAR_COMPONENT", 308, 319], ["Methyl-\u03b2-cyclodextrin", "SIMPLE_CHEMICAL", 345, 366], ["M\u03b2CD", "SIMPLE_CHEMICAL", 368, 372], ["cholesterol", "SIMPLE_CHEMICAL", 407, 418], ["Ilangumaran", "SIMPLE_CHEMICAL", 420, 431], ["PRRSV", "ORGANISM", 482, 487], ["PRRSV", "SPECIES", 81, 86], ["PRRSV", "SPECIES", 131, 136], ["PRRSV", "SPECIES", 225, 230], ["PRRSV", "SPECIES", 269, 274], ["PRRSV", "SPECIES", 482, 487], ["lipid rafts in cell membrane", "TREATMENT", 26, 54], ["PRRSV replication", "TREATMENT", 81, 98], ["lipid rafts in PRRSV envelope", "TREATMENT", 116, 145], ["its infection", "PROBLEM", 168, 181], ["cellular cholesterol inhibits PRRSV infection", "PROBLEM", 195, 240], ["PRRSV infection", "PROBLEM", 269, 284], ["intact lipid rafts", "TREATMENT", 301, 319], ["Methyl-\u03b2-cyclodextrin (M\u03b2CD", "TREATMENT", 345, 372], ["a drug", "TREATMENT", 375, 381], ["different PRRSV strains", "TREATMENT", 472, 495], ["lipid rafts", "OBSERVATION", 26, 37], ["cell membrane", "OBSERVATION", 41, 54], ["PRRSV replication", "OBSERVATION", 81, 98], ["infection", "OBSERVATION", 172, 181], ["cellular cholesterol", "OBSERVATION", 195, 215], ["PRRSV infection", "OBSERVATION", 225, 240], ["infection", "OBSERVATION", 275, 284], ["infection", "OBSERVATION", 459, 468], ["PRRSV strains", "OBSERVATION", 482, 495]]], ["Previous studies have shown that upon treatment with M\u03b2CD membrane cholesterol levels will remain low for 9\u201312 h (Li et al., 2007, Rojek et al., 2008).", [["membrane", "ANATOMY", 58, 66], ["cholesterol", "CHEMICAL", 67, 78], ["cholesterol", "CHEMICAL", 67, 78], ["M\u03b2CD", "SIMPLE_CHEMICAL", 53, 57], ["membrane", "CELLULAR_COMPONENT", 58, 66], ["cholesterol", "SIMPLE_CHEMICAL", 67, 78], ["Previous studies", "TEST", 0, 16], ["treatment", "TREATMENT", 38, 47], ["M\u03b2CD membrane cholesterol levels", "TEST", 53, 85]]], ["Indeed, treatment with M\u03b2CD for 1 h effectively reduced the level of cellular cholesterol in both Marc-145 cells and PAMs by approximate 80\u201390% compared to that in untreated cells at the concentration of 20 mM (Fig. 1A).", [["cellular", "ANATOMY", 69, 77], ["Marc-145 cells", "ANATOMY", 98, 112], ["cells", "ANATOMY", 174, 179], ["M\u03b2CD", "CHEMICAL", 23, 27], ["cholesterol", "CHEMICAL", 78, 89], ["M\u03b2CD", "CHEMICAL", 23, 27], ["cholesterol", "CHEMICAL", 78, 89], ["M\u03b2CD", "SIMPLE_CHEMICAL", 23, 27], ["cellular", "CELL", 69, 77], ["cholesterol", "SIMPLE_CHEMICAL", 78, 89], ["Marc-145 cells", "CELL", 98, 112], ["PAMs", "CELL", 117, 121], ["cells", "CELL", 174, 179], ["Marc-145 cells", "CELL_LINE", 98, 112], ["PAMs", "CELL_TYPE", 117, 121], ["untreated cells", "CELL_TYPE", 164, 179], ["M\u03b2CD", "TREATMENT", 23, 27], ["cellular cholesterol", "TEST", 69, 89], ["PAMs", "TEST", 117, 121], ["cellular cholesterol", "OBSERVATION", 69, 89], ["145 cells", "OBSERVATION_MODIFIER", 103, 112], ["20 mM", "OBSERVATION_MODIFIER", 204, 209]]], ["Moreover, 2 h following treatment with 30 mM M\u03b2CD, the Marc-145 cells or PAMs retained relative viability of 100% compared with controls (Fig. 1B), ruling out the possible nonspecific effects of cytotoxicity caused by M\u03b2CD.", [["Marc-145 cells", "ANATOMY", 55, 69], ["M\u03b2CD", "CHEMICAL", 218, 222], ["M\u03b2CD", "CHEMICAL", 45, 49], ["M\u03b2CD", "CHEMICAL", 218, 222], ["M\u03b2CD", "SIMPLE_CHEMICAL", 45, 49], ["Marc-145 cells", "CELL", 55, 69], ["PAMs", "CELL", 73, 77], ["M\u03b2CD", "SIMPLE_CHEMICAL", 218, 222], ["Marc-145 cells", "CELL_LINE", 55, 69], ["PAMs", "CELL_TYPE", 73, 77], ["treatment", "TREATMENT", 24, 33], ["30 mM M\u03b2CD", "TREATMENT", 39, 49], ["PAMs", "PROBLEM", 73, 77], ["cytotoxicity", "PROBLEM", 195, 207], ["viability", "OBSERVATION_MODIFIER", 96, 105]]], ["Next, we treated Marc-145 cells with M\u03b2CD (0, 2.5, 5, 7.5, 10, and 20 mM) for 1 h prior to infection with PRRSV strain CH1a (MOI=1), and examined PRRSV infection using indirect immunofluorescent staining and quantified PRRSV titers of the supernatant 24 h post infection.", [["Marc-145 cells", "ANATOMY", 17, 31], ["supernatant", "ANATOMY", 239, 250], ["M\u03b2CD", "CHEMICAL", 37, 41], ["infection", "DISEASE", 91, 100], ["PRRSV infection", "DISEASE", 146, 161], ["infection", "DISEASE", 261, 270], ["M\u03b2CD", "CHEMICAL", 37, 41], ["Marc-145 cells", "CELL", 17, 31], ["M\u03b2CD", "SIMPLE_CHEMICAL", 37, 41], ["PRRSV", "ORGANISM", 106, 111], ["PRRSV", "ORGANISM", 146, 151], ["PRRSV", "ORGANISM", 219, 224], ["Marc-145 cells", "CELL_LINE", 17, 31], ["PRRSV", "SPECIES", 146, 151], ["PRRSV strain CH1a (MOI=1", "SPECIES", 106, 130], ["PRRSV", "SPECIES", 146, 151], ["PRRSV", "SPECIES", 219, 224], ["M\u03b2CD", "TREATMENT", 37, 41], ["infection", "PROBLEM", 91, 100], ["PRRSV strain CH1a", "PROBLEM", 106, 123], ["MOI", "TEST", 125, 128], ["PRRSV infection", "PROBLEM", 146, 161], ["indirect immunofluorescent staining", "TEST", 168, 203], ["infection", "PROBLEM", 261, 270], ["145 cells", "OBSERVATION_MODIFIER", 22, 31], ["infection", "OBSERVATION", 91, 100], ["PRRSV infection", "OBSERVATION", 146, 161], ["infection", "OBSERVATION", 261, 270]]], ["As shown in Fig. 1C and D, CH1a infection was significantly inhibited by M\u03b2CD in a dose-dependent manner.", [["infection", "DISEASE", 32, 41], ["M\u03b2CD", "CHEMICAL", 73, 77], ["M\u03b2CD", "CHEMICAL", 73, 77], ["D", "SIMPLE_CHEMICAL", 24, 25], ["CH1a", "SIMPLE_CHEMICAL", 27, 31], ["M\u03b2CD", "SIMPLE_CHEMICAL", 73, 77], ["CH1a infection", "PROBLEM", 27, 41], ["Fig", "OBSERVATION", 12, 15], ["infection", "OBSERVATION", 32, 41]]], ["And a titer-reduction of more than 104-fold was observed at the concentration of 20 mM when compared with the non-M\u03b2CD-treated cells (Fig. 1D).", [["cells", "ANATOMY", 127, 132], ["non-M\u03b2CD", "CHEMICAL", 110, 118], ["non-M\u03b2CD", "SIMPLE_CHEMICAL", 110, 118], ["cells", "CELL", 127, 132], ["non-M\u03b2CD-treated cells", "CELL_LINE", 110, 132], ["a titer-reduction", "TREATMENT", 4, 21], ["the non-M\u03b2CD-treated cells", "TREATMENT", 106, 132], ["reduction", "OBSERVATION_MODIFIER", 12, 21]]], ["To investigate whether this anti-PRRSV activity is strain specific, we did the same treatment with PAMs and then infected it with HP-PRRSV strain Hpv (MOI=1).", [["anti-PRRSV", "CANCER", 28, 38], ["HP-PRRSV", "ORGANISM", 130, 138], ["PAMs", "TREATMENT", 99, 103], ["HP", "PROBLEM", 130, 132]]], ["Our results showed that M\u03b2CD also inhibited Hpv infection in PAMs, and a more than 1000-fold suppression was observed at the concentration of 20 mM (Fig. 1E).Depletion of cellular cholesterol inhibits PRRSV infection ::: ResultTo confirm that the inhibition of PRRSV infectivity is not due to any nonspecific effect of M\u03b2CD, we performed a cholesterol reconstitution experiment (Fig. 1F).", [["cellular", "ANATOMY", 171, 179], ["M\u03b2CD", "CHEMICAL", 24, 28], ["infection", "DISEASE", 48, 57], ["cholesterol", "CHEMICAL", 180, 191], ["PRRSV infection", "DISEASE", 201, 216], ["M\u03b2CD", "CHEMICAL", 319, 323], ["cholesterol", "CHEMICAL", 340, 351], ["M\u03b2CD", "CHEMICAL", 24, 28], ["cholesterol", "CHEMICAL", 180, 191], ["M\u03b2CD", "CHEMICAL", 319, 323], ["cholesterol", "CHEMICAL", 340, 351], ["M\u03b2CD", "SIMPLE_CHEMICAL", 24, 28], ["Hpv", "GENE_OR_GENE_PRODUCT", 44, 47], ["PAMs", "CELL", 61, 65], ["cellular", "CELL", 171, 179], ["cholesterol", "SIMPLE_CHEMICAL", 180, 191], ["PRRSV", "ORGANISM", 201, 206], ["PRRSV", "ORGANISM", 261, 266], ["M\u03b2CD", "SIMPLE_CHEMICAL", 319, 323], ["cholesterol", "SIMPLE_CHEMICAL", 340, 351], ["PAMs", "CELL_TYPE", 61, 65], ["M\u03b2CD", "PROTEIN", 319, 323], ["PRRSV", "SPECIES", 201, 206], ["PRRSV", "SPECIES", 261, 266], ["M\u03b2CD", "PROBLEM", 24, 28], ["Hpv infection in PAMs", "PROBLEM", 44, 65], ["cellular cholesterol inhibits PRRSV infection", "PROBLEM", 171, 216], ["PRRSV infectivity", "PROBLEM", 261, 278], ["any nonspecific effect of M\u03b2CD", "PROBLEM", 293, 323], ["a cholesterol reconstitution experiment", "TREATMENT", 338, 377], ["infection", "OBSERVATION", 48, 57], ["cellular cholesterol", "OBSERVATION", 171, 191], ["PRRSV infection", "OBSERVATION", 201, 216]]], ["Marc-145 cells were pretreated with 10 mM M\u03b2CD for 1 h, followed by addition of cholesterol to replenish cells for 1 h.", [["Marc-145 cells", "ANATOMY", 0, 14], ["cells", "ANATOMY", 105, 110], ["M\u03b2CD", "CHEMICAL", 42, 46], ["cholesterol", "CHEMICAL", 80, 91], ["M\u03b2CD", "CHEMICAL", 42, 46], ["cholesterol", "CHEMICAL", 80, 91], ["Marc-145 cells", "CELL", 0, 14], ["M\u03b2CD", "SIMPLE_CHEMICAL", 42, 46], ["cholesterol", "SIMPLE_CHEMICAL", 80, 91], ["cells", "CELL", 105, 110], ["Marc-145 cells", "CELL_LINE", 0, 14], ["replenish cells", "CELL_TYPE", 95, 110], ["10 mM M\u03b2CD", "TREATMENT", 36, 46], ["cholesterol to replenish cells", "TREATMENT", 80, 110], ["145 cells", "OBSERVATION_MODIFIER", 5, 14], ["replenish cells", "OBSERVATION", 95, 110]]], ["Cells were then infected with CH1a (MOI=1) and virus yield was analyzed 24 h post infection.", [["Cells", "ANATOMY", 0, 5], ["infection", "DISEASE", 82, 91], ["Cells", "CELL", 0, 5], ["CH1a", "TEST", 30, 34], ["MOI", "TEST", 36, 39], ["virus yield", "TREATMENT", 47, 58], ["infection", "PROBLEM", 82, 91], ["infection", "OBSERVATION", 82, 91]]], ["As expected, PRRSV infection was successfully restored by cholesterol supplementation, confirming that the inhibition by M\u03b2CD is due to its specific sequestering of cholesterol.", [["PRRSV infection", "DISEASE", 13, 28], ["cholesterol", "CHEMICAL", 58, 69], ["M\u03b2CD", "CHEMICAL", 121, 125], ["cholesterol", "CHEMICAL", 165, 176], ["cholesterol", "CHEMICAL", 58, 69], ["cholesterol", "CHEMICAL", 165, 176], ["PRRSV", "ORGANISM", 13, 18], ["cholesterol", "SIMPLE_CHEMICAL", 58, 69], ["M\u03b2CD", "SIMPLE_CHEMICAL", 121, 125], ["cholesterol", "SIMPLE_CHEMICAL", 165, 176], ["PRRSV", "SPECIES", 13, 18], ["PRRSV infection", "PROBLEM", 13, 28], ["cholesterol supplementation", "TREATMENT", 58, 85], ["PRRSV", "OBSERVATION_MODIFIER", 13, 18], ["infection", "OBSERVATION", 19, 28]]], ["These results indicated that cellular cholesterol depletion could inhibit PRRSV infection, implicating that PRRSV infection might be associated with cellular lipid rafts.Cellular cholesterol depletion inhibits PRRSV entry but has no effect on PRRSV binding ::: ResultTo further explore how lipid rafts influence PRRSV infection, we first determine whether the depletion of cellular cholesterol affects PRRSV entry to the cells.", [["cellular", "ANATOMY", 29, 37], ["cellular lipid rafts", "ANATOMY", 149, 169], ["Cellular", "ANATOMY", 170, 178], ["lipid rafts", "ANATOMY", 290, 301], ["cellular", "ANATOMY", 373, 381], ["cells", "ANATOMY", 421, 426], ["cholesterol", "CHEMICAL", 38, 49], ["PRRSV infection", "DISEASE", 74, 89], ["PRRSV infection", "DISEASE", 108, 123], ["cholesterol", "CHEMICAL", 179, 190], ["PRRSV infection", "DISEASE", 312, 327], ["cholesterol", "CHEMICAL", 382, 393], ["cholesterol", "CHEMICAL", 38, 49], ["cholesterol", "CHEMICAL", 179, 190], ["cholesterol", "CHEMICAL", 382, 393], ["cellular", "CELL", 29, 37], ["cholesterol", "SIMPLE_CHEMICAL", 38, 49], ["PRRSV", "ORGANISM", 74, 79], ["PRRSV", "ORGANISM", 108, 113], ["cellular", "CELL", 149, 157], ["lipid rafts", "CELLULAR_COMPONENT", 158, 169], ["Cellular", "CELL", 170, 178], ["cholesterol", "SIMPLE_CHEMICAL", 179, 190], ["PRRSV", "ORGANISM", 210, 215], ["PRRSV", "ORGANISM", 243, 248], ["lipid rafts", "CELLULAR_COMPONENT", 290, 301], ["PRRSV", "ORGANISM", 312, 317], ["cellular", "CELL", 373, 381], ["cholesterol", "SIMPLE_CHEMICAL", 382, 393], ["PRRSV", "ORGANISM", 402, 407], ["cells", "CELL", 421, 426], ["PRRSV", "SPECIES", 74, 79], ["PRRSV", "SPECIES", 108, 113], ["PRRSV", "SPECIES", 210, 215], ["PRRSV", "SPECIES", 243, 248], ["PRRSV", "SPECIES", 312, 317], ["PRRSV", "SPECIES", 402, 407], ["cellular cholesterol depletion", "PROBLEM", 29, 59], ["PRRSV infection", "PROBLEM", 74, 89], ["PRRSV infection", "PROBLEM", 108, 123], ["cellular lipid rafts", "PROBLEM", 149, 169], ["Cellular cholesterol depletion", "PROBLEM", 170, 200], ["PRRSV entry", "PROBLEM", 210, 221], ["PRRSV infection", "PROBLEM", 312, 327], ["cellular cholesterol", "PROBLEM", 373, 393], ["cellular", "OBSERVATION", 29, 37], ["cholesterol depletion", "OBSERVATION", 38, 59], ["PRRSV infection", "OBSERVATION", 74, 89], ["PRRSV infection", "OBSERVATION", 108, 123], ["might be associated with", "UNCERTAINTY", 124, 148], ["cellular", "OBSERVATION", 149, 157], ["lipid rafts", "OBSERVATION", 158, 169], ["cholesterol depletion", "OBSERVATION", 179, 200], ["no", "UNCERTAINTY", 230, 232], ["cellular cholesterol", "OBSERVATION", 373, 393]]], ["The process of PRRSV entry includes early attachment and subsequent internalization.", [["PRRSV", "ORGANISM", 15, 20], ["PRRSV", "SPECIES", 15, 20], ["PRRSV entry", "PROBLEM", 15, 26], ["early attachment", "PROBLEM", 36, 52], ["PRRSV entry", "OBSERVATION", 15, 26]]], ["To address whether M\u03b2CD can inhibit PRRSV binding, Marc-145 cells were pretreated with M\u03b2CD and then incubated with CH1a at 4 \u00b0C (in this way, virions will bind to the cells without penetration).", [["Marc-145 cells", "ANATOMY", 51, 65], ["cells", "ANATOMY", 168, 173], ["M\u03b2CD", "CHEMICAL", 19, 23], ["M\u03b2CD", "CHEMICAL", 87, 91], ["CH1a", "CHEMICAL", 116, 120], ["M\u03b2CD", "CHEMICAL", 19, 23], ["M\u03b2CD", "CHEMICAL", 87, 91], ["M\u03b2CD", "SIMPLE_CHEMICAL", 19, 23], ["PRRSV", "ORGANISM", 36, 41], ["Marc-145 cells", "CELL", 51, 65], ["M\u03b2CD", "SIMPLE_CHEMICAL", 87, 91], ["CH1a", "SIMPLE_CHEMICAL", 116, 120], ["cells", "CELL", 168, 173], ["M\u03b2CD", "PROTEIN", 19, 23], ["Marc-145 cells", "CELL_LINE", 51, 65], ["PRRSV", "SPECIES", 36, 41], ["PRRSV", "SPECIES", 36, 41], ["PRRSV binding", "PROBLEM", 36, 49], ["M\u03b2CD", "TREATMENT", 87, 91], ["CH1a", "TREATMENT", 116, 120], ["virions", "TREATMENT", 143, 150]]], ["The level of cell-bound viral RNA was analyzed.", [["cell", "ANATOMY", 13, 17], ["cell", "CELL", 13, 17], ["viral RNA", "RNA", 24, 33], ["cell-bound viral RNA", "PROBLEM", 13, 33], ["viral RNA", "OBSERVATION", 24, 33]]], ["As shown inFig.", [["Fig", "OBSERVATION", 11, 14]]], ["2A, the amount of bound virions was not affected even if a 20 mM M\u03b2CD was used.", [["M\u03b2CD", "CHEMICAL", 65, 69], ["M\u03b2CD", "CHEMICAL", 65, 69], ["2A", "GENE_OR_GENE_PRODUCT", 0, 2], ["M\u03b2CD", "SIMPLE_CHEMICAL", 65, 69], ["bound virions", "PROBLEM", 18, 31], ["a 20 mM M\u03b2CD", "TREATMENT", 57, 69], ["amount", "OBSERVATION_MODIFIER", 8, 14], ["bound virions", "OBSERVATION", 18, 31]]], ["PAMs treated as above also showed little variation on their capability to bind Hpv virions (Fig. 2B).", [["Hpv", "GENE_OR_GENE_PRODUCT", 79, 82], ["little variation", "PROBLEM", 34, 50]]], ["These data suggest that cholesterol depletion has no effects on virus attachment to the cells.Cellular cholesterol depletion inhibits PRRSV entry but has no effect on PRRSV binding ::: ResultPrevious studies have reported that PRRSV is completely internalized from the surface of Marc-145 cells within 3\u20136 h (Kreutz and Ackermann, 1996, Nauwynck et al., 1999).", [["cells", "ANATOMY", 88, 93], ["Cellular", "ANATOMY", 94, 102], ["surface", "ANATOMY", 269, 276], ["Marc-145 cells", "ANATOMY", 280, 294], ["cholesterol", "CHEMICAL", 24, 35], ["cholesterol", "CHEMICAL", 103, 114], ["cholesterol", "CHEMICAL", 24, 35], ["cholesterol", "CHEMICAL", 103, 114], ["cholesterol", "SIMPLE_CHEMICAL", 24, 35], ["cells", "CELL", 88, 93], ["Cellular", "CELL", 94, 102], ["cholesterol", "SIMPLE_CHEMICAL", 103, 114], ["PRRSV", "ORGANISM", 134, 139], ["PRRSV", "ORGANISM", 167, 172], ["PRRSV", "ORGANISM", 227, 232], ["surface", "CELLULAR_COMPONENT", 269, 276], ["Marc-145 cells", "CELL", 280, 294], ["Marc-145 cells", "CELL_LINE", 280, 294], ["PRRSV", "SPECIES", 134, 139], ["PRRSV", "SPECIES", 167, 172], ["PRRSV", "SPECIES", 227, 232], ["These data", "TEST", 0, 10], ["cholesterol depletion", "PROBLEM", 24, 45], ["virus attachment", "PROBLEM", 64, 80], ["Cellular cholesterol depletion", "PROBLEM", 94, 124], ["PRRSV entry", "PROBLEM", 134, 145], ["ResultPrevious studies", "TEST", 185, 207], ["PRRSV", "PROBLEM", 227, 232], ["cholesterol depletion", "OBSERVATION", 24, 45], ["cholesterol depletion", "OBSERVATION", 103, 124], ["no", "UNCERTAINTY", 154, 156]]], ["To examine whether cellular cholesterol depletion affects PRRSV internalization into Marc-145 cells, cells were pretreated with M\u03b2CD and then incubated with CH1a at 4 \u00b0C. Cells were subsequently shifted to 37 \u00b0C to allow virus internalization for 3 h and the level of internalized viral RNA in cells was analyzed (Fig. 2C).", [["cellular", "ANATOMY", 19, 27], ["Marc-145 cells", "ANATOMY", 85, 99], ["cells", "ANATOMY", 101, 106], ["Cells", "ANATOMY", 171, 176], ["cells", "ANATOMY", 294, 299], ["cholesterol", "CHEMICAL", 28, 39], ["M\u03b2CD", "CHEMICAL", 128, 132], ["CH1a", "CHEMICAL", 157, 161], ["cholesterol", "CHEMICAL", 28, 39], ["M\u03b2CD", "CHEMICAL", 128, 132], ["cellular", "CELL", 19, 27], ["cholesterol", "SIMPLE_CHEMICAL", 28, 39], ["PRRSV", "ORGANISM", 58, 63], ["Marc-145 cells", "CELL", 85, 99], ["cells", "CELL", 101, 106], ["M\u03b2CD", "SIMPLE_CHEMICAL", 128, 132], ["Cells", "CELL", 171, 176], ["cells", "CELL", 294, 299], ["Marc-145 cells", "CELL_LINE", 85, 99], ["internalized viral RNA", "RNA", 268, 290], ["PRRSV", "SPECIES", 58, 63], ["cellular cholesterol depletion", "PROBLEM", 19, 49], ["M\u03b2CD", "TREATMENT", 128, 132], ["CH1a", "TREATMENT", 157, 161], ["Cells", "TEST", 171, 176], ["virus internalization", "TREATMENT", 221, 242], ["internalized viral RNA in cells", "PROBLEM", 268, 299], ["cholesterol depletion", "OBSERVATION", 28, 49], ["145 cells", "OBSERVATION_MODIFIER", 90, 99], ["viral RNA", "OBSERVATION", 281, 290]]], ["M\u03b2CD exhibited an obvious dose-dependent inhibitory effect on CH1a in Marc-145 cells, showing about 50% and 90.0% reductions of internalized PRRSV RNA in cells treated with 5 mM and 20 mM M\u03b2CD compared to that in untreated cells, respectively.", [["Marc-145 cells", "ANATOMY", 70, 84], ["cells", "ANATOMY", 154, 159], ["cells", "ANATOMY", 223, 228], ["M\u03b2CD", "CHEMICAL", 0, 4], ["M\u03b2CD", "CHEMICAL", 188, 192], ["M\u03b2CD", "CHEMICAL", 0, 4], ["M\u03b2CD", "CHEMICAL", 188, 192], ["M\u03b2CD", "SIMPLE_CHEMICAL", 0, 4], ["CH1a", "SIMPLE_CHEMICAL", 62, 66], ["Marc-145 cells", "CELL", 70, 84], ["PRRSV", "ORGANISM", 141, 146], ["cells", "CELL", 154, 159], ["M\u03b2CD", "SIMPLE_CHEMICAL", 188, 192], ["cells", "CELL", 223, 228], ["Marc-145 cells", "CELL_LINE", 70, 84], ["PRRSV RNA", "RNA", 141, 150], ["untreated cells", "CELL_TYPE", 213, 228], ["PRRSV", "SPECIES", 141, 146], ["dependent inhibitory effect", "PROBLEM", 31, 58], ["internalized PRRSV RNA in cells", "PROBLEM", 128, 159], ["5 mM and 20 mM M\u03b2CD", "TREATMENT", 173, 192], ["PRRSV RNA", "OBSERVATION", 141, 150]]], ["A similar reduction was observed when we did the same experiment with PAMs (Fig. 2D).", [["A similar reduction", "TREATMENT", 0, 19], ["similar", "OBSERVATION_MODIFIER", 2, 9], ["reduction", "OBSERVATION", 10, 19]]], ["We also attempted to reverse the PRRSV entry by supplementing the cells with exogenous cholesterol.", [["cells", "ANATOMY", 66, 71], ["cholesterol", "CHEMICAL", 87, 98], ["cholesterol", "CHEMICAL", 87, 98], ["PRRSV", "ORGANISM", 33, 38], ["cells", "CELL", 66, 71], ["cholesterol", "SIMPLE_CHEMICAL", 87, 98], ["PRRSV", "SPECIES", 33, 38], ["the PRRSV entry", "TREATMENT", 29, 44], ["exogenous cholesterol", "OBSERVATION", 77, 98]]], ["Marc-145 cells were pretreated with 20 mM M\u03b2CD for 1 h, followed by addition of cholesterol to replenish cells for 1 h.", [["Marc-145 cells", "ANATOMY", 0, 14], ["cells", "ANATOMY", 105, 110], ["M\u03b2CD", "CHEMICAL", 42, 46], ["cholesterol", "CHEMICAL", 80, 91], ["M\u03b2CD", "CHEMICAL", 42, 46], ["cholesterol", "CHEMICAL", 80, 91], ["Marc-145 cells", "CELL", 0, 14], ["M\u03b2CD", "SIMPLE_CHEMICAL", 42, 46], ["cholesterol", "SIMPLE_CHEMICAL", 80, 91], ["cells", "CELL", 105, 110], ["Marc-145 cells", "CELL_LINE", 0, 14], ["replenish cells", "CELL_TYPE", 95, 110], ["20 mM M\u03b2CD", "TREATMENT", 36, 46], ["cholesterol to replenish cells", "TREATMENT", 80, 110], ["145 cells", "OBSERVATION_MODIFIER", 5, 14], ["replenish cells", "OBSERVATION", 95, 110]]], ["Then, cells were incubated with CH1a at 4 \u00b0C for 1 h and subsequently shifted to 37 \u00b0C to allow virus internalization for 3 h.", [["cells", "ANATOMY", 6, 11], ["CH1a", "CHEMICAL", 32, 36], ["CH1a", "CHEMICAL", 32, 36], ["cells", "CELL", 6, 11], ["CH1a", "SIMPLE_CHEMICAL", 32, 36], ["CH1a", "TREATMENT", 32, 36], ["virus internalization", "TREATMENT", 96, 117]]], ["Then the level of internalized viral RNA in cells was analyzed after non-internalized virions were washed away.", [["cells", "ANATOMY", 44, 49], ["virions", "ANATOMY", 86, 93], ["cells", "CELL", 44, 49], ["internalized viral RNA", "RNA", 18, 40], ["internalized viral RNA in cells", "PROBLEM", 18, 49], ["non-internalized virions", "TREATMENT", 69, 93], ["viral RNA", "OBSERVATION", 31, 40]]], ["As expected, PRRSV entry was restored by cholesterol supplementation in high concentration (Fig. 2E), confirming that the inhibition of PRRSV entry by M\u03b2CD is due to its specific sequestering of cholesterol.", [["cholesterol", "CHEMICAL", 41, 52], ["M\u03b2CD", "CHEMICAL", 151, 155], ["cholesterol", "CHEMICAL", 195, 206], ["cholesterol", "CHEMICAL", 41, 52], ["cholesterol", "CHEMICAL", 195, 206], ["PRRSV", "ORGANISM", 13, 18], ["cholesterol", "SIMPLE_CHEMICAL", 41, 52], ["PRRSV", "ORGANISM", 136, 141], ["M\u03b2CD", "SIMPLE_CHEMICAL", 151, 155], ["cholesterol", "SIMPLE_CHEMICAL", 195, 206], ["PRRSV", "SPECIES", 13, 18], ["PRRSV", "SPECIES", 136, 141], ["PRRSV entry", "TREATMENT", 13, 24], ["cholesterol supplementation", "TREATMENT", 41, 68], ["high concentration", "OBSERVATION_MODIFIER", 72, 90]]], ["These observations suggest that cellular cholesterol depletion imposes an inhibition on the onset of PRRSV infection.Raft-distributed receptor CD163 might contribute to the association of PRRSV glycoproteins with cellular lipid raft during entry ::: ResultOur experimental data with the cholesterol inhibitor M\u03b2CD suggest that that lipid rafts might be associated with PRRSV entry.", [["cellular", "ANATOMY", 32, 40], ["cellular", "ANATOMY", 213, 221], ["raft", "ANATOMY", 228, 232], ["lipid rafts", "ANATOMY", 332, 343], ["cholesterol", "CHEMICAL", 41, 52], ["PRRSV infection", "DISEASE", 101, 116], ["cholesterol", "CHEMICAL", 287, 298], ["M\u03b2CD", "CHEMICAL", 309, 313], ["cholesterol", "CHEMICAL", 41, 52], ["cholesterol", "CHEMICAL", 287, 298], ["M\u03b2CD", "CHEMICAL", 309, 313], ["cellular", "CELL", 32, 40], ["cholesterol", "SIMPLE_CHEMICAL", 41, 52], ["PRRSV", "ORGANISM", 101, 106], ["CD163", "GENE_OR_GENE_PRODUCT", 143, 148], ["PRRSV", "ORGANISM", 188, 193], ["cellular", "CELL", 213, 221], ["lipid raft", "CELLULAR_COMPONENT", 222, 232], ["cholesterol", "SIMPLE_CHEMICAL", 287, 298], ["M\u03b2CD", "SIMPLE_CHEMICAL", 309, 313], ["lipid rafts", "CELLULAR_COMPONENT", 332, 343], ["PRRSV", "ORGANISM", 369, 374], ["Raft-distributed receptor CD163", "PROTEIN", 117, 148], ["PRRSV glycoproteins", "PROTEIN", 188, 207], ["PRRSV", "SPECIES", 101, 106], ["PRRSV", "SPECIES", 188, 193], ["PRRSV", "SPECIES", 369, 374], ["These observations", "TEST", 0, 18], ["cellular cholesterol depletion", "PROBLEM", 32, 62], ["PRRSV infection", "PROBLEM", 101, 116], ["PRRSV glycoproteins", "PROBLEM", 188, 207], ["the cholesterol inhibitor M\u03b2CD", "TREATMENT", 283, 313], ["lipid rafts", "TREATMENT", 332, 343], ["PRRSV entry", "PROBLEM", 369, 380], ["cellular", "OBSERVATION", 32, 40], ["cholesterol depletion", "OBSERVATION", 41, 62], ["PRRSV", "OBSERVATION_MODIFIER", 101, 106], ["infection", "OBSERVATION", 107, 116], ["lipid raft", "OBSERVATION", 222, 232]]], ["To provide direct evidence for virion association with lipid rafts during PRRSV entry, we infected PAMs with Hpv at 4 \u00b0C for 1 h.", [["lipid rafts", "ANATOMY", 55, 66], ["lipid rafts", "CELLULAR_COMPONENT", 55, 66], ["PRRSV", "ORGANISM", 74, 79], ["PRRSV", "SPECIES", 74, 79], ["virion association", "PROBLEM", 31, 49], ["lipid rafts", "TREATMENT", 55, 66], ["Hpv", "TREATMENT", 109, 112]]], ["The cells were washed and subsequently shifted to 37 \u00b0C to initiate membrane fusion and virion penetration.", [["cells", "ANATOMY", 4, 9], ["membrane", "ANATOMY", 68, 76], ["virion", "ANATOMY", 88, 94], ["cells", "CELL", 4, 9], ["membrane", "CELLULAR_COMPONENT", 68, 76], ["membrane fusion", "TREATMENT", 68, 83], ["virion penetration", "TREATMENT", 88, 106], ["membrane fusion", "OBSERVATION", 68, 83], ["virion penetration", "OBSERVATION", 88, 106]]], ["Cell lysates were harvested 2 h post the temperature shift, and detergent-resistant membranes were isolated by sucrose sedimentation as described in Materials and Methods.", [["Cell lysates", "ANATOMY", 0, 12], ["membranes", "ANATOMY", 84, 93], ["sucrose", "CHEMICAL", 111, 118], ["sucrose", "CHEMICAL", 111, 118], ["Cell lysates", "CELL", 0, 12], ["membranes", "CELLULAR_COMPONENT", 84, 93], ["sucrose", "SIMPLE_CHEMICAL", 111, 118], ["Cell lysates", "TREATMENT", 0, 12], ["the temperature shift", "TEST", 37, 58], ["resistant membranes", "PROBLEM", 74, 93], ["sucrose sedimentation", "PROBLEM", 111, 132], ["resistant membranes", "OBSERVATION", 74, 93]]], ["We then performed immunoblot analysis with fractions using antibodies that are reactive to individual viral envelope proteins (Gp3, Gp4, and Gp5) (Fig. 3A).", [["Gp3", "GENE_OR_GENE_PRODUCT", 127, 130], ["Gp4", "GENE_OR_GENE_PRODUCT", 132, 135], ["Gp5", "GENE_OR_GENE_PRODUCT", 141, 144], ["antibodies", "PROTEIN", 59, 69], ["viral envelope proteins", "PROTEIN", 102, 125], ["Gp3", "PROTEIN", 127, 130], ["Gp4", "PROTEIN", 132, 135], ["Gp5", "PROTEIN", 141, 144], ["Fig. 3A", "PROTEIN", 147, 154], ["immunoblot analysis", "TEST", 18, 37], ["antibodies", "TEST", 59, 69], ["individual viral envelope proteins", "TEST", 91, 125], ["Gp3", "TEST", 127, 130], ["Gp4", "TEST", 132, 135]]], ["A moderate staining of Gp3 and Gp4 proteins was present in the caveolin-rich raft-fraction, indicating that PRRSV Gp3 and Gp4 enveloped proteins were associated with lipid rafts during entry.", [["raft", "ANATOMY", 77, 81], ["lipid rafts", "ANATOMY", 166, 177], ["Gp3", "GENE_OR_GENE_PRODUCT", 23, 26], ["Gp4", "GENE_OR_GENE_PRODUCT", 31, 34], ["caveolin", "GENE_OR_GENE_PRODUCT", 63, 71], ["PRRSV", "ORGANISM", 108, 113], ["Gp3", "GENE_OR_GENE_PRODUCT", 114, 117], ["Gp4", "GENE_OR_GENE_PRODUCT", 122, 125], ["lipid rafts", "CELLULAR_COMPONENT", 166, 177], ["Gp3", "PROTEIN", 23, 26], ["Gp4 proteins", "PROTEIN", 31, 43], ["caveolin", "PROTEIN", 63, 71], ["PRRSV Gp3 and Gp4 enveloped proteins", "PROTEIN", 108, 144], ["PRRSV", "SPECIES", 108, 113], ["A moderate staining of Gp3 and Gp4 proteins", "PROBLEM", 0, 43], ["PRRSV Gp3", "PROBLEM", 108, 117], ["Gp4 enveloped proteins", "PROBLEM", 122, 144], ["lipid rafts", "TREATMENT", 166, 177], ["moderate", "OBSERVATION_MODIFIER", 2, 10], ["staining", "OBSERVATION", 11, 19], ["caveolin", "ANATOMY", 63, 71], ["rich raft", "OBSERVATION", 72, 81], ["PRRSV Gp3", "OBSERVATION", 108, 117], ["lipid rafts", "OBSERVATION", 166, 177]]], ["However, the protein Gp5 was almost excluded from the lipid raft fractions and recovered in non-raft fractions associated with the non-raft maker CD71 (Harder et al., 1998).", [["lipid raft fractions", "ANATOMY", 54, 74], ["non-raft fractions", "ANATOMY", 92, 110], ["Gp5", "GENE_OR_GENE_PRODUCT", 21, 24], ["CD71", "GENE_OR_GENE_PRODUCT", 146, 150], ["protein Gp5", "PROTEIN", 13, 24], ["CD71", "PROTEIN", 146, 150], ["the protein Gp5", "TEST", 9, 24], ["non-raft fractions", "PROBLEM", 92, 110], ["lipid raft fractions", "OBSERVATION", 54, 74], ["non-raft fractions", "OBSERVATION", 92, 110]]], ["However, when the PAMs were pretreated with 20 mM M\u03b2CD for 1 h, we did not succeed in isolating lipid raft and Gp3 and Gp4 were recovered in the fraction with the non-raft protein CD71 (Fig. 3B), These results suggest that lipid rafts might play a role in PRRSV entry.Raft-distributed receptor CD163 might contribute to the association of PRRSV glycoproteins with cellular lipid raft during entry ::: ResultIt has been reported that CD163 is essential for internalization and fusion, and a functional CD163 SRCR domain 5 can interact with the Gp2 and Gp4 glycoproteins which form trimers with Gp3 (Van Gorp et al., 2010).", [["lipid raft", "ANATOMY", 96, 106], ["lipid rafts", "ANATOMY", 223, 234], ["cellular", "ANATOMY", 364, 372], ["raft", "ANATOMY", 379, 383], ["M\u03b2CD", "CHEMICAL", 50, 54], ["M\u03b2CD", "CHEMICAL", 50, 54], ["PAMs", "CELL", 18, 22], ["M\u03b2CD", "SIMPLE_CHEMICAL", 50, 54], ["lipid raft", "CELLULAR_COMPONENT", 96, 106], ["Gp3", "GENE_OR_GENE_PRODUCT", 111, 114], ["Gp4", "GENE_OR_GENE_PRODUCT", 119, 122], ["CD71", "GENE_OR_GENE_PRODUCT", 180, 184], ["Fig. 3B", "GENE_OR_GENE_PRODUCT", 186, 193], ["lipid rafts", "CELLULAR_COMPONENT", 223, 234], ["PRRSV", "ORGANISM", 256, 261], ["CD163", "GENE_OR_GENE_PRODUCT", 294, 299], ["PRRSV", "ORGANISM", 339, 344], ["cellular", "CELL", 364, 372], ["lipid raft", "CELLULAR_COMPONENT", 373, 383], ["CD163", "GENE_OR_GENE_PRODUCT", 433, 438], ["CD163", "GENE_OR_GENE_PRODUCT", 501, 506], ["5", "GENE_OR_GENE_PRODUCT", 519, 520], ["Gp2", "GENE_OR_GENE_PRODUCT", 543, 546], ["Gp4 glycoproteins", "GENE_OR_GENE_PRODUCT", 551, 568], ["PAMs", "CELL_TYPE", 18, 22], ["Gp3", "PROTEIN", 111, 114], ["Gp4", "PROTEIN", 119, 122], ["non-raft protein", "PROTEIN", 163, 179], ["CD71", "PROTEIN", 180, 184], ["Fig. 3B", "PROTEIN", 186, 193], ["Raft-distributed receptor CD163", "PROTEIN", 268, 299], ["PRRSV glycoproteins", "PROTEIN", 339, 358], ["CD163", "PROTEIN", 433, 438], ["CD163", "PROTEIN", 501, 506], ["SRCR domain 5", "PROTEIN", 507, 520], ["Gp2 and Gp4 glycoproteins", "PROTEIN", 543, 568], ["PRRSV", "SPECIES", 256, 261], ["PRRSV", "SPECIES", 339, 344], ["20 mM M\u03b2CD", "TREATMENT", 44, 54], ["Gp3", "TEST", 111, 114], ["Gp4", "TEST", 119, 122], ["the non-raft protein CD71", "TEST", 159, 184], ["lipid rafts", "TREATMENT", 223, 234], ["PRRSV glycoproteins", "PROBLEM", 339, 358], ["CD163", "TEST", 433, 438], ["internalization and fusion", "TREATMENT", 456, 482], ["the Gp2 and Gp4 glycoproteins", "TREATMENT", 539, 568], ["lipid raft", "OBSERVATION", 96, 106], ["lipid rafts", "OBSERVATION", 223, 234], ["lipid raft", "OBSERVATION", 373, 383], ["CD163", "OBSERVATION", 433, 438]]], ["Since the enveloped proteins of PRRSV associated with lipid rafts on plasma membrane are Gp3 and Gp4 but not Gp5, we assume that CD163 might be located in lipid raft microdomains.", [["lipid rafts", "ANATOMY", 54, 65], ["plasma membrane", "ANATOMY", 69, 84], ["lipid raft microdomains", "ANATOMY", 155, 178], ["PRRSV", "ORGANISM", 32, 37], ["lipid rafts", "CELLULAR_COMPONENT", 54, 65], ["plasma membrane", "CELLULAR_COMPONENT", 69, 84], ["Gp3", "GENE_OR_GENE_PRODUCT", 89, 92], ["Gp4", "GENE_OR_GENE_PRODUCT", 97, 100], ["Gp5", "GENE_OR_GENE_PRODUCT", 109, 112], ["CD163", "GENE_OR_GENE_PRODUCT", 129, 134], ["lipid raft microdomains", "CELLULAR_COMPONENT", 155, 178], ["enveloped proteins", "PROTEIN", 10, 28], ["Gp3", "PROTEIN", 89, 92], ["Gp4", "PROTEIN", 97, 100], ["Gp5", "PROTEIN", 109, 112], ["CD163", "PROTEIN", 129, 134], ["PRRSV", "SPECIES", 32, 37], ["PRRSV", "SPECIES", 32, 37], ["PRRSV", "PROBLEM", 32, 37], ["lipid rafts", "TREATMENT", 54, 65], ["plasma membrane", "TREATMENT", 69, 84], ["CD163", "PROBLEM", 129, 134], ["PRRSV", "OBSERVATION", 32, 37], ["lipid rafts", "OBSERVATION", 54, 65], ["CD163", "OBSERVATION", 129, 134], ["lipid raft microdomains", "OBSERVATION", 155, 178]]], ["To verify this hypothesis, we also studied the distribution of CD163 during PRRSV entry (Fig. 3A).", [["CD163", "GENE_OR_GENE_PRODUCT", 63, 68], ["PRRSV", "ORGANISM", 76, 81], ["CD163", "PROTEIN", 63, 68], ["PRRSV", "SPECIES", 76, 81], ["CD163", "OBSERVATION", 63, 68]]], ["As expected, CD163 was found to be enriched in the raft-fractions, indicating that CD163 may be a raft-located receptor.", [["raft-fractions", "ANATOMY", 51, 65], ["raft", "ANATOMY", 98, 102], ["CD163", "GENE_OR_GENE_PRODUCT", 13, 18], ["raft", "CELLULAR_COMPONENT", 51, 55], ["CD163", "GENE_OR_GENE_PRODUCT", 83, 88], ["raft", "CELLULAR_COMPONENT", 98, 102], ["CD163", "PROTEIN", 13, 18], ["CD163", "PROTEIN", 83, 88], ["raft-located receptor", "PROTEIN", 98, 119], ["CD163", "TEST", 13, 18], ["CD163", "PROBLEM", 83, 88], ["raft", "ANATOMY_MODIFIER", 51, 55], ["CD163", "OBSERVATION", 83, 88]]], ["However, it is also possible that binding of glycoproteins of PRRSV to rafts recruits CD163 to these domains from non-raft components.", [["rafts", "ANATOMY", 71, 76], ["PRRSV", "ORGANISM", 62, 67], ["rafts", "CELLULAR_COMPONENT", 71, 76], ["CD163", "GENE_OR_GENE_PRODUCT", 86, 91], ["CD163", "PROTEIN", 86, 91], ["PRRSV", "SPECIES", 62, 67], ["glycoproteins of PRRSV", "TREATMENT", 45, 67], ["non-raft components", "PROBLEM", 114, 133]]], ["Thus, we next investigated whether CD163 was a raft-protein in uninfected cells.", [["raft", "ANATOMY", 47, 51], ["cells", "ANATOMY", 74, 79], ["CD163", "GENE_OR_GENE_PRODUCT", 35, 40], ["raft", "CELLULAR_COMPONENT", 47, 51], ["cells", "CELL", 74, 79], ["CD163", "PROTEIN", 35, 40], ["raft-protein", "PROTEIN", 47, 59], ["uninfected cells", "CELL_TYPE", 63, 79], ["CD163", "TEST", 35, 40], ["uninfected cells", "OBSERVATION", 63, 79]]], ["We transfected CD163 into Hela cells and then treated cells with 20 mM M\u03b2CD for 1 h at 24 h post transfection.", [["Hela cells", "ANATOMY", 26, 36], ["cells", "ANATOMY", 54, 59], ["M\u03b2CD", "CHEMICAL", 71, 75], ["M\u03b2CD", "CHEMICAL", 71, 75], ["CD163", "GENE_OR_GENE_PRODUCT", 15, 20], ["Hela cells", "CELL", 26, 36], ["cells", "CELL", 54, 59], ["M\u03b2CD", "SIMPLE_CHEMICAL", 71, 75], ["CD163", "PROTEIN", 15, 20], ["Hela cells", "CELL_LINE", 26, 36], ["Hela cells", "TREATMENT", 26, 36], ["Hela cells", "OBSERVATION", 26, 36]]], ["The CD163 distribution on M\u03b2CD-treated cell membrane was compared with that of untreated cells using Immunofluorescent assay.", [["cell membrane", "ANATOMY", 39, 52], ["cells", "ANATOMY", 89, 94], ["M\u03b2CD", "CHEMICAL", 26, 30], ["CD163", "GENE_OR_GENE_PRODUCT", 4, 9], ["M\u03b2CD", "SIMPLE_CHEMICAL", 26, 30], ["cell membrane", "CELL", 39, 52], ["cells", "CELL", 89, 94], ["CD163", "PROTEIN", 4, 9], ["M\u03b2CD", "PROTEIN", 26, 30], ["untreated cells", "CELL_TYPE", 79, 94], ["M\u03b2CD", "TEST", 26, 30], ["treated cell membrane", "PROBLEM", 31, 52], ["Immunofluorescent assay", "TEST", 101, 124], ["CD163", "OBSERVATION_MODIFIER", 4, 9], ["distribution", "OBSERVATION_MODIFIER", 10, 22], ["treated cell membrane", "OBSERVATION", 31, 52]]], ["As shown in Fig. 3C, CD163 proteins on untreated cellular membrane were speckled while these spots disappeared and changed into a uniform distribution on cellular membrane upon M\u03b2CD treatment.", [["cellular membrane", "ANATOMY", 49, 66], ["cellular membrane", "ANATOMY", 154, 171], ["M\u03b2CD", "CHEMICAL", 177, 181], ["M\u03b2CD", "CHEMICAL", 177, 181], ["CD163", "GENE_OR_GENE_PRODUCT", 21, 26], ["cellular membrane", "CELLULAR_COMPONENT", 49, 66], ["cellular membrane", "CELLULAR_COMPONENT", 154, 171], ["M\u03b2CD", "SIMPLE_CHEMICAL", 177, 181], ["CD163 proteins", "PROTEIN", 21, 35], ["CD163 proteins", "TEST", 21, 35], ["untreated cellular membrane", "PROBLEM", 39, 66], ["M\u03b2CD treatment", "TREATMENT", 177, 191], ["cellular membrane", "OBSERVATION", 49, 66], ["uniform", "OBSERVATION_MODIFIER", 130, 137], ["distribution", "OBSERVATION_MODIFIER", 138, 150], ["cellular membrane", "OBSERVATION", 154, 171]]], ["To further confirm the CD163 location in uninfected PAMs, we directly used sucrose gradients to isolate detergent-insoluble fractions from PAMs and performed immunoblot to analyze CD163 in fractions (Fig. 3D).", [["fractions", "ANATOMY", 124, 133], ["sucrose", "CHEMICAL", 75, 82], ["sucrose", "CHEMICAL", 75, 82], ["CD163", "GENE_OR_GENE_PRODUCT", 23, 28], ["PAMs", "CELL", 52, 56], ["sucrose", "SIMPLE_CHEMICAL", 75, 82], ["PAMs", "CELL", 139, 143], ["CD163", "GENE_OR_GENE_PRODUCT", 180, 185], ["CD163", "PROTEIN", 23, 28], ["PAMs", "CELL_TYPE", 139, 143], ["CD163", "PROTEIN", 180, 185], ["sucrose gradients", "TREATMENT", 75, 92], ["PAMs", "PROBLEM", 139, 143], ["immunoblot", "TEST", 158, 168], ["uninfected PAMs", "OBSERVATION", 41, 56]]], ["A substantial portion of CD163 was found to be restricted in the raft-fractions.", [["raft-fractions", "ANATOMY", 65, 79], ["CD163", "GENE_OR_GENE_PRODUCT", 25, 30], ["CD163", "PROTEIN", 25, 30], ["substantial", "OBSERVATION_MODIFIER", 2, 13], ["portion", "OBSERVATION_MODIFIER", 14, 21], ["CD163", "OBSERVATION", 25, 30], ["raft", "ANATOMY_MODIFIER", 65, 69]]], ["These results suggest that CD163 proteins are distributed in lipid rafts on cell membrane in PAMs, which may mediate the association of PRRSV glycoproteins with rafts during viral entry.Lipid raft plays an important role in PRRSV replication ::: ResultRNA replication of virtually all positive-strand RNA viruses requires certain intracellular membrane structures including endoplasmic reticulums (ER), Golgi apparatus and lysosomes (Restrepo-Hartwig and Ahlquist, 1996, Shi et al., 1999, van der Meer et al., 1999).", [["lipid rafts", "ANATOMY", 61, 72], ["cell membrane", "ANATOMY", 76, 89], ["Lipid raft", "ANATOMY", 186, 196], ["intracellular membrane structures", "ANATOMY", 330, 363], ["endoplasmic reticulums", "ANATOMY", 374, 396], ["ER", "ANATOMY", 398, 400], ["Golgi apparatus", "ANATOMY", 403, 418], ["lysosomes", "ANATOMY", 423, 432], ["CD163", "GENE_OR_GENE_PRODUCT", 27, 32], ["lipid rafts", "CELLULAR_COMPONENT", 61, 72], ["cell membrane", "CELLULAR_COMPONENT", 76, 89], ["PRRSV glycoproteins", "GENE_OR_GENE_PRODUCT", 136, 155], ["rafts", "CELLULAR_COMPONENT", 161, 166], ["Lipid raft", "CELLULAR_COMPONENT", 186, 196], ["PRRSV", "ORGANISM", 224, 229], ["intracellular", "CELLULAR_COMPONENT", 330, 343], ["membrane structures", "CELLULAR_COMPONENT", 344, 363], ["endoplasmic reticulums", "CELLULAR_COMPONENT", 374, 396], ["ER", "GENE_OR_GENE_PRODUCT", 398, 400], ["Golgi apparatus", "CELLULAR_COMPONENT", 403, 418], ["lysosomes", "CELLULAR_COMPONENT", 423, 432], ["CD163 proteins", "PROTEIN", 27, 41], ["PAMs", "CELL_TYPE", 93, 97], ["PRRSV glycoproteins", "PROTEIN", 136, 155], ["ER", "PROTEIN", 398, 400], ["PRRSV", "SPECIES", 136, 141], ["PRRSV", "SPECIES", 224, 229], ["CD163 proteins", "PROBLEM", 27, 41], ["cell membrane in PAMs", "TREATMENT", 76, 97], ["PRRSV glycoproteins", "PROBLEM", 136, 155], ["strand RNA viruses", "PROBLEM", 294, 312], ["CD163", "OBSERVATION", 27, 32], ["lipid rafts", "OBSERVATION", 61, 72], ["cell membrane", "OBSERVATION", 76, 89], ["PRRSV glycoproteins", "OBSERVATION", 136, 155], ["strand RNA viruses", "OBSERVATION", 294, 312], ["intracellular membrane", "OBSERVATION", 330, 352], ["endoplasmic reticulums", "OBSERVATION", 374, 396]]], ["Some of these viruses induce distinct membrane structural scaffold to provide platforms for viral RNA replication, such as the formation of lipid raft associated HCV RNA replication complex (Aizaki et al., 2004, Gosert et al., 2002, Westaway et al., 1997).", [["membrane", "ANATOMY", 38, 46], ["lipid raft", "ANATOMY", 140, 150], ["membrane", "CELLULAR_COMPONENT", 38, 46], ["lipid raft", "CELLULAR_COMPONENT", 140, 150], ["HCV RNA replication complex", "PROTEIN", 162, 189], ["HCV", "SPECIES", 162, 165], ["these viruses", "PROBLEM", 8, 21], ["distinct membrane structural scaffold", "PROBLEM", 29, 66], ["viral RNA replication", "TREATMENT", 92, 113], ["lipid raft", "TREATMENT", 140, 150], ["viruses", "OBSERVATION", 14, 21], ["structural scaffold", "OBSERVATION", 47, 66], ["lipid raft", "OBSERVATION", 140, 150], ["HCV RNA", "OBSERVATION", 162, 169]]], ["Therefore, we attempted to investigate whether lipid rafts are required for PRRSV RNA production.", [["lipid rafts", "ANATOMY", 47, 58], ["PRRSV", "ORGANISM", 76, 81], ["PRRSV RNA", "RNA", 76, 85], ["PRRSV", "SPECIES", 76, 81], ["lipid rafts", "TREATMENT", 47, 58], ["PRRSV RNA production", "PROBLEM", 76, 96]]], ["We infected PAMs with the Hpv (MOI=1) and then replaced the cell medium with fresh medium containing 10 mM M\u03b2CD 12 h later.", [["cell", "ANATOMY", 60, 64], ["M\u03b2CD", "CHEMICAL", 107, 111], ["M\u03b2CD", "CHEMICAL", 107, 111], ["cell", "CELL", 60, 64], ["the cell medium", "TREATMENT", 56, 71], ["infected", "OBSERVATION_MODIFIER", 3, 11], ["PAMs", "OBSERVATION", 12, 16]]], ["Viral RNA levels in cells were quantitated using real-time PCR at 0, 6, and 12 h after medium switching (Fig. 4A).", [["cells", "ANATOMY", 20, 25], ["cells", "CELL", 20, 25], ["Viral RNA levels", "TEST", 0, 16], ["real-time PCR", "TEST", 49, 62], ["RNA levels", "OBSERVATION", 6, 16]]], ["Compared with the PBS-treated cells, a significant reduction of the intracellular viral RNA was observed after M\u03b2CD treatment, suggesting that lipid rafts might be involved in PRRSV replication.", [["cells", "ANATOMY", 30, 35], ["intracellular", "ANATOMY", 68, 81], ["lipid rafts", "ANATOMY", 143, 154], ["M\u03b2CD", "CHEMICAL", 111, 115], ["M\u03b2CD", "CHEMICAL", 111, 115], ["cells", "CELL", 30, 35], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 68, 81], ["M\u03b2CD", "SIMPLE_CHEMICAL", 111, 115], ["PRRSV", "ORGANISM", 176, 181], ["PBS-treated cells", "CELL_LINE", 18, 35], ["intracellular viral RNA", "RNA", 68, 91], ["PRRSV", "SPECIES", 176, 181], ["the PBS", "TEST", 14, 21], ["the intracellular viral RNA", "PROBLEM", 64, 91], ["M\u03b2CD treatment", "TREATMENT", 111, 125], ["lipid rafts", "TREATMENT", 143, 154], ["PRRSV replication", "TREATMENT", 176, 193], ["significant", "OBSERVATION_MODIFIER", 39, 50], ["reduction", "OBSERVATION_MODIFIER", 51, 60], ["intracellular", "OBSERVATION_MODIFIER", 68, 81], ["viral RNA", "OBSERVATION", 82, 91], ["lipid rafts", "OBSERVATION", 143, 154]]], ["Next, we further examined the distribution of Nsp9, the RNA dependent RNA polymerase of PRRSV after flotation analysis of PAMs which were infected with Hpv (MOI=1) for 24 h (Fig. 4B).", [["Nsp9", "GENE_OR_GENE_PRODUCT", 46, 50], ["PRRSV", "ORGANISM", 88, 93], ["Nsp9", "PROTEIN", 46, 50], ["RNA dependent RNA polymerase", "PROTEIN", 56, 84], ["PAMs", "CELL_TYPE", 122, 126], ["PRRSV", "SPECIES", 88, 93], ["Nsp9", "PROBLEM", 46, 50], ["the RNA dependent RNA polymerase of PRRSV", "PROBLEM", 52, 93], ["flotation analysis", "TEST", 100, 118], ["PAMs", "PROBLEM", 122, 126], ["Hpv", "PROBLEM", 152, 155], ["MOI", "TEST", 157, 160]]], ["Significantly, a substantial portion of Nsp9 was in the fraction referred to be as the lipid raft.", [["lipid raft", "ANATOMY", 87, 97], ["Nsp9", "GENE_OR_GENE_PRODUCT", 40, 44], ["lipid raft", "CELLULAR_COMPONENT", 87, 97], ["Nsp9", "PROTEIN", 40, 44], ["a substantial portion of Nsp9", "PROBLEM", 15, 44], ["substantial", "OBSERVATION_MODIFIER", 17, 28], ["portion", "OBSERVATION_MODIFIER", 29, 36], ["lipid raft", "OBSERVATION", 87, 97]]], ["However, when these infected PAMs were treated with 20 mM M\u03b2CD for 1 h, little lipid rafts were isolated and Nsp9 were co-recovered with CD71 (Fig. 4C).", [["lipid rafts", "ANATOMY", 79, 90], ["M\u03b2CD", "CHEMICAL", 58, 62], ["M\u03b2CD", "CHEMICAL", 58, 62], ["PAMs", "CELL", 29, 33], ["M\u03b2CD", "SIMPLE_CHEMICAL", 58, 62], ["lipid rafts", "CELLULAR_COMPONENT", 79, 90], ["Nsp9", "GENE_OR_GENE_PRODUCT", 109, 113], ["CD71", "GENE_OR_GENE_PRODUCT", 137, 141], ["PAMs", "CELL_TYPE", 29, 33], ["Nsp9", "PROTEIN", 109, 113], ["CD71", "PROTEIN", 137, 141], ["these infected PAMs", "PROBLEM", 14, 33], ["20 mM M\u03b2CD", "TREATMENT", 52, 62], ["little lipid rafts", "PROBLEM", 72, 90], ["Nsp9", "TEST", 109, 113], ["CD71", "TEST", 137, 141]]], ["These results suggest that PRRSV RNA synthesis may occur in lipid raft membrane microdomains.Lipid raft disruption by cholesterol depletion enhances the production of abnormal PRRSV particles ::: ResultLipid rafts have been reported to be implicated in the release of a wide variety of viruses, including human immunodeficiency (HIV), Newcastle disease virus (NDV) and influenza (Barman and Nayak, 2007, Laliberte et al., 2006, Nguyen and Hildreth, 2000).", [["lipid raft membrane microdomains", "ANATOMY", 60, 92], ["raft", "ANATOMY", 99, 103], ["cholesterol", "CHEMICAL", 118, 129], ["human immunodeficiency (HIV), Newcastle disease virus (NDV) and influenza", "DISEASE", 305, 378], ["cholesterol", "CHEMICAL", 118, 129], ["PRRSV", "ORGANISM", 27, 32], ["lipid raft", "CELLULAR_COMPONENT", 60, 70], ["membrane microdomains", "CELLULAR_COMPONENT", 71, 92], ["Lipid raft", "CELLULAR_COMPONENT", 93, 103], ["cholesterol", "SIMPLE_CHEMICAL", 118, 129], ["PRRSV", "ORGANISM", 176, 181], ["human immunodeficiency (HIV)", "ORGANISM", 305, 333], ["Newcastle disease virus", "ORGANISM", 335, 358], ["NDV", "ORGANISM", 360, 363], ["PRRSV RNA", "RNA", 27, 36], ["human", "SPECIES", 305, 310], ["immunodeficiency (HIV", "SPECIES", 311, 332], ["Newcastle disease virus", "SPECIES", 335, 358], ["NDV", "SPECIES", 360, 363], ["PRRSV", "SPECIES", 27, 32], ["PRRSV", "SPECIES", 176, 181], ["human immunodeficiency", "SPECIES", 305, 327], ["HIV", "SPECIES", 329, 332], ["Newcastle disease virus", "SPECIES", 335, 358], ["NDV", "SPECIES", 360, 363], ["PRRSV RNA synthesis", "PROBLEM", 27, 46], ["Lipid raft disruption", "TREATMENT", 93, 114], ["cholesterol depletion", "PROBLEM", 118, 139], ["abnormal PRRSV particles", "PROBLEM", 167, 191], ["a wide variety of viruses", "PROBLEM", 268, 293], ["human immunodeficiency (HIV)", "PROBLEM", 305, 333], ["Newcastle disease virus", "PROBLEM", 335, 358], ["influenza", "PROBLEM", 369, 378], ["PRRSV RNA", "OBSERVATION", 27, 36], ["lipid raft", "OBSERVATION", 60, 70], ["membrane microdomains", "OBSERVATION", 71, 92], ["raft disruption", "OBSERVATION", 99, 114], ["cholesterol depletion", "OBSERVATION", 118, 139], ["PRRSV particles", "OBSERVATION", 176, 191], ["viruses", "OBSERVATION", 286, 293]]], ["Thus, we attempted to investigate the effect of cholesterol depletion by M\u03b2CD treatment on PRRSV release.", [["cholesterol", "CHEMICAL", 48, 59], ["M\u03b2CD", "CHEMICAL", 73, 77], ["cholesterol", "CHEMICAL", 48, 59], ["M\u03b2CD", "CHEMICAL", 73, 77], ["cholesterol", "SIMPLE_CHEMICAL", 48, 59], ["M\u03b2CD", "SIMPLE_CHEMICAL", 73, 77], ["PRRSV", "ORGANISM", 91, 96], ["PRRSV", "SPECIES", 91, 96], ["cholesterol depletion", "TREATMENT", 48, 69], ["M\u03b2CD treatment", "TREATMENT", 73, 87], ["PRRSV release", "TREATMENT", 91, 104], ["cholesterol depletion", "OBSERVATION", 48, 69]]], ["Marc-145 cells and PAMs were infected with CH1a and Hpv for 24 h, respectively, and then medium was replaced with fresh medium containing M\u03b2CD (0, 10, and 20 mM).", [["Marc-145 cells", "ANATOMY", 0, 14], ["M\u03b2CD", "CHEMICAL", 138, 142], ["M\u03b2CD", "CHEMICAL", 138, 142], ["Marc-145 cells", "CELL", 0, 14], ["PAMs", "CELL", 19, 23], ["M\u03b2CD", "SIMPLE_CHEMICAL", 138, 142], ["Marc-145 cells", "CELL_LINE", 0, 14], ["PAMs", "CELL_TYPE", 19, 23], ["PAMs", "PROBLEM", 19, 23], ["CH1a", "TREATMENT", 43, 47], ["Hpv", "TREATMENT", 52, 55], ["fresh medium containing M\u03b2CD", "TREATMENT", 114, 142], ["145 cells", "OBSERVATION_MODIFIER", 5, 14]]], ["At 1 h later, the amount of virus released into the medium was quantified by analysis of PRRSV envelope protein Gp5 (Fig. 5A).", [["PRRSV", "ORGANISM", 89, 94], ["Gp5", "GENE_OR_GENE_PRODUCT", 112, 115], ["PRRSV envelope protein", "PROTEIN", 89, 111], ["Gp5", "PROTEIN", 112, 115], ["Fig. 5A", "PROTEIN", 117, 124], ["PRRSV", "SPECIES", 89, 94], ["virus", "PROBLEM", 28, 33], ["PRRSV envelope protein Gp5", "TREATMENT", 89, 115], ["virus", "OBSERVATION", 28, 33]]], ["Our results showed that the Gp5 release was enhanced with the increasing concentration of M\u03b2CD treatment.", [["M\u03b2CD", "CHEMICAL", 90, 94], ["M\u03b2CD", "CHEMICAL", 90, 94], ["Gp5", "GENE_OR_GENE_PRODUCT", 28, 31], ["M\u03b2CD", "SIMPLE_CHEMICAL", 90, 94], ["Gp5", "PROTEIN", 28, 31], ["M\u03b2CD treatment", "TREATMENT", 90, 104]]], ["However, the RNA level and titer of the released virus particles had no obvious difference when treated with either 10 mM or 20 mM M\u03b2CD compared to that of the no-treatment control (Fig. 5B and C).", [["M\u03b2CD", "CHEMICAL", 131, 135], ["M\u03b2CD", "CHEMICAL", 131, 135], ["M\u03b2CD", "SIMPLE_CHEMICAL", 131, 135], ["the RNA level", "TEST", 9, 22], ["the released virus particles", "PROBLEM", 36, 64], ["the no-treatment control", "TREATMENT", 156, 180], ["no obvious", "UNCERTAINTY", 69, 79]]], ["It is possible that M\u03b2CD-treatment causes the release of more immature viral particles from infected cells compared with that in untreated infected cells.", [["cells", "ANATOMY", 101, 106], ["cells", "ANATOMY", 148, 153], ["M\u03b2CD", "CHEMICAL", 20, 24], ["M\u03b2CD", "CHEMICAL", 20, 24], ["M\u03b2CD", "SIMPLE_CHEMICAL", 20, 24], ["cells", "CELL", 101, 106], ["cells", "CELL", 148, 153], ["infected cells", "CELL_TYPE", 92, 106], ["untreated infected cells", "CELL_TYPE", 129, 153], ["M\u03b2CD", "TREATMENT", 20, 24], ["treatment", "TREATMENT", 25, 34], ["immature viral particles", "PROBLEM", 62, 86], ["infected cells", "PROBLEM", 92, 106], ["untreated infected cells", "PROBLEM", 129, 153], ["viral particles", "OBSERVATION", 71, 86], ["infected cells", "OBSERVATION", 92, 106], ["infected cells", "OBSERVATION", 139, 153]]], ["There is also a possibility that M\u03b2CD-treatment changed the virion components of the released PRRSV particles.Depletion of cholesterol from the viral envelope impairs PRRSV infection ::: ResultTo clarify whether cholesterol elimination of virions affects PRRSV infectivity, we depleted cholesterol of CH1a and Hpv virions by M\u03b2CD treatment prior to infection.", [["virions", "ANATOMY", 239, 246], ["Hpv virions", "ANATOMY", 310, 321], ["M\u03b2CD", "CHEMICAL", 33, 37], ["cholesterol", "CHEMICAL", 123, 134], ["PRRSV infection", "DISEASE", 167, 182], ["cholesterol", "CHEMICAL", 212, 223], ["cholesterol", "CHEMICAL", 286, 297], ["M\u03b2CD", "CHEMICAL", 325, 329], ["infection", "DISEASE", 349, 358], ["M\u03b2CD", "CHEMICAL", 33, 37], ["cholesterol", "CHEMICAL", 123, 134], ["cholesterol", "CHEMICAL", 212, 223], ["cholesterol", "CHEMICAL", 286, 297], ["M\u03b2CD", "SIMPLE_CHEMICAL", 33, 37], ["PRRSV", "ORGANISM", 94, 99], ["cholesterol", "SIMPLE_CHEMICAL", 123, 134], ["PRRSV", "ORGANISM", 167, 172], ["cholesterol", "SIMPLE_CHEMICAL", 212, 223], ["PRRSV", "ORGANISM", 255, 260], ["cholesterol", "SIMPLE_CHEMICAL", 286, 297], ["CH1a", "SIMPLE_CHEMICAL", 301, 305], ["Hpv", "GENE_OR_GENE_PRODUCT", 310, 313], ["M\u03b2CD", "SIMPLE_CHEMICAL", 325, 329], ["PRRSV", "SPECIES", 167, 172], ["PRRSV", "SPECIES", 255, 260], ["PRRSV", "SPECIES", 94, 99], ["PRRSV", "SPECIES", 167, 172], ["PRRSV", "SPECIES", 255, 260], ["M\u03b2CD-treatment", "TREATMENT", 33, 47], ["the virion components", "TREATMENT", 56, 77], ["the released PRRSV particles", "TREATMENT", 81, 109], ["Depletion of cholesterol", "PROBLEM", 110, 134], ["the viral envelope impairs PRRSV infection", "PROBLEM", 140, 182], ["cholesterol elimination of virions", "PROBLEM", 212, 246], ["PRRSV infectivity", "PROBLEM", 255, 272], ["CH1a", "TREATMENT", 301, 305], ["Hpv virions", "TREATMENT", 310, 321], ["M\u03b2CD treatment", "TREATMENT", 325, 339], ["infection", "PROBLEM", 349, 358], ["PRRSV particles", "OBSERVATION", 94, 109], ["cholesterol", "OBSERVATION_MODIFIER", 123, 134], ["viral envelope", "OBSERVATION", 144, 158], ["PRRSV infection", "OBSERVATION", 167, 182], ["infection", "OBSERVATION", 349, 358]]], ["Purified PRRSV were treated with 0, 10, 20, 30, 50, or 80 mM M\u03b2CD for 1 h at 37 \u00b0C, and then the drug was removed by ultracentrifugation as described in Materials and Methods.", [["M\u03b2CD", "CHEMICAL", 61, 65], ["M\u03b2CD", "CHEMICAL", 61, 65], ["PRRSV", "ORGANISM", 9, 14], ["M\u03b2CD", "SIMPLE_CHEMICAL", 61, 65], ["PRRSV", "SPECIES", 9, 14], ["PRRSV", "SPECIES", 9, 14], ["ultracentrifugation", "TREATMENT", 117, 136]]], ["The residual cholesterol content in viral preparations was measured after M\u03b2CD treatment.", [["cholesterol", "CHEMICAL", 13, 24], ["M\u03b2CD", "CHEMICAL", 74, 78], ["cholesterol", "CHEMICAL", 13, 24], ["M\u03b2CD", "CHEMICAL", 74, 78], ["cholesterol", "SIMPLE_CHEMICAL", 13, 24], ["M\u03b2CD", "SIMPLE_CHEMICAL", 74, 78], ["The residual cholesterol content", "PROBLEM", 0, 32], ["viral preparations", "TREATMENT", 36, 54], ["M\u03b2CD treatment", "TREATMENT", 74, 88], ["residual", "OBSERVATION_MODIFIER", 4, 12], ["cholesterol content", "OBSERVATION", 13, 32], ["viral preparations", "OBSERVATION", 36, 54]]], ["As shown inFig.", [["Fig", "OBSERVATION", 11, 14]]], ["6A, both the envelopes of CH1a and Hpv virions contained a certain amount of cholesterol and a remarkable dose-dependent decline was observed after M\u03b2CD treatment (approximately 90.0% at 80 mM M\u03b2CD).", [["cholesterol", "CHEMICAL", 77, 88], ["M\u03b2CD", "CHEMICAL", 148, 152], ["cholesterol", "CHEMICAL", 77, 88], ["M\u03b2CD", "CHEMICAL", 148, 152], ["M\u03b2CD", "CHEMICAL", 193, 197], ["6A", "GENE_OR_GENE_PRODUCT", 0, 2], ["CH1a", "GENE_OR_GENE_PRODUCT", 26, 30], ["Hpv", "GENE_OR_GENE_PRODUCT", 35, 38], ["cholesterol", "SIMPLE_CHEMICAL", 77, 88], ["M\u03b2CD", "SIMPLE_CHEMICAL", 148, 152], ["CH1a", "PROTEIN", 26, 30], ["CH1a", "TREATMENT", 26, 30], ["Hpv virions", "TREATMENT", 35, 46], ["dependent decline", "PROBLEM", 111, 128], ["M\u03b2CD treatment", "TREATMENT", 148, 162], ["dependent", "OBSERVATION_MODIFIER", 111, 120], ["decline", "OBSERVATION", 121, 128]]], ["Then, we used M\u03b2CD-treated CH1a virions to infect Marc-145 cells and examined the infected cells using an indirect immunofluorescent assay 24 h post infection.", [["virions", "ANATOMY", 32, 39], ["Marc-145 cells", "ANATOMY", 50, 64], ["cells", "ANATOMY", 91, 96], ["M\u03b2CD", "CHEMICAL", 14, 18], ["infection", "DISEASE", 149, 158], ["M\u03b2CD", "CHEMICAL", 14, 18], ["M\u03b2CD", "SIMPLE_CHEMICAL", 14, 18], ["CH1a", "ORGANISM", 27, 31], ["Marc-145 cells", "CELL", 50, 64], ["cells", "CELL", 91, 96], ["M\u03b2CD", "PROTEIN", 14, 18], ["Marc-145 cells", "CELL_LINE", 50, 64], ["infected cells", "CELL_TYPE", 82, 96], ["Marc-145", "SPECIES", 50, 58], ["M\u03b2CD", "TREATMENT", 14, 18], ["CH1a virions", "TREATMENT", 27, 39], ["the infected cells", "PROBLEM", 78, 96], ["an indirect immunofluorescent assay", "TEST", 103, 138], ["infection", "PROBLEM", 149, 158], ["infected cells", "OBSERVATION", 82, 96], ["infection", "OBSERVATION", 149, 158]]], ["As shown in Fig. 6B, a significant dose-dependent reduction was observed for the number of infected cells.", [["cells", "ANATOMY", 100, 105], ["6B", "GENE_OR_GENE_PRODUCT", 17, 19], ["cells", "CELL", 100, 105], ["infected cells", "CELL_TYPE", 91, 105], ["a significant dose-dependent reduction", "TREATMENT", 21, 59], ["infected cells", "PROBLEM", 91, 105], ["Fig", "OBSERVATION", 12, 15], ["significant", "OBSERVATION_MODIFIER", 23, 34], ["dependent", "OBSERVATION_MODIFIER", 40, 49], ["reduction", "OBSERVATION", 50, 59], ["infected cells", "OBSERVATION", 91, 105]]], ["We also analyzed the direct effects of M\u03b2CD treatment on the titers of CH1a and Hpv virions.", [["M\u03b2CD", "CHEMICAL", 39, 43], ["M\u03b2CD", "CHEMICAL", 39, 43], ["M\u03b2CD", "SIMPLE_CHEMICAL", 39, 43], ["CH1a", "GENE_OR_GENE_PRODUCT", 71, 75], ["Hpv", "GENE_OR_GENE_PRODUCT", 80, 83], ["CH1a", "PROTEIN", 71, 75], ["M\u03b2CD treatment", "TREATMENT", 39, 53], ["CH1a and Hpv virions", "TREATMENT", 71, 91], ["Hpv virions", "OBSERVATION", 80, 91]]], ["M\u03b2CD induced a significant dose-dependent titer-reduction for CH1a, and a more than 106-fold reduction was observed at the concentration of 80 mM compared with the untreated virus (Fig. 6C).", [["M\u03b2CD", "CHEMICAL", 0, 4], ["CH1a", "CHEMICAL", 62, 66], ["M\u03b2CD", "CHEMICAL", 0, 4], ["M\u03b2CD", "SIMPLE_CHEMICAL", 0, 4], ["CH1a", "SIMPLE_CHEMICAL", 62, 66], ["CH1a", "TREATMENT", 62, 66], ["106-fold reduction", "TREATMENT", 84, 102], ["the untreated virus", "TREATMENT", 160, 179], ["significant", "OBSERVATION_MODIFIER", 15, 26], ["dependent", "OBSERVATION_MODIFIER", 32, 41], ["titer", "OBSERVATION", 42, 47]]], ["Similarly, M\u03b2CD treatment induced a more than 104-fold reduction for the titer of Hpv at the concentration of 80 mM when compared with the untreated virus (Fig. 6D).Depletion of cholesterol from the viral envelope impairs PRRSV infection ::: ResultTo further verify that the decrease in PRRSV infectivity is caused by cholesterol depletion in the virus envelope, we attempted to reverse the infectivity by supplementing virions with exogenous cholesterol.", [["M\u03b2CD", "CHEMICAL", 11, 15], ["Hpv", "CHEMICAL", 82, 85], ["cholesterol", "CHEMICAL", 178, 189], ["PRRSV infection", "DISEASE", 222, 237], ["PRRSV infectivity", "DISEASE", 287, 304], ["cholesterol", "CHEMICAL", 318, 329], ["cholesterol", "CHEMICAL", 443, 454], ["M\u03b2CD", "CHEMICAL", 11, 15], ["cholesterol", "CHEMICAL", 178, 189], ["cholesterol", "CHEMICAL", 318, 329], ["cholesterol", "CHEMICAL", 443, 454], ["M\u03b2CD", "SIMPLE_CHEMICAL", 11, 15], ["Hpv", "GENE_OR_GENE_PRODUCT", 82, 85], ["cholesterol", "SIMPLE_CHEMICAL", 178, 189], ["PRRSV", "ORGANISM", 222, 227], ["PRRSV", "ORGANISM", 287, 292], ["cholesterol", "SIMPLE_CHEMICAL", 318, 329], ["cholesterol", "SIMPLE_CHEMICAL", 443, 454], ["Hpv", "PROTEIN", 82, 85], ["PRRSV", "SPECIES", 222, 227], ["PRRSV", "SPECIES", 222, 227], ["PRRSV", "SPECIES", 287, 292], ["M\u03b2CD treatment", "TREATMENT", 11, 25], ["104-fold reduction", "TREATMENT", 46, 64], ["Hpv", "PROBLEM", 82, 85], ["Depletion of cholesterol", "PROBLEM", 165, 189], ["the viral envelope impairs PRRSV infection", "PROBLEM", 195, 237], ["the decrease in PRRSV infectivity", "PROBLEM", 271, 304], ["cholesterol depletion", "PROBLEM", 318, 339], ["the virus envelope", "PROBLEM", 343, 361], ["the infectivity", "PROBLEM", 387, 402], ["exogenous cholesterol", "TREATMENT", 433, 454], ["cholesterol", "OBSERVATION_MODIFIER", 178, 189], ["viral envelope", "OBSERVATION", 199, 213], ["PRRSV infection", "OBSERVATION", 222, 237], ["decrease", "OBSERVATION_MODIFIER", 275, 283], ["PRRSV infectivity", "OBSERVATION", 287, 304], ["cholesterol depletion", "OBSERVATION", 318, 339], ["exogenous cholesterol", "OBSERVATION", 433, 454]]], ["After extraction of viral cholesterol in CH1a by 20 mM M\u03b2CD for 1 h, virus was supplemented with exogenous cholesterol (0, 50, 100, 200, and 500 \u03bcM) for 30 min at 37 \u00b0C, and then the titer of the virus was tested.", [["cholesterol", "CHEMICAL", 26, 37], ["CH1a", "CHEMICAL", 41, 45], ["M\u03b2CD", "CHEMICAL", 55, 59], ["cholesterol", "CHEMICAL", 107, 118], ["cholesterol", "CHEMICAL", 26, 37], ["M\u03b2CD", "CHEMICAL", 55, 59], ["cholesterol", "CHEMICAL", 107, 118], ["cholesterol", "SIMPLE_CHEMICAL", 26, 37], ["CH1a", "SIMPLE_CHEMICAL", 41, 45], ["M\u03b2CD", "SIMPLE_CHEMICAL", 55, 59], ["cholesterol", "SIMPLE_CHEMICAL", 107, 118], ["viral cholesterol", "TEST", 20, 37], ["virus", "PROBLEM", 69, 74], ["exogenous cholesterol", "TEST", 97, 118], ["the virus", "PROBLEM", 192, 201], ["viral cholesterol", "OBSERVATION", 20, 37]]], ["The infectivity of M\u03b2CD-treated virus particles was recovered upon cholesterol replenishment in a dose-dependent manner, even though it was not completely restored up to 500 \u03bcM cholesterol (Fig. 6E).", [["M\u03b2CD", "CHEMICAL", 19, 23], ["cholesterol", "CHEMICAL", 67, 78], ["cholesterol", "CHEMICAL", 177, 188], ["M\u03b2CD", "CHEMICAL", 19, 23], ["cholesterol", "CHEMICAL", 67, 78], ["cholesterol", "CHEMICAL", 177, 188], ["M\u03b2CD", "SIMPLE_CHEMICAL", 19, 23], ["cholesterol", "SIMPLE_CHEMICAL", 67, 78], ["cholesterol", "SIMPLE_CHEMICAL", 177, 188], ["M\u03b2CD", "PROTEIN", 19, 23], ["The infectivity of M\u03b2CD", "PROBLEM", 0, 23], ["virus particles", "TREATMENT", 32, 47], ["cholesterol replenishment", "TREATMENT", 67, 92], ["infectivity", "OBSERVATION_MODIFIER", 4, 15]]], ["These data suggest that the effect of M\u03b2CD on PRRSV infectivity is mainly due to the reduced cholesterol levels in the virus envelope and the infection of PRRSV to target cells is dependent on the integrity of the lipid raft in the virus envelope.Depletion of cholesterol from the PRRSV envelope results in permeabilization of virions ::: ResultSince our data show that the cholesterol reduction in viral envelope can inhibit PRRSV infectivity, it is possible that viral lipid raft disruption induced by cholesterol removal disrupts PRRSV virus particles.", [["cells", "ANATOMY", 171, 176], ["lipid raft", "ANATOMY", 214, 224], ["raft", "ANATOMY", 477, 481], ["M\u03b2CD", "CHEMICAL", 38, 42], ["cholesterol", "CHEMICAL", 93, 104], ["infection", "DISEASE", 142, 151], ["cholesterol", "CHEMICAL", 260, 271], ["cholesterol", "CHEMICAL", 374, 385], ["cholesterol", "CHEMICAL", 504, 515], ["cholesterol", "CHEMICAL", 93, 104], ["cholesterol", "CHEMICAL", 260, 271], ["cholesterol", "CHEMICAL", 374, 385], ["cholesterol", "CHEMICAL", 504, 515], ["M\u03b2CD", "GENE_OR_GENE_PRODUCT", 38, 42], ["PRRSV", "ORGANISM", 46, 51], ["cholesterol", "SIMPLE_CHEMICAL", 93, 104], ["PRRSV", "ORGANISM", 155, 160], ["cells", "CELL", 171, 176], ["lipid raft", "CELLULAR_COMPONENT", 214, 224], ["cholesterol", "SIMPLE_CHEMICAL", 260, 271], ["PRRSV", "ORGANISM", 281, 286], ["cholesterol", "SIMPLE_CHEMICAL", 374, 385], ["PRRSV", "ORGANISM", 426, 431], ["cholesterol", "SIMPLE_CHEMICAL", 504, 515], ["PRRSV virus particles", "ORGANISM", 533, 554], ["target cells", "CELL_TYPE", 164, 176], ["PRRSV", "SPECIES", 426, 431], ["PRRSV", "SPECIES", 46, 51], ["PRRSV", "SPECIES", 155, 160], ["PRRSV", "SPECIES", 281, 286], ["PRRSV", "SPECIES", 426, 431], ["PRRSV virus", "SPECIES", 533, 544], ["M\u03b2CD", "TREATMENT", 38, 42], ["PRRSV infectivity", "PROBLEM", 46, 63], ["the reduced cholesterol levels", "PROBLEM", 81, 111], ["the virus envelope", "PROBLEM", 115, 133], ["the infection of PRRSV to target cells", "PROBLEM", 138, 176], ["the lipid raft", "TREATMENT", 210, 224], ["the virus envelope", "PROBLEM", 228, 246], ["Depletion of cholesterol", "PROBLEM", 247, 271], ["our data", "TEST", 351, 359], ["the cholesterol reduction", "TREATMENT", 370, 395], ["viral envelope", "PROBLEM", 399, 413], ["PRRSV infectivity", "PROBLEM", 426, 443], ["viral lipid raft disruption", "TREATMENT", 465, 492], ["cholesterol removal", "TREATMENT", 504, 523], ["PRRSV virus particles", "PROBLEM", 533, 554], ["reduced", "OBSERVATION_MODIFIER", 85, 92], ["cholesterol", "OBSERVATION", 93, 104], ["infection", "OBSERVATION", 142, 151], ["lipid raft", "OBSERVATION", 214, 224], ["virus envelope", "OBSERVATION", 232, 246], ["cholesterol", "OBSERVATION_MODIFIER", 260, 271], ["viral envelope", "OBSERVATION", 399, 413], ["PRRSV infectivity", "OBSERVATION", 426, 443], ["viral lipid", "OBSERVATION", 465, 476], ["raft disruption", "OBSERVATION", 477, 492], ["cholesterol removal", "OBSERVATION", 504, 523]]], ["To extend our understanding of this effect, purified CH1a virions were treated with 0, 10, 20, 30, 50, or 80 mM M\u03b2CD for 1 h at 37 \u00b0C and re-purified by ultracentrifugation as described in Materials and Methods.", [["M\u03b2CD", "CHEMICAL", 112, 116], ["M\u03b2CD", "CHEMICAL", 112, 116], ["CH1a virions", "CELL", 53, 65], ["M\u03b2CD", "SIMPLE_CHEMICAL", 112, 116], ["purified CH1a virions", "TREATMENT", 44, 65]]], ["Western blotting was then performed to determine whether M\u03b2CD treatment has effects on viral envelope protein (Gp5) or Nucleocapsid protein (N protein).", [["M\u03b2CD", "CHEMICAL", 57, 61], ["M\u03b2CD", "CHEMICAL", 57, 61], ["M\u03b2CD", "SIMPLE_CHEMICAL", 57, 61], ["viral envelope protein", "GENE_OR_GENE_PRODUCT", 87, 109], ["Gp5", "GENE_OR_GENE_PRODUCT", 111, 114], ["Nucleocapsid protein", "GENE_OR_GENE_PRODUCT", 119, 139], ["N protein", "GENE_OR_GENE_PRODUCT", 141, 150], ["viral envelope protein", "PROTEIN", 87, 109], ["Gp5", "PROTEIN", 111, 114], ["Nucleocapsid protein", "PROTEIN", 119, 139], ["N protein", "PROTEIN", 141, 150], ["Western blotting", "TEST", 0, 16], ["M\u03b2CD treatment", "TREATMENT", 57, 71], ["viral envelope protein", "PROBLEM", 87, 109], ["Nucleocapsid protein", "TEST", 119, 139]]], ["As shown inFig.", [["Fig", "OBSERVATION", 11, 14]]], ["7A, the amount of N protein exhibited a dose-dependent reduction induced by M\u03b2CD treatment, while the amount of Gp5 was fairly constant up to 80 mM M\u03b2CD.", [["M\u03b2CD", "CHEMICAL", 76, 80], ["M\u03b2CD", "CHEMICAL", 76, 80], ["M\u03b2CD", "CHEMICAL", 148, 152], ["M\u03b2CD", "SIMPLE_CHEMICAL", 76, 80], ["Gp5", "GENE_OR_GENE_PRODUCT", 112, 115], ["M\u03b2CD", "SIMPLE_CHEMICAL", 148, 152], ["N protein", "PROTEIN", 18, 27], ["Gp5", "PROTEIN", 112, 115], ["N protein", "TREATMENT", 18, 27], ["a dose-dependent reduction", "TREATMENT", 38, 64], ["M\u03b2CD treatment", "TREATMENT", 76, 90], ["the amount of Gp5", "PROBLEM", 98, 115]]], ["The permeabilization was defined as a greater decrease of the capsid protein relative to the envelope glycoprotein.", [["capsid protein", "PROTEIN", 62, 76], ["envelope glycoprotein", "PROTEIN", 93, 114], ["The permeabilization", "TREATMENT", 0, 20], ["a greater decrease of the capsid protein", "PROBLEM", 36, 76], ["the envelope glycoprotein", "TREATMENT", 89, 114], ["greater", "OBSERVATION_MODIFIER", 38, 45], ["decrease", "OBSERVATION_MODIFIER", 46, 54], ["capsid protein", "OBSERVATION", 62, 76]]], ["Thus, depletion of cholesterol from viral envelope resulted in permeabilization of PRRSV virions.", [["cholesterol", "CHEMICAL", 19, 30], ["cholesterol", "CHEMICAL", 19, 30], ["cholesterol", "SIMPLE_CHEMICAL", 19, 30], ["PRRSV", "ORGANISM", 83, 88], ["PRRSV", "SPECIES", 83, 88], ["depletion of cholesterol", "TREATMENT", 6, 30], ["viral envelope", "PROBLEM", 36, 50], ["PRRSV virions", "PROBLEM", 83, 96], ["viral envelope", "OBSERVATION", 36, 50], ["PRRSV virions", "OBSERVATION", 83, 96]]], ["We also tested the viral RNA levels of the M\u03b2CD-treated CH1a virions to determine whether viral RNA is retained in PRRSV virions (Fig. 7B).", [["CH1a virions", "ANATOMY", 56, 68], ["M\u03b2CD", "CHEMICAL", 43, 47], ["M\u03b2CD", "SIMPLE_CHEMICAL", 43, 47], ["CH1a virions", "CELL", 56, 68], ["PRRSV", "ORGANISM", 115, 120], ["M\u03b2CD", "PROTEIN", 43, 47], ["viral RNA", "RNA", 90, 99], ["PRRSV", "SPECIES", 115, 120], ["the viral RNA levels", "TEST", 15, 35], ["CH1a virions", "TREATMENT", 56, 68], ["viral RNA", "PROBLEM", 90, 99], ["viral RNA", "OBSERVATION", 90, 99], ["PRRSV virions", "OBSERVATION", 115, 128]]], ["Our results showed little change in the amount of viral RNA in CH1a virions after M\u03b2CD treatment, suggesting that PRRSV particles do not lose viral RNA after permeabilization by M\u03b2CD.", [["CH1a virions", "ANATOMY", 63, 75], ["M\u03b2CD", "CHEMICAL", 82, 86], ["M\u03b2CD", "CHEMICAL", 178, 182], ["M\u03b2CD", "CHEMICAL", 82, 86], ["CH1a virions", "ORGANISM", 63, 75], ["M\u03b2CD", "SIMPLE_CHEMICAL", 82, 86], ["PRRSV", "ORGANISM", 114, 119], ["M\u03b2CD", "SIMPLE_CHEMICAL", 178, 182], ["viral RNA", "RNA", 50, 59], ["viral RNA", "RNA", 142, 151], ["M\u03b2CD", "PROTEIN", 178, 182], ["PRRSV", "SPECIES", 114, 119], ["little change", "PROBLEM", 19, 32], ["viral RNA in CH1a virions", "PROBLEM", 50, 75], ["M\u03b2CD treatment", "TREATMENT", 82, 96], ["PRRSV particles", "PROBLEM", 114, 129], ["viral RNA", "PROBLEM", 142, 151], ["little", "OBSERVATION_MODIFIER", 19, 25], ["change", "OBSERVATION_MODIFIER", 26, 32], ["amount", "OBSERVATION_MODIFIER", 40, 46], ["viral RNA", "OBSERVATION", 50, 59]]], ["These results reveal that depletion of viral cholesterol may impair PRRSV infectivity due to the virion disruption and leak of nucleocapsid protein.DiscussionLipid rafts exist in cell plasma membranes, intracellular organelles and viral envelopes, which are different in their composition, physical properties, and biological functions (Brown and London, 1998, Chazal and Gerlier, 2003, Ikonen, 2001).", [["cell plasma membranes", "ANATOMY", 179, 200], ["intracellular organelles", "ANATOMY", 202, 226], ["cholesterol", "CHEMICAL", 45, 56], ["cholesterol", "CHEMICAL", 45, 56], ["cholesterol", "SIMPLE_CHEMICAL", 45, 56], ["PRRSV", "ORGANISM", 68, 73], ["cell", "CELLULAR_COMPONENT", 179, 183], ["plasma membranes", "CELLULAR_COMPONENT", 184, 200], ["intracellular organelles", "CELLULAR_COMPONENT", 202, 226], ["nucleocapsid protein", "PROTEIN", 127, 147], ["PRRSV", "SPECIES", 68, 73], ["viral cholesterol", "TREATMENT", 39, 56], ["PRRSV infectivity", "PROBLEM", 68, 85], ["the virion disruption", "PROBLEM", 93, 114], ["leak of nucleocapsid protein", "PROBLEM", 119, 147], ["DiscussionLipid rafts", "TREATMENT", 148, 169], ["cell plasma membranes", "TREATMENT", 179, 200], ["intracellular organelles", "PROBLEM", 202, 226], ["viral envelopes", "PROBLEM", 231, 246], ["viral cholesterol", "OBSERVATION", 39, 56], ["PRRSV infectivity", "OBSERVATION", 68, 85], ["virion disruption", "OBSERVATION", 97, 114], ["leak", "OBSERVATION", 119, 123], ["nucleocapsid protein", "OBSERVATION", 127, 147], ["cell plasma membranes", "OBSERVATION", 179, 200], ["intracellular organelles", "OBSERVATION", 202, 226], ["viral envelopes", "OBSERVATION", 231, 246], ["different", "OBSERVATION_MODIFIER", 258, 267]]], ["The significance of lipid rafts in either the viral envelope or the target cell membrane has been demonstrated for many viruses.", [["lipid rafts", "ANATOMY", 20, 31], ["cell membrane", "ANATOMY", 75, 88], ["lipid rafts", "CELLULAR_COMPONENT", 20, 31], ["cell membrane", "CELLULAR_COMPONENT", 75, 88], ["lipid rafts", "PROBLEM", 20, 31], ["the viral envelope", "PROBLEM", 42, 60], ["the target cell membrane", "PROBLEM", 64, 88], ["many viruses", "PROBLEM", 115, 127], ["lipid rafts", "OBSERVATION", 20, 31], ["viral envelope", "OBSERVATION", 46, 60], ["target cell membrane", "OBSERVATION", 68, 88], ["viruses", "OBSERVATION", 120, 127]]], ["Here, we investigated the importance of lipid rafts in viral envelope and cellular membranes for PRRSV infection.DiscussionOur work showed that cellular cholesterol was important in establishing PRRSV infection both in Marc-145 cells and PAMs.", [["lipid rafts", "ANATOMY", 40, 51], ["cellular membranes", "ANATOMY", 74, 92], ["cellular", "ANATOMY", 144, 152], ["Marc-145 cells", "ANATOMY", 219, 233], ["PRRSV infection", "DISEASE", 97, 112], ["cholesterol", "CHEMICAL", 153, 164], ["PRRSV infection", "DISEASE", 195, 210], ["cholesterol", "CHEMICAL", 153, 164], ["lipid rafts", "CELLULAR_COMPONENT", 40, 51], ["cellular membranes", "CELLULAR_COMPONENT", 74, 92], ["PRRSV", "ORGANISM", 97, 102], ["cellular", "CELL", 144, 152], ["cholesterol", "SIMPLE_CHEMICAL", 153, 164], ["PRRSV", "ORGANISM", 195, 200], ["Marc-145 cells", "CELL", 219, 233], ["PAMs", "CELL", 238, 242], ["Marc-145 cells", "CELL_LINE", 219, 233], ["PAMs", "CELL_TYPE", 238, 242], ["PRRSV", "SPECIES", 97, 102], ["PRRSV", "SPECIES", 195, 200], ["lipid rafts", "TREATMENT", 40, 51], ["viral envelope", "TREATMENT", 55, 69], ["cellular membranes", "TREATMENT", 74, 92], ["PRRSV infection", "PROBLEM", 97, 112], ["cellular cholesterol", "TEST", 144, 164], ["PRRSV infection", "PROBLEM", 195, 210], ["PAMs", "PROBLEM", 238, 242], ["lipid rafts", "OBSERVATION", 40, 51], ["viral envelope", "OBSERVATION", 55, 69], ["cellular membranes", "OBSERVATION", 74, 92], ["infection", "OBSERVATION", 103, 112], ["cellular cholesterol", "OBSERVATION", 144, 164], ["PRRSV infection", "OBSERVATION", 195, 210], ["145 cells", "OBSERVATION_MODIFIER", 224, 233]]], ["By incubating cells with cholesterol-depletion drug before virus infection, only cellular cholesterol will be removed, allowing viral cholesterol and infectivity to remain intact.", [["cells", "ANATOMY", 14, 19], ["cellular", "ANATOMY", 81, 89], ["cholesterol", "CHEMICAL", 25, 36], ["infection", "DISEASE", 65, 74], ["cholesterol", "CHEMICAL", 90, 101], ["cholesterol", "CHEMICAL", 134, 145], ["cholesterol", "CHEMICAL", 25, 36], ["cholesterol", "CHEMICAL", 90, 101], ["cholesterol", "CHEMICAL", 134, 145], ["cells", "CELL", 14, 19], ["cholesterol", "SIMPLE_CHEMICAL", 25, 36], ["cellular", "CELL", 81, 89], ["cholesterol", "SIMPLE_CHEMICAL", 90, 101], ["cholesterol", "SIMPLE_CHEMICAL", 134, 145], ["cholesterol-depletion drug", "TREATMENT", 25, 51], ["virus infection", "PROBLEM", 59, 74], ["cellular cholesterol", "TREATMENT", 81, 101], ["cellular cholesterol", "OBSERVATION", 81, 101], ["viral cholesterol", "OBSERVATION", 128, 145], ["intact", "OBSERVATION", 172, 178]]], ["Under such condition, the efficiency of infection is dependent on the amount of cholesterol residual on cell membrane.", [["cell membrane", "ANATOMY", 104, 117], ["infection", "DISEASE", 40, 49], ["cholesterol", "CHEMICAL", 80, 91], ["cholesterol", "CHEMICAL", 80, 91], ["cholesterol", "SIMPLE_CHEMICAL", 80, 91], ["cell membrane", "CELLULAR_COMPONENT", 104, 117], ["infection", "PROBLEM", 40, 49], ["cholesterol residual on cell membrane", "PROBLEM", 80, 117], ["infection", "OBSERVATION", 40, 49], ["dependent", "OBSERVATION_MODIFIER", 53, 62], ["cholesterol residual", "OBSERVATION", 80, 100], ["cell membrane", "OBSERVATION", 104, 117]]], ["Direct replenishment of exogenous cholesterol to cells after drug-mediated cholesterol depletion substantially restored PRRSV infection.", [["cells", "ANATOMY", 49, 54], ["cholesterol", "CHEMICAL", 34, 45], ["cholesterol", "CHEMICAL", 75, 86], ["PRRSV infection", "DISEASE", 120, 135], ["cholesterol", "CHEMICAL", 34, 45], ["cholesterol", "CHEMICAL", 75, 86], ["cholesterol", "SIMPLE_CHEMICAL", 34, 45], ["cells", "CELL", 49, 54], ["cholesterol", "SIMPLE_CHEMICAL", 75, 86], ["PRRSV", "ORGANISM", 120, 125], ["PRRSV", "SPECIES", 120, 125], ["drug-mediated cholesterol depletion", "TREATMENT", 61, 96], ["PRRSV infection", "PROBLEM", 120, 135], ["exogenous cholesterol", "OBSERVATION", 24, 45], ["PRRSV infection", "OBSERVATION", 120, 135]]], ["These data indicate that the efficiency of PRRSV infection at least in part is associated with the cholesterol level on cell membranes.DiscussionMolecular simulations of model membranes show that the integrity of lipid raft microdomains is sensitive to minor changes of cholesterol (Risselada and Marrink, 2008).", [["cell membranes", "ANATOMY", 120, 134], ["membranes", "ANATOMY", 176, 185], ["lipid raft microdomains", "ANATOMY", 213, 236], ["PRRSV infection", "DISEASE", 43, 58], ["cholesterol", "CHEMICAL", 99, 110], ["cholesterol", "CHEMICAL", 270, 281], ["cholesterol", "CHEMICAL", 99, 110], ["cholesterol", "CHEMICAL", 270, 281], ["PRRSV", "ORGANISM", 43, 48], ["cholesterol", "SIMPLE_CHEMICAL", 99, 110], ["cell membranes", "CELLULAR_COMPONENT", 120, 134], ["membranes", "CELLULAR_COMPONENT", 176, 185], ["lipid raft microdomains", "CELLULAR_COMPONENT", 213, 236], ["cholesterol", "SIMPLE_CHEMICAL", 270, 281], ["PRRSV", "SPECIES", 43, 48], ["PRRSV infection", "PROBLEM", 43, 58], ["the cholesterol level on cell membranes", "PROBLEM", 95, 134], ["model membranes", "TREATMENT", 170, 185], ["efficiency", "OBSERVATION_MODIFIER", 29, 39], ["PRRSV", "OBSERVATION_MODIFIER", 43, 48], ["infection", "OBSERVATION", 49, 58], ["cholesterol", "OBSERVATION", 99, 110], ["cell membranes", "OBSERVATION", 120, 134]]], ["Thus, cholesterol is a major component of lipid raft microdomains, and manipulation of cholesterol present within membranes is frequently used to implicate lipid rafts.", [["lipid raft microdomains", "ANATOMY", 42, 65], ["membranes", "ANATOMY", 114, 123], ["lipid rafts", "ANATOMY", 156, 167], ["cholesterol", "CHEMICAL", 6, 17], ["cholesterol", "CHEMICAL", 87, 98], ["cholesterol", "CHEMICAL", 6, 17], ["cholesterol", "CHEMICAL", 87, 98], ["cholesterol", "SIMPLE_CHEMICAL", 6, 17], ["lipid raft microdomains", "CELLULAR_COMPONENT", 42, 65], ["cholesterol", "SIMPLE_CHEMICAL", 87, 98], ["membranes", "CELLULAR_COMPONENT", 114, 123], ["lipid rafts", "CELLULAR_COMPONENT", 156, 167], ["lipid raft microdomains", "TREATMENT", 42, 65], ["manipulation of cholesterol", "TREATMENT", 71, 98], ["lipid rafts", "TREATMENT", 156, 167], ["lipid raft microdomains", "OBSERVATION", 42, 65], ["lipid rafts", "OBSERVATION", 156, 167]]], ["Therefore, we further investigated whether and how PRRSV infection was affected by cellular lipid rafts.", [["cellular", "ANATOMY", 83, 91], ["PRRSV infection", "DISEASE", 51, 66], ["PRRSV", "ORGANISM", 51, 56], ["cellular", "CELL", 83, 91], ["lipid rafts", "CELLULAR_COMPONENT", 92, 103], ["PRRSV", "SPECIES", 51, 56], ["PRRSV infection", "PROBLEM", 51, 66], ["infection", "OBSERVATION", 57, 66], ["lipid rafts", "OBSERVATION", 92, 103]]], ["PRRSV entry process is mediated by receptor-specific endocytosis, where the virus attachment, internalization and membrane fusion occur sequentially (Nauwynck et al., 1999).", [["membrane", "ANATOMY", 114, 122], ["PRRSV", "ORGANISM", 0, 5], ["membrane", "CELLULAR_COMPONENT", 114, 122], ["PRRSV", "SPECIES", 0, 5], ["PRRSV entry process", "PROBLEM", 0, 19], ["receptor-specific endocytosis", "PROBLEM", 35, 64], ["the virus attachment", "PROBLEM", 72, 92], ["internalization and membrane fusion", "TREATMENT", 94, 129], ["specific", "OBSERVATION_MODIFIER", 44, 52], ["endocytosis", "OBSERVATION", 53, 64], ["membrane fusion", "OBSERVATION", 114, 129]]], ["Previous study has reported the significant suppression of cellular cholesterol depletion on PRRSV entry, which is in consistent with our results (Sun et al., 2011).", [["cellular", "ANATOMY", 59, 67], ["cholesterol", "CHEMICAL", 68, 79], ["cholesterol", "CHEMICAL", 68, 79], ["cellular", "CELL", 59, 67], ["cholesterol", "SIMPLE_CHEMICAL", 68, 79], ["PRRSV", "ORGANISM", 93, 98], ["PRRSV", "SPECIES", 93, 98], ["Previous study", "TEST", 0, 14], ["cellular cholesterol depletion", "PROBLEM", 59, 89], ["significant", "OBSERVATION_MODIFIER", 32, 43], ["suppression", "OBSERVATION_MODIFIER", 44, 55], ["cellular cholesterol depletion", "OBSERVATION", 59, 89], ["consistent with", "UNCERTAINTY", 118, 133]]], ["These results are similar to the findings observed on some other members of the order Nidovirales such as HCoV-229E, MHV and SARS-CoV (Choi et al., 2005, Li et al., 2007, Nomura et al., 2004, Thorp and Gallagher, 2004).", [["Nidovirales", "GENE_OR_GENE_PRODUCT", 86, 97], ["HCoV-229E", "ORGANISM", 106, 115], ["MHV", "ORGANISM", 117, 120], ["SARS-CoV", "ORGANISM", 125, 133], ["HCoV-229E", "SPECIES", 106, 115], ["MHV", "SPECIES", 117, 120], ["SARS-CoV", "SPECIES", 125, 133]]], ["However, how lipid rafts contribute to PRRSV entry is not explicit, Although it has been reported that Gp4 is located in lipid rafts when it is exogenously expressed in HeLa cells and that Gp4 and CD163 co-located in lipid rafts in a porcine kidney cell line (Du et al., 2012), there is no direct and convincing evidence to show the association of Gp4, CD163, and other glycoproteins with lipid rafts in PAMs during PRRSV entry.", [["lipid rafts", "ANATOMY", 13, 24], ["lipid rafts", "ANATOMY", 121, 132], ["HeLa cells", "ANATOMY", 169, 179], ["lipid rafts", "ANATOMY", 217, 228], ["kidney cell line", "ANATOMY", 242, 258], ["lipid rafts", "ANATOMY", 389, 400], ["lipid rafts", "CELLULAR_COMPONENT", 13, 24], ["PRRSV", "ORGANISM", 39, 44], ["Gp4", "GENE_OR_GENE_PRODUCT", 103, 106], ["lipid rafts", "CELLULAR_COMPONENT", 121, 132], ["HeLa cells", "CELL", 169, 179], ["Gp4", "GENE_OR_GENE_PRODUCT", 189, 192], ["CD163", "GENE_OR_GENE_PRODUCT", 197, 202], ["lipid rafts", "CELLULAR_COMPONENT", 217, 228], ["kidney cell line", "CELL", 242, 258], ["Gp4", "GENE_OR_GENE_PRODUCT", 348, 351], ["CD163", "GENE_OR_GENE_PRODUCT", 353, 358], ["lipid rafts", "CELLULAR_COMPONENT", 389, 400], ["PAMs", "CELL", 404, 408], ["PRRSV", "ORGANISM", 416, 421], ["Gp4", "PROTEIN", 103, 106], ["HeLa cells", "CELL_LINE", 169, 179], ["Gp4", "PROTEIN", 189, 192], ["CD163", "PROTEIN", 197, 202], ["porcine kidney cell line", "CELL_LINE", 234, 258], ["Gp4", "PROTEIN", 348, 351], ["CD163", "PROTEIN", 353, 358], ["glycoproteins", "PROTEIN", 370, 383], ["PRRSV", "SPECIES", 39, 44], ["PRRSV", "SPECIES", 416, 421], ["PRRSV entry", "PROBLEM", 39, 50], ["HeLa cells", "TEST", 169, 179], ["Gp4", "TEST", 189, 192], ["CD163 co-", "TEST", 197, 206], ["a porcine kidney cell line", "TREATMENT", 232, 258], ["Gp4", "TEST", 348, 351], ["CD163", "TEST", 353, 358], ["lipid rafts", "TREATMENT", 389, 400], ["lipid rafts", "OBSERVATION", 121, 132], ["HeLa cells", "OBSERVATION", 169, 179], ["lipid rafts", "OBSERVATION", 217, 228], ["porcine", "ANATOMY_MODIFIER", 234, 241], ["kidney", "ANATOMY", 242, 248], ["cell line", "OBSERVATION", 249, 258], ["no", "UNCERTAINTY", 287, 289], ["lipid rafts", "OBSERVATION", 389, 400]]], ["By the use of Triton X-100 extract and discontinuous sucrose gradient fractionation, we showed that the viral envelope proteins Gp3 and Gp4, but not Gp5, were partitioned in lipid rafts during virus penetration of PAMs.", [["lipid rafts", "ANATOMY", 174, 185], ["Triton X-100 extract", "CHEMICAL", 14, 34], ["sucrose", "CHEMICAL", 53, 60], ["sucrose", "CHEMICAL", 53, 60], ["Triton X-100", "SIMPLE_CHEMICAL", 14, 26], ["sucrose", "SIMPLE_CHEMICAL", 53, 60], ["Gp3", "GENE_OR_GENE_PRODUCT", 128, 131], ["Gp4", "GENE_OR_GENE_PRODUCT", 136, 139], ["Gp5", "GENE_OR_GENE_PRODUCT", 149, 152], ["lipid rafts", "CELLULAR_COMPONENT", 174, 185], ["viral envelope proteins", "PROTEIN", 104, 127], ["Gp3", "PROTEIN", 128, 131], ["Gp4", "PROTEIN", 136, 139], ["Gp5", "PROTEIN", 149, 152], ["Triton X", "TREATMENT", 14, 22], ["discontinuous sucrose gradient fractionation", "TREATMENT", 39, 83], ["the viral envelope proteins Gp3", "PROBLEM", 100, 131], ["Gp5", "PROBLEM", 149, 152], ["PAMs", "PROBLEM", 214, 218], ["lipid rafts", "OBSERVATION", 174, 185]]], ["These results correspond well with their roles in PRRSV entry.", [["PRRSV", "ORGANISM", 50, 55], ["PRRSV", "SPECIES", 50, 55]]], ["Gp5 interacts with the sialoadhesin receptor to mediate virus-cell binding and initial endocytosis (Van Breedam et al., 2010b), while Gp3 and Gp4, which form trimers with Gp2, interacting with CD163 are essential for the following internalization and fusion (Van Gorp et al., 2010).", [["cell", "ANATOMY", 62, 66], ["Gp5", "GENE_OR_GENE_PRODUCT", 0, 3], ["sialoadhesin receptor", "GENE_OR_GENE_PRODUCT", 23, 44], ["cell", "CELL", 62, 66], ["Gp3", "GENE_OR_GENE_PRODUCT", 134, 137], ["Gp4", "GENE_OR_GENE_PRODUCT", 142, 145], ["Gp2", "GENE_OR_GENE_PRODUCT", 171, 174], ["CD163", "GENE_OR_GENE_PRODUCT", 193, 198], ["Gp5", "PROTEIN", 0, 3], ["sialoadhesin receptor", "PROTEIN", 23, 44], ["Gp3", "PROTEIN", 134, 137], ["Gp4", "PROTEIN", 142, 145], ["Gp2", "PROTEIN", 171, 174], ["CD163", "PROTEIN", 193, 198], ["the sialoadhesin receptor", "TREATMENT", 19, 44], ["mediate virus", "PROBLEM", 48, 61], ["cell binding", "PROBLEM", 62, 74], ["initial endocytosis", "PROBLEM", 79, 98], ["cell binding", "OBSERVATION", 62, 74]]], ["These data imply that lipid rafts probably utilize cellular receptor CD163 to mediate its association with PRRSV envelope proteins during entry.", [["lipid rafts", "ANATOMY", 22, 33], ["cellular", "ANATOMY", 51, 59], ["lipid rafts", "CELLULAR_COMPONENT", 22, 33], ["cellular", "CELL", 51, 59], ["CD163", "GENE_OR_GENE_PRODUCT", 69, 74], ["PRRSV envelope proteins", "GENE_OR_GENE_PRODUCT", 107, 130], ["CD163", "PROTEIN", 69, 74], ["PRRSV envelope proteins", "PROTEIN", 107, 130], ["PRRSV", "SPECIES", 107, 112], ["lipid rafts", "TREATMENT", 22, 33], ["cellular receptor CD163", "TREATMENT", 51, 74], ["PRRSV envelope proteins", "TREATMENT", 107, 130]]], ["Consistent with this assumption, we showed that CD163 was mainly located in lipid raft microdomain of PAM membrane, and the distribution of the CD163 on cell membrane was found to be altered by cholesterol depletion.", [["lipid raft microdomain", "ANATOMY", 76, 98], ["PAM membrane", "ANATOMY", 102, 114], ["cell membrane", "ANATOMY", 153, 166], ["cholesterol", "CHEMICAL", 194, 205], ["cholesterol", "CHEMICAL", 194, 205], ["CD163", "GENE_OR_GENE_PRODUCT", 48, 53], ["lipid raft microdomain", "CELLULAR_COMPONENT", 76, 98], ["PAM membrane", "CELLULAR_COMPONENT", 102, 114], ["CD163", "GENE_OR_GENE_PRODUCT", 144, 149], ["cell membrane", "CELLULAR_COMPONENT", 153, 166], ["cholesterol", "SIMPLE_CHEMICAL", 194, 205], ["CD163", "PROTEIN", 48, 53], ["CD163", "PROTEIN", 144, 149], ["CD163", "TEST", 48, 53], ["cell membrane", "TREATMENT", 153, 166], ["cholesterol depletion", "PROBLEM", 194, 215], ["CD163", "OBSERVATION", 48, 53], ["lipid raft microdomain", "OBSERVATION", 76, 98], ["PAM membrane", "OBSERVATION", 102, 114], ["CD163", "OBSERVATION", 144, 149], ["cell membrane", "OBSERVATION", 153, 166], ["cholesterol depletion", "OBSERVATION", 194, 215]]], ["Moreover, PRRSV enters cells by a process of clathrin-mediated endocytosis which is distinguished from lipid raft-mediated endocytosis pathway (Kreutz and Ackermann, 1996, Mercer et al., 2010, Nauwynck et al., 1999).", [["cells", "ANATOMY", 23, 28], ["lipid raft", "ANATOMY", 103, 113], ["PRRSV", "ORGANISM", 10, 15], ["cells", "CELL", 23, 28], ["clathrin", "GENE_OR_GENE_PRODUCT", 45, 53], ["lipid raft", "CELLULAR_COMPONENT", 103, 113], ["clathrin", "PROTEIN", 45, 53], ["PRRSV", "SPECIES", 10, 15], ["PRRSV enters cells", "PROBLEM", 10, 28], ["clathrin-mediated endocytosis", "PROBLEM", 45, 74], ["endocytosis", "OBSERVATION", 63, 74]]], ["Therefore, we infer that lipid rafts probably contribute to membrane fusion but not endocytosis in PRRSV entry.", [["lipid rafts", "ANATOMY", 25, 36], ["membrane", "ANATOMY", 60, 68], ["lipid rafts", "CELLULAR_COMPONENT", 25, 36], ["membrane", "CELLULAR_COMPONENT", 60, 68], ["PRRSV", "ORGANISM", 99, 104], ["PRRSV", "SPECIES", 99, 104], ["lipid rafts", "TREATMENT", 25, 36], ["membrane fusion", "PROBLEM", 60, 75], ["endocytosis in PRRSV entry", "PROBLEM", 84, 110], ["membrane fusion", "OBSERVATION", 60, 75]]], ["The glycoproteins\u2013receptor interaction may trigger the raft clustering to form platforms, which may function in PRRSV membrane fusion.DiscussionViral RNA replication is a multistep process involving a replication complex that is formed by viral and cellular components with the viral genomic RNA template.", [["raft", "ANATOMY", 55, 59], ["membrane", "ANATOMY", 118, 126], ["cellular", "ANATOMY", 249, 257], ["glycoproteins\u2013receptor", "GENE_OR_GENE_PRODUCT", 4, 26], ["raft", "CELLULAR_COMPONENT", 55, 59], ["PRRSV", "ORGANISM", 112, 117], ["membrane", "CELLULAR_COMPONENT", 118, 126], ["cellular components", "CELLULAR_COMPONENT", 249, 268], ["replication complex", "PROTEIN", 201, 220], ["viral genomic RNA template", "RNA", 278, 304], ["PRRSV", "SPECIES", 112, 117], ["The glycoproteins\u2013receptor interaction", "TREATMENT", 0, 38], ["PRRSV membrane fusion", "TREATMENT", 112, 133], ["DiscussionViral RNA replication", "TREATMENT", 134, 165], ["a multistep process", "PROBLEM", 169, 188], ["a replication complex", "PROBLEM", 199, 220], ["viral and cellular components", "PROBLEM", 239, 268], ["the viral genomic RNA template", "TREATMENT", 274, 304], ["PRRSV membrane fusion", "OBSERVATION", 112, 133], ["viral", "OBSERVATION", 239, 244], ["cellular components", "OBSERVATION", 249, 268]]], ["This replication complex is embedded within particular virus-induced membrane vesicles, which serve as the anchoring sites for the PRRSV replication complex to mediate migration of the replication complex between cellular organelles (Bost et al., 2003, den Boon and Ahlquist, 2010, Netherton and Wileman, 2011).", [["membrane vesicles", "ANATOMY", 69, 86], ["cellular organelles", "ANATOMY", 213, 232], ["membrane vesicles", "CELLULAR_COMPONENT", 69, 86], ["cellular organelles", "CELLULAR_COMPONENT", 213, 232], ["replication complex", "PROTEIN", 5, 24], ["PRRSV replication complex", "PROTEIN", 131, 156], ["replication complex", "PROTEIN", 185, 204], ["PRRSV", "SPECIES", 131, 136], ["This replication complex", "PROBLEM", 0, 24], ["induced membrane vesicles", "PROBLEM", 61, 86], ["the PRRSV replication", "TREATMENT", 127, 148], ["membrane vesicles", "OBSERVATION", 69, 86], ["PRRSV replication", "OBSERVATION", 131, 148], ["migration", "OBSERVATION_MODIFIER", 168, 177], ["replication", "OBSERVATION_MODIFIER", 185, 196], ["complex", "OBSERVATION_MODIFIER", 197, 204]]], ["In the present study, a significant reduction of the intracellular viral RNA resulted from cholesterol depletion, indicating that lipid rafts are probably involved in PRRSV RNA production.", [["intracellular", "ANATOMY", 53, 66], ["lipid rafts", "ANATOMY", 130, 141], ["cholesterol", "CHEMICAL", 91, 102], ["cholesterol", "CHEMICAL", 91, 102], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 53, 66], ["cholesterol", "SIMPLE_CHEMICAL", 91, 102], ["lipid rafts", "CELLULAR_COMPONENT", 130, 141], ["PRRSV", "ORGANISM", 167, 172], ["intracellular viral RNA", "RNA", 53, 76], ["PRRSV RNA", "RNA", 167, 176], ["PRRSV", "SPECIES", 167, 172], ["the present study", "TEST", 3, 20], ["a significant reduction", "PROBLEM", 22, 45], ["the intracellular viral RNA", "PROBLEM", 49, 76], ["cholesterol depletion", "PROBLEM", 91, 112], ["lipid rafts", "PROBLEM", 130, 141], ["PRRSV RNA production", "PROBLEM", 167, 187], ["significant", "OBSERVATION_MODIFIER", 24, 35], ["reduction", "OBSERVATION_MODIFIER", 36, 45], ["intracellular", "OBSERVATION_MODIFIER", 53, 66], ["viral RNA", "OBSERVATION", 67, 76], ["cholesterol depletion", "OBSERVATION", 91, 112], ["lipid rafts", "OBSERVATION", 130, 141], ["probably involved", "UNCERTAINTY", 146, 163], ["PRRSV RNA production", "OBSERVATION", 167, 187]]], ["PRRSV replication is directed by at least 14 replicase proteins that have both common enzymatic activities, especially the viral RNA-dependent RNA polymerase Nsp9 (Fang and Snijder, 2010, Yun and Lee, 2013).", [["PRRSV", "ORGANISM", 0, 5], ["Nsp9", "GENE_OR_GENE_PRODUCT", 158, 162], ["replicase proteins", "PROTEIN", 45, 63], ["viral RNA-dependent RNA polymerase Nsp9", "PROTEIN", 123, 162], ["PRRSV", "SPECIES", 0, 5], ["PRRSV replication", "TREATMENT", 0, 17], ["the viral RNA", "TEST", 119, 132], ["viral RNA", "OBSERVATION", 123, 132]]], ["Flotation analysis of infected PAMs showed that Nsp9 was distributed in lipid raft fractions.", [["lipid raft fractions", "ANATOMY", 72, 92], ["PAMs", "CELL", 31, 35], ["Nsp9", "GENE_OR_GENE_PRODUCT", 48, 52], ["lipid raft", "CELLULAR_COMPONENT", 72, 82], ["Nsp9", "PROTEIN", 48, 52], ["Flotation analysis", "TEST", 0, 18], ["infected PAMs", "PROBLEM", 22, 35], ["Nsp9", "PROBLEM", 48, 52], ["infected PAMs", "OBSERVATION", 22, 35], ["lipid raft fractions", "OBSERVATION", 72, 92]]], ["Thus, lipid rafts might serve as the sites for viral RNA replication complex anchored to PRRSV-induced special membrane structural scaffold.", [["lipid rafts", "ANATOMY", 6, 17], ["membrane", "ANATOMY", 111, 119], ["lipid rafts", "CELLULAR_COMPONENT", 6, 17], ["PRRSV", "ORGANISM", 89, 94], ["membrane", "CELLULAR_COMPONENT", 111, 119], ["viral RNA replication complex", "PROTEIN", 47, 76], ["PRRSV", "SPECIES", 89, 94], ["lipid rafts", "TREATMENT", 6, 17], ["viral RNA replication complex", "TREATMENT", 47, 76], ["special membrane structural scaffold", "TREATMENT", 103, 139], ["membrane structural scaffold", "OBSERVATION", 111, 139]]], ["However, the precise mechanism for this association of special membrane structure with viral replication complex remains to be determined.", [["membrane", "ANATOMY", 63, 71], ["membrane", "CELLULAR_COMPONENT", 63, 71], ["viral replication complex", "PROTEIN", 87, 112], ["special membrane structure", "PROBLEM", 55, 81], ["viral replication complex", "TREATMENT", 87, 112], ["viral replication", "OBSERVATION", 87, 104]]], ["Membrane lipid rafts have been implicated in the assembly and release of many enveloped viruses.", [["Membrane lipid rafts", "ANATOMY", 0, 20], ["Membrane", "CELLULAR_COMPONENT", 0, 8], ["lipid rafts", "CELLULAR_COMPONENT", 9, 20], ["Membrane lipid rafts", "TREATMENT", 0, 20], ["many enveloped viruses", "PROBLEM", 73, 95], ["lipid rafts", "OBSERVATION", 9, 20], ["enveloped", "OBSERVATION_MODIFIER", 78, 87], ["viruses", "OBSERVATION", 88, 95]]], ["Our results also showed that lipid raft disruption increased the release of PRRSV particles.", [["lipid raft", "ANATOMY", 29, 39], ["PRRSV", "ORGANISM", 76, 81], ["PRRSV", "SPECIES", 76, 81], ["lipid raft disruption", "PROBLEM", 29, 50], ["PRRSV particles", "PROBLEM", 76, 91], ["lipid", "OBSERVATION", 29, 34], ["raft disruption", "OBSERVATION", 35, 50], ["PRRSV particles", "OBSERVATION", 76, 91]]], ["For some virus such as influenza virus, lipid rafts and their underlying cortical cytoskeleton probably provide a framework for specific and ordered viral protein-protein interactions required for proper assembly (Roberts and Compans, 1998, Simpson-Holley et al., 2002).", [["lipid rafts", "ANATOMY", 40, 51], ["cortical cytoskeleton", "ANATOMY", 73, 94], ["influenza", "DISEASE", 23, 32], ["influenza virus", "ORGANISM", 23, 38], ["lipid rafts", "CELLULAR_COMPONENT", 40, 51], ["cortical cytoskeleton", "CELLULAR_COMPONENT", 73, 94], ["viral protein", "PROTEIN", 149, 162], ["influenza virus", "SPECIES", 23, 38], ["influenza virus", "SPECIES", 23, 38], ["some virus", "PROBLEM", 4, 14], ["influenza virus", "PROBLEM", 23, 38], ["lipid rafts", "TREATMENT", 40, 51], ["viral protein-protein interactions", "TREATMENT", 149, 183], ["virus", "OBSERVATION", 9, 14], ["influenza virus", "OBSERVATION", 23, 38], ["cortical cytoskeleton", "OBSERVATION", 73, 94]]], ["Cholesterol depletion could induce rearrangement of the cortical actin cytoskeleton in many cells and cortical actin rearrangements also could induce reorganization of lipid raft microdomains (Chadda et al., 2007, Francis et al., 1999, Simpson-Holley et al., 2002).", [["cortical", "ANATOMY", 56, 64], ["cytoskeleton", "ANATOMY", 71, 83], ["cells", "ANATOMY", 92, 97], ["cortical", "ANATOMY", 102, 110], ["lipid raft microdomains", "ANATOMY", 168, 191], ["Cholesterol", "CHEMICAL", 0, 11], ["Cholesterol", "CHEMICAL", 0, 11], ["Cholesterol", "SIMPLE_CHEMICAL", 0, 11], ["cortical actin", "GENE_OR_GENE_PRODUCT", 56, 70], ["cytoskeleton", "CELLULAR_COMPONENT", 71, 83], ["cells", "CELL", 92, 97], ["cortical actin", "GENE_OR_GENE_PRODUCT", 102, 116], ["lipid", "CELLULAR_COMPONENT", 168, 173], ["raft microdomains", "CELLULAR_COMPONENT", 174, 191], ["actin", "PROTEIN", 65, 70], ["actin", "PROTEIN", 111, 116], ["Cholesterol depletion", "PROBLEM", 0, 21], ["the cortical actin cytoskeleton in many cells", "PROBLEM", 52, 97], ["cortical actin rearrangements", "PROBLEM", 102, 131], ["depletion", "OBSERVATION", 12, 21], ["cortical", "ANATOMY_MODIFIER", 56, 64], ["actin cytoskeleton", "OBSERVATION", 65, 83], ["many cells", "OBSERVATION", 87, 97], ["cortical", "OBSERVATION", 102, 110], ["actin rearrangements", "OBSERVATION", 111, 131], ["lipid raft", "OBSERVATION", 168, 178]]], ["Therefore, perturbation of actin cytoskeleton caused by cholesterol depletion might contribute to the enhanced release of PRRSV particles envelope proteins.", [["cytoskeleton", "ANATOMY", 33, 45], ["cholesterol", "CHEMICAL", 56, 67], ["cholesterol", "CHEMICAL", 56, 67], ["actin", "GENE_OR_GENE_PRODUCT", 27, 32], ["cytoskeleton", "CELLULAR_COMPONENT", 33, 45], ["cholesterol", "SIMPLE_CHEMICAL", 56, 67], ["PRRSV", "ORGANISM", 122, 127], ["actin", "PROTEIN", 27, 32], ["PRRSV particles envelope proteins", "PROTEIN", 122, 155], ["PRRSV", "SPECIES", 122, 127], ["actin cytoskeleton", "PROBLEM", 27, 45], ["cholesterol depletion", "PROBLEM", 56, 77], ["PRRSV particles envelope proteins", "PROBLEM", 122, 155], ["actin cytoskeleton", "OBSERVATION", 27, 45], ["cholesterol depletion", "OBSERVATION", 56, 77]]], ["However, no increase in viral RNA level or virus infectivity was observed for the PRRSV particles released from lipid raft disrupted cells.", [["lipid raft", "ANATOMY", 112, 122], ["cells", "ANATOMY", 133, 138], ["PRRSV", "ORGANISM", 82, 87], ["lipid raft", "CELLULAR_COMPONENT", 112, 122], ["cells", "CELL", 133, 138], ["viral RNA", "RNA", 24, 33], ["lipid raft disrupted cells", "CELL_TYPE", 112, 138], ["PRRSV", "SPECIES", 82, 87], ["increase in viral RNA level", "PROBLEM", 12, 39], ["virus infectivity", "PROBLEM", 43, 60], ["the PRRSV particles", "PROBLEM", 78, 97], ["no", "UNCERTAINTY", 9, 11], ["increase", "OBSERVATION_MODIFIER", 12, 20], ["viral RNA", "OBSERVATION", 24, 33], ["lipid raft", "OBSERVATION", 112, 122], ["disrupted cells", "OBSERVATION", 123, 138]]], ["It is possible that lipid raft disruption might induce abnormal assembly and release of PRRSV particles.DiscussionCholesterol depletion may also mediate disruption of PRRSV particles and directly cause the reduction in viral infectivity.", [["lipid raft", "ANATOMY", 20, 30], ["Cholesterol", "CHEMICAL", 114, 125], ["Cholesterol", "CHEMICAL", 114, 125], ["lipid raft", "CELLULAR_COMPONENT", 20, 30], ["PRRSV", "ORGANISM", 88, 93], ["Cholesterol", "SIMPLE_CHEMICAL", 114, 125], ["PRRSV", "ORGANISM", 167, 172], ["PRRSV", "SPECIES", 88, 93], ["PRRSV", "SPECIES", 167, 172], ["lipid raft disruption", "PROBLEM", 20, 41], ["abnormal assembly", "PROBLEM", 55, 72], ["PRRSV particles", "PROBLEM", 88, 103], ["Cholesterol depletion", "PROBLEM", 114, 135], ["PRRSV particles", "PROBLEM", 167, 182], ["viral infectivity", "PROBLEM", 219, 236], ["lipid raft", "OBSERVATION", 20, 30], ["PRRSV particles", "OBSERVATION", 88, 103], ["PRRSV particles", "OBSERVATION", 167, 182], ["reduction", "OBSERVATION_MODIFIER", 206, 215], ["viral infectivity", "OBSERVATION", 219, 236]]], ["PRRSV virions contain a certain amount of cholesterol and this lipid feature seems to be critical in sustaining its integrity.", [["cholesterol", "CHEMICAL", 42, 53], ["cholesterol", "CHEMICAL", 42, 53], ["PRRSV", "ORGANISM", 0, 5], ["cholesterol", "SIMPLE_CHEMICAL", 42, 53], ["PRRSV", "SPECIES", 0, 5], ["PRRSV", "SPECIES", 0, 5], ["PRRSV virions", "TREATMENT", 0, 13], ["virions", "OBSERVATION", 6, 13], ["certain", "OBSERVATION_MODIFIER", 24, 31], ["amount", "OBSERVATION_MODIFIER", 32, 38], ["cholesterol", "OBSERVATION", 42, 53]]], ["Our results showed that both CH1a and Hpv infectivity was decreased in a dose-dependent manner when the viruses were treated with cholesterol-depletion drug.", [["CH1a", "CHEMICAL", 29, 33], ["cholesterol", "CHEMICAL", 130, 141], ["cholesterol", "CHEMICAL", 130, 141], ["CH1a", "GENE_OR_GENE_PRODUCT", 29, 33], ["Hpv", "GENE_OR_GENE_PRODUCT", 38, 41], ["cholesterol", "SIMPLE_CHEMICAL", 130, 141], ["Hpv infectivity", "PROBLEM", 38, 53], ["the viruses", "PROBLEM", 100, 111], ["cholesterol-depletion drug", "TREATMENT", 130, 156], ["Hpv infectivity", "OBSERVATION", 38, 53]]], ["Measuring the residual cholesterol in PRRSV virions exposed to increasing concentrations of M\u03b2CD indicated that the loss of infectivity was closely associated with reduction in virion cholesterol.", [["cholesterol", "CHEMICAL", 23, 34], ["M\u03b2CD", "CHEMICAL", 92, 96], ["cholesterol", "CHEMICAL", 184, 195], ["cholesterol", "CHEMICAL", 23, 34], ["M\u03b2CD", "CHEMICAL", 92, 96], ["cholesterol", "CHEMICAL", 184, 195], ["cholesterol", "SIMPLE_CHEMICAL", 23, 34], ["PRRSV virions", "ORGANISM", 38, 51], ["M\u03b2CD", "SIMPLE_CHEMICAL", 92, 96], ["cholesterol", "SIMPLE_CHEMICAL", 184, 195], ["PRRSV", "SPECIES", 38, 43], ["PRRSV virions", "TREATMENT", 38, 51], ["increasing concentrations of M\u03b2CD", "PROBLEM", 63, 96], ["the loss of infectivity", "PROBLEM", 112, 135], ["reduction in virion cholesterol", "PROBLEM", 164, 195], ["residual cholesterol", "OBSERVATION", 14, 34], ["PRRSV virions", "OBSERVATION", 38, 51], ["increasing", "OBSERVATION_MODIFIER", 63, 73], ["concentrations", "OBSERVATION_MODIFIER", 74, 88], ["loss", "OBSERVATION_MODIFIER", 116, 120], ["infectivity", "OBSERVATION", 124, 135], ["virion cholesterol", "OBSERVATION", 177, 195]]], ["The loss of viral infectivity after cholesterol depletion is likely due to partly structure destruction such as loss of viral structure proteins or loss of viral RNA.", [["cholesterol", "CHEMICAL", 36, 47], ["cholesterol", "CHEMICAL", 36, 47], ["cholesterol", "SIMPLE_CHEMICAL", 36, 47], ["viral structure proteins", "PROTEIN", 120, 144], ["viral RNA", "RNA", 156, 165], ["The loss of viral infectivity", "PROBLEM", 0, 29], ["cholesterol depletion", "PROBLEM", 36, 57], ["structure destruction", "PROBLEM", 82, 103], ["loss of viral structure proteins", "PROBLEM", 112, 144], ["loss of viral RNA", "PROBLEM", 148, 165], ["loss", "OBSERVATION_MODIFIER", 4, 8], ["viral infectivity", "OBSERVATION", 12, 29], ["cholesterol depletion", "OBSERVATION", 36, 57], ["likely due to", "UNCERTAINTY", 61, 74], ["structure", "OBSERVATION_MODIFIER", 82, 91], ["destruction", "OBSERVATION", 92, 103], ["viral structure", "OBSERVATION", 120, 135], ["loss", "OBSERVATION_MODIFIER", 148, 152], ["viral RNA", "OBSERVATION", 156, 165]]], ["Indeed, PRRSV viral envelopes were permeabilized when treated with M\u03b2CD at a high concentration, evidenced by the loss of PRRSV nucleoprotein (N).", [["M\u03b2CD", "CHEMICAL", 67, 71], ["M\u03b2CD", "CHEMICAL", 67, 71], ["PRRSV", "ORGANISM", 8, 13], ["M\u03b2CD", "SIMPLE_CHEMICAL", 67, 71], ["PRRSV nucleoprotein", "GENE_OR_GENE_PRODUCT", 122, 141], ["PRRSV nucleoprotein", "PROTEIN", 122, 141], ["PRRSV", "SPECIES", 8, 13], ["PRRSV", "SPECIES", 122, 127], ["PRRSV viral envelopes", "PROBLEM", 8, 29], ["M\u03b2CD", "TREATMENT", 67, 71], ["the loss of PRRSV nucleoprotein", "PROBLEM", 110, 141]]], ["Accordingly, we were unable to completely restore virus infectivity by adding back cholesterol to permeabilized virions.", [["virions", "ANATOMY", 112, 119], ["cholesterol", "CHEMICAL", 83, 94], ["cholesterol", "CHEMICAL", 83, 94], ["cholesterol", "SIMPLE_CHEMICAL", 83, 94], ["virus infectivity", "PROBLEM", 50, 67], ["back cholesterol to permeabilized virions", "TREATMENT", 78, 119], ["virus", "OBSERVATION", 50, 55]]], ["Presumably, even though the large holes in the viral membrane can be repaired by cholesterol, patching the membrane probably cannot overcome the loss of critical viral proteins.", [["membrane", "ANATOMY", 53, 61], ["membrane", "ANATOMY", 107, 115], ["cholesterol", "CHEMICAL", 81, 92], ["cholesterol", "CHEMICAL", 81, 92], ["membrane", "CELLULAR_COMPONENT", 53, 61], ["cholesterol", "SIMPLE_CHEMICAL", 81, 92], ["membrane", "CELLULAR_COMPONENT", 107, 115], ["viral proteins", "PROTEIN", 162, 176], ["the large holes in the viral membrane", "PROBLEM", 24, 61], ["patching the membrane", "TREATMENT", 94, 115], ["the loss of critical viral proteins", "PROBLEM", 141, 176], ["large", "OBSERVATION_MODIFIER", 28, 33], ["holes", "OBSERVATION", 34, 39], ["viral membrane", "OBSERVATION", 47, 61], ["viral proteins", "OBSERVATION", 162, 176]]], ["Recent cryo-electron tomographic structure determination of PRRSV has provided a possible model for the nucleocapsid\u2013RNA organization in the virion.", [["virion", "ANATOMY", 141, 147], ["nucleocapsid\u2013", "CHEMICAL", 104, 117], ["PRRSV", "ORGANISM", 60, 65], ["virion", "CELLULAR_COMPONENT", 141, 147], ["PRRSV", "SPECIES", 60, 65], ["Recent cryo-electron tomographic structure", "PROBLEM", 0, 42], ["PRRSV", "PROBLEM", 60, 65], ["RNA organization in the virion", "PROBLEM", 117, 147], ["virion", "ANATOMY", 141, 147]]], ["This model speculates that two layers of N dimers form a linked, twisted chain with the RNA in the middle, and this chain is then bundled into a roughly spherical shape that leaves a hollow interior (Dokland, 2010, Spilman et al., 2009).", [["N", "CHEMICAL", 41, 42], ["N dimers", "PROTEIN", 41, 49], ["twisted chain", "PROTEIN", 65, 78], ["two", "OBSERVATION_MODIFIER", 27, 30], ["layers", "OBSERVATION_MODIFIER", 31, 37], ["middle", "ANATOMY_MODIFIER", 99, 105], ["roughly", "OBSERVATION_MODIFIER", 145, 152], ["spherical shape", "OBSERVATION", 153, 168], ["hollow", "OBSERVATION_MODIFIER", 183, 189]]], ["The disordered appearance of the PRRSV core may suggest a more loosely organized nucleocapsid which makes it easier for the N protein to leak upon M\u03b2CD treatment.", [["M\u03b2CD", "CHEMICAL", 147, 151], ["PRRSV", "ORGANISM", 33, 38], ["nucleocapsid", "CELLULAR_COMPONENT", 81, 93], ["M\u03b2CD", "SIMPLE_CHEMICAL", 147, 151], ["N protein", "PROTEIN", 124, 133], ["PRRSV", "SPECIES", 33, 38], ["a more loosely organized nucleocapsid", "PROBLEM", 56, 93], ["the N protein to leak", "PROBLEM", 120, 141], ["M\u03b2CD treatment", "TREATMENT", 147, 161], ["more loosely", "OBSERVATION_MODIFIER", 58, 70], ["nucleocapsid", "OBSERVATION", 81, 93], ["leak", "OBSERVATION", 137, 141]]], ["However, the permeabilization of PRRSV virions may not be enough to result in the loss of the entire genome.", [["PRRSV", "ORGANISM", 33, 38], ["genome", "CELLULAR_COMPONENT", 101, 107], ["PRRSV", "SPECIES", 33, 38], ["the permeabilization of PRRSV virions", "TREATMENT", 9, 46], ["the loss of the entire genome", "PROBLEM", 78, 107], ["PRRSV virions", "OBSERVATION", 33, 46], ["may not be", "UNCERTAINTY", 47, 57], ["loss", "OBSERVATION_MODIFIER", 82, 86], ["entire", "OBSERVATION_MODIFIER", 94, 100], ["genome", "OBSERVATION", 101, 107]]], ["Therefore, disassembly of lipid rafts on the virus envelope affected integrity of viral envelope and caused the viral envelope leakage of viral proteins to adversely affect virus infectivity.DiscussionIn summary, our results have shown that PRRSV infection depends on the presence of lipid rafts in both cellular membrane and viral envelope.", [["lipid rafts", "ANATOMY", 26, 37], ["lipid rafts", "ANATOMY", 284, 295], ["cellular membrane", "ANATOMY", 304, 321], ["PRRSV infection", "DISEASE", 241, 256], ["lipid rafts", "CELLULAR_COMPONENT", 26, 37], ["PRRSV", "ORGANISM", 241, 246], ["lipid rafts", "CELLULAR_COMPONENT", 284, 295], ["cellular membrane", "CELLULAR_COMPONENT", 304, 321], ["viral proteins", "PROTEIN", 138, 152], ["PRRSV", "SPECIES", 241, 246], ["lipid rafts", "TREATMENT", 26, 37], ["the virus envelope", "TREATMENT", 41, 59], ["viral envelope", "PROBLEM", 82, 96], ["the viral envelope leakage of viral proteins", "PROBLEM", 108, 152], ["virus infectivity", "PROBLEM", 173, 190], ["PRRSV infection", "PROBLEM", 241, 256], ["lipid rafts", "PROBLEM", 284, 295], ["viral envelope", "PROBLEM", 326, 340], ["lipid rafts", "OBSERVATION", 26, 37], ["viral envelope", "OBSERVATION", 82, 96], ["viral envelope leakage", "OBSERVATION", 112, 134], ["viral proteins", "OBSERVATION", 138, 152], ["infection", "OBSERVATION", 247, 256], ["lipid rafts", "OBSERVATION", 284, 295], ["both", "ANATOMY_MODIFIER", 299, 303], ["cellular membrane", "OBSERVATION", 304, 321], ["viral envelope", "OBSERVATION", 326, 340]]], ["Cellular lipid rafts play an essential role in PRRSV entry, replication and release, and viral lipid raft structures are required to maintain virion core integrity to ensure PRRSV infectivity.", [["Cellular lipid rafts", "ANATOMY", 0, 20], ["lipid raft structures", "ANATOMY", 95, 116], ["Cellular", "CELL", 0, 8], ["lipid rafts", "CELLULAR_COMPONENT", 9, 20], ["PRRSV", "ORGANISM", 47, 52], ["PRRSV", "ORGANISM", 174, 179], ["PRRSV", "SPECIES", 47, 52], ["PRRSV", "SPECIES", 174, 179], ["Cellular lipid rafts", "TREATMENT", 0, 20], ["replication and release", "TREATMENT", 60, 83], ["viral lipid raft structures", "TREATMENT", 89, 116], ["virion core integrity", "TREATMENT", 142, 163], ["PRRSV infectivity", "PROBLEM", 174, 191], ["lipid rafts", "OBSERVATION", 9, 20], ["PRRSV infectivity", "OBSERVATION", 174, 191]]], ["These findings promote us to further investigate how viral proteins are associated with lipid rafts and how lipid raft domains function in the organization of a mature PRRSV particle production.", [["lipid rafts", "ANATOMY", 88, 99], ["lipid raft", "ANATOMY", 108, 118], ["lipid rafts", "CELLULAR_COMPONENT", 88, 99], ["lipid raft", "CELLULAR_COMPONENT", 108, 118], ["PRRSV", "ORGANISM", 168, 173], ["viral proteins", "PROTEIN", 53, 67], ["lipid raft domains", "PROTEIN", 108, 126], ["PRRSV", "SPECIES", 168, 173], ["viral proteins", "PROBLEM", 53, 67], ["lipid rafts", "TREATMENT", 88, 99], ["a mature PRRSV particle production", "PROBLEM", 159, 193], ["mature", "OBSERVATION_MODIFIER", 161, 167], ["PRRSV particle", "OBSERVATION", 168, 182]]], ["Also, the perturbation of membrane lipid rafts by small molecules to interfere with PRRSV infection could provide a means for development of antiviral agents.Cells and viruses ::: Materials and methodsMarc-145 cells and Hela cells were maintained in Dulbecco\u05f3s minimum essential medium (DMEM) supplemented with 10% FBS.", [["membrane lipid rafts", "ANATOMY", 26, 46], ["Cells", "ANATOMY", 158, 163], ["Marc-145 cells", "ANATOMY", 201, 215], ["Hela cells", "ANATOMY", 220, 230], ["FBS", "ANATOMY", 315, 318], ["PRRSV infection", "DISEASE", 84, 99], ["membrane", "CELLULAR_COMPONENT", 26, 34], ["lipid rafts", "CELLULAR_COMPONENT", 35, 46], ["PRRSV", "ORGANISM", 84, 89], ["Cells", "CELL", 158, 163], ["Marc-145 cells", "CELL", 201, 215], ["Hela cells", "CELL", 220, 230], ["FBS", "ORGANISM_SUBSTANCE", 315, 318], ["Marc-145 cells", "CELL_LINE", 201, 215], ["Hela cells", "CELL_LINE", 220, 230], ["PRRSV", "SPECIES", 84, 89], ["membrane lipid rafts", "TREATMENT", 26, 46], ["small molecules", "PROBLEM", 50, 65], ["PRRSV infection", "PROBLEM", 84, 99], ["antiviral agents", "TREATMENT", 141, 157], ["methodsMarc", "TEST", 194, 205], ["Hela cells", "TREATMENT", 220, 230], ["Dulbecco\u05f3s minimum essential medium (DMEM", "TREATMENT", 250, 291], ["small molecules", "OBSERVATION", 50, 65], ["infection", "OBSERVATION", 90, 99], ["viruses", "OBSERVATION", 168, 175], ["145 cells", "OBSERVATION_MODIFIER", 206, 215], ["Hela cells", "OBSERVATION", 220, 230]]], ["Porcine alveolar macrophages (PAMs) were obtained from postmortem lung lavage of 8-week-old specific pathogen free (SPF) pigs, and maintained in RPMI 1640 medium with 10% FBS.", [["alveolar macrophages", "ANATOMY", 8, 28], ["PAMs", "ANATOMY", 30, 34], ["lung lavage", "ANATOMY", 66, 77], ["FBS", "ANATOMY", 171, 174], ["Porcine", "ORGANISM", 0, 7], ["alveolar macrophages", "CELL", 8, 28], ["PAMs", "CELL", 30, 34], ["lung lavage", "MULTI-TISSUE_STRUCTURE", 66, 77], ["pigs", "ORGANISM", 121, 125], ["FBS", "ORGANISM_SUBSTANCE", 171, 174], ["Porcine alveolar macrophages", "CELL_TYPE", 0, 28], ["PAMs", "CELL_TYPE", 30, 34], ["Porcine", "SPECIES", 0, 7], ["pigs", "SPECIES", 121, 125], ["pigs", "SPECIES", 121, 125], ["Porcine alveolar macrophages", "PROBLEM", 0, 28], ["postmortem lung lavage", "TEST", 55, 77], ["alveolar macrophages", "OBSERVATION", 8, 28], ["lung", "ANATOMY", 66, 70], ["lavage", "OBSERVATION", 71, 77]]], ["All the cells were cultured and maintained at 37 \u00b0C with 5% CO2.", [["cells", "ANATOMY", 8, 13], ["CO2", "CHEMICAL", 60, 63], ["CO2", "CHEMICAL", 60, 63], ["cells", "CELL", 8, 13], ["CO2", "SIMPLE_CHEMICAL", 60, 63], ["5% CO2", "TREATMENT", 57, 63]]], ["PRRSV strains, CH1a (a type 2 PRRSV strain isolated in China) and Hpv (a highly pathogenic PRRSV (HP-PRRSV) isolate), were propagated and titrated in Marc-145 cells and PAMs.", [["Marc-145 cells", "ANATOMY", 150, 164], ["PRRSV", "ORGANISM", 0, 5], ["CH1a (a type 2 PRRSV", "ORGANISM", 15, 35], ["Hpv", "GENE_OR_GENE_PRODUCT", 66, 69], ["PRRSV", "ORGANISM", 91, 96], ["HP-PRRSV", "ORGANISM", 98, 106], ["Marc-145 cells", "CELL", 150, 164], ["PAMs", "CELL", 169, 173], ["Marc-145 cells", "CELL_LINE", 150, 164], ["PAMs", "CELL_TYPE", 169, 173], ["PRRSV", "SPECIES", 0, 5], ["PRRSV", "SPECIES", 30, 35], ["PRRSV", "SPECIES", 91, 96], ["PRRSV", "SPECIES", 0, 5], ["PRRSV", "SPECIES", 30, 35], ["PRRSV", "SPECIES", 91, 96], ["PRRSV", "SPECIES", 101, 106], ["Marc-145", "SPECIES", 150, 158], ["PRRSV strains", "PROBLEM", 0, 13], ["CH1a", "PROBLEM", 15, 19], ["a type 2 PRRSV strain", "PROBLEM", 21, 42], ["Hpv", "PROBLEM", 66, 69], ["a highly pathogenic PRRSV", "PROBLEM", 71, 96], ["PAMs", "PROBLEM", 169, 173]]], ["Briefly, PRRSV was serially diluted 10-fold in complete DMEM or RPMI 1640 to infect 5\u00d7104 Marc-145 cells or PAMs in 96-well plates.", [["5\u00d7104 Marc-145 cells", "ANATOMY", 84, 104], ["PRRSV", "ORGANISM", 9, 14], ["Marc-145 cells", "CELL", 90, 104], ["PAMs", "CELL", 108, 112], ["5\u00d7104 Marc-145 cells", "CELL_LINE", 84, 104], ["PRRSV", "SPECIES", 9, 14], ["PRRSV", "PROBLEM", 9, 14], ["Marc", "TEST", 90, 94], ["PAMs", "TEST", 108, 112]]], ["PRRSV infection was determined 48 h post infection using immunofluorescent staining for the PRRSV N protein.", [["PRRSV infection", "DISEASE", 0, 15], ["PRRSV", "ORGANISM", 0, 5], ["PRRSV", "ORGANISM", 92, 97], ["PRRSV N protein", "PROTEIN", 92, 107], ["PRRSV", "SPECIES", 0, 5], ["PRRSV", "SPECIES", 0, 5], ["PRRSV", "SPECIES", 92, 97], ["PRRSV infection", "PROBLEM", 0, 15], ["infection", "PROBLEM", 41, 50], ["immunofluorescent staining", "TEST", 57, 83], ["the PRRSV N protein", "TREATMENT", 88, 107], ["infection", "OBSERVATION", 6, 15]]], ["The viral titer was determined by the Reed-Muench method and expressed as tissue culture infective dose 50% (TCID50).Antibodies and reagents ::: Materials and methodsMethyl-\u03b2-cyclodextrin (M\u03b2CD) was from Sigma-Aldrich.", [["tissue", "ANATOMY", 74, 80], ["Methyl-\u03b2-cyclodextrin", "CHEMICAL", 166, 187], ["M\u03b2CD", "CHEMICAL", 189, 193], ["Methyl-\u03b2-cyclodextrin", "CHEMICAL", 166, 187], ["M\u03b2CD", "CHEMICAL", 189, 193], ["tissue", "TISSUE", 74, 80], ["Methyl-\u03b2-cyclodextrin", "SIMPLE_CHEMICAL", 166, 187], ["M\u03b2CD", "SIMPLE_CHEMICAL", 189, 193], ["Sigma-Aldrich", "SIMPLE_CHEMICAL", 204, 217], ["The viral titer", "TEST", 0, 15], ["tissue culture infective dose", "TREATMENT", 74, 103], ["methodsMethyl-\u03b2-cyclodextrin (M\u03b2CD", "TREATMENT", 159, 193], ["viral titer", "OBSERVATION", 4, 15]]], ["Antibody against caveolin-1 was purchased from Cell Signaling Technology.", [["Cell", "ANATOMY", 47, 51], ["caveolin-1", "GENE_OR_GENE_PRODUCT", 17, 27], ["Cell", "CELL", 47, 51], ["caveolin-1", "PROTEIN", 17, 27], ["Antibody", "TEST", 0, 8], ["caveolin", "TEST", 17, 25]]], ["Anti-CD71 antibody was purchased from Acris Antibodies GmbH.", [["Anti-CD71", "GENE_OR_GENE_PRODUCT", 0, 9], ["Anti-CD71 antibody", "PROTEIN", 0, 18], ["Acris Antibodies GmbH", "PROTEIN", 38, 59], ["Anti-CD71 antibody", "TEST", 0, 18]]], ["Anti-PRRSV N protein monoclonal antibody was purchased from Rural Technologies.", [["Anti-PRRSV", "PROTEIN", 0, 10], ["N protein monoclonal antibody", "PROTEIN", 11, 40], ["Anti-PRRSV", "SPECIES", 0, 10], ["Anti-PRRSV", "TREATMENT", 0, 10], ["N protein monoclonal antibody", "TEST", 11, 40], ["monoclonal antibody", "OBSERVATION", 21, 40]]], ["Anti-Gp3 antibody was a gift from Dr. Zhi-jun Tian (Harbin Veterinary Research Institute, CAAS, China).", [["Gp3", "GENE_OR_GENE_PRODUCT", 5, 8], ["Anti-Gp3 antibody", "PROTEIN", 0, 17]]], ["The antisera for Gp4, Gp5, and Nsp9 were prepared by our lab.", [["Gp4", "GENE_OR_GENE_PRODUCT", 17, 20], ["Gp5", "GENE_OR_GENE_PRODUCT", 22, 25], ["Nsp9", "GENE_OR_GENE_PRODUCT", 31, 35], ["Gp4", "PROTEIN", 17, 20], ["Gp5", "PROTEIN", 22, 25], ["Nsp9", "PROTEIN", 31, 35]]], ["Antibody against CD163 was purchased from AbD Serotec Company.", [["CD163", "GENE_OR_GENE_PRODUCT", 17, 22], ["AbD", "GENE_OR_GENE_PRODUCT", 42, 45], ["CD163", "PROTEIN", 17, 22], ["AbD Serotec", "PROTEIN", 42, 53], ["AbD", "SPECIES", 42, 45], ["Antibody", "TEST", 0, 8], ["CD163", "TEST", 17, 22], ["AbD", "ANATOMY", 42, 45]]], ["Goat anti-mouse or anti-rabbit IgG secondary antibodies were also purchased from Santa Cruz.", [["Goat anti-mouse", "PROTEIN", 0, 15], ["anti-rabbit IgG secondary antibodies", "PROTEIN", 19, 55], ["Santa Cruz", "PROTEIN", 81, 91], ["Goat", "SPECIES", 0, 4], ["anti-mouse", "SPECIES", 5, 15], ["anti-rabbit", "SPECIES", 19, 30], ["Goat", "SPECIES", 0, 4], ["anti-rabbit", "SPECIES", 19, 30], ["Goat anti-mouse", "TREATMENT", 0, 15], ["anti-rabbit IgG secondary antibodies", "PROBLEM", 19, 55]]], ["Goat anti-porcine IgG secondary antibody was purchased from Bethyl Laboratories.", [["Goat", "GENE_OR_GENE_PRODUCT", 0, 4], ["Goat anti-porcine IgG secondary antibody", "PROTEIN", 0, 40], ["Goat", "SPECIES", 0, 4], ["Goat", "SPECIES", 0, 4], ["Goat anti-porcine IgG secondary antibody", "TREATMENT", 0, 40]]], ["Rabbit anti-goat IgG secondary antibody was purchased from EASYBIO Company.Plasmid ::: Materials and methodsThe cDNA encoding porcine CD163 was amplified using reverse transcription-PCR (RT-PCR) from total RNAs extracted from porcine alveolar macrophages (PAMs) and cloned into pcDNA3.1.Cholesterol measurement ::: Materials and methodsCholesterol was measured using an Amplex Red cholesterol assay kit (Molecular Probes, Eugene, Oreg.) following the manufacturer\u05f3s introduction.Cell viability assay ::: Materials and methodsCytotoxic effects of M\u03b2CD were evaluated by the MTT (3-(4,5)-dimethylthiahiazo(-z-y1)-3,5-di-phenytetrazolimromide) assay.", [["alveolar macrophages", "ANATOMY", 234, 254], ["PAMs", "ANATOMY", 256, 260], ["Cell", "ANATOMY", 479, 483], ["Cholesterol", "CHEMICAL", 336, 347], ["cholesterol", "CHEMICAL", 381, 392], ["M\u03b2CD", "CHEMICAL", 546, 550], ["MTT", "CHEMICAL", 573, 576], ["3-(4,5)-dimethylthiahiazo(-z-y1)-3,5-di-phenytetrazolimromide", "CHEMICAL", 578, 639], ["Cholesterol", "CHEMICAL", 287, 298], ["Cholesterol", "CHEMICAL", 336, 347], ["cholesterol", "CHEMICAL", 381, 392], ["M\u03b2CD", "CHEMICAL", 546, 550], ["MTT", "CHEMICAL", 573, 576], ["3-(4,5)-dimethylthiahiazo(-z-y1)-3,5-di-phenytetrazolimromide", "CHEMICAL", 578, 639], ["Rabbit", "ORGANISM", 0, 6], ["porcine", "ORGANISM", 126, 133], ["CD163", "GENE_OR_GENE_PRODUCT", 134, 139], ["porcine", "ORGANISM", 226, 233], ["alveolar macrophages", "CELL", 234, 254], ["PAMs", "CELL", 256, 260], ["pcDNA3", "GENE_OR_GENE_PRODUCT", 278, 284], ["Cholesterol", "SIMPLE_CHEMICAL", 287, 298], ["Cholesterol", "SIMPLE_CHEMICAL", 336, 347], ["Cell", "CELL", 479, 483], ["M\u03b2CD", "SIMPLE_CHEMICAL", 546, 550], ["3-(4,5)-dimethylthiahiazo(-z-y1)-3,5-di-phenytetrazolimromide", "SIMPLE_CHEMICAL", 578, 639], ["Rabbit anti-goat IgG secondary antibody", "PROTEIN", 0, 39], ["cDNA", "DNA", 112, 116], ["porcine CD163", "PROTEIN", 126, 139], ["porcine alveolar macrophages", "CELL_TYPE", 226, 254], ["PAMs", "CELL_TYPE", 256, 260], ["pcDNA3", "DNA", 278, 284], ["Rabbit", "SPECIES", 0, 6], ["anti-goat", "SPECIES", 7, 16], ["porcine", "SPECIES", 126, 133], ["porcine", "SPECIES", 226, 233], ["Rabbit", "SPECIES", 0, 6], ["porcine", "SPECIES", 126, 133], ["Rabbit anti-goat IgG", "TEST", 0, 20], ["The cDNA encoding porcine CD163", "TREATMENT", 108, 139], ["reverse transcription", "TREATMENT", 160, 181], ["PCR", "TEST", 182, 185], ["RT-PCR", "TEST", 187, 193], ["total RNAs", "TREATMENT", 200, 210], ["porcine alveolar macrophages", "TREATMENT", 226, 254], ["Cholesterol measurement", "TEST", 287, 310], ["methodsCholesterol", "TEST", 329, 347], ["an Amplex Red cholesterol assay kit", "TREATMENT", 367, 402], ["the manufacturer\u05f3s introduction", "TREATMENT", 447, 478], ["M\u03b2CD", "TREATMENT", 546, 550], ["dimethylthiahiazo", "TREATMENT", 586, 603], ["alveolar macrophages", "OBSERVATION", 234, 254]]], ["Marc-145 cells or PAMs in a 96-well plate were cultured in 100 \u03bcl DMEM or RPMI 1640 containing 0, 2, 4, 6, 8, 10, 15, 20, or 30 mM M\u03b2CD for 2 h at 37 \u00b0C. Next, the culture medium was replaced with fresh medium containing 20 \u03bcl of 5 mg/ml MTT after washing three times with PBS, and cells were further cultured for 4 h at 37 \u00b0C. Cells were then washed carefully and 150 \u03bcl DMSO was added per well to dissolve the crystals for 10 min.", [["Marc-145 cells", "ANATOMY", 0, 14], ["cells", "ANATOMY", 282, 287], ["Cells", "ANATOMY", 328, 333], ["RPMI 1640", "CHEMICAL", 74, 83], ["M\u03b2CD", "CHEMICAL", 131, 135], ["DMSO", "CHEMICAL", 372, 376], ["M\u03b2CD", "CHEMICAL", 131, 135], ["MTT", "CHEMICAL", 238, 241], ["DMSO", "CHEMICAL", 372, 376], ["Marc-145 cells", "CELL", 0, 14], ["PAMs", "CELL", 18, 22], ["M\u03b2CD", "SIMPLE_CHEMICAL", 131, 135], ["MTT", "SIMPLE_CHEMICAL", 238, 241], ["cells", "CELL", 282, 287], ["Cells", "CELL", 328, 333], ["DMSO", "SIMPLE_CHEMICAL", 372, 376], ["Marc-145 cells", "CELL_LINE", 0, 14], ["PAMs", "CELL_TYPE", 18, 22], ["PAMs", "TEST", 18, 22], ["RPMI", "TEST", 74, 78], ["the culture medium", "TEST", 160, 178], ["fresh medium", "TREATMENT", 197, 209], ["PBS", "TREATMENT", 273, 276], ["cells", "TEST", 282, 287], ["Cells", "TEST", 328, 333], ["DMSO", "TREATMENT", 372, 376], ["145 cells", "OBSERVATION_MODIFIER", 5, 14]]], ["The resulting absorbance of each well was recorded at 490 nm using a plate reader.Indirect immunofluorescent assay ::: Materials and methodsCells were fixed with methanol\u2013acetone solution (1:1) for 10 min at 4 \u00b0C, and then were blocked with 5% goat serum in PBS for 30 min at 37 \u00b0C. PRRSV N protein or CD163 was detected using corresponding specific monoclonal antibody, MAb SDOW17 (1:10,000; Rural Technologies) or MAb MCA2311 (1:5000; AbD Serotec), and the secondary goat anti-mouse IgG (H+L) conjugated with FITC (1:200, Jackson ImmunoResearch).", [["Cells", "ANATOMY", 140, 145], ["serum", "ANATOMY", 249, 254], ["methanol\u2013acetone", "CHEMICAL", 162, 178], ["methanol\u2013acetone", "CHEMICAL", 162, 178], ["FITC", "CHEMICAL", 511, 515], ["Cells", "CELL", 140, 145], ["methanol\u2013acetone", "SIMPLE_CHEMICAL", 162, 178], ["goat", "ORGANISM", 244, 248], ["serum", "ORGANISM_SUBSTANCE", 249, 254], ["PRRSV N protein", "GENE_OR_GENE_PRODUCT", 283, 298], ["CD163", "GENE_OR_GENE_PRODUCT", 302, 307], ["AbD Serotec", "GENE_OR_GENE_PRODUCT", 437, 448], ["goat", "ORGANISM", 469, 473], ["FITC", "SIMPLE_CHEMICAL", 511, 515], ["PRRSV N protein", "PROTEIN", 283, 298], ["CD163", "PROTEIN", 302, 307], ["monoclonal antibody", "PROTEIN", 350, 369], ["MAb SDOW17", "PROTEIN", 371, 381], ["MAb MCA2311", "PROTEIN", 416, 427], ["1:5000", "PROTEIN", 429, 435], ["AbD Serotec", "PROTEIN", 437, 448], ["secondary goat anti-mouse IgG", "PROTEIN", 459, 488], ["H+L", "PROTEIN", 490, 493], ["FITC (1:200, Jackson ImmunoResearch", "PROTEIN", 511, 546], ["goat", "SPECIES", 244, 248], ["PRRSV", "SPECIES", 283, 288], ["goat", "SPECIES", 469, 473], ["anti-mouse", "SPECIES", 474, 484], ["goat", "SPECIES", 244, 248], ["PRRSV", "SPECIES", 283, 288], ["goat", "SPECIES", 469, 473], ["H+L", "SPECIES", 490, 493], ["a plate reader", "TREATMENT", 67, 81], ["methanol\u2013acetone solution", "TREATMENT", 162, 187], ["5% goat serum in PBS", "TREATMENT", 241, 261], ["PRRSV N protein", "TEST", 283, 298], ["CD163", "TEST", 302, 307], ["specific monoclonal antibody", "TEST", 341, 369], ["MAb SDOW17", "TEST", 371, 381], ["Rural Technologies", "TEST", 393, 411], ["MAb MCA2311", "TEST", 416, 427], ["AbD Serotec", "TEST", 437, 448], ["the secondary goat anti-mouse IgG", "TEST", 455, 488], ["FITC", "TEST", 511, 515], ["absorbance", "OBSERVATION_MODIFIER", 14, 24], ["AbD", "ANATOMY", 437, 440]]], ["Nuclei were stained with 4, 6-diamidino-2-phenylindole (DAPI).", [["Nuclei", "ANATOMY", 0, 6], ["4, 6-diamidino-2-phenylindole", "CHEMICAL", 25, 54], ["4, 6-diamidino-2-phenylindole", "CHEMICAL", 25, 54], ["DAPI", "CHEMICAL", 56, 60], ["Nuclei", "ORGANISM_SUBSTANCE", 0, 6], ["4, 6-diamidino-2-phenylindole", "SIMPLE_CHEMICAL", 25, 54], ["DAPI", "SIMPLE_CHEMICAL", 56, 60], ["Nuclei", "TEST", 0, 6], ["diamidino", "TREATMENT", 30, 39]]], ["Immunofluorescence was observed using Leica Microsystems CMS GmbH.PRRSV binding and internalization assay ::: Materials and methodsFor binding assay, Marc-145 cells or PAMs were pretreated with M\u03b2CD (0, 5, 10, 15, and 20 mM) for 1 h and then incubated with CH1a (MOI=5) or Hpv (MOI=5) at 4 \u00b0C for 1 h.", [["Marc-145 cells", "ANATOMY", 150, 164], ["M\u03b2CD", "CHEMICAL", 194, 198], ["CH1a", "CHEMICAL", 257, 261], ["M\u03b2CD", "CHEMICAL", 194, 198], ["PRRSV", "ORGANISM", 66, 71], ["Marc-145 cells", "CELL", 150, 164], ["PAMs", "CELL", 168, 172], ["M\u03b2CD", "SIMPLE_CHEMICAL", 194, 198], ["Marc-145 cells", "CELL_LINE", 150, 164], ["PAMs", "CELL_TYPE", 168, 172], ["PRRSV", "SPECIES", 66, 71], ["PRRSV", "SPECIES", 66, 71], ["Immunofluorescence", "TEST", 0, 18], ["binding assay", "TEST", 135, 148], ["PAMs", "PROBLEM", 168, 172], ["M\u03b2CD", "TREATMENT", 194, 198], ["CH1a (MOI", "TREATMENT", 257, 266], ["Hpv (MOI", "TREATMENT", 273, 281]]], ["Then, the unbound viruses in supernatants were removed and the level of cell-bound viral RNA was analyzed by real-time PCR.", [["supernatants", "ANATOMY", 29, 41], ["cell", "ANATOMY", 72, 76], ["cell", "CELL", 72, 76], ["viral RNA", "RNA", 83, 92], ["the unbound viruses in supernatants", "PROBLEM", 6, 41], ["cell-bound viral RNA", "PROBLEM", 72, 92], ["unbound", "OBSERVATION_MODIFIER", 10, 17], ["viruses", "OBSERVATION", 18, 25], ["viral RNA", "OBSERVATION", 83, 92]]], ["For entry assay, Marc-145 cells or PAMs were pretreated with M\u03b2CD (0, 5, 10, 15, and 20 mM) for 1 h and then incubated with CH1a (MOI=5) or Hpv (MOI=5) at 4 \u00b0C for 1 h.", [["Marc-145 cells", "ANATOMY", 17, 31], ["M\u03b2CD", "CHEMICAL", 61, 65], ["CH1a", "CHEMICAL", 124, 128], ["M\u03b2CD", "CHEMICAL", 61, 65], ["Marc-145 cells", "CELL", 17, 31], ["PAMs", "CELL", 35, 39], ["M\u03b2CD", "SIMPLE_CHEMICAL", 61, 65], ["Marc-145 cells", "CELL_LINE", 17, 31], ["PAMs", "CELL_TYPE", 35, 39], ["entry assay", "TEST", 4, 15], ["PAMs", "PROBLEM", 35, 39], ["M\u03b2CD", "TREATMENT", 61, 65], ["CH1a (MOI", "TREATMENT", 124, 133], ["Hpv (MOI", "TREATMENT", 140, 148]]], ["The inoculums were replaced with fresh culture medium to eliminate the unbound virus particles and cells were subsequently shifted to 37 \u00b0C to allow virus internalization for 3 h.", [["inoculums", "ANATOMY", 4, 13], ["cells", "ANATOMY", 99, 104], ["cells", "CELL", 99, 104], ["fresh culture medium", "TREATMENT", 33, 53], ["the unbound virus particles", "PROBLEM", 67, 94], ["virus internalization", "TREATMENT", 149, 170]]], ["Then cells were carefully washed with phosphate buffered saline (PBS) three times to remove the noninternalized virions and the level of viral RNA in cells was analyzed using real-time PCR.Quantitation of viral RNA ::: Materials and methodsThe RNA of purified virus was extracted with the viral RNA kit (OMEGA).", [["cells", "ANATOMY", 5, 10], ["virions", "ANATOMY", 112, 119], ["cells", "ANATOMY", 150, 155], ["phosphate", "CHEMICAL", 38, 47], ["phosphate", "CHEMICAL", 38, 47], ["cells", "CELL", 5, 10], ["phosphate buffered saline", "SIMPLE_CHEMICAL", 38, 63], ["cells", "CELL", 150, 155], ["viral RNA", "RNA", 137, 146], ["viral RNA", "RNA", 205, 214], ["phosphate buffered saline (PBS)", "TREATMENT", 38, 69], ["the noninternalized virions", "TREATMENT", 92, 119], ["viral RNA in cells", "PROBLEM", 137, 155], ["purified virus", "PROBLEM", 251, 265], ["viral RNA", "OBSERVATION", 137, 146], ["viral RNA", "OBSERVATION", 205, 214], ["virus", "OBSERVATION", 260, 265]]], ["Total RNA from Marc-145 cells or PAMs was extracted using the TRIzol reagent.", [["Marc-145 cells", "ANATOMY", 15, 29], ["Marc-145 cells", "CELL", 15, 29], ["PAMs", "CELL", 33, 37], ["Marc-145 cells", "CELL_LINE", 15, 29], ["PAMs", "CELL_TYPE", 33, 37], ["Total RNA", "TEST", 0, 9], ["PAMs", "PROBLEM", 33, 37], ["the TRIzol reagent", "TREATMENT", 58, 76], ["145 cells", "OBSERVATION_MODIFIER", 20, 29]]], ["RNAs were converted to cDNA using Superscript III Reverse Transcriptase (Invitrogen).", [["Superscript III Reverse Transcriptase", "GENE_OR_GENE_PRODUCT", 34, 71], ["Invitrogen", "GENE_OR_GENE_PRODUCT", 73, 83], ["RNAs", "RNA", 0, 4], ["cDNA", "DNA", 23, 27], ["Superscript III Reverse Transcriptase", "PROTEIN", 34, 71], ["Superscript III Reverse Transcriptase (Invitrogen)", "TREATMENT", 34, 84]]], ["For the quantification of purified virus, PRRSV RNA was analyzed using quantitative real-time RT-PCR with primers designed against PRRSV ORF7 (Patel et al., 2008).", [["PRRSV", "ORGANISM", 42, 47], ["PRRSV", "ORGANISM", 131, 136], ["PRRSV RNA", "RNA", 42, 51], ["PRRSV", "SPECIES", 42, 47], ["PRRSV", "SPECIES", 131, 136], ["purified virus", "PROBLEM", 26, 40], ["PRRSV RNA", "TREATMENT", 42, 51], ["primers", "TREATMENT", 106, 113], ["virus", "OBSERVATION", 35, 40]]], ["A plasmid containing ORF7 sequence was used to generate a standard curve, and RNA copies in all samples were calculated based on it (Han et al., 2009).", [["plasmid", "ANATOMY", 2, 9], ["samples", "ANATOMY", 96, 103], ["ORF7", "GENE_OR_GENE_PRODUCT", 21, 25], ["ORF7 sequence", "DNA", 21, 34], ["RNA copies", "RNA", 78, 88], ["A plasmid containing ORF7 sequence", "TREATMENT", 0, 34], ["a standard curve", "TEST", 56, 72], ["RNA copies", "TEST", 78, 88], ["all samples", "TEST", 92, 103]]], ["The transcript levels of cell-associated viral RNA were relatively quantified by the 2-\u0394\u0394CT Method (Livak and Schmittgen, 2001). glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA was set as a control.Lipid raft isolation ::: Materials and methodsLow-density detergent-insoluble lipid raft fractions were isolated as described previously with modifications (Chung et al., 2005).", [["cell", "ANATOMY", 25, 29], ["raft", "ANATOMY", 210, 214], ["lipid raft fractions", "ANATOMY", 282, 302], ["glyceraldehyde-3-phosphate", "CHEMICAL", 129, 155], ["glyceraldehyde-3-phosphate", "CHEMICAL", 129, 155], ["cell", "CELL", 25, 29], ["glyceraldehyde-3-phosphate dehydrogenase", "GENE_OR_GENE_PRODUCT", 129, 169], ["GAPDH", "GENE_OR_GENE_PRODUCT", 171, 176], ["viral RNA", "RNA", 41, 50], ["glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA", "RNA", 129, 182], ["The transcript levels", "TEST", 0, 21], ["cell-associated viral RNA", "PROBLEM", 25, 50], ["glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA", "TREATMENT", 129, 182], ["methods", "TEST", 243, 250], ["Low-density detergent", "TREATMENT", 250, 271], ["insoluble lipid raft fractions", "PROBLEM", 272, 302], ["cell", "OBSERVATION", 25, 29], ["viral RNA", "OBSERVATION", 41, 50], ["raft isolation", "OBSERVATION", 210, 224], ["Low-density", "OBSERVATION_MODIFIER", 250, 261], ["raft fractions", "OBSERVATION", 288, 302]]], ["Briefly, PAMs were scraped with a rubber policeman into ice-cold PBS and collected by centrifugation at 1000g for 3 min at 4 \u00b0C. Then pelleted cells were lysed using 0.3 ml of ice-cold TNE buffer (25 mM Tris [pH 7.5], 150 mM NaCl, 5 mM EDTA) containing 1% Triton X-100 (Merck), 1 mM NaF, and a cocktail of protease inhibitors (Thermo) at 4 \u00b0C for 30 min with gentle agitation.", [["cells", "ANATOMY", 143, 148], ["NaCl", "CHEMICAL", 225, 229], ["Triton X-100", "CHEMICAL", 256, 268], ["NaF", "CHEMICAL", 283, 286], ["agitation", "DISEASE", 366, 375], ["NaCl", "CHEMICAL", 225, 229], ["EDTA", "CHEMICAL", 236, 240], ["NaF", "CHEMICAL", 283, 286], ["PAMs", "CELL", 9, 13], ["cells", "CELL", 143, 148], ["TNE", "SIMPLE_CHEMICAL", 185, 188], ["EDTA", "SIMPLE_CHEMICAL", 236, 240], ["Triton X-100", "SIMPLE_CHEMICAL", 256, 268], ["Merck", "SIMPLE_CHEMICAL", 270, 275], ["NaF", "SIMPLE_CHEMICAL", 283, 286], ["a rubber policeman", "TREATMENT", 32, 50], ["cold PBS", "TREATMENT", 60, 68], ["ice-cold TNE buffer", "TREATMENT", 176, 195], ["pH", "TEST", 209, 211], ["NaCl", "TEST", 225, 229], ["5 mM EDTA)", "TREATMENT", 231, 241], ["1% Triton", "TREATMENT", 253, 262], ["1 mM NaF", "TREATMENT", 278, 286], ["a cocktail of protease inhibitors", "TREATMENT", 292, 325], ["gentle agitation", "PROBLEM", 359, 375]]], ["Then, the cell lysates were centrifuged at 4 \u00b0C for 10 min at 3500g to remove nuclei and insoluble materials.", [["cell lysates", "ANATOMY", 10, 22], ["nuclei", "ANATOMY", 78, 84], ["cell lysates", "CELL", 10, 22], ["nuclei", "CELLULAR_COMPONENT", 78, 84], ["the cell lysates", "TREATMENT", 6, 22], ["insoluble materials", "OBSERVATION", 89, 108]]], ["The supernatants were collected and mixed with equal volumes of 80% (wt/vol) sucrose in TNE buffer and then placed in the bottoms of ultracentrifuge tubes.", [["supernatants", "ANATOMY", 4, 16], ["sucrose", "CHEMICAL", 77, 84], ["sucrose", "CHEMICAL", 77, 84], ["sucrose", "SIMPLE_CHEMICAL", 77, 84], ["TNE", "SIMPLE_CHEMICAL", 88, 91], ["sucrose in TNE buffer", "TREATMENT", 77, 98], ["ultracentrifuge tubes", "TREATMENT", 133, 154], ["ultracentrifuge tubes", "OBSERVATION", 133, 154]]], ["A discontinuous sucrose gradient was formed by sequentially overlaying 2.1 ml of 30% and 1.2 ml of 5% sucrose in TNE buffer.", [["sucrose", "CHEMICAL", 16, 23], ["sucrose", "CHEMICAL", 102, 109], ["TNE", "CHEMICAL", 113, 116], ["sucrose", "CHEMICAL", 16, 23], ["sucrose", "CHEMICAL", 102, 109], ["sucrose", "SIMPLE_CHEMICAL", 16, 23], ["sucrose", "SIMPLE_CHEMICAL", 102, 109], ["TNE", "SIMPLE_CHEMICAL", 113, 116], ["A discontinuous sucrose gradient", "TREATMENT", 0, 32], ["5% sucrose in TNE buffer", "TREATMENT", 99, 123], ["sucrose gradient", "OBSERVATION", 16, 32]]], ["These mixtures were centrifuged at 4 \u00b0C for 18 h at 250,000g in a SW 55 Ti rotor (Beckman).", [["Ti", "CHEMICAL", 72, 74]]], ["After centrifugation, lipid rafts could be visible as an opaque band at the boundary between the 5% and 30% sucrose solutions.", [["lipid rafts", "ANATOMY", 22, 33], ["sucrose", "CHEMICAL", 108, 115], ["sucrose", "CHEMICAL", 108, 115], ["sucrose", "SIMPLE_CHEMICAL", 108, 115], ["centrifugation", "TREATMENT", 6, 20], ["lipid rafts", "TREATMENT", 22, 33], ["an opaque band", "TREATMENT", 54, 68], ["30% sucrose solutions", "TREATMENT", 104, 125], ["lipid rafts", "OBSERVATION", 22, 33]]], ["A total of 11 gradient fractions were collected from the top to bottom and stored at \u221280 \u00b0C until use.Purification of virus and preparation of M\u03b2CD-treated virus ::: Materials and methodsCulture supernatants were clarified by centrifugation at 2500g for 5 min and then viruses were isolated from clarified cell culture supernatants subjected to sedimentation through 20% sucrose (wt/vol) to 65% sucrose interface by centrifuging at 4 \u00b0C for 10 h at 100,000g in a SW50.1 rotor (Beckman).", [["supernatants", "ANATOMY", 195, 207], ["cell", "ANATOMY", 306, 310], ["supernatants", "ANATOMY", 319, 331], ["M\u03b2CD", "CHEMICAL", 143, 147], ["sucrose", "CHEMICAL", 371, 378], ["sucrose", "CHEMICAL", 395, 402], ["sucrose", "CHEMICAL", 371, 378], ["sucrose", "CHEMICAL", 395, 402], ["M\u03b2CD", "SIMPLE_CHEMICAL", 143, 147], ["cell", "CELL", 306, 310], ["sucrose", "SIMPLE_CHEMICAL", 371, 378], ["sucrose", "SIMPLE_CHEMICAL", 395, 402], ["A total of 11 gradient fractions", "TREATMENT", 0, 32], ["Purification of virus", "PROBLEM", 102, 123], ["preparation of M\u03b2CD", "TREATMENT", 128, 147], ["methodsCulture supernatants", "TEST", 180, 207], ["viruses", "PROBLEM", 269, 276], ["cell culture supernatants", "TEST", 306, 331], ["sedimentation", "TEST", 345, 358], ["20% sucrose (wt/vol)", "TREATMENT", 367, 387], ["total", "OBSERVATION_MODIFIER", 2, 7], ["virus", "OBSERVATION", 118, 123]]], ["After virion flotation, purified virus was taken from 20% to 65% sucrose interface fractions and stored at \u221280 \u00b0C until use.Purification of virus and preparation of M\u03b2CD-treated virus ::: Materials and methodsM\u03b2CD-treated virus was prepared by incubating virus in the presence of the indicated concentration of M\u03b2CD for 1 h at 37 \u00b0C with gentle mixing.", [["sucrose", "CHEMICAL", 65, 72], ["M\u03b2CD", "CHEMICAL", 165, 169], ["\u03b2CD", "CHEMICAL", 210, 213], ["M\u03b2CD", "CHEMICAL", 311, 315], ["sucrose", "CHEMICAL", 65, 72], ["M\u03b2CD", "CHEMICAL", 311, 315], ["sucrose", "SIMPLE_CHEMICAL", 65, 72], ["M\u03b2CD", "SIMPLE_CHEMICAL", 165, 169], ["methodsM\u03b2CD", "SIMPLE_CHEMICAL", 202, 213], ["M\u03b2CD", "SIMPLE_CHEMICAL", 311, 315], ["virion flotation", "TREATMENT", 6, 22], ["purified virus", "PROBLEM", 24, 38], ["Purification of virus", "PROBLEM", 124, 145], ["preparation of M\u03b2CD", "TREATMENT", 150, 169], ["Materials", "TREATMENT", 188, 197], ["methodsM\u03b2CD", "TREATMENT", 202, 213], ["treated virus", "PROBLEM", 214, 227], ["gentle mixing", "TREATMENT", 338, 351], ["virus", "OBSERVATION", 140, 145]]], ["Virus was then re-purified by ultracentrifugation at 4 \u00b0C for 2 h at 200,000g in a SW 55 Ti rotor (Beckman).", [["Ti", "CHEMICAL", 89, 91], ["Virus", "ORGANISM", 0, 5], ["Virus", "PROBLEM", 0, 5]]], ["The resulting pellet obtained for each treatment condition was re-suspended to the same volume of PBS.", [["each treatment condition", "TREATMENT", 34, 58]]], ["Treated and concentrated virus was divided into aliquots in small volumes and stored at \u221280 \u00b0C until use.Western blot analysis ::: Materials and methodsSimilar amount of volume from each sample was resolved by SDS-PAGE and transferred to polyvinylidene difluoride (PVDF) membranes (Millipore).", [["sample", "ANATOMY", 187, 193], ["SDS-PAGE", "CHEMICAL", 210, 218], ["polyvinylidene difluoride", "CHEMICAL", 238, 263], ["PVDF", "CHEMICAL", 265, 269], ["membranes", "CELLULAR_COMPONENT", 271, 280], ["concentrated virus", "TREATMENT", 12, 30], ["polyvinylidene difluoride (PVDF) membranes", "TREATMENT", 238, 280], ["amount", "OBSERVATION_MODIFIER", 160, 166], ["volume", "OBSERVATION_MODIFIER", 170, 176]]], ["Membranes were blocked with 5% nonfat milk in phosphate-buffered saline with 0.05% Tween 20 (PBST) and incubated for 2 h at room temperature with the primary antibodies at a suitable dilution (anti-Gp3 and \u2013Gp4 at 1:200, anti-CD71 at 1:500, anti-caveolin at 1:1000, anti-N protein at 1:2000, anti-Nsp9 at 1:3000, and anti-Gp5 and \u2013CD163 at 1:5000).", [["Membranes", "ANATOMY", 0, 9], ["milk", "ANATOMY", 38, 42], ["phosphate", "CHEMICAL", 46, 55], ["phosphate", "CHEMICAL", 46, 55], ["Tween 20", "CHEMICAL", 83, 91], ["Membranes", "ORGANISM_SUBSTANCE", 0, 9], ["milk", "ORGANISM_SUBSTANCE", 38, 42], ["phosphate-buffered saline", "SIMPLE_CHEMICAL", 46, 71], ["Tween 20", "SIMPLE_CHEMICAL", 83, 91], ["Gp3", "GENE_OR_GENE_PRODUCT", 198, 201], ["\u2013Gp4", "GENE_OR_GENE_PRODUCT", 206, 210], ["CD71", "GENE_OR_GENE_PRODUCT", 226, 230], ["anti-caveolin", "GENE_OR_GENE_PRODUCT", 241, 254], ["anti-Nsp9", "GENE_OR_GENE_PRODUCT", 292, 301], ["anti-Gp5", "GENE_OR_GENE_PRODUCT", 317, 325], ["CD163", "GENE_OR_GENE_PRODUCT", 331, 336], ["primary antibodies", "PROTEIN", 150, 168], ["anti", "PROTEIN", 193, 197], ["Gp3", "PROTEIN", 198, 201], ["\u2013Gp4", "PROTEIN", 206, 210], ["CD71", "PROTEIN", 226, 230], ["anti-caveolin", "PROTEIN", 241, 254], ["anti", "PROTEIN", 266, 270], ["N protein", "PROTEIN", 271, 280], ["Nsp9", "PROTEIN", 297, 301], ["1:3000", "PROTEIN", 305, 311], ["Gp5", "PROTEIN", 322, 325], ["CD163", "PROTEIN", 331, 336], ["5% nonfat milk in phosphate-buffered saline", "TREATMENT", 28, 71], ["anti-Gp3", "TREATMENT", 193, 201], ["\u2013Gp4", "TREATMENT", 206, 210], ["anti-CD71", "TREATMENT", 221, 230], ["anti-caveolin", "TREATMENT", 241, 254], ["anti-N protein", "TREATMENT", 266, 280], ["anti-Nsp9", "TREATMENT", 292, 301], ["anti-Gp5", "TREATMENT", 317, 325]]], ["The membranes were washed by PBST and then incubated with the appropriate secondary antibody for 1 h at a dilution of 1:10,000.", [["membranes", "ANATOMY", 4, 13], ["membranes", "CELLULAR_COMPONENT", 4, 13]]], ["The membranes were washed by PBST again and the antibodies were visualized by use of the enhanced chemiluminescence (ECL) reagent according to the manufacturer\u05f3s instructions.Statistical analysis ::: Materials and methodsAll experiments were performed with at least three independent replicates.", [["membranes", "ANATOMY", 4, 13], ["membranes", "CELLULAR_COMPONENT", 4, 13], ["antibodies", "PROTEIN", 48, 58], ["the antibodies", "TEST", 44, 58], ["the enhanced chemiluminescence (ECL) reagent", "TREATMENT", 85, 129]]], ["P<0.05 was considered to be statistically significant.", [["significant", "OBSERVATION", 42, 53]]]], "c81fee99a83c98d7a79e4854bc445dbfa6998e41": [["The coronavirus disease 2019 (COVID-19) pandemic has spread worldwide in a few months.", [["coronavirus disease", "DISEASE", 4, 23], ["COVID-19", "CHEMICAL", 30, 38], ["coronavirus", "ORGANISM", 4, 15], ["COVID-19", "ORGANISM", 30, 38], ["coronavirus disease 2019 (COVID-19", "SPECIES", 4, 38], ["The coronavirus disease", "PROBLEM", 0, 23], ["COVID", "TEST", 30, 35], ["pandemic", "PROBLEM", 40, 48], ["coronavirus disease", "OBSERVATION", 4, 23], ["spread", "OBSERVATION_MODIFIER", 53, 59], ["worldwide", "OBSERVATION_MODIFIER", 60, 69]]], ["1, 2 In the emerging literature, skin seemed to be involved in only 0.2% of patients, and notations of cutaneous findings have been generically described as \"rash\".", [["skin", "ANATOMY", 33, 37], ["cutaneous", "ANATOMY", 103, 112], ["rash", "DISEASE", 158, 162], ["skin", "ORGAN", 33, 37], ["patients", "ORGANISM", 76, 84], ["patients", "SPECIES", 76, 84], ["cutaneous findings", "PROBLEM", 103, 121], ["rash", "PROBLEM", 158, 162], ["skin", "ANATOMY", 33, 37], ["cutaneous", "ANATOMY", 103, 112]]], ["3 During the rapid spread of SARS-CoV-2 infection in Italy, pediatric dermatologists received pictures from pediatricians reporting young patients with pernio-like lesions.", [["pernio-like lesions", "ANATOMY", 152, 171], ["SARS-CoV-2 infection", "DISEASE", 29, 49], ["SARS-CoV-2", "ORGANISM", 29, 39], ["patients", "ORGANISM", 138, 146], ["pernio-like lesions", "CANCER", 152, 171], ["CoV-2", "SPECIES", 34, 39], ["patients", "SPECIES", 138, 146], ["SARS-CoV-2", "SPECIES", 29, 39], ["SARS", "PROBLEM", 29, 33], ["pernio-like lesions", "PROBLEM", 152, 171], ["rapid", "OBSERVATION_MODIFIER", 13, 18], ["spread", "OBSERVATION_MODIFIER", 19, 25], ["SARS", "OBSERVATION", 29, 33], ["infection", "OBSERVATION", 40, 49], ["lesions", "OBSERVATION", 164, 171]]], ["4 The clinical features appeared to be stereotypical, with the sudden onset of slightly painful or pruritic violaceous plaques and nodules, some- We actually think that after the first negative results of the screening program, the correlation of these lesions with the COVID-19 infection is far from being confirmed, so clinicians have not to worry parents, avoiding to forward urgently children to the nearest hospital to perform all the COVID examinations.", [["pruritic violaceous plaques", "ANATOMY", 99, 126], ["nodules", "ANATOMY", 131, 138], ["lesions", "ANATOMY", 253, 260], ["plaques", "DISEASE", 119, 126], ["infection", "DISEASE", 279, 288], ["violaceous plaques", "PATHOLOGICAL_FORMATION", 108, 126], ["nodules", "PATHOLOGICAL_FORMATION", 131, 138], ["lesions", "CANCER", 253, 260], ["children", "ORGANISM", 388, 396], ["children", "SPECIES", 388, 396], ["COVID-19", "SPECIES", 270, 278], ["slightly painful or pruritic violaceous plaques", "PROBLEM", 79, 126], ["nodules", "PROBLEM", 131, 138], ["the screening program", "TEST", 205, 226], ["these lesions", "PROBLEM", 247, 260], ["the COVID", "TEST", 266, 275], ["infection", "PROBLEM", 279, 288], ["all the COVID examinations", "TEST", 432, 458], ["slightly", "OBSERVATION_MODIFIER", 79, 87], ["painful", "OBSERVATION_MODIFIER", 88, 95], ["pruritic", "OBSERVATION_MODIFIER", 99, 107], ["violaceous", "OBSERVATION_MODIFIER", 108, 118], ["plaques", "OBSERVATION", 119, 126], ["nodules", "OBSERVATION", 131, 138], ["lesions", "OBSERVATION", 253, 260], ["infection", "OBSERVATION", 279, 288]]]]}